

Acta Haematologica

International Journal of Haematology - Journal International
d'Hématologie - Internationale Zeitschrift für Hämatologie

Official Organ of the European Division of the International Society
of Haematology

Editors

A. ALDER, Aarau	L. GROSS, Bronx, N.Y.	L. M. MAYER, Brooklyn, N.Y.
H. ALFONSO, Santiago	J. GUARCE, Barcelona	W. P. MURPHY, Boston, Mass.
G. BUCKEL, Genève	G. HENKELER, Lausanne	N. G. NORDENFLOV, Stockholm
E. L. von BORMANN, Helsinki	A. HITTMAIR, Innsbruck	A. PAVLOVSKY, Buenos Aires
W. O. CAIRNS, Rio de Janeiro	P. LITTON, Pavia	E. POWERS, Burlington, Vermont
C. R. DAS GUPTA, Calcutta	F. KOLLER, Basel	F. RANMARK, Uppsala
C. JACOBI, Madrid	J. H. LAWRENCE, Berkeley, Calif.	L. SAPPERS, Brooklyn, N.Y.
H. DUBOIS-FERETTER, Genève	P. LEVINE, Raritan, N.J.	E. STORRI, Modena
P. FARRERAS, Barcelona	W. LÖFFLER, Zürich	E. URSUTZ, Basel
A. FERRARI, Genova	J. MALLARD, Paris	M. VAKELA, Buenos Aires
		M. C. VERLOOF, Utrecht

Contributing Editors

L. Heilmeyer
Freiburg im Br.

S. Moeschlin
Solothurn

A. Videbaek
Copenhagen

J. Waldenström
Malmö

Editors-in-Chief

H. Lööf
Basel

G. Rosenow
New York, N.Y.



1968


Vol. 40

BASEL (Schweiz)

S. KARGER

NEW YORK

ALFVIZOU-TERZAKI, V. vide KENNE ELIAS, M.	
ALTUCCI, P. CORAOGIO, F.; COTO, V.; VARGAS, F. DE and VARGAS, G. L.: Isolation of Mycoplasma in Leukemia and Other Diseases	9
ALTUCCI, P. BOGAARD, G.; COCCO, F.; VARGAS, F. DE and VARGAS, G. L.: On the I Antigen of red Cells in Leukemia and its I interaction with Mycoplasma in vivo and in vitro	154
AREDE, T. GUEVARA, J. M. and RAMIREZ, J. R.: Congenital Deficiency of Fibrin-Stabilizing Factor (Factor XIII) A Report of the First Case from Latin America	329
ARIMA, M. vide SHIRAKURA, T.	
BARCO, J. vide SILVERSTEIN, E.	
BLANKENHOFF, EVELYN G. and BLANKENHOFF, W. K.: Eosinophils and Dietary Histamine in the Rat	59
BLANKENHOFF, W. K. vide BLANKENHOFF, EVELYN G.	
BÖHLER, E. vide FAIRLY, A. M.	
BOMI, M.; DACH, M. and FORMANN, G. Neonatal Hemolysis Due to Torsion Severity of Inherited Pyruvate Deficiency	166
BRADSTEINER, H. vide SCHMALEL, F.	
BRIDGES, J. M. vide SLOAN, KATHERINE, M.	
BUONARDO, G. vide ALTUCCI, P.	
BURKETT, R. C. vide LEE-ING, L. E.	
BURKUM, R. W.; FORSTER, L. and WACHS, H. A Trial of Slow Release Ferrous Sulfate (Ferrogradumet®) in Prevention of Iron Deficiency in Pregnancy	200
BUTLER, R. vide LOPEZ, V.	
CARDI, E. vide RONDANELLI, E. G.	
CASTELLO, R. vide SAN MICOLE, J. G.	
CEKKEL, M.; KODAR, V. and JERSTON, B. Fatal Peroral Iron Poisoning in a Young Woman	
CHATTERJEA, J. B. vide GHOSH, S. K.	
COCCO, F. vide ALTUCCI, P.	
COLLER, D. vide TITMAY, G.	
CORAOGIO, F. vide ALTUCCI, P.	
COTO, V. vide ALTUCCI, P.	
CRONIN, W. H. vide WHEATLEY, M. B.	
DACH, M. vide BOMI, M.	
DACH, M. vide RONDANELLI, E. G.	
DÖPFERSCHMIDT, H. vide FAIRLY, A. M.	
FAIRLY, A. M.; DÖPFERSCHMIDT, H. and BÖHLER, E.: Untersuchungen über den Einfluss von Natrium-Oleat auf die Aggregation menschlicher Thrombozyten	205
FARRAR, P. vide PARDO, P.	
FICKER, R. and HENCKELMANN, H. H. Über den Nachweis der Thiaminpyrophosphatase (Golgiposphatase) in Blut- und Knochenmarksteifen	177
FORRE, I. J. vide LAWTON, J. W. M.	
FORMANN, G. vide BOMI, M.	
GARDOLAI, C. Modes of Presentation of Thalassemia minor	34
GARDOLAI, C.; LYBERATOR, C.; PYROVOLAKIS, J. and PAPAYANIS, A. The Effect of Adrenergic Blockers on the Action of Adrenaline on the Factor VIII Activity in the Plasma	216
GHOSH, S. K. SWARUP-MITRA, SURESH and CHATTERJEA, J. B. A Rapid Clinical Method for the Estimation of Activity of Aconitine in Blood	104
GRAF REYERHOLZ, D. Über den Abbau von Zellen im Knochenmark des Menschen und der Ratte	252
GRON, L. Transmission of Mouse Leukemia by Oral Route	1



GRUNDIGER, F. J. : Change from Fetal to Adult Hemoglobin in Relation to Changes in the A Antigen of Human Erythrocytes	322
GUTVARR, J. M. vide ARNDT, T.	
GUTVARR, E. vide KENN-ELLAS, M.	
HEIDENRUMER, H. H. vide FISCHER, R.	
JAKOBYVICY, A. J. PLOTKE, V. J. and SPEKTER, C. J. DNA Synthesis by Erythroblasts in Normal Man and in Some Disorders of Erythropoiesis	315
JERKOT, S. vide CORKILL, M.	
KARLSSON, H. vide LECHE, H.	
KENN-ELLAS, M.; GUTVARR, E.; ALEXANDER-TURKAL, V. and KOKKOLONMATI, A. Reticulocyte and Normoblast Labelling with Leucine- ³ H in Thalassemic and non Thalassemic Subjects	37
KNOX, FRED P. SHARIT, MURIN J. and YACOBOWITZ, STEPHAN. Cytogenetic Studies in Acute Leukemia	192
KELLANDER, A. and WERNER, I. Maintenance Therapy of Pernicious Anemia. Comparison of Cyanocobalamin, Hydroxycobalamin and Cyanocobalamin-Zinc Tartrate Complex	303
KOKKOLONMATI, A. vide KENN-ELLAS, M.	
KURKE, P. vide POLLER, J.	
KURKE, V. vide CORKILL, M.	
LACHMANN, R. Chromosomal Aberrations and Neoplastic Potentialities of Thymus Cells during Leukemogenesis	142
LAWTON, J. W. M. and FORBES, I. J. Measurements of Protein Synthesis by Lymphocytes <i>in vitro</i> in Diseases of the Lymphoid Tissues	241
LECHE, H. RUTHE, H.; WALDMANN, W. and KARLSSON, H. Verbrauchskegelpathie bei metastasierendem Prostatakarzinom	93
LEDER, L. D. vide LÖFFLER, H.	
LEE LYO, L. E.; WANG, A. C. and BURGESS, R. C. Another Family Showing the Interaction of the Genes for Hb G and Hb S	286
LÖFFLER, H. and LEDER, L.-D. Primäres mit Panhämocytopenie	75
LOPEX, V.; FLEISCHMANN, R. and BUTLER, R. A Specific Inhibitor of Human Clotting Factor V	275
LYTHBATOR, C. vide GARDIAS, C.	
MAEKAWA, T. vide SHIBASAKI, T.	
MAGNULO, E. vide RONDANELLI, E. G.	
MADORE, T. K. vide SCHUMACHER, H. R.	
McFEELEY, A. E. vide SCHUMACHER, H. R.	
MOLOVET William C. vide RONDANELLI, D. S.	
PABLO, P.; SOAD, E.; FARRERAS, P. and RIBAS-MIXO, M. Complete Remission in Chronic Lymphocytic Leukemia. Report of Case	230
PFLEGERMANN, R. vide LOPEX, V.	
PLOTKE, V. J. vide JAKOBYVICY, A. J.	
POLLER, J. and KURKE, P. Acid Phosphatase of Platelets during Coagulation and Storage of Blood	48
POLLER, L. vide BÜBLER, R. W.	
PROVOSTA, J. vide GARDIAS, C.	
RANDOL, J. R. vide ARNDT, T.	
RECHT, H. vide LECHE, H.	
RITANO, G. vide SILVERMAN, E.	
RIBAS-MIXO, M. vide PABLO, P.	
RONDANELLI, E. G.; MAGNULO, E.; CARON, G. and DIROSSI, D. Cytoplasmic Shedding as Mode of Formation of Lymphocyte-Like Blast Cells by Newt Erythrocytes	67
RONDANELLI, D. S.; SEARIN, ARTHUR T. and MOLOVET William C. Serum Lactic Dehydrogenase Activity in Refractory Anemia	187

ROEMAN, C.; WOERNER, S. and SALT SERRANIA, J: Acute Erythromyeloidis after Benzene Poisoning	231
SALT SERRANIA, J: vide ROEMAN, C.	
SAN MIOUËL, J. G. and CASTELLO, R. Investigation of Uremic Thrombopathy	113
SCHLESINGER, E. M. Reticulohistiocytic Origin of the Blood Basophil in Human Marrow	162
SCHMALZ, F. and BRAUNSTEINER, H. Zur Diagnose monocytärer Leukämien mit zytochemischen Methoden	121
SCHNEIDER, J. J.: A Survey for Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency in Rumania	44
SCHNACHTER, H. R. McFEELEY, A. E. and MACQUEL, T. K. The Mononuclears and Leukemic Cell II. RNA Synthesis	28
SHAKER, MUMER, J. vide KNOWL, FARID P.	
SHKRYER, C. J. vide JAROMKIEWICZ, A. J.	
SHIRAKURA, T. ATODA, M. and MAEKAWA, T.: Effect of Androgen Antagonist on Erythropoietic Action of Testosterone	299
SILVESTROU, E. BIANCO, I. and RITANO, G. Three Cases of Haemoglobin β -Thalassaemia (or Microcytosis) with High Haemoglobin F in a Sicilian Family	270
SOMO, E. vide PARDO, P.	
SEARIN, ARTHUR T. vide ROSENTHAL, D. S.	
SLOAN, KATHERINE M. and BRIDGES, J. M. The in vivo Uptake of 45 S-L-leucine by Normal and Leukemic Leucocytes	18
SWARUP-MITRA, SUTICOLA vide GROSS, S. L.	
TYSTRONEN, J. vide VERSTRAETE, M.	
TYTOO, G.; COLLIER, D. VERKER, R. DE and VERSTRAETE, M. Investigations on the Fibrinolytic System in Liver Cirrhosis	263
VAROAS, F. DE vide ALTUDU, P.	
VAROAS, G. L. vide ALTUDU, P.	
VERMYLEN, J. vide VERSTRAETE, M.	
VERSTRAETE, M. VERMYLEN, J. and TYSTRONEN, J.: Double Blind Evaluation of the Haemostatic Effect of Adrenochrome Monomethylcarbonate, Conjugated Oestrogens and Epiklonaminosopropic Acid after Adenotomectomy	154
VERSTRAETE, M. vide TYTOO, G.	
VERKER, R. DE vide TYTOO, G.	
WACKER, H. vide BUEHLER, R. W.	
WALDMÄCHER, W. vide LECHNER, H.	
WANO, A. C. vide LEE I-YO, L. E.	
WERNSTEIN, M. B. and GROSS, W. H. Bone Marrow Injury and Repair Irradiation and Mechanical Disruption	55
WERNER, I. vide KELLAMER, A.	
WOERNER, S. vide ROEMAN, C.	
YENKOSKEA, STEPHAN vide KNOWL, FARID P.	
Libri	110, 176, 238, 336
Varia	176, 240
Index rerum ad Vol. 36-40	339
Index autorum ad Vol. 36-40	374

All rights, including that of translation into other languages, reserved.

Photomechanical reproduction (photocopy, microcopy) of this book or parts thereof without special permission of the publisher is prohibited.



Copyright 1968 by S. Karger AG, Basel

Printed in Switzerland by Buchdruckerei National-Zeitungs AG, Basel
 (Chester-Becker & Co. AG, Basel)

Cancer Research Unit, Veterans Administration Hospital, Bronx, N Y

Transmission of Mouse Leukemia by Oral Route¹

LUDWIK GROSS

It has been observed in earlier studies that the mouse leukemia virus could be transmitted with the milk of nursing female mice to their offspring, or to foster-nursed mice [7 8] results of these experiments suggested clearly, that under certain experimental conditions the mouse leukemia virus could be transmitted by oral route. However under experimental conditions employed in these previous studies transmission of the virus through the intestinal tract was accomplished in newborn mice the question remained to be answered whether infection by oral route may also occur in animals beyond the very early infant age.

In an attempt to determine whether experimental transmission of leukemia could be accomplished by oral route in young adult animals, young weanling C3H(f) mice, 3 to 4 weeks old, received a single meal consisting of a ground leukemic cell suspension mixed with milk and bread. As a result, and rather unexpectedly all animals which ingested the leukemic cell extract developed after several months disseminated lymphosarcomas.

Materials and Methods

Animals. Young, weanling C3H(f) female mice, 3 to 4 weeks old, from our colony were used for this experiment. Several litters were employed and split so that mice in the experimental and in the control groups were litter-mates.

When left undisturbed, mice of the C3H(f) strain bred in our laboratory have a very low incidence of spontaneous leukemia. The rare cases of spontaneous leukemia which developed in untreated C3H(f) mice in our colony have been observed in animals over 12 months old during the past 10 years the total incidence has not exceeded 0.5 to 1%.

Aided, in part, by grants from the Damon Runyon Memorial Fund and the American Cancer Society

Preparation of the leukemic extract for feeding. Fragments of thymic lymphomas, leukemic lymph nodes and spleens were removed aseptically from C3H (f) mouse donors. The fragments were cut with sterile scissors, and ground by hand in a mortar with a small quantity of physiological saline solution added. Pasteurized cow milk was then added to obtain a cell suspension of approximately 20% concentration.

Voluntary ingestion of a meal containing leukemic cell extract. The leukemic cell extract was then poured over small pieces of bread and placed in an open sterile petri dish on the bottom of a cage containing a group of 12 young adult C3H (f) mice. The mice, which had been kept without food and water for the preceding 20 h, fed voluntarily on the experimental meal containing the leukemic cell suspension. This was the only treatment these mice received. Seven hours after this treatment the mice received their usual daily meal consisting of Purina Laboratory Chow pellets and tap water. Twice a week they also received oats and fresh lettuce. They were kept for observation without any further treatment.

Control Group. The control group consisted of 8 C3H (f) female mice, 3 to 4 weeks old, litter-mates of those employed in the experimental group. The 8 mice in the control group were left for 20 h without food and water. After this lapse of time, leukemic cell suspension, heated to 56°C for 1 hour and mixed with pasteurized cow milk and bread, was placed in an open petri dish at the bottom of their cage. Seven hours later the control mice received their regular daily food consisting of Purina Laboratory Chow pellets and tap water. They also received twice weekly oats and fresh lettuce. They were kept for observation without any additional treatment.

Results

The results are summarized in table 1. Twelve mice in the experimental group ingested voluntarily a single meal consisting of fresh leukemic cell suspension mixed with milk and bread, and all developed generalized leukemia at ages varying from 4 to 12 months, i.e. 3 to 11 months after the ingestion of the virus-containing meal. All 12 animals which developed leukemia in this group developed disseminated

Table 1. Transmission of mouse leukemia by oral route

	No. of mice inoc.	No. dev. leuk.	Leuk. onset	Avg. age leuk. dev. mice
Experimental group	12	12	100	7.6
Controls	8	0		

Virus inoculation consisted of voluntary ingestion of a meal containing leukemic cell suspension in bread and milk. The control animals received heated (56°C for 1 hour) leukemic cell suspension with bread and milk. All mice were 3 to 4 weeks old at the time they received the virus.

Age range: Leukemia developed 4 to 12 months.



Figure 1 This C3H/1 female mouse No. 541 ingested, when 3 weeks old, leukemic cell suspension mixed with bread and milk; the voluntarily ingested meal was the only treatment this mouse received. Three months later at the age of 4 months, this mouse developed generalized lymphatic leukemia (WBC 61 400/mm³ with 48% of lymphoblasts in peripheral blood) Not the very large thymic tumor large spleen, large oblong mesenteric tumor and enlarged inguinal, axillary and cervical lymph nodes.

Preparation of the leukemic extract for feeding. Fragments of thymic lymphomas, leukemic lymph nodes and spleens were removed aseptically from C3H(f) mouse donors with passage A virus-induced leukemia; the tissue fragments were cut with sterile scissors, and ground by hand in a mortar with small quantity of physiological saline solution added; pasteurized cow milk was then added to obtain cell suspension of approximately 20% concentration.

Voluntary ingestion of meal containing leukemic cell extract. The leukemic cell extract was then poured over small pieces of bread and placed in an open sterile petri dish on the bottom of cage containing group of 12 young adult C3H(f) mice; the mice which had been kept without food and water for the preceding 20 h, fed voluntarily on the experimental meal containing the leukemic cell suspension. This was the only treatment these mice received. Seven hours after this treatment the mice received their usual daily meal consisting of Purina Laboratory Chow pellets and tap water; twice a week they also received oats and fresh lettuce. They were kept for observation without any further treatment.

Control Group. The control group consisted of 8 C3H(f) female mice, 3 to 4 weeks old, litter mates of those employed in the experimental group. The 8 mice in the control group were left for 20 h without food and water after this lapse of time leukemic cell suspension, heated to 56° C for ¼ hour and mixed with pasteurized cow milk and bread, was placed in an open petri dish at the bottom of their cage. Seven hours later the control mice received their regular daily food consisting of Purina Laboratory Chow pellets and tap water; they also received twice weekly oats and fresh lettuce. They were kept for observation without any additional treatment.

Results

The results are summarized in table I. Twelve mice in the experimental group ingested voluntarily a single meal consisting of fresh leukemic cell suspension mixed with milk and bread and all developed generalized leukemia at ages varying from 4 to 12 months, i.e. 3 to 11 months after the ingestion of the virus-containing meal. All 12 animals which developed leukemia in this group developed disseminated

Table I. Transmission of mouse leukemia by oral route

	No. of mice not.	No. dev leuk.	Leuk. incid. %	Avg. age leuk. dev. mos.
Experimental group	12	12	100	7.6
Controls	8			

Virus inoculation consisted of voluntary ingestion of meal containing leukemic cell suspension in bread and milk. The control animals received heated (56° C for ¼ hour) leukemic cell suspension with bread and milk. All mice were 3 to 4 weeks old at the time they received virus.

Age range leukemia developed 4 to 12 months.

lymphosarcomas involving predominantly the thymus, liver spleen, and peripheral lymph nodes (fig 1) Electron micrographs of virus particles from a thymic lymphoma are shown in figure 2. Their peripheral blood counts ranged from 11 000 to 94 600 WBC/mm³ The predominant white blood cells were of the lymphocytic series the relative incidence of lymphoblasts in peripheral blood observed in 9 of the 12 leukemic animals ranged from 2 to 51 Most of these mice had also a moderate to moderately-severe anemia.

In the control group, all 8 mice remained in good health they are now 15 months old.

Discussion

Even though only a small number of animals was employed in the experiment described in this preliminary report, the results obtained suggest clearly that under certain experimental conditions, using a potent leukemogenic virus, mouse leukemia can be transmitted by oral route by a single, voluntarily ingested meal, to 3 to 4-week-old mice of a susceptible inbred line Thus far we have not observed a similar virus transmission following feeding of young weanling C3H(f) mice with a single meal containing a leukemic cell suspension prepared from organs of Ak mice with spontaneous leukemia, mixed with bread and milk however this experiment is still in progress, and positive results may be obtained at a later date. It is quite possible, nevertheless, that a more potent passaged virus may be needed to transmit leukemia by oral route. An experiment dealing with an attempt to transmit mouse leukemia by feeding of passage A virus filtrate, instead of leukemic cell suspension, mixed with milk and bread, is also in progress.

Although we have employed a leukemic cell extract for the preparation of the experimental meal in this study it is reasonable to assume that transmission of the disease was accomplished by a virus released by the leukemic cells present in the ingested food. Leukemia which developed in the experimental mice appeared after a rather long latency varying from 3 to 11 months, and was generalized involving thymus, spleen, and peripheral lymph nodes in all animals it is unlikely that leukemic cells would have survived and that they became implanted somewhere along the intestinal tract after oral ingestion furthermore, had the transmission been caused by accidental implantation of leukemic cells ingested with the meal one would have rather expected a shorter latency and the development of lymphoid tumors

at the site of implantation somewhere along the intestinal tract, with generalization of the disease occurring only as a delayed and secondary manifestation.

We have demonstrated in previous studies that under normal life conditions the common pattern of virus transmission in mouse leukemia follows the vertical route, from parents to offspring directly through the germinal cells [5-6]. The observation that the mouse leukemia virus can induce disease following a single administration by oral route suggests that under certain experimental conditions, employing a potent passage virus, transmission may not necessarily be limited to a vertical route, but may also occur in the more conventional manner commonly observed in many bacterial and viral diseases. Whether this may occur under natural life conditions, however, remains to be determined.

Transmission by oral route thus far accomplished required a highly potent passage virus and highly susceptible mice. These are rather artificial laboratory conditions which may not be readily duplicated in nature. On the other hand, the result of this experiment may also imply that under certain limited conditions transmission of leukemia by oral route should be considered as a possibility not only in mice but in other species also. This has been previously recognized in studies dealing with natural transmission of chicken lymphomatosis [1-2].

Digestive System Site of Entry and also of Multiplication of the Mouse Leukemia Virus

The observation that effective virus infection leading to the development of disease can be obtained in mice following voluntary ingestion of a single meal containing a leukemic cell extract is of considerable interest. It indicates that the mucous membranes of the digestive tract are susceptible to virus penetration, and that the virus may resist inactivation and destruction by the secretions of the digestive system.

Electron microscopic studies carried out in our laboratory in cooperation with Dr. H. G. FELDMAN on C3H/1 mice injected, when newborn, with the passage A virus (Gross) demonstrated that the mouse leukemia virus can multiply and accumulate in the salivary glands and in the pancreas (fig. 3) [3, 4]. The development of virus particles by the process of budding at the edge of cytoplasmic membranes of the epithelial cells was observed in both organs. The virus




Fig. 3. Electron micrographs of ultrathin sections prepared from organs of the digestive system of CSH/7 mice in which leukemia was induced by routine intramuscular inoculation of the passage A mouse leukemia virus filtrate. (A) *Spleen* *plasma*: Virus particle (b) budding from epithelial cell and doughnut-like immature (l) and mature (m) type C virus particles, with nucleocapsid, in intercellular space (30,000 \times). (B) *Pancreas*: Type C virus particles (m) in intercellular space between 2 pancreatic acinar cells (42,800 \times). (C) *Duodenum*: Virus particle budding (b) from epithelial cell and mature type C virus particles (m) in intercellular space (42,800 \times). (D) *Colon*: Virus particle budding (b) from epithelial cell and mature type C virus particle (m) in intercellular space (33,600 \times).

was then released into the intercellular spaces. Virus particles were also found in the ducts of the salivary glands and of the pancreas.

In more recent electron microscopic studies replication of the virus and formation by the process of budding was also observed in the intestinal tract, particularly in the epithelial cells of the duodenum, jejunum, and colon of virus-injected C3H(f) mice

Summary

Three to four week-old C3H(f) female mice received a single meal consisting of passage A virus-induced leukemic cell suspension mixed with milk and bread. The meal was not forcibly fed, the mice consumed this mixture voluntarily. All 12 mice (100%) developed leukemia after latency varying from 3 to 11 months. In control group 8 C3H(f) mice ingested a single meal consisting of heated (56°C for 1/2 hour) leukemic cell suspension mixed with milk and bread. All mice in the control group remained in good health; they are now 15 months old. Electron microscopic studies of organs of C3H(f) mice that had been inoculated routinely with passage A mouse leukemia virus revealed the presence of clusters of characteristic virus particles, and multiplication of virus particles by budding, in salivary glands, in pancreas, and also in epithelial cells of the duodenum, jejunum and colon.

References

1. BURKHOLDER, B. R. The vertical and horizontal transmission of avian visceral lymphomatosis. *Cold Spr. Harb. Symp. quant. Biol.* 27: 471-477 (1962).
2. BURKHOLDER, B. R. and GARTLEY, R. F. A study of possible avenues of infection with the virus of avian visceral lymphomatosis. *Proc. 91st Ann. Meet. Amer. Vet. Med. Ass.*, pp.311-316 (1954).
3. FELDMAN, D. G. and GROSS, L. Electron-microscopic study of the mouse leukemia virus (Gross) and of tumors from mice with virus-induced leukemia. *Cancer Res.* 24: 1760-1783 (1964).
4. FELDMAN, D. G. and GROSS, L. Electron microscopic study of the distribution of the mouse leukemia virus (Gross) in organs of mice and rats with virus-induced leukemia. *Cancer Res.* 26: 411-426 (1966).
5. GROSS, L. Pathogenic properties, and 'vertical' transmission of the mouse leukemia agent. *Proc. Soc. exp. Biol.*, N.Y. 78: 342-348 (1951).
6. GROSS, L. Viral (egg-borne) etiology of mouse leukemia. Filtered extracts from leukemic C58 mice, causing leukemia (or parotid tumors) following inoculation into new born C57 Brown, or C3H mice. *Cancer* 9: 778-791 (1956).
7. GROSS, L. Transmission of mouse leukemia virus through milk of virus-injected C3H female mice. *Proc. Soc. exp. Biol.*, N.Y. 102: 830-836 (1962).
8. LAW, L. W. and MOKOVICH, J. B. Studies of congenital transmission of leukemia virus in mice. *Proc. Soc. exp. Biol.*, N.Y. 100: 715-723, 1961.

Institute of Medical Pathology University of Naples, Naples

Isolation of Mycoplasmas in Leukemia and Other Diseases¹

P. ALTUCCI, F. CORAGGIO, V. COTO
F. DE VARGAS and E. L. VARONE

The conflicting data reported by a number of investigators on the relationships between Mycoplasmas and leukemias, malignancies and other systemic diseases, together with our previous studies on the etiological role of these microorganisms in the pathogenesis of some human diseases, called our attention to the possibility of isolating these agents from leukemias and related diseases.

Positive isolations of Mycoplasmas from leukemic materials have been reported by MURPHY *et al.* [23-24]. They were able to isolate Mycoplasmas in nearly 50% of the leukemic specimens tested. Higher incidence of isolation has been found after passages of the specimens in cell cultures. A fairly high incidence of isolation (40%) has also been reported by BARILE *et al.* [5-7]. On the contrary a very low incidence of positive isolation has been reported by HAYFLICK and KOPROWSKI [17], HAYFLICK and STANBRIDGE [18] and by DRYER [12]. SIKKOVICS [29] obtained negative results in all of the leukemic cases studied.

It has to be pointed out that all these attempts have been done by direct plating on acellular media, so that the possibility that the isolates could be derived from latently infected cell cultures used for assay rather than from the clinical specimens has been ruled out. Nevertheless, earlier studies on the isolation of Mycoplasmas in tissue cultures infected with leukemic materials have been reported by GRACE *et al.* [15], by NEGROMI [25] and by DALDORFF and BERGAMINI [8, 9].

This work is a part of the research program worked out, since many years, in our laboratories, on the possibility to isolate viruslike agents

This work has been conducted with grant of CNR (Gruppo Nazionale di Medicina Sperimentale, Sezione Virologia).

from leukemic patients and to study their relationships with human leukemia.

Materials and Methods

The media employed in these studies for the isolation of *Mycoplasmas* consisted basically of *Dako PPLO* agar or broth at a concentration of 5.4% to which the following ingredients were added to enrich them according to *MICHAUD et al.* [23]: Brain heart infusion (3.7%) human or gamma-horse serum (final concentration 20%) baker yeast extract (25%) 3% AGVD stock solution (per 100 ml: 2.1 g of arginine, 3.0 g of glutamine, 5.0 g of dextran 10 ml of Eagle's 100 X basal Vitamins). The final pH of the media has been adjusted to 7.4-7.6. We have not still done attempts to isolate *Mycoplasmas* in media at a lower pH as indicated more recently by some authors [24-18], on the basis of the observation that most *Mycoplasmas* prefer alkaline conditions.

Bone marrow specimens obtained by sternal puncture from leukemic and non leukemic patients were directly inoculated into liquid media at 1:20 dilution within 1 to 3 h after collection. The samples were then incubated at 37°C in microaerophilia (95% N₂, 5% CO₂).

Each material received 2-3 successive passages on fluid and solid media at intervals of 4 to 6 days, before being considered negative.

Two out of four *Mycoplasma* strains isolated were classified through the complement fixation test. The technique employed both in preparing complement-fixing antigens (used, in this case, not inactivated) and in performing the reaction has already been described [1,2].

Thirty-two cases of leukemia have been examined (9 cases of chronic myelogenous leukemia, 6 cases of chronic lymphatic leukemia, 17 cases of acute leukemia). Bone marrow specimens were taken from the patients in three different stages in the course of the disease: usually when the initial symptoms appeared, during remission (clinical and hematological) and during relapse of the disease. In parallel to the leukemic specimens, 9 cases of malignancies of the lympho-reticuloendothelial type, 16 cases of leioepithelias other than leukemia, 4 cases of collagen diseases and 12 cases of various pathological conditions have been studied (table I).

Results

So far, only four strains of *Mycoplasma* have been isolated. Of these, two were isolated from two cases of acute leukemia. One of these strains showed tiny colonies on agar and slight growth capacity. It has been lost after two passages in cell-free media. The second one, which was reisolated on two occasions from two different marrow specimens from the same patient, was serologically related to *Mycoplasma fermentans* as shown by the complement fixation test (table II).

The other two isolated strains were obtained from a case of a pure erythroblastic aplasia and from a case of hypochromic hypochromic anemia, respectively. The strain isolated from erythroblastic aplasia has also been lost after few serial passages in cell-free media. This strain showed on agar colonies of medium size with a center well differentiated from the periphery. The other strain was found to be similar to *Myo-*

Table 1 Attempts to isolate Mycoplasmas from leukemias and other pathological conditions

Diseases	No. of cases	No. of passages performed	No. of strains isolated	Characteristics of the isolated strains
Acute leukemia	17	3	2	LAL V tiny colonies strain, lost in serial passages -C.E. strain serologically related to <i>M. fermentans</i>
Chronic myelocytic leukemia	9	3	0	
Chronic lymphocytic leukemia	6	3	0	
Marrow aplasias	4	2	1	-RI large colonies strain, lost in serial passages
Anemias (of various type)	7	2	1	TAM.A. strain serologically related to <i>M. orale</i>
Plasmacytoma	5	2	0	
Hodgkin's disease	5	2	0	
Lympho- or reticulosarcoma	4	2	0	
Collagen diseases	4	2	0	
Epithelial neoplasms	2	2	0	
Other conditions	12	2	0	
Spleen diseases, hepatic cirrhosis, renal diseases, etc.				

plasma orale both for the characteristics of the colonies and for the serological behaviour as shown by the complement fixation test.

Discussion and Conclusions

The data reported here show that Mycoplasmas could be isolated from bone marrow specimens obtained from leukemic and non leukemic patients in very low percentage. Furthermore, it appears to be no differences in the rate of isolations between leukemic and control materials. It has also to be pointed out, however that the positive

Table II. Serological characterization of *Mycoplasmas* isolated from C. E. (acute leukemia) and from TALLA. (hypochromic anemia)

Sera	Complement fixation test	
	<i>Mycoplasma</i> antigen isolated from C. E.	<i>Mycoplasma</i> antigen isolated from TALLA.
Patient's serum	<10/<10	<10/<10
Anti <i>Mycoplasma pneumoniae</i> (FH)	10/10	<10/<10
Anti <i>Mycoplasma fermentans</i> (FG 18)	40/20	<10/<10
Anti <i>Mycoplasma hominis</i> 1 (FG. 21)	10/10	<10/<10
Anti <i>Mycoplasma hominis</i> 2 (FG. 27)	10/10	<10/<10
Anti <i>Mycoplasma orale</i> ² (Pati)	-	80/40
Anti <i>Mycoplasma</i> P ¹	10/10	<10/<10

All the antisera, except these from patients, have been previously absorbed (1 h at 37°C, 18 h at 4°C, successive centrifugation 2 h at 15,000 rpm) with normal antigens (normal culture medium). The numerator gives the reciprocal of the highest antigen dilution yet positive the denominator the reciprocal of the highest serum dilution yet positive.

From Robbins Lab., Cleveland, N.Y. All other sera have been prepared in rabbits [12].

P strains have been isolated from latently infected amniotic human cells (as shown by positivity of BAXTER and SCHÖNEN's agglutination-inactivation test) when these cell cultures were inoculated with chick embryo materials infected with human leukemic marrow and had shown a clear CPE.

isolation from the case of erythroblastic aplasia cannot be considered as an isolation from a control material owing to the hemato-chemical characteristics of this patient (monoclonal gammopathy disorder)

It seems to us that the low rate of isolation cannot be due to eventual inadequacies of the methods used. In fact, using the same isolation procedures, *Mycoplasmas* could be isolated in MURPHY's Laboratories with high incidence from leukemic patients. Further more, in our laboratories, *Mycoplasmas* have been isolated from the upper and lower respiratory and from genitourinary tracts with relatively high incidence¹

It must be also remembered that, when, in successive studies, the color changing techniques were adapted to the studies of *Mycoplasma*

It has to be pointed out, however that we were unable to propagate in cell-free media three PFLO strains (K_{10} , K_{20} , Z_{10}) received through the courtesy of Dr. ALTUCCI. Only with the K_{10} strain, it was possible to observe some colonies during the first passage on agar. All further attempts to propagate this strain were unsuccessful. This indicates that it is possible to get variable results in different laboratories. Another explanation could be the progressive inactivation the strains underwent to during shipment of the materials to our laboratories.

growth in cell-free media (glucose and phenol red as an indicator for the growth of *M. Pneumoniae* and *M. fermentans* arginine and chresol red for large colonies *Mycoplasma* strains which metabolize this aminoacid) we could often note a lack of correlation between the growth in fluid media, which was positive, and the growth on agar negative. This means that the same test has to be used also in the studies of isolation of PPLO from leukemic materials before the problem can be definitely settled out.

The easy loss of the isolated strains during serial passages further strengthens the idea of the difficult adaptation of the new isolated strains to the cell-free media. The two isolated strains which we were able to propagate in serial passages turned out to be serologically related to *M. fermentans* and *M. orale*, respectively

However no correlation has been found between isolated strains and presence of antibodies in the blood of the patients from which the strains were isolated. These results agree with those of BARILE [6] and MILLIAN and SJOLIND [22] and are in contrast with those of MURPHY *et al.* [24]

From these results a critical conclusion can be drawn on the frequency and the significance of the isolation of Mycoplasmas from leukemias and other malignancies in human pathology. The results obtained by various authors, together with the number of their observations and several of the methodological peculiarities, are summarized in table III. First of all, it appears that the frequency of isolation of Mycoplasmas from tissue of leukemic patients and of patients suffering for other malignancies is higher than that observed in control subjects.

✓ MURPHY *et al.* [24] affirm that Mycoplasmas may cause active infections in leukemic patients, presumably because of decreased host resistance during progression of the disease. They say that Mycoplasmas may play a role in the pathogenesis of leukemia and contribute to its clinical course inciting hyperplastic changes in the spleen, lymphnodes, thymus, bone marrow and also a febrile response and possibly toxemia.

✓ On the contrary SARIN [27] HUEBNER (personal communication) and LEClerc and SILVESTRE [20] consider Mycoplasmas isolated from leukemic tissues as contaminants in patients with a disease which severely impairs host defenses against all the types of infections. The results of most authors and our results seem to support more strongly this last interpretation: especially when considering the general

saprophytism of *Mycoplasma* species isolated from leukemias with frequencies which also seem partially related with the different working laboratories.

Nevertheless, it has to be remembered that phenomena of cellular transformation by *Mycoplasmas* have been reported [21] similarly to what happens with *Polyoma virus*. Anyway the general significance of cellular transformation has not yet been fully understood. Furthermore, it is also well known that non oncogenic viruses (i. e. Myxoviruses [28]) may in particular conditions, determine the same phenomenon.

Among the afore mentioned controversies it has also to be remembered that some authors consider *Mycoplasmas* either as secondary invaders, eventually capable to display a pathogenic action [15-16] or as agents capable to exercise, in association with viruses, a pathogenic synergism [20] or finally as agents that might play a 'helper' role in conjunction with other entities (viruses) [15].

These studies and interpretations open very interesting problems considering the variety and the discrepancies of the results obtained by various authors, it seems to us suitable to remain in a waiting position which does not necessarily imply a complete autognoyny between *Mycoplasmas* and viruses in the etiology of human leukemia. In order to clarify further this problem, we think that investigations on the parallel isolation of both *Mycoplasma* and viruses from the same materials have to be worked out. Researches on this line are now in progress in our laboratories.

During the publication of this work, Sarrin *et al.* (Arch. ges. Virusforsch. 30: 294-1968) have also reported negative results as far as concerns the isolation of *Mycoplasmas* from 107 leukemic patients.

Summary

Attempts have been made to isolate in acellular media *Mycoplasmas* from bone marrow specimens of patients both leukemic and suffering for other diseases.

Two *Mycoplasma* strains were isolated from two acute leukemia cases of 32 studied: one, showing minute and tiny colonies on agar growth, was lost in successive passages; another was serologically related to *Mycoplasma fermentans* and it was isolated twice from two different marrow samples.

Other two *Mycoplasma* strains (large colonies *Mycoplasma* *Mycoplasma orale*) were isolated from two cases of erythroblastic: plasia and hypochromic anemia, respectively.

The data reported show that *Mycoplasmas* could be isolated from bone marrow specimens obtained from leukemic and non leukemic patients in very low percentage. Furthermore it appears to be no differences in the rate of isolations between leukemic and non leukemic materials.

Department of Clinical Pathology Royal Victoria Hospital, Belfast

The *in vitro* Uptake of ^{35}S L-Methionine by Normal and Leukaemic Leucocytes

KATHERINE M. SLOAN and J. M. BRIDGES

The present paper reports some observations on the *in vitro* uptake of methionine labelled with ^{35}S and its incorporation into protein by leucocytes from normal subjects and patients with various types of leukaemia. This study followed from the observation that patients with leukaemia had an increased level of methionine in the urine [5]. One of the important biological functions of this amino acid is to act as a methyl group donor in the metabolism of vitamin B₁₂ [9] and studies were carried out on the influence of the level of this vitamin on the methionine uptake. It has been found that subjects with chronic myeloid leukaemia have an increased serum level of vitamin B₁₂ [3, 6, 10] and their leucocytes contain more S-adenosyl methionine than do those of normal subjects [2].

Materials and Methods

Healthy laboratory personnel served as control subjects.

Twenty patients with leukaemia, all but one of whom were adults, were studied. Of these 8 had acute, 6 had chronic myeloid and 6 had chronic lymphatic leukaemia. Blood from these subjects was tested on many occasions, at various stages of their illness, and while they were being treated with a variety of chemotherapeutic agents.

Leucocyte suspensions were prepared from blood anticoagulated with EDTA (10 ml blood to 0.2 ml 10% dipotassium sequesteric acid), by incubation at 37°C for approximately 60 min. The supernatant plasma was harvested and the leucocyte count determined. This was adjusted either by dilution, with autologous leucocyte free plasma, or concentration by centrifugation so that it lay within the range of 7,000 to 12,000 cells/mm³.

One ml of this suspension was incubated with 0.5 ml 0.135 µg/ml non-radioactive methionine and 0.1 ml ^{35}S methionine (0.05 mCi/100 ml) in a stoppered, graduated 10 ml tube for 120 min at 37°C. The reaction was then stopped by immersing the reaction vessel in ice cold water for 5 min. The leucocytes were then separated by centrifugation at approximately

300 g for 10 min and the supernatant discarded. The leucocyte button was mixed with 5 ml ice cold distilled water. 30 sec later 5 ml EDTA iminazole buffered saline (10 g succinate acid and 3 g iminazole in 1 l, 0.9% saline) was added; this caused lysis of the remaining red cells. The cells were again deposited by centrifugation and washed with 10 ml buffered saline (10 g EDTA and 3 g iminazole in 2 l, 0.9% saline) after which they were resuspended in 1 ml of this solution.

After incubation and washing, an aliquot of the final suspension was removed for a white cell count and 0.2 ml was placed in counting vial with 10 ml scintillation fluid (3 g PPO, 2.5-Diphenylloxazole, 0.3 g Dimethyl POPOP 1:4:1 [2-(4-Methyl-5-Phenyl)-oxazole]) Benzene, 750 ml Toluene and 250 ml Ethanol) and 0.5 ml hydride of hyamine. The radioactivity was counted in Packard Tricarb scintillation counter.

With each experiment a high standard (0.1 ml ^{35}S methionine, 0.5 ml hydride of hyamine and 10 ml scintillation fluid) low standard (0.1 ml non-radioactive methionine, hyamine and scintillation fluid, as above) and blank (0.5 ml hyamine and 10 ml scintillation fluid) were counted. In the calculation of results from counts thus obtained, allowance for quenching effect was omitted, since the composition of the contents of each vial were similar.

The results were expressed as pg of methionine taken up per million cells. These were calculated using the formula

$$0.0135 \times \text{counts/minute of suspension} \times 10^6 / \left\{ \begin{array}{l} \text{counts/minute} \\ \text{for high standard} \end{array} \right\} \times \left\{ \begin{array}{l} \text{white cell count/ml} \\ \text{of suspension} \end{array} \right\}$$

In order to establish the optimum conditions for the uptake of methionine by human leucocytes, the cells were incubated at temperatures of 4°C, 20°C, 37°C and 56°C. This, and an experiment in which the reaction was carried out in the presence and absence of 1 drop of formalin, were also performed to illustrate that the uptake of ^{35}S methionine is an active process.

To show the effect of added vitamin B₁₂, the above reaction was carried out on cells which had been incubated with 0.1 ml cyanocobalamin (0.5 µg/ml) for 60 min at 37°C prior to the addition of methionine.

In experiments in which the incorporation of ^{35}S methionine into the protein of the cells was studied, 0.2 ml of the final white cell suspension was added to 1 ml of 15% ice cold trichloroacetic acid (TCA) and the resulting precipitate separated off by centrifugation at approximately 1500 g for 10 min.

The precipitate was washed in 1 ml of fresh ice cold TCA and then in 1 ml of ethanol before being dissolved in 1 ml hydride of hyamine and 10 ml scintillation fluid. This was treated similarly to other radioactive samples for counting.

Vitamin B₁₂ levels were measured using *Lactobacillus leichmannii* and folic acid levels were measured by the method of WATERS and MOLLER [11].

Results

The uptake of ^{35}S methionine in pg/million cells by the leucocytes from normal subjects and those with acute, chronic myeloid and chronic lymphatic leukaemia is illustrated in figure 1. For the normal subjects this varied from 5.5 to 21.3 pg/million cells. These subjects all had whole blood white cell counts, serum folic acid and vitamin B₁₂ levels within the normal range and there was no correlation between the uptake of methionine and these parameters.




Fig 1 Scattergram illustrating the uptake of ³⁵S methionine by normal and leukaemic leucocytes.

One of the subjects with acute leukaemia was in complete remission at the time of study and the uptake by his white cells was 7.0 and 4.7 pg/million cells, tested on separate occasions. In the remaining subjects with acute leukaemia the uptake varied from 9.2 to 328.0 pg/million cells (table I). There is no obvious correlation between the level of methionine uptake and the peripheral blood leucocyte count in our subjects with acute leukaemia.

The cells from our patients with chronic lymphatic leukaemia exhibited an uptake mostly within the normal range, there being only two which showed a slightly raised methionine uptake. As in the case

Table I. Whole blood leucocyte count compared with uptake of ^{35}S methionine by cells from patients with acute leukaemia

Subject No.	Leucocyte count/mm ³	Uptake pg/million cells
1	5,600	7.07
	4,400	4.74
2	22,000	9.37
	90,000	29.56
3	—	29.0
	1 150	75.31
4	82,000	328.1
5	—	18.95
	78,000	188.5
	5,800	79.97
6	27,000	20.63
7	16,000	22.1
8	64,000	32.74

Table II. Whole blood leucocyte count compared with ^{35}S methionine uptake by cells from chronic lymphatic leukaemia patients

Subject No.	Leucocyte count/mm ³	Uptake pg/million cells
9	304,000	6.9
10	35,600	11.7
	30,500	15.0
11	48,400	17.4
	8,000	24.7
12	11 400	7.9
13	5,100	14.2

of the acute leukaemics, no relationship could be observed between the peripheral blood white cell count and methionine uptake (table II)

The uptake, which in each individual with chronic myeloid leukaemia was tested on several occasions, varied greatly (table III). Thus uptake did not correlate with the serum vitamin B₁₂ and folic acid levels, nor with the white cell count of the whole blood, nor could it be related to any pattern in regard to the patient's clinical state or therapy.

Table III. Chronic myeloid leucocyte uptakes and their correlation with whole blood leucocyte count B₁₂ level and folic acid level

Patient No.	Leucocyte count cells/mm	Uptake pg/million cells	B ₁₂ pg/ml	Folic acid ng/ml
15	-	24.7	1,000	4.4
	13,700	13.7	2,742	6.5
	10,800	13.43	1,164	6.4
	11,400	16.87	1,269	5.3
	9,800	17.68	1,371	8.0
	-	14.19	1,227	9.2
16	13,900	7.16	7,000	5.8
	11,200	9.78	2,619	-
	10,200	-	1,800	8.3
	7,600	8.8	>3,000	5.7
17	29,800	6.38	>3,000	4.2
	30,000	6.61	3,000	6.2
	-	24.49	-	-
	14,400	18.79	4,500	5.1
	16,300	27.7	6,900	-
18	19,900	31.7	343	4.5
	-	53.0	843	13.9
	21,300	32.19	567	8.7
	26,500	32.99	732	8.0
19	15,100	3.28	1,098	4.3
	17,900	11.06	-	-
	20,800	10.91	1,980	5.5
	24,400	13.86	1,575	2.4
20	13,500	84.7	1,920	4.5
	14,200	4.37	2,772	4.2
	-	6.82	2,725	4.5
	13,000	22.64	3,075	3.5

The relationship between the incubation temperature and methionine uptake is shown in table IV. A considerable variation occurs in the methionine uptake at different temperatures, with an optimum uptake at 37°C.

When the uptake test was performed on cells fixed with formalin and on live cells from the same population (table V) the live cells gave normal readings but the fixed cells gave results which were very similar to that of the low standard.

The results of the experiment on the incorporation of methionine into the proteins of the white cells indicate that approximately 30%

Table IV Effect of incubation temperature on uptake of methionine

Subject No.	Uptake, pg/million cells			
	37°C	21°C	37°C	55°C
Normal				
14	—	7.99	21.28	13.04
Chronic myeloid leukaemia				
15	3.10	7.32	12.03	—
16	1.93	5.84	10.91	—
17	8.97	13.96	17.00	—
18	2.75	5.88	24.49	—
19	2.32	5.94	13.45	0.60
Mean	3.85	7.79	15.57	0.68
Acute leukaemia				
21	6.70	15.01	29.56	0.39
22	5.58	18.01	29.00	—
Mean	6.14	16.51	29.28	0.39

Table V Comparison of 35 S methionine uptake by live leucocytes and formalin fixed cells from the same population

Uptake by live cells pg/million cells	Uptake by fixed cells pg/million cells
6.929	0.864
5.005	0
5.15	0.7
6.17	0.02
3.76	0.04

of the methionine taken up by the white cells is incorporated into the protein within the two hour incubation period (table VI)

In table VII is set out the uptake of methionine following the addition of vitamin B₁₂

DISCUSSION

The method employed in the present work was very similar to that used by WENZGROB *et al.* [13] who found the methionine uptake by normal leucocytes to be 23 100 counts/min/ml packed leucocytes.

Table VI. Uptake of methionine ³⁵S by white cells compared with its incorporation into protein by cells of the same population

Test No.	Uptake pg/million cells	Incorporation into protein pg/million cells	% total uptake incorporated in protein
1	84.07	28.02	33.2
2	109.53	35.74	32.8
3	8.456	2.579	30.2
4	9.56	3.073	32.5
5	21.28	5.81	27.4
6	8.92	2.27	25.5
7	9.33	2.93	31.4
8	18.2	5.67	31.1
9	4.0	1.14	28.5

Table VII. Comparison between uptake of ³⁵S methionine by leucocytes in presence or absence of added vitamin B₁₂

Test No.	Uptake without added B ₁₂	Uptake with added B ₁₂	Serum B ₁₂ pg/ml
Normals			
1	12.40	15.95	396
2	10.58	12.25	392
3	9.73	12.29	-
4	15.28	16.44	519
5	6.86	7.84	374
Acute leukaemia			
1	9.48	8.03	597
2	11.71	11.68	156
3	19.25	18.60	> 600
4	15.34	14.73	-
5	16.82	15.70	876
6	16.40	15.39	-
Chronic lymphatic leukaemia			
1	7.07	7.89	2,790
2	19.42	13.02	-
3	7.89	8.05	1,883
4	13.79	14.76	259
Chronic myeloid leukaemia			
1	6.15	10.64	3,000
2	10.51	11.89	-
3	27.72	28.22	-
4	12.09	15.33	2,742
5	3.76	5.03	2,772
6	5.83	7.58	3,000
7	8.78	10.78	2,619

Using appropriate data given by these authors, this would be equivalent to approximately 10.01 pg methionine/million cells, a result very similar to ours. At 37°C the uptake was definitely greater than at the other temperatures, not only for normals, but also for subjects with leukaemia. WEISSBERGER and LEVINE [12] also found 37°C to be the optimum temperature for methionine uptake.

When formalin was added to the leucocyte suspension prior to the addition of methionine, the uptake of methionine was greatly impaired. These results would suggest that under the conditions of these experiments the uptake of methionine is predominantly due to an active transport process. HELMREICH and KUPITS [4] studied the uptake, by lymph node cells, of an amino acid analogue, 'which has a common transport system with methionine' and found that the mechanism of uptake was dependent on the concentration of the amino acid.

Our subjects with acute and chronic myeloid leukaemia showed different patterns of methionine uptake to that of the control subjects, whereas those with the chronic lymphatic type of disease were essentially similar to the controls. The subjects with acute leukaemia, not in complete remission, showed a higher than normal uptake and in one instance of a child with acute leukaemia, this was of the order of 15 times greater than that shown in any control.

In patients with chronic myeloid leukaemia we found that the level of uptake tended to be higher than normal, but the most striking feature was the variation, not only from patient to patient, but in the same patient tested on separate occasions. This could not be correlated with the clinical status, therapy or peripheral blood leucocyte count. In the majority of our patients the vitamin B_{12} level was greatly raised, being similar to those reported by other authors [3, 6, 10]. However the B_{12} level could not be associated with any pattern in methionine uptake and the addition of this vitamin *in vitro* had no effect on the degree of methionine uptake.

We studied the incorporation of ^{35}S methionine into protein in nine of the subjects under observation and correlated this with their level of methionine uptake. The incorporation in all cases studied, when expressed as a percentage of the uptake, showed a remarkably constant relationship being in all cases very close to 30%. Other authors have studied the incorporation of amino acids into the protein of leucocytes, but none appear to have observed a direct relationship between the amount taken into the cell from the surrounding medium and the proportion of this incorporated into protein [1 7 8].

The phenomenon of uptake and incorporation of amino acids by leukaemic leucocytes may be of practical import in the near future, because of the demonstration that the sensitivity of the leukaemic cell to treatment with L-asparaginase may be predicted from its 'handling' of amino acids.

Acknowledgements

We are indebted to Dr M. G. NELSON and Dr G. L. GIBSON for help with this work and to Miss DEBORAH BOLGER and Miss ROSALEE NIMLOCK for their skilled technical assistance.

Miss SLAANE is a Research Fellow of the Northern Ireland Leukaemia Research Fund, whose generous financial support allowed this work to be carried out.

Summary

The *in vitro* uptake of ^{35}S methionine by leucocytes from 15 control subjects and 20 subjects with leukaemia was studied. Leucocytes from patients with acute and chronic myeloid leukaemia had greater than normal uptake and for the subjects with chronic myeloid leukaemia this varied considerably from time to time. No correlation could be demonstrated with the level of serum B_{12} and the addition of this vitamin *in vitro* did not influence the level of uptake. Uptake was greatest at 37°C and did not occur in the presence of formalin. The amount of ^{35}S methionine incorporated into the protein of the cell was remarkably constant for the normal and leukaemic cells.

References

1. BAKER, W. H., ZAMECHK, P. C. and STEINBERG, M. L. *In vitro* incorporation of ^{14}C -DL-Leucine into normal and leukaemic white cells. *Blood* 12: 822-828 (1957).
2. BALOGHBIRO, R. J. and BELL, W. R. Methionine-activating enzyme and catechol-O-methyl transferase activity in normal and leukaemic white blood cells. *Nature, Lond.* 208: 78 (1965).
3. BRAND, M. P.; FITNEY, W. R. and SANDHEAN, E. H. Serum concentrations of Vitamin B_{12} in patients suffering from leukaemia. *Blood* 9: 789 (1954).
4. HELMREICH, E. and KIRBY, D. M. Amino acid transport in lymph node cells. *J. biol. Chem.* 237: 262 (1962).
5. LEE, M. B.; NEILL, D. W. and BARON, J. M. Urinary amino acid excretion in subjects with leukaemia. *J. clin. Path.* 20: 70 (1967).
6. MOLLIN, D. L. and KIM, O. I. M. Serum Vitamin B_{12} concentrations in leukaemia and in some other haematological conditions. *Brit. J. Haemat.* 1: 155 (1955).
7. NADLER, S. B., HANSEN, H. J.; SPRAGUE, G. C. and BERENMAN, H. The effect of 6-Mercaptopurine on the incorporation of labelled amino acids into cellular protein of chronic granulocytic leukaemia leucocytes. *Blood* 18: 336-342 (1961).
8. PROCTA, A. V.; BARR, S. N.; DALY, M.; RUTWALDT, M.; OLIVER, M. and METZGER, G. O. Studies on agranulocytosis. II. The effect of chlorpromazine upon the influx of ^{35}S L-cysteine and L-methionine into human leucocytes. *Blood* 16: 1436-1468 (1960).
9. TAKAYAMA, S., HATCH, P. T. and BUCHANAN, J. M. Enzymatic synthesis of the methyl group of methionine. II. Involvement of Vitamin B_{12} . *J. biol. Chem.* 236: 1102 (1961).

10. THOMAS, J. W. and ANDERSON, R. R. Vitamin B₁₂ content of normal and leukaemic leucocytes. *Brit. J. Haemat.* 2, 41 (1956).
11. WATERS, A. H. and MOLLER, D. L. Studies on the folic acid activity of human serum. *J. clin. Path.* 14, 335 (1961).
12. WEISSBERGER, A. S. and LEVINE, R. Incorporation of radioactive L-cystine by normal and leukaemic leucocytes *in vivo*. *Blood* 9, 1082 (1954).
13. WEISSBERGER, A. S.; SCHERLAMO, L. G. and GROSS, R. C. Incorporation of radioactive L-cystine and L-methionine by leukaemic leucocytes *in vivo*. *Blood* 9, 1095 (1954).

The Hematology Research Laboratories, York Hospital, York, Pa.

The Mononucleosis and Leukemic Cell

II. RNA Synthesis

H. R. SCHUMACHER, A. E. McFEELY and T. K. MAUGEL

In previous studies [1] ribonucleic acid (RNA) synthesis in infectious mononucleosis was shown to be increased in the peripheral atypical lymphocytes at the onset of the disease when compared to normal controls. This increased synthesis declined with a corresponding decrease in atypical lymphocytes. RNA synthesis in acute leukemia was also increased in some leukemic cells, but was variable during the illness in the blast cells of the same patient and among patients with a similar type of leukemia [2, 3]. Also aberrant cytoplasmic RNA synthesis suggested differences between the benign and the malignant disorder [4]. To study further the difference of RNA synthesis between leukemic and mononucleosis leukocytes, actinomycin D was used in this investigation.

Methods and Materials

Fifteen acute leukemias were diagnosed from clinical findings, peripheral blood and bone marrow examination. Seven had acute lymphoblastic, 4 acute monocytic, 3 acute myelocytic, and 1 acute eosinophilic leukemia. When possible serial studies were performed at onset, onset after induction, remission, relapse and during the terminal state of the disease.

Eleven patients with infectious mononucleosis were diagnosed from clinical, serological, and peripheral blood findings. All were investigated early in the disease process when the percentage of atypical lymphocytes was greatest. Twelve normal individuals were used as controls.

Twenty ml of venous blood were divided in the following manner: 4 ml of blood were placed into 3 sterile plastic tubes, each containing 0.5 ml of 10% dextran in 5% glucose, and

This investigation was supported by Public Health Service Research Grants CA 08245-01 and CA 08245-02 from the National Cancer Institute.

Presented in part at the International Infectious Mononucleosis Symposium, Washington, D.C. March 27-28, 1967

0.5 ml of 1% EDTA in 1.4% saline. One tube contained 5 μ Ci of tritiated uridine (specific activity 5.0 Ci/mm) and was incubated for 1 h at 37°C. The remaining four tubes were incubated for 1 and 2 h with and without actinomycin D³ before tritiated uridine was added. The final concentration of the drug was 5 μ g/ml. After 1 h incubation with tritiated uridine, the leukocytes in the supernatant were prepared for radioassay as previously described [3]. The results were expressed as disintegrations per minute per 10⁶ leukocytes. After logarithmic transformation, the differences between the samples, unexposed and exposed to actinomycin D, were analyzed by means of DUNNAN's method for all possible comparisons of means [5]. Since the leukemic leukocytes showed no significant difference among stages II depression of uridine incorporation by actinomycin D, they were combined into one large group for analysis.

Prior to preparation for liquid scintillation counting, autoradiographic studies were performed on the leukocytes incubated for 2 h with and without actinomycin D according to modified technique of BORN and co-workers [6, 7]. Five hundred mononuclear cells were counted and the percentage of labeled cells was determined. Background counts were evaluated and only cells containing greater than 4 grains were considered labeled. For each patient, the ratio of percentage labelling with actinomycin D to percentage labelling without actinomycin D was calculated. For each group, the geometric means of these ratios in percentage form was calculated as a measure of central tendency for the group.

Results

Clinical information. In patients with infectious mononucleosis the atypical lymphocytes ranged from 24–88%.

The white blood counts of the leukemic patients were in a comparable range to the infectious mononucleosis group. Also, in most instances, the number of blast cells did not account for the majority of cells observed. Not all patients were studied in each stage because of the nature of the disease.

Liquid scintillation. Sixty three liquid scintillation studies were performed on 12 normals, 11 mononucleosis and 15 leukemic patients. In normal subjects the proportion of disintegrations with actinomycin D at 2 h was 11% of that without the drug (geometric mean). In infectious mononucleosis patients this value was only 2%. In acute leukemic patients the result was 20%. As a measure of subject to subject variation within groups, the average coefficient of variation was 42% of these geometric mean values.

In figure 1 the ratio of results for the actinomycin treated to those for untreated leukocytes is depicted for normals, infectious mononucleosis and leukemic leukocytes. The depression of uridine uptake by the drug into leukemic leukocytes at 1 h was significantly less than either normal or infectious mononucleosis leukocytes ($P < 0.05$ and $P < 0.001$ respectively). After 2 h of inhibition with actinomycin D




Fig 1 Ratio of results for actinomycin treated leukocytes to untreated leukocytes for the three groups.

the leukemic leukocytes continued to show less depression than those of mononucleosis ($P < 0.001$). However no significant difference in depression was noted after 2 h exposure to the drug between normal and leukemic leukocytes.

Overall evaluation of the entire experiment revealed differences in depression of tritiated uridine incorporation between leukemic and mononucleosis leukocytes, and between leukemic and normal leukocytes ($P < 0.001$ and $P < 0.05$ respectively). There was also a greater depression in mononucleosis leukocytes when compared to normal white cells ($P < 0.001$).

Autoradiography Fifty-seven autoradiographic studies were performed on 10 normals, 9 mononucleosis and 13 leukemic patients. The average grains in the mononucleosis and leukemic leukocytes were much greater than normal controls. The ratio of cells labeled with and without drug exposure at the two hour period was expressed as a geometric mean and was significant for normal ($P < 0.01$), mononucleosis ($P < 0.01$) and leukemic groups ($P < 0.05$). The predominant cell labeled for mononucleosis patients was the atypical lymphocyte. In leukemics the blast cell in general showed heavier labeling but was not the predominant cell labeled. In the majority of stages (onset, onset after medication and relapse) the reduction in cell labeling was less for blasts than non-blasts.

Discussion

Actinomycin D has been demonstrated to inhibit selectively cellular DNA directed synthesis of RNA by attaching to the guanine residues [8, 9]. The drug also inhibits RNA synthesis of most DNA viruses, but permits normal or supranormal growth of most RNA viruses [8].

The marked decline in uridine incorporation, noted after mononucleosis cells were exposed to the drug, needs explanation. It would appear from the abundant number of mononucleosis cells and autoradiographic data that the drug effect was greatest in the atypical lymphocyte. Virtually nothing concerning DNA structure of mononucleosis leukocytes or drug permeability of such cells is known to explain this result. However NIEDERMAN *et al.* [10] have recently shown that a herpes-like virus may be the etiologic agent of this disease. Such herpes-like viruses have been observed in cultured cells derived from patients with infectious mononucleosis [11]. Similar viruses obtained from Burkitt lymphoma cell lines have been shown to contain DNA [12]. Also REINAUER [13] has observed particles having the morphology of viruses in the cytoplasm of a few mononucleosis cells. The presence of viral activity on a phynologic basis was further suggested by the autoradiographic results of SCHUMACHER *et al.* [14] who, using tritiated thymidine, demonstrated aberrant grains of possible viral origin in a few mononucleosis cells.

In leukemia, due to small sample size, we were unable to demonstrate statistically that the resistance was of blast cell origin. However in the majority of stages of leukemia, the blast cell showed the greatest resistance to the drug. This is supported by the findings of STORRI and TORRELLI [15] who showed that RNA synthesis in leukemic blasts was less inhibited by actinomycin D than in normal myeloblasts or myelocytes. This finding cannot be explained on the basis of DNA structure [16, 17] nor can it be explained on the basis of drug action unrelated to RNA synthesis [16].

Variations in permeability of the drug could account for the result. KENZEL [19] demonstrated no difference in penetrance of the drug in normal and leukemic leukocytes, but retention was less in resistant leukemic cells. This might explain our results, but needs clarification by further experimentation on drug binding.

Since the growth of most DNA viruses is suppressed by actinomycin D [8] our findings cannot be explained by such an organism. However uridine incorporation by an RNA virus would not ordinarily be

inhibited by the antibiotic [8]. At the present time four viruses have been associated with human leukemia [20]. One is the herpes-like virus similar to the one previously described in mononucleosis. The other three belong to groups which are known RNA viruses [21]. If leukemia is a viral disease, viruses of these latter groups would best explain the findings in this investigation.

Acknowledgment

The authors are indebted to Professor HYMAN MADONN, Department of Biostatistics at Jefferson Medical College for statistical aid in the preparation of this manuscript. They are also indebted to Mrs. BEVERLY REDDOLLAR for her secretarial assistance.

Summary

In vitro studies employing autoradiographic and liquid scintillation techniques on leukocytes from 12 normal individuals, 11 patients with infectious mononucleosis, and 15 patients with acute leukemia were performed. The incorporation of tritiated uridine into the peripheral blood leukocytes of these groups was studied with and without exposure to actinomycin D. As shown by quantitative results, the incorporation of tritiated uridine into mononucleosis leukocytes was depressed more by actinomycin D than were the other groups. Autoradiographic results showed that the mononucleosis cells were those markedly depressed by the drug. The incorporation of tritiated uridine into leukemic leukocytes was depressed less by the drug than were the other groups. The leukemic blast cell may have been responsible for the quantitative abnormality.

References

1. EPERON, L. B. and BIRCHES, G. DNA and RNA synthesis of circulating atypical lymphocytes in infectious mononucleosis. *Blood* 25: 197 (1965).
2. SCHUMACHER, H. R.; GOSWOOD, J. J.; SALLON, G.; FORTZ, P. R. and LARSEN, C. E. Observations on the metabolism of peripheral leukocytes in acute leukemia. II. Uridine and phenylalanine incorporation. *Amer. J. med. Sci.* 250: 448 (1965).
3. SCHUMACHER, H. R. and SALLON, G. Serial observation on the metabolism of peripheral acute leukemic leukocytes. *Cancer* 18: 819 (1965).
4. SCHUMACHER, H. R.; HOOVER, R. A.; McFARLEY, A. E. and MADONN, T. K. Infectious mononucleosis: Hematology and relation to blood dyscrasias. International Infectious Mononucleosis Symposium, Washington, D.C. March 27, 1967 (in press).
5. HARTIG, H. L. Critical values for DUNCAN's new multiple range test. *Biometrics* 16: 671 (1960).
6. BORN, V. P.; CROWTHER, E. P.; FLETCHER, T. M. and SCHWARTZ, P. Deoxyribonucleic acid synthesizing cells in peripheral blood of normal human beings. *Science* 123: 702 (1958).
7. BORN, V. P. et al. Proliferative potentials of bone marrow and blood cells studied by *in vitro* uptake of ³H-thymidine. *Acta haemat., Basel* 21: 1 (1959).

8. REICH, E. and GOLDBERG, I. H.: Actinomycin and nucleic acid function in D. VIDUOS and CORN's Progress in nucleic acid research and molecular biology p. 183 (Academic Press, New York 1964)
9. GOLDBERG, I. H., RAMSOVITZ, M. and REICH, E. Basis of actinomycin action. I. DNA binding and inhibition of RNA-polymerase synthetic reactions by actinomycin. Proc. nat. Acad. Sci. 48: 7094 (1962)
10. NITTERMANN, J. C.; MCCOLLUM, R. W.; HEDLE, G. and HEDLE, W. Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies. J. Amer. med. Ass. 203: 205 (1968)
11. HEDLE, G., HEDLE, W. and DUEHL, V. Relation of Burkitt tumor associated herpes type virus to infectious mononucleosis. Proc. nat. Acad. Sci. 59: 94 (1968).
12. JULIUS HOROWITZ: Roswell Park Memorial Institute, Personal communication.
13. REINKAUF, H. Morphologische Befunde und Lymphknoten bei infektiöser Mononukleose. Virchows Arch. path. Anat. 132: 56 (1939).
14. SCHUMACHER, H. R.; MUGGER, R. B.; McFARLEY, A. E. and MAHONY, T. K.: The infectious mononucleosis cell. I. DNA synthesis. Acta haemat., Basel 38: 257 (1967)
15. STORST, E. and TORRELLI, U. RNA and protein metabolism in normal and leukemic leukocytes, as studied by autoradiography in HAYSON's Current Research in Leukemia, p. 121 (Cambridge University Press, New York 1965)
16. CORNIO, G.; BRASCHI, M.; ORSILLI, E. and PULLI, E. Heterogeneity of base composition of DNA extracted from human leukemic leukocytes. Europ. J. Cancer 2: 307 (1966)
17. HAMILTON, L. D. *et al.*: Similarity of the structure of DNA from variety of sources. J. biophys. biochem. Optol. 5: 397 (1939)
18. LASKO, J.; MILLER, D. S.; MCCARTHY, K. S. and HOCHSTEIN, P. Actinomycin D: Inhibition of respiration and glycolysis. Science 151: 1007 (1966)
19. KEMMEL, D. Personal Communication - Children's Cancer Research Foundation, Inc. Boston, Mass.
20. VETLA, M. V. *et al.*: Virus-like particles in patient with chronic lymphatic leukemia. New Engl. J. Med. 277: 503 (1967)
21. GREEN, M. Major groups of animal viruses; in HORSWALL and TAN' Viral and Rickettsial Infections of Man, p. 12 (Lippincott, Philadelphia 1963)

2nd Medical Unit, Evangelismos Hospital, Athens

Modes of Presentation of Thalassaemia minor

C. GARDIKAS

This short paper describes the various clinical pictures under which patients with thalassaemia minor came to seek medical advice. Patients with the anomaly known prior to their first visit have not been included. The present material consists of 260 patients seen in my wards and my private practice during the last ten years. Mainly adults are included, as children are usually referred to pediatric units or to consultant pediatricians. There were 140 males and 120 females; their age varied from 16 to 62 years. The laboratory criteria for establishing the diagnosis of thalassaemia minor were: Morphological changes of the erythrocytes, increase of HbA₂ above 3.8%, increased serum iron and frequently presence of HbF.

I Anaemia. 123 patients came for anaemia of unknown origin, the Hb-level varying from 7.5 to 11.5 g/100 ml. Many of these patients were previously treated for iron deficiency anaemia, naturally without success: it was for this refractoriness to iron treatment that they were referred. Table I gives the distribution of the Hb levels of these patients.

Table I. Hb levels on 123 patients with thalassaemia minor

g Hb/100 ml	Number of patients
7-8	6
8-9	16
9-10	25
10-11	52
> 11	24

2 *Splenomegaly* 14 patients were referred on account of a splenomegaly found by their doctor on a routine examination.

3 *Hepatomegaly* In 32 patients the presenting finding was hepatomegaly of various degree. Flocculation tests were occasionally abnormal, but the transaminase levels were within normal limits.

4 *Episodes of mild jaundice* 16 patients came with a history of repeated attacks of mild jaundice. Some of them were considered as suffering from mild chronic hepatitis, whilst some others came with a diagnosis of congenital hyperbilirubinaemia.

5 *Loss of energy and lassitude* 12 patients complained of fatigue and lassitude. As the ordinary blood test had shown no significant anaemia, the complaints were attributed to psychoneurosis. There was no correlation between the Hb-level and the intensity of the symptoms. The lack of energy could perhaps be attributed to impaired synthesis of the various intracellular iron-containing enzymes (cytochrome, peroxidase, etc.) Information regarding the disturbance of these enzymes in thalassaemic syndromes is very scanty.

6 *Gall stones* 22 patients came on account of gall stones. The young age of most of these patients was suggestive of a chronic haemolytic condition.

7 *Mild pyrexia* 5 patients were referred for mild pyrexia (98.6–99.2 F) for which no cause was found in spite of a complete laboratory and radiological investigation. Most patients were young. There is no plausible explanation for this mild pyrexia in thalassaemia minor.

8. *Erythrocytosis* 4 patients were referred for erythrocytosis with RBC counts varying from 6 to 6.5 millions/mm³. Two of them were thought of suffering from polycythaemia vera. Naturally all these four patients had an Hb level below normal and the mean corpuscular haemoglobin was characteristically low. Erythrocytosis in a few patients with thalassaemia minor is a known fact.

9 *Leucocytosis* 4 patients were referred because their white cell count was constantly raised, varying between 10,000 and 13,000/mm³. These patients had already undergone a thorough laboratory investigation for detection of the cause of the leucocytosis, but this had remained obscure. It seems probable that the raised activity of the bone marrow brought about by the increased rate of haemolysis was the cause of the leucocytosis.

10 *Premature beats* 2 persons aged 32 and 45 respectively had been suffering from extrasystoles. Complete physical examination was negative, and the ECG apart from ventricular premature beats

Table II The presenting disturbance which led to the diagnosis of thalassaemia minor in 260 cases

Symptoms or signs	Number of Patients	%
Anaemia	123	47
Splenomegaly	14	5.4
Hepatomegaly	32	12.3
Jaundice	16	6.2
Loss of energy and lassitude	12	4.6
Gall stones	22	8.5
Mild pyrexia	5	1.9
Erythrocytosis	4	1.5
Leucocytosis	4	1.5
Extrapyknots	2	0.8
Accidental findings	26	10

showed no abnormality. One might surmise that a certain degree of haemochromatosis of the heart is the cause of this disturbance. The heart failure which often is the cause of death in thalassaemia major is attributed to haemochromatosis of the cardiac muscle, the excessive erythropoiesis in the overactive marrow itself stimulating the bowel to over-absorption of iron which causes its deposition in the tissues [LEIDMANN].

11 Finally there were 26 cases who came with various complaints, the detection of the thalassaemic trait being completely accidental.

Table II summarises the various disturbances which led to the diagnosis of thalassaemia minor.

Summary

The clinical modes of presentation of thalassaemia minor in 260 Greek adult patients are given.

Reference

LEIDMANN, H. Thalassaemia. *Acta haemat.* 36: 257 (1966)

Department of Clinical Therapeutics, University of Athens (Director Prof. B. SALAMONIS)
and Radioisotope Laboratory Alexandra Hospital, Athens

Reticulocyte and Normoblast Labelling with Leucine - ^3H in Thalassaemic and non Thalassaemic Subjects

M. KESSE ELIAS, E. GYFTAKI, V. ALEVIZOU TERZAKI and
A. KOUKOULOMIATI

The purpose of the present work is to study by autoradiography in thalassaemic immature red cells, appearing in the peripheral blood, the capacity to synthesize haemoglobin and compare the data with those of non thalassaemic subjects. In the peripheral blood of thalassaemic patients the presence of nucleated red cells, in addition to a high number of reticulocytes, is a characteristic finding [9]. Non thalassaemic patients with immature forms of the red series in their peripheral blood were selected for comparison.

During the course of maturation erythroid cells lose the ability to synthesize DNA and to divide and their nucleus is lost [5]. It is known further that in reticulocytes after the loss of the nucleus, protein synthesis continues, and that the synthesized protein is haemoglobin. The three types of RNA known to play a role in protein synthesis must be present in reticulocytes. Since no synthesis of new RNA occurs in reticulocytes, RNA synthesized in the nucleus and migrating to the cytoplasm is retained in the cytoplasm after the loss of the nucleus [6]. Any reticulocyte, coming from a normoblast, has therefore a supply of RNA in its cytoplasm.

The basophilic network, which appears in the reticulocytes after supravital staining, contains RNA [3] and it is likely that throughout the life of the reticulocyte there is a gradual decrease in the amount of RNA containing reticulum with a slowing down of protein synthesis [6].

The present study has been performed *in vitro*. In order to follow haemoglobin synthesis, peripheral blood was incubated with leucine - ^3H and the smears were autoradiographed.

Table 1. Hematological data (continued)

Case No.	Age, years	Sex	Hematological status	Hb g %	RTC %	Nucleated red cells /100 white cells	Erythroblasts with traces of basophilic ribbons, %	Orthochromatic erythroblasts, %	Hb leucophorens
15	30	F	Thalassemia major splenectomy	6.8	3.1	4.0	0	100.0	A, A ₂ P 40%
16	16	F	Thalassemia major splenectomy	6.8	11.4	376.0	21.8	97.2	A, A ₂ P 80%
17	9	F	Thalassemia major splenectomy	7.4	8.4	594.0	21.5	77.7	A > P A ₁
18	7	M	Thalassemia major splenectomy	8.4	6.5	250.0	8.4	91.6	A ₂ P > A
19	10	F	Thalassemia major splenectomy	9.0	3.0	20.0	22.5	77.5	A, A ₂ P 60%
20	27	F	Sickle cell-Thalassemia, splenectomy	8.7	17.6	345.0	9.7	90.3	S > P A
21	28	F	Spleen hypoplasia	8.8	1.5	20.8	100.0	0	
22	36	M	Acute leukemia	9.5	2.1	3.4	29.0	61.0	
23	48	F	Posthemorrhagic anemia	8.0	1.8	1.0	66.6	33.3	
24	46	M	Refractory anemia	6.0	3.6	4.0	80.5	19.5	
25	23	M	Peliosis	6.7	7.8	5.0	75.0	25.0	
26	19	M	Splenectomy after an accident	14.3	5.0	5.0	100.0	0	
27	24	F	Refractory anemia	6.8	3.8	24.0	61.0	9.0	

Table II. Labelling of erythroid precursors of peripheral blood with leucine - ^3H

Case No.	Haematological status	Labelled RTO %	Labelled erythroblasts with traces of basophils, %
1	Thalassaemia major	66.6	0
2	Thalassaemia major	63.6	0
3	Thalassaemia major	73.5	0
4	Thalassaemia major	64.4	0
5	Thalassaemia major	71.9	55.2
6	Thalassaemia major	58.6	68.6
7	Thalassaemia major	62.9	100.0
8	Thalassaemia major	63.2	72.5
9	Thalassaemia major	61.6	100.0
10	Thalassaemia major	64.5	100.0
11	Thalassaemia major splenectomy	86.9	67.0
12	Thalassaemia major splenectomy	56.1	100.0
13	Thalassaemia major splenectomy	62.5	77.5
14	Thalassaemia major splenectomy	53.2	92.2
15	Thalassaemia major splenectomy	69.8	0
16	Thalassaemia major splenectomy	56.9	100.0
17	Thalassaemia major splenectomy	72.4	76.9
18	Thalassaemia major splenectomy	73.5	76.1
19	Thalassaemia major splenectomy	55.2	90.6
20	Sickle cell-Thalassaemia, splenectomy	60.0	24.7
		mean 64.8	mean 80.0
21	Spleen lymphosarcoma	71.4	100.0
22	Acute leukaemia	68.2	66.6
23	Posthaemorrhagic anaemia	70.4	100.0
24	Refractory anaemia	72.0	100.0
25	Favism	64.7	90.9
26	Splenectomy after an accident	62.0	100.0
27	Refractory anaemia	67.5	89.6
		mean 67.7	mean 82.4

None of the orthochromatic erythroblasts was found labelled with leucine - ^3H

Results

In thalassaemic subjects most of the erythroblasts appearing in the peripheral blood, are orthochromatic with fully acidophilic cytoplasm and pyknotic nucleus without any structure (table I fig 1b). None of these orthochromatic erythroblasts was labelled with leucine ^{-3}H . Table II gives the data on the percentage labelling of reticulocytes and normoblasts, containing traces of basophilic substance in their cytoplasm, from thalassaemic and non thalassaemic subjects.

In the 19 thalassaemic subjects and one with S-thalassaemia, the mean value of the labelling index ($=\%$ labelled cells) is 64.8 for reticulocytes and 80.0 for erythroblasts containing in the cytoplasm basophilic substance and in non thalassaemic 67.7 and 92.4 respectively.

Correlation of the labelling index between the two groups studied revealed for reticulocytes $P > 0.2$, for erythroblasts containing in their cytoplasm basophilic substance $P > 0.1$. Consequently there is no difference in the labelling index between the two groups either for reticulocytes or for erythroblasts.

Comments

Comparing the two groups studied, it is obvious that there is not any significant difference in the labelling index either for reticulocytes or erythroblasts containing in their cytoplasm traces of basophilic substance. It seems that for the same last steps of erythroid cell precursors no difference between thalassaemic and non thalassaemic subjects can be detected concerning the capacity of the cells to synthesize haemoglobin. No quantitative informations are drawn through this study.

Reticulocytes seem to be more immature than fully acidophilic normoblasts. It would thus appear that reticulocytes arise from more immature erythroblasts as has been stated by other investigators after incubation of bone marrow with ^{59}Fe and autoradiographic examination of the cells [4-7].

The high percentage of completely acidophilic unlabelled normoblasts in peripheral blood of thalassaemic subjects is explained if we accept the hypothesis that the loss of the nucleus in bone marrow is slowed down in late stages of erythroid cell precursors [1]. This would allow a large proportion of normoblasts to undergo numerous mitoses,

although the cytoplasm matures, filling up the bone marrow with orthochromatic erythroblasts and causes an increase of bone marrow output in orthochromatic erythroblasts [8]

Acknowledgements

This work was in part supported by special fund of Athens University and in part by fund of FARAN (Greek Drug Company). We wish to thank Dr. P. FRASAS (Head of Haematology Dept. and blood transfusion service Alexandra Hospital) for most of the data in table I.

Summary

Peripheral blood from thalassaemic and non thalassaemic patients was incubated for 3 h with leucine - ^3H . The selected non thalassaemic patients had immature forms of the red series in their peripheral blood. Smears were prepared and autoradiographed. None of the fully orthochromatic erythroblasts was found labelled with leucine - ^3H . The labelling index of the two groups studied did not show any difference for reticulocytes or erythroblasts containing traces of basophilic substance in their cytoplasm.

References

1. ASTALDI, F. Differentiation, proliferation and maturation of haemopoietic cells studied in tissue culture; in WOLSTENHOLME and O'CONNOR's Haemopoiesis (Chirechill, London 1967).
2. BARNES, R. and KREIBER, W. E. Effects of histologic and histochemical procedures on the intensity of the label in radioautographs of cells labeled with tritiated compounds. *Lab. Invest.* 12: 648-656 (1963).
3. HAM, A. W. Histology, 4th ed. (Lippincott, Philadelphia 1961).
4. LAJTHA, L. G. and SUTHERLAND, H. D. Uptake of radioactive iron (^{59}Fe) by nucleated red cells. *Brit. J. Haemat.* 1: 55-61 (1955).
5. MARKS, P. A., RIVKIND, R. A. and DANOW, D. Maturation of erythroid cells. Biochemical and ultrastructural analysis. *Trans. Am. soc. exp. Phys.* 36: 34-44 (1963).
6. PIERCE, P. J., LINDSAY, C. P. and DIXON, R. Synthetic capacity of reticulocytes as shown by radioautography after incubation with labeled precursors of proteins or RNA. *Exp. cell Res.* 11: 517-537 (1963).
7. WARD, H. P., TAYLOR, W. M. and KILLY, J. M. ^{59}Fe autoradiography of bone-marrow culture from normal subject and patients with uraemia and pernicious anaemia. *Brit. J. Haemat.* 12: 99-104 (1966).
8. WASSERMAN, M. L. and KIRBY, H. True red blood cell survival with radiochromium by correcting for percentage of activity not bound to hemoglobin. Demonstration of two erythrocyte populations in normals and in thalassaemia minor. Erythropoiesis and the thalassaemia trait. *Ann. N.Y. Acad. Sci.* 119: 586-606 (1964).
9. WINTROW, M. M. Clinical Hematology- Fifth ed. (Len & Febiger Philadelphia 1961)

Author's address: Drs. M. KISS-ELIAS, E. GYTIARI, V. ALEXIZOU-TETZAKI and A. KOO-KOULOMATI, Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens 611 (Greece)

Department of Paediatrics, State Hospital, Hrud

A Survey for Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency in Rumania

J H SCHNEER

Hemolytic disorders following consumption of certain vegetables and drugs have long been known, but only 12 years ago it was recognized that the deficiency of erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) is in the background of these disorders [2]. The G-6-PD deficiency is prevalent amongst some ethnic groups including American and African Negroes, Caucasians of Mediterranean countries and some South-east Asian populations [6, 8, 9, 12]. In Central and Northern Europe, the G-6-PD deficiency appears too, but only sporadically [3, 4, 5, 13].

In Rumania, the first case of G-6-PD deficiency – a chronic non-spherocytic anemia – was observed in 1964 by KONDI *et al.* [7]. One year later we reported two cases of favism and the investigation of the relatives revealed other three defective subjects [10]. The absence of previous data regarding the incidence of this enzymopathy in our country prompted us to conduct a search for G-6-PD deficiency among a Rumanian population and in 1966 we exposed the preliminary results [11].

The purpose of this paper is to report the actual data of our survey.

Materials and Methods

Venous blood specimens were obtained from randomly selected patients and normal individuals, from the Department of Paediatrics and the Polyclinic of Hrud (Rumania).

The qualitative G-6-PD activity was determined on freshly-drawn heparinized blood, by the methemoglobin reduction test of BURWICK *et al.* [1]. Subsequently the deficient individuals and their relatives were investigated clinically, hematologically and genetically.

Table G-6-PD deficient individuals

No.	Subject	Years	Sex	Pedigree	Diagnosis	Methemoglobin reduction test
1	G. O.	3	M	propositus	favism	complete deficiency
2	G. R.	25	F	mother	healthy	partial deficiency
3	G. V.	28	F	sunt	healthy	partial deficiency
4	G. A.	2	M	cousin	healthy	complete deficiency
5	M. D.	1	M	propositus	favism	complete deficiency
6	M. C.	29	F	mother	healthy	partial deficiency
7	B. C.	49	F	grandmother	healthy	complete deficiency
8	B. V.	11	M	uncle	healthy	complete deficiency
9	G. C.	15	M	propositus	hemophilia A, acute hemolytic anemia	complete deficiency
10	G. L.	37	F	mother	healthy	complete deficiency
11	S. V.	17	M	propositus	healthy	complete deficiency
12	S. E.	47	F	mother	healthy	partial deficiency
13	S. R.	9	M	brother	healthy	complete deficiency
14	S. F.	7	M	brother	healthy	complete deficiency
15	D. A.	64	F	grandmother	healthy	complete deficiency
16	B. E.	37	F	sunt	healthy	partial deficiency
17	A. A.	0.5	F	propositus	acute hemolytic anemia	complete deficiency
18	A. L.	43	M	father	healthy	complete deficiency
19	L. G.	66	M	propositus	thalassemia minor	complete deficiency
20	H. M.	27	F	daughter	healthy	complete deficiency
21	D. A.	31	F	daughter	healthy	complete deficiency
22	D. V.	4	M	grandson	adactylia of the right hand	complete deficiency
23	G. A.	31	F	propositus	history of favism	complete deficiency
24	G. E.	72	F	mother	chronic anemia	complete deficiency
25	G. D.	81	M	father	healthy	complete deficiency
26	G. E.	13	F	daughter	healthy	partial deficiency
27	G. C.	9	M	son	healthy	complete deficiency
28	O. G.	3	M	propositus	favism	complete deficiency
29	O. A.	24	F	mother	healthy	complete deficiency
30	D. C.	68	M	grandfather	healthy	complete deficiency
31	M. T.	35	F	aunt	healthy	complete deficiency
32	M. P.	6	M	cousin	healthy	complete deficiency

In this study the screening test employed, did not detect as propositus, partially G-6-PD deficient females.

Results

The methemoglobin reduction test was performed on 890 males and 792 females. Complete G-6-PD deficiency was found in 8 probands

and the survey of 94 relatives revealed other 24 deficient individuals. All the deficient subjects are of Rumanian origin between their families are no relation. The clinical and hematological data for these 32 deficient individuals are listed in the table

Discussions

This is the first attempt at estimating the incidence of G-6-PD deficiency in a Rumanian population, randomly selected. Considering only the test performed on males, the G-6-PD deficiency appears to attain 1.8% (gene frequency 0.0067-0.018)

It is difficult to explain the appearance of the enzymopathy. Since in our country malaria was endemic in previous years, the G-6-PD deficiency could be explained by the controversial malaria theory. Another possibility is that the genopathy was brought by the mediterranean peoples who colonized the ancient territory of Rumania (the ancient Dacia)

We suppose that the G-6-PD deficiency is not restricted to the area investigated in our survey and we think that it would be advisable to continue such studies, not only for the genetic and anthropological significance of this estimation but also for the prevention of the hemolytic states in defective subjects.

Summary

A survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency was carried out amongst 1682, randomly selected Rumanian individuals, by the methemoglobin reduction test. 32 individuals were found to have a G-6-PD deficiency. Considering only the G-6-PD deficient males, the enzymopathy appears to attain 1.8% (gene frequency: 0.0067-0.018).

References

1. BRETHER, G. J. TARLOV A. R. and ALVORD, A. S. Methemoglobin reduction test. *Bull. WHO* 22: 633 (1960)
2. CARSON, P. E. FLANNAGAN, C. L.; ICHER, C. L. and ALVORD, A. S. Enzymatic deficiency in primaquine-sensitive erythrocytes. *Science* 124: 484 (1956)
3. DREYFUS, J. C. MALESDIA, M. et KAPLAN, J. C. Recherches sur le déficit en glucose-6-phosphate déshydrogénase en France. *Nouv. Rev. franc. Hémat.* 4: 791 (1964).
4. DOLYGIN, S. M. KATYREY, M. P. and SATUNOVA, L. V. Skutchni ostroi genozhiti sketshi avnisi avlaxennol defitsitosa fermenta glukozo-6-fosfat dehidrogenal. *Vopr. Obr. Mater. Detsvo*, 17:81 (1967).

5. GIERMAK, G.; STURM, A. JR. und AMELING, D. Favismus in Deutschland. *Dtsch. med. Wochschr.* 89: 1863 (1963).
6. KELLERMEYER, R. W.; TARLOW A. R., BREWER, G. J., CARSON, P. E. and ALVORD, A. S.: Hemolytic effect of therapeutic drugs. *J. Amer. med. Ass.* 182: 328 (1962).
7. KORDA, V.; MITREA, N.; IACOBESCU A. and BALAN, St. Deficienta de glucoza-6-fosfat dehidrogenaza. *Med. Int. (Bucuresti)* 16: 899 (1964).
8. OMS: Hémoglobinoopathies et troubles apparentés. OMS Sér. Rapp. techn. No. 388 (1966).
9. OMS: Normalisation des techniques d'étude de la glucose-6-phosphate déshydrogénase. OMS, Sér. Rapp. techn. No. 366 (1967).
10. SCHÖTTER, J. H.; SCHÖTTER, L. and CRANGARU, A. Consideratii asupra doua cazuri de favism. *Med. Int. (Bucuresti)* 18: 777 (1966).
11. SCHÖTTER, J. H.; SCHÖTTER, L. and BAILESCU, I. Contributii la cunoasterea deficientei de glucoza-6-fosfat dehidrogenaza. *Viata med. (Bucuresti)* 14: 161 (1967).
12. TARLOW A. R., BREWER, G. J.; CARSON, P. E. and ALVORD, A. S. Primaquine sensitivity. *Arch. intern. Med.* 109: 709 (1962).
13. WEIDTMAN, V. und TÖTZ, O.: Glukose-6-Phosphat-Dehydrogenase-Mangel der Erythrozyten bei drei deutschen Kindern. Nachweis einer frischen Mutation. *Klin. Wochschr.* 44: 446 (1966).

Second Medical Clinic of Palacky University Olomouc, Hospital's Central Laboratories
Čadca

Acid Phosphatases of Platelets during Coagulation and Storage of Blood

J. POLÁŠEK and P. KUBANZ

Platelet factor 3 (PF3) belongs to the basic properties of platelets by which the haemostatic function of these blood elements is realized. It is evident that we can speak about lipoprotein the exact localisation of which in the ultrastructure of platelets is still open [1]

In the previous work it was shown that the acid phosphatases (APh) liberated from the platelets into serum during the coagulation of blood are probably linked to lipoprotein which is responsible for the so called platelet like activity of serum [2]

In this work we tried to find the basic correlation between activity of APh and PF3. From the point of view of lysosomal theory APh can be used as biochemical marker of lipoprotein of lysosomal origin [3]

Material and Methods

Blood was taken from healthy volunteers. The serum for studying PF3 like activity was acquired from native platelet rich plasma (PRP) without use of anticoagulant as described previously as well as the setting of the activity of APh of serum or plasma without the use and with the use of detergent-analogon Triton X-100 [2].

The shortest fibrinogen time (SFT) was set as O'BANON described [4].

APS ("activité plaquettaire du sérum") was carried out according to ALAÏOLLE and SOULIER [5]. Results are given as differences in prothrombin consumption between 4-6 min after recalcification of test mixture. The substrate plasma without platelets was prepared for both coagulation tests according to the last mentioned method.

The fresh blood stored in ACD solution was kindly supplied by Transfusion Service Libna. The blood was stored at 4°C and in certain intervals the samples were taken under sterile conditions. Platelets were counted by the PIERRE method [6]. Plasma was separated from the samples by centrifugation at 4°C at 2,000×g twice each centrifugation lasting




Fig. 1 Time dependence of liberation of acid phosphatase (APh) and PF3 like activity into serum from native platelet rich plasma (PRP). SFT = shortest fibrinogen time. APh = platelet activity of serum.

30 min. No formed elements could be observed in this plasma under the phase microscope. In the plasma we observed the haemoglobin content [7], the activity of APh without and with detergent.

The thromboplastic activity by means of methods mentioned above [4-5] with modification forced by using of citrate plasma instead of serum as tested material. The basic mixture which was the same for both methods contained 0.3 ml of platelet poor substrate plasma and 0.2 ml of tested plasma. To recalcification 0.3 ml of 0.025 M CaCl_2 were used.

Haemoblast was prepared by dilution of isolated erythrocytes by distilled water to desired concentration of haemoglobin [8].

Results

The time dependence of liberation of APh and PF3 activities into serum is given in figure 1. The curves show the correlation between both activities. The activities in serum seem to depend on the retrac

Table II. Changes in some activities in plasma from blood stored in ACD solution at 4°C

Blood No.	Day	Thrombocytes	Haemoglobin mg%	Acid phosphatase $\mu\text{M}/\text{ml}/\text{h}$		SFT sec	APF sec
				no deterg.	with deterg.		
1	0	163 000	10	0.140	0.216	68	0
	7	132 000	20	0.224	0.714	24	3.7
	14	94 000	66	0.478	0.843	16	12.3
	21	50 000	208	1.204	2.534	13	20
2	0	223 000	14	0.250	0.420	52	2
	7	192 000	14	0.545	0.870	30	8
	14	169 000	47	0.435	0.970	22	10
	21	101 000	71	0.770	1.540	20	20
3	0	217 000	28	0.276	0.232	31	0.5
	7	188 000	48	0.546	1.172	18	18
	14	130 000	126	0.868	1.680	18	23
	21	66 000	181	0.742	1.594	18	23
4	0	186 000	16	0.084	0.112	110	0
	7	130 000	50	0.350	0.560	31	3
	14	101 000	128	0.882	1.338	20	20.2
	21	95 000	198	0.700	0.994	18	14.2
5	0	207 000	28	0.126	0.196	68	0
	7	128 000	48	0.294	1.134	17	10.5
	14	98 000	144	0.568	1.680	17	16.5
	21	48 000	226	1.148	2.072	17	22

Horowitz *et al.* [9] shows as for quantitative changes after ultra-centrifugation the similar values as the activity of APb. About 15–20% of the activity APb liberated into serum remains also after centrifugation at $20\,000\times g$ in the supernatant. In such supernatant no thromboplastic activity could be traced by coagulation tests we used.

When following the curves showing the changes of given values in plasma obtained from the stored blood, the time correlation of the appearance of thromboplastic activity concomitantly with the activity of APb is also evident. We assume that we dealt with material of platelet origin according to Wolf [10] who described the platelet dust liberated into plasma during storage of blood. The enormously high values of APb obtained especially by means of detergent indicate that there must be a rest of the platelet lysosomes. This should prove electromorphological findings [11]. Even if the older samples of plasma show comparatively high values of haemoglobin, erythrocytes participated in both observed activities only very little. Haemolysate of isolated

erythrocytes the value of which was 200 mg% haemoglobin shows the activity of AP_h with detergent about 0.1 units of BESSEY LOWRY. No thromboplastic activity could be traced by tests used by us.

The fact that during storage of blood, except others, also the rest of platelet lysosomes is liberated into plasma is interesting both from theoretical and from practical points of view. If the correlation between by AP_h labeled lipoprotein and PF3 activity is proved by further experiments, it could help to solve the question of PF3 origin. We should also mention the finding of KOWALSKI *et al.* [12] that platelet AP_h is activated by kaolin when the values approached the values obtained by means of Triton X 100 only. On the other side the activity of PF3 was proved by means of the very kaolin [13, 14].

The fact that highly active sediment of serum acquired by ultra centrifugation is completely captured in coagulum of native PPP might mean that during retraction of coagulum a part of thromboplastic activity liberates into serum and perhaps is to ensure the perfect course of coagulation.

The increased availability of PF3 in plasma of stored blood could probably help to explain the well known clinical experience regarding the unsuitability of transfusion of stored blood to patients suffering from thromboembolic diseases.

Acknowledgement

We are indebted to Mrs. L. KOSÁKOVÁ for her excellent technical assistance in the conduct of these studies.

Summary

A time correlation of appearance of acid phosphatase and platelet factor 3 activities in the serum obtained from native platelet rich plasma has been found. But none of these activities was liberated from the platelets into plasma or serum close to the time when the coagulum developed *in vitro*. The liberation of both activities could be observed only after retraction of the coagulum.

Concomitantly with the liberation of acid phosphatases the platelet factor 3 activity in plasma obtained from stored blood raised. The high values of acid phosphatases in plasma give evidence to their platelet lysosomal origin.

References

1. MACCUB, A. J. and ZUCKER, M. B. The physiology of blood platelets (Grune and Stratton, New York 1965).

2. POLÁKOVÁ, J.: Particulate nature of acid phosphatase released from thrombocytes. *Thromb. Diath. haemorrh.* (accepted for publication).
3. DE DUVE, C.: The lysosome concept. In *Lysosomes, Ciba Foundation Symposium*, p. 1 (Churchill, London 1963).
4. O'BRIEN, J. R.: The platelet-like activity of serum. *Brit. J. Haemat.* 1: 223 (1955).
5. ALAGILLE, D. et SOULIER, J. P.: Le test d'activité plaquettaire du sérum. *Rev. franç. Et. clin. biol.* 2: 231 (1957).
6. PIETTE, M. et PIETTE, C.: Numération des plaquettes sanguines utilisant un liquide hypotonique base de chlorhydrate de procaine. *Sang.* 30: 144 (1939).
7. CROWY, W. H. and FINEB, F. W.: Modification of the Bensidine method for measurement of hemoglobin in plasma and urine. *Blood* 11: 380 (1956).
8. KIRY U. und HIRSH, P.: Über den Einfluss des Erythrozytins auf die Blutgerinnung. *Blut* 13: 90 (1966).
9. HOKOWITZ, H. I. and PARADIMOU, M. F.: Release of nonedimentable platelet factor 3 during coagulation. *J. Lab. clin. Med.* 69: 1005 (1967).
10. WOLF, P.: The nature and significance of platelet products in human plasma. *Brit. J. Haemat.* 13: 269 (1967).
11. FIDON, A. M. and ADAMS, W. R.: Virus-like particles in human plasma and serum. Role of platelet lysosomes. *J. nat. Cancer Inst.* 37: 159 (1966).
12. KOWALSKI, E., KOPKA, Z., WISNIEWSKI, M., HOMER, M. and BODZIMSKI, A. Z.: A lysosomal concept of the platelet release reaction and viscous metamorphosis. *Thromb. Diath. haemorrh.* 16: 134 (1966).
13. HARDY, R. M. and HUTTON, R. A.: The kaolin clotting time of platelet-rich plasma. A test of platelet factor-3 availability. *Brit. J. Haemat.* 11: 238 (1965).
14. SPAET, T. H. and COHEN, J.: Studies on platelet factor-3 availability. *Brit. J. Haemat.* 11: 269 (1965).

Blood Research Laboratory, New England Medical Center Hospitals and Department of Medicine, Tufts University School of Medicine, Boston, Mass.

Bone Marrow Injury and Repair

Irradiation and Mechanical Disruption¹

M. B. WEINSTEIN² and W. H. CROSBY

Exposure of the femur and tibia of the rat to 4 000 r of x irradiation results in permanent aplasia of the bone marrow [1]. Two months post irradiation, when the aplasia has been well established, autologous marrow removed from an unirradiated bone and implanted in the irradiated area can reconstitute hemopoietic activity [2]. It has been proposed that the limiting factor which determines the existence of aplasia or hemopoiesis is the condition of the microcirculation of the marrow. This sinusoidal structure is evidently uniquely capable of supporting the proliferation of hemopoietic tissue. When it is destroyed by irradiation, or otherwise, the hemopoietic marrow atrophies. The restoration of normal activity in the irradiated marrow cavity by transplantation of tissue is presumably accomplished by adventitial cells capable of proliferating to reconstitute the microcirculation. This experiment was designed to learn if normal marrow from the shielded portion of an irradiated bone could be induced by mechanical mixing to proliferate in the aplastic portion.

Materials and Methods

Radiation was performed on the distal half of the tibia in groups of 10 male Wistar rats of about 400 g. The rats were placed in individual boxes and shielded by layers of lead to protect the body, upper legs and feet. The radiation source was 250 kvp-15 mA with 5 mm

These studies supported with funds from US Public Health Service Grant No. CA 04168-10 from the National Cancer Institute.

Trainee in Hematology supported by US Public Health Service Grant No. AM 5210-07

copper and 1 mm aluminum filter. The target-to-skin distance was 35 cm. Dose rate was 250 r/min, and exposure time was 13.5 min. The half-value layer was 1.2 mm copper. The total exposure dose was 4,000 r. The original groups of 10 rats were reduced by 20 % because of autocomputation of irradiated legs. Shielding the feet during irradiation prevented this.

When anesthesia was required, pentobarbital was injected intraperitoneally. Mechanical disruption of tibial marrow was accomplished by introducing a 1½ in, 21 gauge needle into the marrow cavity at the femorotibial joint. Then a stainless steel wire was passed through the needle into the cavity and the marrow was mixed by 20 up-and-down strokes of the wire trochar.

The marrow was disrupted at varying intervals after the irradiation (table I). In one group of animals the operation was performed before irradiation and in one group it was performed without irradiation. Only marrow of the left leg was disrupted so that the right could serve as control.

The animals were killed with ether and the tibiae were removed and fixed in buffered formalin for 3 days, decalcified in Perenyi's solution for 5 days, imbedded in paraffin, sectioned at 6 µm and stained with hematoxylin and eosin.

Results

Those bones in which the marrow was not mechanically disrupted were examined at intervals up to 8 weeks after irradiation and the typical cycle of changes was observed: sinusoidal dilation, intra medullary hemorrhages, hyperplasia and then hypoplasia [1]. In all

Table I. Recovery of hemopoiesis in hemirradiated tibia: 4000 r to distal end followed by mechanical disruption of marrow

Group (10 rats each)	Marrow disrupted after irradiation weeks	Interval from disruption of marrow until death, weeks	Interval from irradiation of marrow until death, weeks	Recovery of hemopoiesis
1 A	1	9	10	yes
B	1	13	14	yes
C	1	13	16	yes
2 A	2	6	8	yes
B	2	8	III	yes
3 A	4	4	8	yes
B	4	6	10	yes
C	4	8	12	no
D	4	10	14	no
4 A	6	4	10	no
B	6	6	12	no
C	6	10	III	no
5 A	8	2	10	no
B	8	6	14	no

of the irradiated tibiae there was a line of demarcation by the 8th week in the distal end of the cavity the hemopoietic marrow was replaced by loose connective tissue, rare lymphocytes and plasma cells and few erythrocytes. The proximal end contained normal marrow.

The effect of mechanical disruption of marrow in the unirradiated tibia was studied after the 5th postoperative day. Marked endosteal proliferation was seen and in some areas the medullary cavity became completely filled with trabecular bone. Two, 3 and 4 weeks after disruption of the marrow some trabecular bone remained in the cavity but endosteal proliferation subsided with time.

Disruption of marrow preceding irradiation by 5 days did not modify the effects of irradiation. At 8 weeks there was fibrosis in the distal end of the cavity and in the proximal end there was normal hemopoietic marrow plus trabecular bone. The irradiated distal right tibia in every animal became fibrotic and aplastic. Results of the combined injury are shown in table I. When mechanical disruption of the left tibial marrow followed irradiation by one or two weeks (groups 1 and 2) hemopoietic cells were found in the irradiated areas 4 to 15 weeks postoperatively. Hemopoietic tissue and trabecular bone were present through the entire length of the cavity. In some bones islands of normal tissue were scattered among aplastic areas. When disruption followed irradiation by four weeks (group 3) there was recovery of hemopoiesis in the distal cavity of some animals, but not all. When disruption followed irradiation by 6 or 8 weeks (groups 4 and 5) there was only fatty and connective tissue in the distal end of the cavity 2 to 10 weeks postoperatively.

Discussion

When the marrow was mechanically disrupted, the cavity quickly became filled with trabecular bone surrounded by osteoblasts. The endosteum was hypertrophic. In succeeding weeks the hypertrophy subsided. The bony replacement was complete in some bones, patchy in others. Hemopoietic marrow was present in the areas of no bone and in the spaces between the bony trabeculae.

When the marrow was mechanically disrupted after irradiation, the irradiated and unirradiated tissues were tumbled and mixed within the bony cavity. The spotty recovery of the marrow in the irradiated portions of the bone indicate that the intent of the procedure was

accomplished. Normal marrow was forced into the aplastic tissue and established itself there. But the presence of aplastic areas in the proximal cavity suggests that irradiated tissue was moved into the shielded areas and it was not invaded or converted by the adjacent normal tissue.

As the irradiation lesion matured it became more fibrotic. After four weeks the efforts to mix the marrow in the two ends of the cavity were unsuccessful, perhaps because the wire trochar only channeled the irradiated tissue and did not replace it.

It is proposed that the growth of hemopoietic marrow in irradiated portions of the tibia occurred because adventitial tissue was displaced into those areas permitting the marrow's microcirculation to be reestablished there. This would indicate that the marrow's adventitia is not aggressive—it does not propagate into irradiated areas by its own initiative. Hemopoietic tissue, on the other hand, seems to develop wherever there is adventitia to support it.

Summary

Post-irradiation splais in the marrow of the rat's tibia developed only in the irradiated distal half. When the marrow of the unirradiated half was mixed into the irradiated portion by means of mechanical disruption of the bony cavity hemopoietic marrow developed in the irradiated portion.

References

1. KNOPP, W. H., BLUM, J. and CROSBY, W. H. Local irradiation of bone marrow. I. Long term changes in the rat with particular emphasis upon vascular and stromal effects. *Blood* 28: 396 (1966).
2. KNOPP, W. H., BLUM, J. and CROSBY, W. H. Regeneration of locally irradiated bone marrow. II. Induction of regeneration in permanently aplastic medullary cavities. *Blood* 31: 400 (1968).

Authors addresses: Dr. MORRIS E. WERNERIS, Jackson Memorial Hospital, Dept. of Nuclear Medicine, Miami, Fla., Dr. WILLIAM H. CROSBY, New England Med. Center Hospital, Blood Research Laboratory, Boston, Mass. (USA).

Department of Pathology St. Mary' Hospital
Medical School, London

Eosinophils and Dietary Histamine in the Rat

EVELYN C. BLEVINGSOFF and W. K. BLEVINGSOFF

Eosinophils are most numerous in the gastrointestinal tract and the skin and spend most of their life in these tissues [1]. Their function is still obscure, but ARCHER [2] considered that they inactivated histamine: this conclusion was based on the occurrence of a local eosinophilia following intradermal injection of histamine, which could be inhibited by injection of an antihistamine immediately after the injection of histamine. This hypothesis would be strengthened if the turnover or number of eosinophils altered in response to an alteration in histamine balance or in response to the continuous administration of antihistamine. In the present work, continuous infusions of tritiated thymidine were used in rats to investigate the effect of histamine-high diet, histamine-low diet and normal diet with antihistamine, on eosinophil turnover and populations. One of the authors has previously studied eosinophils in normal rats by this technique [1].

Material and Methods

Seven (♂ 1, ♀ 7) adult male black-hooded PVG/C rats (weight 300 g) and 16 (♂ 1, 16) adult male Sprague-Dawley albino rats (weight 180-210 g) were divided into 4 groups according to diet. Each diet was given for 18 days before the rats were killed. In each group, 2, 3 or 4 rats were given 8 or 6 days continuous intraperitoneal infusion [3] of 1 μ C tritiated thymidine (specific activity 3.0 C/mole)/g/day starting 8 or 10 days after the special diets were begun and ending when the animals were killed. The detailed treatments in each group were as follows.

Normal diet. Six control rats (♂ 1, 2 and ♀ 1-4) received a normal cubed 41B diet [4]. Three were infused with tritiated thymidine for 6 days (♂ 1 and ♀ 1, 2) and one for 8 days (♂ 2).

Histamine-high diet. Seven rats (B 3-5 and B 5-8) each received 15 g fresh minced raw meat daily. This diet supplies large quantities of exogenous histamine and probably also stimulates the formation of endogenous histamine [5]. Three rats (B 3 and B 5-6) were infused with tritiated thymidine for 6 days.

Histamine-low diet. Six rats (B 6-7 and B 9-11) each received 15 g daily of diet containing less than 0.05 μ g histamine/g [6]. One rat was infused with tritiated thymidine for 8 days (B 6) and 2 for 6 days (B 9-10).

Antihistamine. Four rats (S 13-16) on a normal 41 B diet each received 2.5 mg Mepyramine maleate/day. This was given in the drinking water to S 15-16 throughout, and in the drinking water to S 13-14 for 10 days, then in a continuous intraperitoneal infusion for 5 days. Rats S 13-14 were infused with tritiated thymidine for 6 days.

After 10 days of the special diets, absolute eosinophil counts [7] were made on blood samples taken from 4 rats in each group (S 1-16). Blood films were taken from the tail veins of each infused rat at intervals during the infusion and fixed in 100% methyl alcohol, marrow smears (fixed in 100% methyl alcohol) and tissue blocks (fixed in formal-saline) were taken at necropsy from each infused rat. Tissue blocks were also taken at necropsy from rats B 4-5 (histamine-high diet) and B 7 (histamine-low diet). Sections (5 μ m) were prepared from the tissue blocks; those from the infused rats, and their blood films and marrow smears, were dipped in Diford K3 nuclear emulsion or covered with Kodak AR 10 stripping film and these autoradiographs were exposed for 4 weeks at 0-4°C. All the sections, films and smears were stained with Mayer's haemalum and Hehrich scarlet to identify the eosinophils [8]. Labelled and unlabelled eosinophil nuclei to a total of between 50 and 200 were counted in each film, smear or section. Eosinophils in the marrow were not differentiated into myelocyte, metamyelocyte, stab form or mature eosinophil.

Results

The marrow smears from each infused rat showed that cells with eosinophil granules formed 8-10% of the total cell population, and the percentage labelling of these cells was 97-100%.

In the black hooded rats, differential cell counts on the blood films showed that eosinophils formed 5% of the circulating white cells, and between 100 and 120 eosinophils were present in each film. These values are within normal limits [1]. In the Sprague-Dawley rats, absolute eosinophil counts on blood samples were between 122 and 268 eosinophils/mm³ which is within the range given by RYTÖMÄÄ [9] for normal rats weighing 210 g. Thus the total number of blood eosinophils was within the normal range irrespective of diet.

The percentage of eosinophils labelled in each blood film was used to establish their rate of turnover. Sequential entry to and random removal from blood has been established for normal rat eosinophils [1] and this requires that

$$\log \left(\frac{1}{1-f} \right) = kt,$$

where f is the fraction of eosinophils labelled at time t , and k is the number of eosinophils added to the circulation in unit time, expressed as a fraction of the number normally present in the circulation. If $\log (1/1-f)$ is plotted against t and a best fitting line is drawn, the slope of this line gives the value of k . k was determined in this way for each rat, and $(1/2k)$ (the half life of an eosinophil in the circulation) is given in table I. The intercept of the line on the abscissa gives the time at which the eosinophils begin to leave the bone marrow and enter the blood. The time between the start of the infusion and this point is the length of time from the end of deoxyribonucleic acid synthesis of an eosinophil myelocyte to the exit from the marrow of the consequent eosinophil leucocyte (table I). The half life of eosinophils in the blood, and the time of appearance of labelled eosinophils in the blood, do not differ significantly from the normal in any dietary group.

In the tissues the distribution of eosinophils was normal in all rats [9]. No significant difference was found in either total number or percentage labelling of eosinophils between black-hooded and Sprague Dawley rats, and the values for the two strains of rat have therefore been pooled for the statistical analysis. There was also no significant difference between the percentage labelling of eosinophils in stomach, small intestine and large intestine, which have therefore also been

Table I. Half-life of eosinophils in the blood and interval between beginning of tritiated thymidine infusion and appearance of labelled eosinophils in the blood

Rat	Diet	Half-life h	Time of appearance of labelled eosinophils h
B 1	Normal	8-12	60-75
B 2			
B 3	Histamine-high	11.5	67 ½
B 6	Histamine-low	10.1	61
S 1	Normal	10.0	51
S 3			
S 5	Histamine-high	8.8	50
S 6		8.4	40
S 8		10.0	40
S 9	Histamine-low	5.9	44
S 10		8.0	48
S 13		9.8	46
S 14	Normal diet with antihistamine	8.3	42

Range of normal from Four [1].

pooled for the analysis. The mean values and the standard deviations for total number and percentage labelling of eosinophils in the tissues are given in tables II and III and comparison using the Student *t* test showed no significant differences between the dietary groups.

Discussion

COND [10] suggested that eosinophils contained histamine, but the amount is insignificant when compared to that in mast cells [11].

There is good evidence that the eosinophil is an antagonist to histamine. This property has been demonstrated in eosinophils from rabbits [12] from horses [13, 14] and from man [14]. WELSH and

Table II. Total number of eosinophils in 2 mm² of a 5 µm section from each rat tissue: mean and standard deviation for each dietary group

Diet	No. of rats	Spleen	Stomach	Small intestine	Large intestine
Normal	4	23 ± 4	206 ± 68	130 ± 35	145 ± 52
Histamine-high	5	19 ± 5	233 ± 75	137 ± 36	139 ± 21
Histamine-low	4	23 ± 12	204 ± 64	132 ± 24	167 ± 34
Normal diet with antihistamine	2	19 ± 6	164 ± 33	111 ± 38	177 ± 40

Table III. Percentage of eosinophils labelled in rat tissues: mean and standard deviation for each dietary group

Diet	No. of rats	Spleen	Stomach and small and large intestine
<i>6-day irradiated thymidine infusion</i>			
Normal	3	79 ± 10	43 ± 21
Histamine-high	3	70 ± 4	40 ± 14
Histamine-low	2	70 ± 7	37 ± 16
Normal diet with antihistamine	2	74 ± 9	50 ± 19
<i>8-day irradiated thymidine infusion</i>			
Normal	1	88	79 ± 8
Histamine-low	1	83	83 ± 10

GREER [15] produced electron micrographs which demonstrated phagocytosis of mast cell granules by eosinophils in the peritoneal fluid of a rat.

There is also good evidence of a chemotactic effect of histamine on eosinophils in some species but not in others. When lesions of urticaria pigmentosa were stroked they showed some degranulation of the mast cells with a slight influx of eosinophils [16] and in man marked local eosinophilia followed injection of histamine in the skin of atopic individuals, although this did not occur in those who were not atopic [17-18]. Marked local eosinophilia followed injection of histamine in horses [2-19] but this effect was not seen in mice [20-21], guinea pigs [22] or dogs [23].

Mast cell granules contain most of the histamine in the body [24] and these granules may be released in the immediate hypersensitivity reaction [25] or in acute inflammation [26] thus producing a local eosinophilia. SHILDOW and BAUER [26] showed that damage to the skin of rats produced by experimental mucormycosis caused degranulation of local mast cells within half an hour followed by a local eosinophilia in about 6 h. pretreatment with compound 48/80 (a histamine liberator) caused degranulation of the mast cells, and inflammation was then not associated with a local eosinophilia. Since local eosinophilia is an uncommon accompaniment to acute inflammation, perhaps the mechanism in this case involved a hypersensitivity reaction.

There is other evidence which suggests that the function of the eosinophil is closely related to the external environment: they are most numerous in the skin, stomach, and small and large intestine, and their number in these tissues is very small at birth but increases markedly during the first 6 months of life [9]. However if the main function of eosinophils is inactivation of histamine, it would be expected that they would be more numerous where mast cells were plentiful: this situation is found in rat skin, but in the rat tongue mast cells are numerous whereas eosinophils are few, and in the rat gastrointestinal tract eosinophils are numerous but mast cells are few. In view of this anomaly and since the rat stomach and small intestine are rich in histamine but poor in mast cells [24] the present authors considered it possible that the many eosinophils in the rat gastrointestinal tract were there because of a high local concentration of histamine derived from the food. In support of this concept, RYTÖMÄ [9] stated that a meat diet increased the number of eosinophils in the alimentary tract (though no reference to the observations was given). This point was

also made by ARCHER [27] who cited the work of BIGGART [28] GODLOWSKI [29-30] and TEIR *et al.* [31] however of these authors only GODLOWSKI [30] used protein rich feeding, and although he considered that two dogs on a raw meat diet had more eosinophils in the blood and intestinal tract than did the control animals, comparison of his tables I and II indicates that the values found in the test animals were within the range found in the controls. In the present work alterations in dietary histamine and probably in endogenous histamine had no effect on the number of eosinophils present in the gastrointestinal tract.

ARCHER [2] found that an antihistamine inhibited the eosinophil response to intradermal injection of histamine in horses, thus an effect on eosinophil kinetics might have been expected when an antihistamine was continuously given to rats. The absence of such an effect, the species differences in the eosinophil response to local injection of histamine, and the finding that injection of histamine into the skin in man is followed by a local eosinophilia only in atopic individuals, suggest that the main function of eosinophils is not the inactivation of histamine.

Although ROBERTS [32] has presented evidence that eosinophils rapidly take up antigen and may thus be concerned in the formation of antibody other workers have been unable to demonstrate this effect [20-33]. There is much evidence that antigen-antibody complexes are eosinotactic and are phagocytosed by eosinophils [20-25, 33-34, 35, 36]. Thus, the main function of eosinophils is probably related to the formation or disposal of antigen-antibody complexes.

Acknowledgement

The authors are grateful to Miss J. Goss, Carew for technical assistance and to the St. Mary's Hospital Research Fund for financial assistance.

Summary

The hypothesis that the main function of eosinophils is the inactivation of histamine was investigated by using continuous infusion of tritiated thymidine to estimate the turnover and number of eosinophils in rats given normal diet, histamine-high diet, histamine-low diet, or normal diet with antihistamine. The turnover and number of eosinophils in the bone marrow, blood and tissues was not altered by any of the treatments given. These results and the known species differences in the eosinophil response to local injection of histamine suggest that the main function of eosinophils is not the inactivation of histamine.

References

1. FOOT, E. C. Eosinophil turnover in the normal rat. *Brit. J. Haemat.* **11**: 439-445 (1963).
2. ARCHER, R. K. The eosinophil leucocytes, p. 60 (Blackwell Oxford 1963b).
3. FOOT, E. C. Eosinophil turnover in the rat. *Nature, Lond.* **196**: 297-298 (1963).
4. WORDEN, A. N. J. WORDEN and LAKE PETER'S The U.F.A.W. Handbook on the Care and Management of Laboratory Animals, 2nd ed., p. 124 (Universities Federation for Animal Welfare, London 1957).
5. MITCHELL, R. G. and COOK, C. F. Effect of diet on urinary excretion of histamine. *J. ppl. Physiol.* **6**: 387-392 (1954).
6. GOTTARSON, B., KARLSON, G. and ROSENBERG, E. Biogenesis of histamine studied by its distribution and urinary excretion in germ free reared and not germ free rats fed on histamine free diet. *Acta physiol. scand.* **41**: 217-228 (1957).
7. DACEY, J. B. and LARSEN, S. M. *Practical Haematology* 3rd ed., p. 59 (Churchill, London 1963).
8. SEXTON, S. S. and LELAND, R. D. Histochemical identification of basic proteins with Bielschowsky's method at alkaline pH. *Stain Technol.* **36**: 365-370 (1961).
9. RYTOMAA, T. Organ distribution and histochemical properties of eosinophil granulocytes in rat. *Acta path. microbiol. scand. Suppl.* **140**: 50 (1960).
10. COOK, C. F. The histamine-like activity of white blood cells. *J. Physiol.* **90**: 485-500 (1937).
11. RILEY, J. F. *The Mast Cells*, p. 116 (Livingstone Edinburgh 1959).
12. KOTVA, A. Antihistamine effect of eosinophil leucocytes. *Experientia* **6**: 349-350 (1950).
13. VERCAUTEREN, R. and PARTHEN, G. On the presence of an antihistaminicum in isolated eosinophilic granulocytes. *Arch. int. Pharmacodyn.* **49**: 10-14 (1952).
14. ARCHER, R. K. *The Eosinophil Leucocytes*, p. 152 (Blackwell, Oxford 1963d).
15. WELSH, R. A. and GILLES, J. C. Phagocytosis of mast cell granules by the eosinophilic leucocyte in the rat. *Amer. J. Path.* **33**: 103-111 (1959).
16. DREYFUS, J. M. The mast cells in urticaria pigmentosa. *J. Path. Bact.* **63**: 513-520 (1951).
17. KLEIN, B. S., COMBS, M. B. and RUDOLPH, J. A. Histologic changes in allergic and nonallergic wheals. *J. Allergy* **3**: 531-541 (1932).
18. KNOTT, F. A. and BEYER FRANKOV, R. S. Eosinophilia in allergic conditions. *Guy's Hosp. Rep.* **41**: 230-236 (1934).
19. ROX, R. F. Studies on allergic dermatitis (Queensland itch) of the horse: the aetiology of the disease. *Austr. J. agric. Res.* **5**: 109-129 (1954).
20. SEXTON, S. S. Physiological approaches to an understanding of the function of eosinophils and basophils. *Ann. N.Y. Acad. Sci.* **39**: 706-731 (1955).
21. GOSWAMI, P. K. Lack of chemotactic effect of histamine upon mouse eosinophils. *Indian J. med. Sci.* **19**: 906-908 (1963).
22. LITT, M. Studies in experimental eosinophilia. IV. Determinants of eosinophil localization. *J. Allergy* **33**: 532-543 (1962).
23. RIDDLE, J. M. and BAUMGART, M. L. The eosinophil as a source for profibrinolytic in acute inflammation. *Blood* **25**: 776-794 (1965).
24. SELYE, H. *The Mast Cells*, p. 310 (Butterworths, Washington 1963).
25. ARCHER, R. K. *The Eosinophil Leucocytes*, p. 107 (Blackwell, Oxford 1963).
26. SKELDON, W. H. and BAKER, H. Tissue mast cells and acute inflammation in experimental mucormycosis of normal, 48/80 treated and diabetic rats. *J. exp. Med.* **122**: 1069-1084 (1960).
27. ARCHER, R. K. *The Eosinophil Leucocytes*, p. 56 (Blackwell, Oxford 1963).
28. BROGART, J. H. Some observations on the eosinophilic cell. *J. Path. Bact.* **35**: 799-816 (1932).

29. GOLLOWITZ, Z. Z. Prevention of hormonal eosinopenia and lymphopenia by inhibition of clotting in blood. *Brit. med. J.* *4*: 854-855 (1951)
30. GOLLOWITZ, Z. Z. The fate of eosinophils in hormonally induced eosinopenia and its significance. *J. Endocrin.* *2*: 102-125 (1952)
31. TIER, H. WIGLIER, O.; SCHWELL, B. PAIVANDER, I. and KUOR, T. Experimental alterations in the tissue eosinophilia of the glandular stomach of the rat. *Acta med. scand.* *152*: 275-283 (1955)
32. ROBERTS, A. N. Rapid uptake of tritiated antigen by mouse eosinophils. *Nature Lond.* *210*: 266-269 (1966)
33. LITT, M. Studies in experimental eosinophilia. VI Uptake of immune complexes by eosinophils. *J. Cell Biol.* *23*: 333-361 (1964a)
34. LITT, M.: Eosinophils and antigen-antibody reactions. *Ann. N.Y. Acad. Sci.* *116*: 964-985 (1964b)
35. SPIES, R. S. and SPIES, E. E.: Cellular reactions to reinjection of antigen. *J. Immunol.* *82*: 340-349 (1964).
36. SARTOR, S. M. A function of the eosinophil: phagocytosis of antigen-antibody complexes. *Proc. Soc. exp. Biol., N.Y.* *117*: 667-670 (1963)

Institute of Medical Clinics, University of Pavia (Director: Prof. P. LEROUX)

Cytoplasmic Shedding as a Mode of Formation of Lymphocyte-Like Blast Cells by Newt Histiocytes

E. G. RONDANELLI, E. MAGLIULO, G. CARONI and D. DIONISI

It is well known that in haemopoietic tissues of man and animals, including amphibians, particular cells are present which, due to their small dimensions and dark staining of chromatin, are variously called 'marrow lymphocytes', 'lymphocyte-like cells', 'lymphoid blast cells' [2, 7, 8, 16, 25, 29]. LEROUX and DESYLLA [9], FERRATA [5], DI GUOLIELMO [3], FIESCHI [6] and ROHR [20] had included among histiocytes a type of small lymphocyte-like cells which may be easily confused with lymphocytes for having a round compact nucleus, with a badly distinguishable nucleolus and a thin rim of slightly basophilic cytoplasm and, unlike lymphocytes, the ability to perform phagocytosis of vital dyes.

FLIEDNER *et al.* [7] described lymphoid blast cells appearing during haemopoietic recovery in irradiated dogs which were transfused with nitrogen-mustard treated marrow. Such cells have a large nucleus unlike that of typical lymphocytes, with a fine nuclear structure, a thin cytoplasmic rim and the capacity to synthesize DNA, thus being presumed to be endowed with stem-cell pluripotentiality. Similar cells are easily found in circulating blood of the newt *Ambystoma Vulgaris* L. [10, 11] and are particularly numerous in early phases of the haemopoietic regeneration which ensues to refeeding the animals after a long period of starvation. Independently from any question concerning the exact role of these lymphocyte-like cells (stem cell pluripotentiality?) we have had the opportunity of observing and describing in the present paper an obsolete though not infrequent mode of formation of lymphoid cells by histiocytes which were shedding in the surrounding medium large fragments of their cytoplasm.

29. GOLLOWSKI, Z. Z. Prevention of hormonal eosinopenia and lymphopenia by inhibition of clotting in blood. *Brit. med. J.* **1**: 854-855 (1951)
30. GOLLOWSKI, Z. Z. The fate of eosinophils in hormonally induced eosinopenia and its significance. *J. Endocrin.* **8**: 102-125 (1952)
31. TIER, H., WIELAND, O., SCHRELL, B., FAIVARZNER, I. and KROCK, T. Experimental alterations in the tissue eosinophilia of the glandular stomach of the rat. *Acta med. scand.* **152**: 275-283 (1953)
32. ROZALITA, A. N. Rapid uptake of tritiated antigen by mouse eosinophils. *Nature, Lond.* **210**: 266-269 (1966).
33. LITTE, M. Studies in experimental eosinophilia. VI. Uptake of immune complexes by eosinophils. *J. Cell Biol.* **23**: 355-361 (1964)
34. LITTE, M. Eosinophils and antigen-antibody reactions. *Ann. N.Y. Acad. Sci.* **115**: 964-983 (1964b)
35. SEIZEN, R. S. and SEIZEN, E. E. Cellular reactions to reinjection of antigens. *J. Immunol.* **92**: 340-349 (1964)
36. SANKER, S. M. A function of the eosinophil: phagocytosis of antigen-antibody complexes. *Proc. Soc. exp. Biol., N.Y.* **112**: 667-670 (1963)




Fig 2. Progressive shedding of large cytoplasmic fragment by newt histiocyte. Frames from phase-contrast cine-recording.]




Fig. 3. Same cell as in figure 2. a-c The progressive stretching and thinning of the connecting cytoplasmic bridge causes the loss of a large portion of cytoplasm from the histocyte. d Retraction of the remnant of the cytoplasmic bridge.

of migratory movement, but the customary shifting in the same direction of the remaining body of the cell does not follow. The cell itself remains fixed in its position.

Still the pseudopodium is provided with a very marked autonomous motility appearing as it was actively pulling on its connection with the cell (fig 2). As a consequence, a progressive thinning of the reunion-trait is being operated, until the cytoplasmic bridge is broken and the pseudopodal mass is completely detached.

While the cell retracts back the remnant of the cytoplasmic bridge and acquires a round shape, with the remaining cytoplasm forming a thin rim around the nucleus (fig 3) the fragment of cytoplasm lost by the cell in the medium performs a rather intense but apparently uncoordinated locomotory activity (fig 4). The final step of the whole process has been the production of a small cell, with a high nucleocytoplasmic ratio still provided with histiocytic potentialities, but remarkably resembling a lymphocyte.




Fig 4 Fate of the portion of cytoplasm lost by the histiocyte. The detached fragment performs uncoordinated locomotory movements in the medium before dissolution.

Discussion

Cytoplasmic shedding which was first described by RANVIER [19] has already been the subject of several reviews [26 12 28, 13 17 18] the phenomenon being variously related to water and food transport or plasma formation or globulin releasing by mononuclear cells [24 26]. Until now the interest of investigators was primarily focused on the probable fate of released cytoplasmic droplets and only in part on the becoming of the original cell. According to DOWNEY and WINTER REICH [4] and to SHIELDS [26] many of the cells undergoing cytoplasmic shedding may eventually differentiate into specific cell types, namely lymphocytes, plasmocytes, etc.

Our phase-contrast cinerecords have now presented the visual evidence in living cells that such a phenomenon may actually occur at least as far as the capacity of histiocytes is concerned of assuming a lymphocyte-like appearance, and is not an artifact of fixation and staining procedures. The resulting cells, though preserving their histiocytic pattern of nuclear chromatin, may be easily confused with lymphocytes according to their dimension and the nucleo-cytoplasmic ratio. The signification of such a phenomenon is not clear but we find it very interesting that these histiocyte-derived lymphocyte-like cells were very numerous in peripheral blood of newts during early phases of post-starvation haemopoietic regeneration, and immediately preceding the appearing in the blood of large undifferentiated blast cells which probably derive from them and which subsequently differentiate into actively dividing erythroblasts.

Lymphocyte-like cells are in this rather similar to lymphoid blast cells which were regularly observed in haemopoietic organs by MAOLULO [14] and MAOLULO *et al.* [15] during early phases of hemopoietic regeneration in irradiated monkeys which had been transfused with autologous and homologous marrow. More recently similar reports were presented also by THOMAS [27] and by FLICKNER [7] strongly suggesting, though not proving a genetic relationship between differentiated hemopoietic cells and those primitive lymphoid blast forms which we have demonstrated may in certain circumstances originate from histiocytes by means of cytoplasmic shedding. It is interesting enough that lymphocyte-like cells may also originate in peripheral blood cultures by means of the mechanism of cytoplasmic shedding from large proteinophilic blasts [1] themselves originating from phytohemagglutinin stimulated small lymphocytes.

Summary

In newts undergoing hemopoietic regeneration after long period of starvation, circulating histiocytes were shown to shed large fragments of their cytoplasm, eventually differentiating into lymphocyte-like cells. The present investigation, which was conducted by means of phase-contrast cinemicrography on living cells, presents the visual evidence of an oblique morphogenetic pattern of cells which may be provided of stem-cell pluripotentiality.

References

1. AXTALDI, G. Personal communication (1968).
2. COHENOWITZ, G.; BERGSTEIN, M. and BERKMAN, G. M. Pluripotent stem cell function of the mouse marrow lymphocyte. *Science* 144: 886 (1964).

3. DE GIOVINEO G. Sistema reticolo-endoteliiale. In FERRATA's *Le emopatie* p.433 (Soc. Editrice Libreria, Milano 1933)
4. DOWNEY H. and WEIDENREICH, F. Über die Bildung der Lymphocyten in Lymphdrüsen und Milz. *Arch. mikr. Anat.* 80- 306 (1912).
5. FERRATA, A. *Le Emopatie*, pp.64 and 97 (Soc. Edit. Libreria, Milano 1933).
6. FERRATI, A. *Semiotologia del Midollo Osseo* (Garzanti, Milano 1946)
7. FLIEDNER, T. M., THOMAS, E. D.; FACCHÉ, D., THOMAS, D. and CROVETTE, E. P. Pattern of regeneration of nitrogen-mustard treated marrow after transfusion into lethally irradiated homologous recipients. In *La greffe des cellules hématopoïétiques allogéniques*, p. 43 Colloques Internationaux du CNRS, Paris 7-9 Sept. 1964 (CNRS, Paris 1965)
8. GOODMAN, J. W. Concerning the capacity of lymphocytes to give rise to erythropoiesis. In *La greffe des cellules hématopoïétiques allogéniques*, p. 31 Colloques Internationaux du CNRS, Paris 7-9 Sept. 1964 (CNRS, Paris 1965)
9. IZZOZZI, P. DI STELLA, G. Contributo allo studio degli elementi reticolo-istocitari del sangue circolante. *Haematologica* 13. 3 (1932).
10. JOLLY J. Recherches expérimentales sur la division indirecte des globules rouges. *Arch. Anat. micr.* 6. 435 (1904)
11. JOLLY J. *Traité technique d'hématologie* (Maloine Paris 1923)
12. LEVY, W. C. and RITZMAN, S. E. Relation of abnormal proteins to formed elements of the blood. *cellular sources.* *Ann. Rev. Med.* 16. 187 (1965)
13. LOUTIT J. F. Immunologic and trophic functions of lymphocytes. *Lancet* ii. 1106 (1962)
14. MAGLITTO, E. Trapianto di midollo osseo omologo in schiacci Rhesus irradiate. *Boll. Soc. Med. Chir. Paris* 78. 173 (1964)
15. MAGLITTO, E. VAN PUTTEN, L. M. DE VRIES, M. J. Risultati del trapianto di midollo osseo omologo in schiacci Rhesus irradiate. *Haematologica* 49: 213 (1964).
16. OSWERY D. G. and EVERETT N. B. Radioautographic studies of bone marrow lymphocytes in rise and in diffusion chamber cultures. *Blood* 21. 1 (1964)
17. POULEARD, A. La clonazione. *Nouv. Rev. franç. Hémat.* 2. 897 (1962)
18. POULEARD, A. Points de vue sur la dynamique de la surface cellulaire. *Nouv. Rev. franç. Hémat.* 3. 739 (1963)
19. RAUVER, L. Des diencitocytes. *C. R. Acad. Sci.* 110. 163 (1890)
20. ROSE, K. *Das mesenchymische Knochenmark* (Georg Thieme-Verlag, Stuttgart 1940)
21. ROMANELLI, E. G.; TRENTA, A.; VANDER, V.; SCOTTI-FOGLIARI, G.; MAGLITTO, E.; PARMA, A.; GERMA, G. Semiotologia delle modificazioni citologiche da piccole dosi di raggi X in cellule eritropoietiche allo stato vitale. *Atti del XII Congr. naz. Soc. ital. Ematol.*, Pavia, 17-18 Marzo 1963
22. ROMANELLI, E. G.; TRENTA, A.; MAGLITTO, E.; VANDER, V. and GERMA, G. Giant cells produced by mitotic reversion in prophase metaphase anaphase after low doses of X-rays. *Exp. Cell. Res.* 41. 1 (1966)
23. ROMANELLI, E. G.; TRENTA, A.; MAGLITTO, E.; VANDER, V.; GERMA, G. et CARON, G. Morphogénèse des cellules à plasméomes par l'action des rayons X. Etude en contraste de phase sur les cellules érythropoïétiques à l'état vivant. *Exp. Cell. Res.* 47. 222 (1967)
24. SAMUE, F. R. Cellular reactions to dye-protein with concept of the mechanism of antibody formation. *J. Exp. Med.* 70. 67 (1939)
25. SCHWARTZ and GRUBB R. Autoradiographic evidence for pluripotential stem cell in the bone marrow. University of California, Lawrence Radiation Laboratory UCRL 10523. 176 (1962)
26. SKILLER, J. W. Mononuclear cells, hyaline bodies, and the plasma. An analytic review. *Blood* 17. 233 (1961)
27. THOMAS, E. D. FLIEDNER, T. M., THOMAS, D. and CROVETTE, E. P. The problem of

- the stem cell: observations in dogs following nitrogen mustard. *J. Lab. clin. Med.* 63: 794 (1963)
28. WINTZ, A. and DOUGHERTY T. F.: The role of lymphocytes in normal and immune globulin production and the mode of release of globulin from lymphocytes. *Ann. N. Y. Acad. Sci.* 46: 839 (1942)
29. YOFFEY J. M.: The lymphocyte. *Annu. Rev. Med.* 15: 125 (1964)

I. Medizinische Universitätsklinik (Direktor: Prof. Dr. med. A. BERNHARDT) und Pathologisches Institut der Universität Kiel (Direktor: Prof. Dr. med. K. LEBER)

Panmyelose mit Panhämooxytopenie

H. LÖFFLER und L. D. LEIDER

Unter dem Begriff «myeloproliferierende Mischformen» hat Dr. GUOLIELMO [5] solche Myelosen aus dem Komplex der myeloproliferativen Krankheiten [3] herausgehoben, bei denen mehrere Zellreihen des Knochenmarkes vom pathologischen Prozess ergriffen sind. Die Beteiligung mehrerer Zellreihen an derartigen Hämoblastosen kann entweder konstant – also während des gesamten Krankheitsverlaufes – oder nur phasenhaft nachweisbar sein. Im einzelnen unterscheidet Dr. GUOLIELMO erythroleukämische, erythromegakaryozytäre, leukomegakaryozytäre und erythroleukomegakaryozytäre Myelosen.

Beim letztgenannten Krankheitsbild welches er auch als Panmyelose bezeichnet, beschreibt Dr. GUOLIELMO [4, 5] zwei Formen: 1. eine über Jahre verlaufende chronische, totale, hyperplastische Panmyelose, die äusserst selten sei und die sich durch eine konstante Pansythämie mässigen Grades (ähnlich der Polycythaemia vera rubra) und zusätzlich durch die Ausschwemmung von unreifen Erythroblasten unreifen Granulozyten sowie kleinen Megakaryozytenfragmenten auszeichnet. 2. erwähnt er eine fast stets akute, unvollständige, hyperplastische Panmyelose. Eine nähere Charakterisierung des letztgenannten Typus gibt Dr. GUOLIELMO allerdings nicht.

Die grosse Seltenheit derartiger Hämoblastosen veranlasst uns, im folgenden über einen Patienten zu berichten, dessen Krankheitsbild nach den Ergebnissen zytologischer fermentzytochemischer und auf optischer Untersuchungen einer Panmyelose entspricht.

Klinische Befunde

66jähriger Mann. 1918 Diphtherie und Ruhr. 1959 Operation eines Ösophagusdivertikels. Sonst keine ernsthaften Erkrankungen. Familienanamnese o.B.

Seit Januar 1962 bei körperlicher Belastung Atemnot und Schwindelgefühl. Ende Juli 1964 schwarzer Stuhl. Deutliche Verschlechterung des Allgemeinbefindens. Zunahme von Atemnot und Schwindelgefühl, mehrmals Ohnmachten.

Erste stationäre Aufnahme am 11.8.1964. Auffällige Blasse, reduzierter Allgemeinzustand. Leber Milz und Lymphknoten nicht vergrößert. Keine hamorrhagische Diathese. Im Stuhl bei mehrfacher Kontrolle kein Blut nachweisbar. Laborbefunde: BSG 25/50 mm. Serumtransaminasen, alkalische Phosphatase, Bilirubin, Serumalbumin, Gerinnungsprotein und Elektrophoreogramm unauffällig. Röntgenologisch zwei Divertikel im unteren Sigma. Magen-Darm-Trakt sonst o.B. Weiterhin schwere normochrome Anämie, Leukozytengesamtzahl an der unteren Normgrenze. Therapie: Inosin mit 9 Bluttransfusionen zu je 500 ml. Anstieg des Hämoglobins von 5,3 auf 11,4 g%, BSG 11/28 mm. Am 11.9.1964 Entlassung.

Erneute Hospitalisierung bei im wesentlichen unveränderten klinischem Befund wegen Zunahme der subjektiven Beschwerden am 21.10.1964. Röntgenologisch an Ösophagus, Magen, Colon, Nieren, Gallenblase und Thoraxorganen kein pathologischer Befund. Hämoglobin 7,9 g%. Leukozytengesamtzahl zwischen 3100 und 6000 mm^3 schwankend. Thrombozyten 59000/ mm^3 . Serum-Eisen 218–319 $\mu\text{g}\%$. HbE 30,6. Retikulozyten 2,10 %. Osmotische Resistenz der Erythrozyten 0,30%–0,34%. Na Cl Geringfügig gesteigert.




Abb. 1 Verhalten von Hämoglobin, Leukozyten und Thrombozyten während des Krankheitsverlaufs.




Abb. 2 () und (b) Junge, megaloblastäre Erythroblasten mit pseudopodienartigen Plasmasanktionen. () Pathologische Erythroblastennukleosomen mit erkrankten Chromosomen. Links unten ein Proerythrocyt. (d) bis (g) Pathologische Erythroblastennukleosomen sowie Erythroblasten mit parasitiformen Chromatinbrüchen. Sternalpunktat. Pappenheim-Färbung ($\times 1400$).

Quick 108%, Gerinnungszeit 2'30", Blutungszeit 15, Faktor II 70%, Faktor V 114%, Faktor VII 86%. Über das Verhalten von Hämoglobin, Leukozyten und Thrombozyten während des Krankheitsverlaufes unterrichtet die Abb. 1. Das Sternalpunktat (28.10.1964 und 7.12.1964, siehe unten) ergab die Diagnose Panmyelose. Therapie: Ab 8.12. täglich 2,5 mg Amethopterin sowie Prednison mit einer anfänglichen Dosis von 200 mg/die, die kontinuierlich bis auf 25 mg/die reduziert wurde. In der Zeit vom 30.10. 14.12.1964 insgesamt 7 Bluttransfusionen zu je 500 ml. Bei der Entlassung am 15.12. Hämoglobin 9,1 g%, Leukozyten 4000/mm³, Thrombozyten 42000/mm³.

Desto stationäre Aufnahme am 2.1.1965. Hb 7,0 g% bei 2,53 Ml/l. Erythrocyten Leukozyten 2900/mm³, Serumwerts 182 und 217 μ g%. Weiterbehandlung mit täglich 25 mg Prednison sowie 2,5 mg Amethopterin. Ausserdem in der Zeit vom 2.1. 14.1.1965 insgesamt 4 Bluttransfusionen zu 500 ml. Entlassung am 14.1.1965.




Abb.3. (a) Blasten, Proerythrocyten und einzelne sogenannte Pseudopelgerformen. (b) Blasten, Proerythrocyten, dazwischen Erythroblasten mit stark verklumpten und verdichteten pyknotisch veränderten Kernen. Sternchenstrich ($\times 1400$)

Vierter stationärer Aufenthalt in der Zeit vom 17. I. 1963 wegen Fieberschüben und ausgedehnten flächenhaften Hautblutungen. Schwere, durch antibiotische Behandlung und Flortecisulfattherapie nicht mehr zu beherrschende Bronchopneumonie. Am 21. I. 1963 Exitus letalis.

Morphologische Befunde

Im peripheren Blutstrich zeigten die Erythrozyten eine hochgradige Anisozytose und Poikilozytose sowie eine ausgeprägte Hypochromasie. Häufig waren sie basophil punktiert und enthielten Cabot'sche Ringe. Auf 100 Leukozyten fanden sich maximal 2 Normoblasten, deren Zytoplasma vacuoliert, zum Teil optisch leer erschien. Im weichen Differentialblutbild wurden zusätzlich 3% Myeloblasten gezählt. Der Anteil der Lymphozyten lag im Normbereich. Die neutrophilen Granulozyten waren vermindert und zum grossen Teil pathologisch verändert. Es fanden sich sogenannte Pseudopelgerformen, weiterhin vereinzel übersegmentierte und polyploide Neutrophile mit eigenartig verklumpten Kernen. Gelegentlich waren im Zytoplasma der stab- und segmentkernigen Neutrophilen Vakuolen und Doehle-Körperchen vorhanden. Auch die Thrombozyten waren atypisch. Sie zeigten eine erhebliche Polymorphie, und es fanden sich Riesenthrombozyten sowie ungranulierte Formen.

Bei den beiden Stoskentrunksternstrichungen, die wir am 28. 10. und am 7. 12. 1964 durchführten, wurden so weitgehend identische Veränderungen gefunden, dass wir sie zusammenfassend darstellen. Die Ausstriche waren recht reichlich. An der Zellvermehrung waren alle drei blutbildenden Zellreihen beteiligt. Am stärksten trat die Erythropoiese hervor. Es fanden sich zahlreiche Anomalien, von denen alle Reifungsstufen betroffen waren (Abb.2) megaloblastare Formen, zwei- und mehrkernige Erythroblasten, atypische

Mitosen sowie sehr häufig Kernverklümpungen und Chromatinabspargungen. Bei manchen Erythroblasten war das Zytoplasma von kleinen runden Chromatinbrocken angefüllt. Solche Veränderungen waren manchmal kaum von pathologischen Mitosen zu unterscheiden. Manche reiferen Erythroblasten zeigten ein auffällig schmales Zytoplasma, andere eine Vakuumisierung. Auch bei den reiferen Erythroblasten waren die Kerne vergrößert, und zwar bestanden sie häufig ein dichtes, klumpiges, fast strukturloses Chromatin, so dass der Eindruck einer Pyknose entstand (Abb. 3b).

In der granulokytären Reihe fielen insbesondere Blasten und Promyelocyten auf (Abb. 3b) die herdförmig zusammenlagern und erhebliche Kernpolymorphien und Granulationsanomalien aufwiesen. Die reiferen Granulocytenvorstufen entsprachen zum Teil sogenannten Pseudopelgerzellen (Abb. 3a) vereinzelt sah man Reusenformen, wie sie bei megaklastärer Anämie auftreten.

Die reichlich vorkommenden Megakaryocyten (Abb. 4) ließen erhebliche Größendifferenzen erkennen. Zytologisch fanden sich zahlreiche Atypien und Abweichungen von der Norm. Neben Megakaryocyten mit stark segmentierten oder gelappten Kernen sahen wir Knochenmarkriesenzellen mit sehr stark verklümptem Chromatin, ähnlich wie bei einer Kernpyknose. Das Zytoplasma der Megakaryocyten war in den meisten Fällen basophil und nicht granuliert sowie von verschiedenen grossen Vakuolen durchsetzt. Die Zellgrenzen waren oft nicht klar erkennbar sondern stark zerklüftet, so dass der Eindruck eines scholligen Plasmaserfalls entstand. Innerhalb von basophilen Zytoplasmabereichen sah man schäumlich umgebürstete oder zart rötlich gefärbte Areale. Auch bei den Megakaryocyten fielen uns zahlreiche Mitosen mit Chromosomenabspargungen und Chromatinverklümpungen auf.

Cytochemische Befunde

Eisenspeicher. 80% der Erythroblasten der Sternabstriche enthielten freies Eisen in Form von kleinen Granula. Dabei waren die Granula gegenüber der Norm vergrößert; sie lagen meist perinukleolar. Weiterhin war eine erhebliche Vermehrung von eisenspeichernden Retikulumzellen zu konstatieren.

Peroxidase-Schiff-Reaktion (PAS) I 12% der Erythroblasten des Knochenmarkes fielen sich eine schwache diffuse positive Reaktion. Die Megakaryocyten waren dagegen häufig negativ; zum Teil auch schwach homogen positiv. Von den Zellen der Granulokytopenie reagierten die Blasten negativ; in den Promyelocyten und den weiteren Ausreifungsstadien fiel die Reaktion zwar positiv aus, aber schwächer als normal.

Alkalische Phosphatase. In den Sternabstrichen zeigten Kapillarendothelien sowie einzelne reife Granulocyten eine positive Reaktion. Im peripheren Blutbild (Untersuchung vom 7. 12. 1964) waren 38% der reifen Granulocyten phosphatase-positiv; wobei ein Index von 44 ermittelt wurde.

α -Naphthylacetat-Esterase. Am stärksten positiv reagierten die Retikulumzellen. Bei den Erythroblasten aller Reifungsstadien war die Aktivität ganz erheblich gesteigert, wobei das Reaktionsprodukt diffus im Zytoplasma verteilt erschien. Auch die Erythroblastomitosen wiesen diese Aktivierungssteigerung auf. In den Megakaryocyten war gelegentlich eine ausserordentlich grobgranuläre Ablagerung von Reaktionsprodukt vorhanden. Die Granulokytopenie zeigte keine Besonderheiten.

Autopsische Befunde (Sekt. N. 73/63)

Makroskopische Befunde. Panmyelose: Dunkelfestes Mark im gesamten Femur; in den Wirbelkörpern und im Sternum. Geringsgradige Vergrößerung von Leber und Milz. Hämorrhagische Diathese: Es zeichnenspezifischgroße Blutungen in der Magenschleimhaut; flächenhafte Blutungen in der Nierenbeckenschleimhaut beiderseits und im Nierenparenchym; rechts pfennigstückgroße, subintimale Blutung im Bereich der Aorta abdominalis; flächenhafte Hautblutungen im Bereich des Stammes und der Extremitäten; kleine, nicht ganz frische




Abb 4 Atypische Megakaryozyten und Megakaryozytenmyelosen. Sternakzustrich. Pappenheim-Färbung (1000)

Hirnblutungen im Putamen-Kleistrambereich links. Schwere chronische katarrhalische Tracheobronchitis. Geringgradige diffuse Bronchiektasen beiderseits. Schwere fibrinreiche Pneumonie beiderseits. Fibrinose Pleuritis beiderseits, rechts stärker als links. Mäßig schweres chronisches subtales Lungenemphysem. Dilatation der rechten Herzkammer. Leberverfettung. Lipidenspeicherung der Nebennierenrinde beiderseits. Geringgradige Arteriosklerose der Aorta. Schwere Coronararteriosklerose mit weitgehendem Verschluss des R. interventriculär der A. coronaria sinistra. Dilatation der linken Herzkammer. Schweres Lungenödem. Cholestase der Gallenblase. Adenomatöse Prostatahyperplasie. Geringgradige Blasenblase.

Histologische Befunde. Im Knochenmark von Wirbel, Sternum und Femur verhielt sich die Spongiosa regelhaft, die Silberfasern waren nicht vermehrt. Die Fettzellen waren fast vollständig geschwunden. Bei schwacher Vergrößerung war bereits eine merkwürdige und ungewöhnliche Vielfalt von Zellen auffällig: Neben sehr kleinen kamen sehr große, neben




Abb. 5. Schnittpreparat vom Femurmark. () Schwund der Fettsäulen. Starker Versatz von atypischen Megakaryozyten und zum Teil mehrkernigen Erythroblasten. Giemsa. (b) Nachweis der Naphthol-AS-D-Chloracetat-Esterase am Paraffinschnitt. Die atypischen, promyelocytenähnlichen Zellen der neutrophilen Granulopoiese heben sich durch ihre positive Reaktion (schwarz, im Original leuchtend rot) heraus ($\times 350$)

stark basophilen oxyphile Elemente mit teils runden, teils auch bizarr, gelappten Kernen vor. Viele der Zellen waren mehrkernig.

Bei stärkerer Vergrößerung (Abb. 5a) waren Megakaryozyten, Erythroblasten und Granulopoiesenzellen zu unterscheiden. Die Megakaryozyten lagen in lockeren Gruppen und besaßen häufig sehr weites, teils basophiles, teils oxyphiles, leicht gekörntes Plasma. Oft waren ihre Plasmagrenzen ausgesprochen unscharf begrenzt. Die Megakaryozytenkerne zeigten ein lockeres, helles Chromatingerüst und waren oft bizarr geformt mit Lappungen und Segmentierungen aller zur erlenklichen Formen. Nukleolen waren deutlich erkennbar, die Kernmembranen meist scharf ausgeprägt.

Die Erythropoiesestellen standen zahlenmäßig durchaus im Vordergrund. Es waren alle Reifungsstufen bis zum oxyphilen Normoblasten in bunter Mannigfaltigkeit zu erkennen, doch bestanden erhebliche Größensunterschiede. Während die Normoblasten durch ihr oxyphiles Plasma relativ gut erkennbar waren, gelang die sichere Identifizierung von unreifen basophilen Erythropoiesevorstufen selbst im Giemsa-Präparat nicht in allen Fällen. Unter den unreifen Erythropoiesezellen fielen häufig zweikernige Exemplare auf. Viele Erythropoiesezellen waren in Mitose begriffen. Dabei fanden sich im Plasma nicht selten abgesprengte Kernteile. Besonders auffällig war das Fehlen der normalerweise immer vorhanden und für die Erythropoiese typischen betont gruppenförmigen Lagerung der Zellen.




Abb 6. Schnittpreparat vom Femurmark. (a) Nachweis der α -Naphthylacetat-Esterase: Atypische Erythroblasten stark positiv mit typisches perinukleärer Reaktion (schwarz, im Original rotbraun). Darzwischen einige sehr stark positive Plasmazellen von Retikulumzellen ($\times 560$). (b) Nachweis der sauren Phosphatase. Im wesentlichen sind die Reticulumzellen positiv (schwarz, im Original rot); daneben wenige Proerythroblasten mit punktförmiger perinukleärer Reaktion (z.B. rechts oben) ($\times 350$).

Die Grundpolkornzellen traten im Präparat zahlenmäßig zurück. Segmentkernige, stabförmige Metamyelozyten und Myelozyten waren kaum vorhanden. Dagegen konnten einzelne Bgunde atypisch gestaltet. Proerythrozyten identifiziert werden. Auch Vorstufen der Eosinophilen kamen gelegentlich vor.

Weiterhin waren Reticulumzellen in mäßiger Anzahl, einige Plasmazellen sowie Lymphozyten eingestreut. Gewebsmastzellen kamen nicht vor.

In der Milz fanden sich innerhalb der Sinus nur wenige Infiltrate aller drei blutbildenden Zellsysteme. Am auffälligsten stachen die Megakaryozyten hervor, die die gleichen pathologischen Veränderungen zeigten wie im Knochenmark. Im Gegensatz zu den Verhältnissen im Knochenmark waren unter den Myelopkornzellen relativ reichlich reife Granulozyten vorhanden. Erythropoiesenzellen kamen nur vereinzelt vor. Die Plasmaretikulumzellen wiesen eine starke Hämociderose auf. Plasmazellen waren reichlich vorhanden.

In der Lunge bestand eine erhebliche obstruktive Bronchopneumonie mit Infiltraten durch gelapptkernige neutrophile Granulozyten, von denen ein größerer Teil als Pseudoepithelien vorlag. In den Alveolen waren ausserdem grosse Mengen esser erweichenden Flüssigkeit im Stau eines Lungenödems vorhanden. Vielfach traf man auf kleine Embolus-herde.

1. *Leber*: Lymphknoten vom Lungenhilus, Tonsillen, Milz und Hdr. ließen keine Besonderheiten aufweisen, keine kulturellen Befunde.

Histologische Befunde: Im Knochenmark reagierten die Megakaryozyten bei der PAS-Färbung sämtlich schwach diffus-positiv. Die Reaktion war jedoch erheblich schwächer als normalerweise. Die Megakaryozyten zeigten weiterhin eine schwache Reaktion beim Nachweis von α -Naphthylazetat-Esterase von Naphthol-AS-acetat-Esterase sowie von saurer Phosphatase. Naphthol-AS-D-Chlorazetat-Esterase und alkalische Phosphatase besaßen die Megakaryozyten nicht.

Die Erythropoiesezellen reagierten beim α -Naphthylazetat-Esterase-Nachweis außerordentlich stark positiv (Abb. 6a) und erreichten fast den Aktivitätsgrad der Reticulocyten, die die am stärksten positiven Knochenmarkszellen darstellen. Besonders intensiv färbten sich große, dem Proerythroblasten an die Seite stellende Elemente an. Sie zeigten bereits nach einer Inkubationszeit von nur 2 min eine deutliche Reaktion. Im Unterschied zum Sternalpunktat war die Fermentaktivität vor allem auf eine schmale, den Kern ummittelbar wie eine Schale umgebende Plasmaschicht konzentriert, wie dies für normale Erythropoiesezellen hochcharakteristisch ist. Beim Nachweis der sauren Phosphatase reagierte ein kleiner Teil der besonders unreifen Erythroblasten mit einer deutlichen Anfärbung innerhalb eines perinukleären Plasmaperikles (Abb. 6b). Naphthol-AS-acetat-Esterase, Naphthol-AS-D-Chlorazetat-Esterase und alkalische Phosphatase konnten in den Erythropoiesezellen nicht nachgewiesen werden.

Mit dem Nachweis der Naphthol-AS-D-Chlorazetat-Esterase stellten sich die neutrophilen Granulopoiesezellen elektiv dar. Sie kamen (Abb. 5b) nur in relativ geringer Anzahl vor und entsprachen etwa den Promyelozyten. Abweichend von den normalen Promyelozyten besaßen sie jedoch unregelmäßig gestaltete Kerne. Manchmal waren sie auch zweikernig. Beim Nachweis der α -Naphthylazetat-Esterase, der Naphthol-AS-acetat-Esterase, der sauren und der alkalischen Phosphatase verhielt sich die Granulopoiese unauffällig.

An den übrigen Organen konnten durch die cytochemischen Untersuchungen keine Befunde erhoben werden, die über diejenigen Gesichtspunkte hinausführten, die bereits durch die histologische Untersuchung gewonnen worden waren.

Diskussion

Die klinischen Befunde unseres Patienten erlaubten zunächst ohne die Untersuchung des Sternalpunkts keine endgültige Diagnose. Zwar bestand von Beginn der Erkrankung an eine Panhämozytopenie mit Anämie, Thrombozytopenie und Leukozytenwerten, die an der unteren Normgrenze lagen oder gering erniedrigt waren, und im Differentialblutbild wurden einzelne Blasten und Erythropoiesezellen gefunden. Doch wiesen diese Befunde, wie auch die qualitativen Veränderungen der neutrophilen Granulozyten mit Pseudopelgerformen, Übersegmentation und Polyploidie und wie die morphologischen Veränderungen der Erythrozyten und Thrombozyten lediglich auf eine schwere Schädigung der Hämatopoiese hin, ohne eine sichere Diagnose zu erlauben.

Erst bei der Untersuchung des Sternalmarkes konnte die Erkrankung in ihrem Wesen klar erkannt werden. Es fand sich eine schwere Hyperplasie aller drei blutbildenden Zellreihen mit hochgradigen

Atypien in der Erythropoese, mit atypischen Blasten und Promyelozyten in der Granulopoese und vor allem mit reichlich polymorphen, unreifen und atypischen Megakaryozyten. Die Erythroblasten und die Megakaryozyten fielen besonders auf. Einzelne Erythroblastenkerne waren fragmentiert, neben noch erhaltenen Kernen fanden sich Ansammlungen von «Chromatinkugeln» und ausserdem sah man sowohl in den Erythroblasten als auch in den Megakaryozyten zahlreiche verschiedengestaltige Mitoseanomalien. Zytochemisch imponierte eine deutliche Vermehrung der Sideroblasten mit vergrößerten Eisengranula. Ferner war die α -Naphthylazetat Esterase-Aktivität der Erythroblasten erheblich gesteigert. Bei der PAS-Reaktion ergab sich allerdings keine wesentliche Erhöhung des Anteiles positiver Erythroblasten gegenüber der Norm. An Hand dieser Befunde konnte die Diagnose einer Panmyelose sicher gestellt werden.

Bei der Autopsie wurde eine eindeutige Hyperplasie des Knochenmarksparenchyms mit einem fast vollständigen Schwund der Fettzellen festgestellt. Ausserdem fanden sich in der Milz Infiltrate von Megakaryozyten, von Granulopoiesezellen und von Erythroblasten. Im Knochenmarksschnitt fiel vor allem die ungewöhnliche Vielfalt der Zellen und die sehr starke Vermehrung von atypischen Megakaryozyten auf, die an manchen Stellen sehr dicht gelagert waren. Zahlenmässig beherrschte jedoch – wie im Knochenmarksaustrich auch – die hochgradig polymorphe und atypische Erythropoese mit vielen mehrkernigen Zellen und reichlich Mitosen das Bild. Die Granulopoese stand dagegen quantitativ zurück, war aber auch im histologischen Schnitt erkennbar pathologisch verändert und insbesondere durch die Anwendung der Naphthol AS-D-Chlorazetat Esterase-Reaktion am Paraffinschnitt [10] gut darzustellen. Damit war auch in Anbetracht der autopsischen Befunde an dem Vorliegen einer Hämoblastose nicht zu zweifeln, wie aus der schweren Infiltration des Knochenmarkes mit Verdrängung der Fettzellen und aus dem Nachweis von atypischen Megakaryozyten, Granulopoiesezellen und Erythropoiesezellen in der Milz hervorgeht. Dass es sich im vorliegenden Falle zweifellos um eine Panmyelose handelt, zeigen die schweren morphologischen Veränderungen an allen drei Knochenmarkszellreihen.

Ausser morphologischen Befunden, die das Vorliegen eines malignen Geschehens bewiesen, waren auch entsprechende zytochemische Befunde vorhanden, wie sie bei anderen malignen Hämoblastosen vorkommen. So imponierte eine deutliche Vermehrung von Sidero-

blasten mit vergrößerten Eisengranula sowie eine Vermehrung von eisenspeichernden Retikulumzellen. Beide Befunde sind als Ausdruck einer Eisenverwertungsstörung zu betrachten und sie kommen – abgesehen von der sideroachrestischen Anämie – auch bei Erythrämien und Erythroleukämien vor [7 15 8]. Im übrigen ist die bei unserer Beobachtung vorliegende Eisenverwertungsstörung im Rahmen einer Abhandlung über die pathologische Anatomie der sideroachrestischen Anämie ausführlicher besprochen [12] so dass sich ein weiteres Eingehen auf diese Problematik erübrigt.

Die erheblich gesteigerte α -Naphthylazetat Esterase Aktivität der Erythroblasten stützt ebenfalls die Annahme einer malignen Entartung der roten Reihe, da ähnliche Aktivitätssteigerungen bisher nur bei Erythrämie und Erythroleukämie beobachtet wurden wenn man von der perniziösen Anämie absieht [16 13 14 11]. Offenbar ist dieser zytochemische Befund immer dann zu erheben, wenn eine in hohem Masse ineffektive Erythropoiese vorliegt.

Die PAS-Reaktion erbrachte allerdings keinen Hinweis auf das Vorliegen einer malignen Veränderung innerhalb der Erythropoiese denn der Anteil positiver Erythroblasten war gegenüber der Norm nicht wesentlich erhöht. Im allgemeinen wird eine deutlich gesteigerte PAS-positive Reaktion eines grossen Teiles der Erythroblasten als sehr charakteristischer Befund bei reiner Erythrämie und bei Erythroleukämie angesehen [1 18, 15]. Dies konnten wir bei eigenen Untersuchungen an 6 Patienten mit Erythroleukämie und an einem Patienten mit erythrämischem Terminalstadium bei chronischer myeloischer Leukämie bestätigen. Bei subakut oder chronisch verlaufenden Neoplasien der Erythropoiese kann die gesteigerte PAS-Reaktion der Erythroblasten aber auch fehlen oder nur sehr gering ausgeprägt sein [22, 7]. Daraus ergibt sich, dass nur der positive Befund als Stütze für die Annahme einer malignen Erkrankung der roten Reihe anzusehen ist, während umgekehrt ein negativer Befund wie er in unserem Falle erhoben wurde, eine solche Möglichkeit keineswegs ausschliesst.

Bei dem von uns beschriebenen Krankheitsbilde handelt es sich um eine besondere Hämoblastose die von anderen myeloproliferativen Erkrankungen, wie der Polycythaemia vera rubra der Osteomyelosklerose und Myelofibrose einschliesslich der Übergangsformen zu chronischen myelösen Leukämien und von der sogenannten Panmyelopathie mit hyperplastischem Mark abgegrenzt werden kann. Von diesen Krankheitszuständen unterscheidet sich unsere Panmyelose durch die sehr schweren Zellatypien. Von der Osteomyelo-

sklerose und von der Myelofibrose ist die Panmyelose durch die fehlende Spongiosa und Faservermehrung abgegrenzt. Gegen das Vorliegen einer Polycythaemia vera rubra sprechen die klinischen Befunde. Eine Panmyelopathie mit hyperplastischem Mark, wie sie in extrem seltenen Fällen als Initialstadium einer chronischen Benzolvergiftung beschrieben ist [2] kann anamnestisch ausgeschlossen werden. Andere Fälle von Panmyelopathie, die meist ätiologisch nicht zu klären sind und vielfach als Autoimmunreaktion gedeutet werden, kommen ebenfalls nicht in Frage, da bei einer solchen Annahme die schweren zytologischen und zytochemischen Veränderungen unverstänlich blieben, die eindeutig auf eine maligne Proliferation der Knochenmarkszellen hinweisen. Im übrigen kann keinesfalls ausgeschlossen werden, dass sich hinter manchen Fällen von derartigen Panmyelopathien mit hyperplastischem Mark in Wirklichkeit Panmyelosen verbergen.

Die Befunde des von uns beobachteten Patienten weichen in verschiedenen Punkten von der Beschreibung des Panmyelosetypus I von DI GUOLIELMO [5] ab. So fehlt z.B. die Panzythämie, und unreife Zellen der Hämatopoese wurden nur bei längerem Suchen in geringer Zahl im peripheren Blutbild gefunden. Schließlich erstreckte sich der Krankheitsverlauf auch nicht wie bei den Fällen DI GUOLIELMO über mehrere Jahre, sondern war sehr kurz. Ob eine Ähnlichkeit mit der zweiten von DI GUOLIELMO erwähnten Verlaufsform der Panmyelose besteht, die er eine «fast stets akute, unvollständige, hyperplastische Panmyelose» nennt, vermögen wir nicht zu entscheiden, da DI GUOLIELMO eine genaue Charakterisierung dieses Krankheitsbildes nicht gegeben hat.

Von manchen werden unter dem Terminus Panmyelose Krankheiten verstanden, die von unserer Beobachtung in vielen Einzelheiten abweichen und die im allgemeinen auch nicht ohne weiteres als maligne Hämoblastosen angesehen werden. So belegen HERZOGAL und Mitarbeiter [9] die Osteomyeloidklierose und verwandte Krankheitsbilder mit dem Ausdruck «panmyélémie» und RAPPAPORT [19] faßt unter dem Begriff Panmyelose die Polycythaemia vera und die «Myeloidklierose mit myeloider Metaplasie» zusammen. Wir sind dagegen der Meinung, dass die Bezeichnung Panmyelose solchen Hämoblastosen vorbehalten bleiben sollte, die eindeutig Zeichen einer malignen Proliferation aller drei blutbildenden Systeme in Form von schweren Zelltypen etc. aufweisen, wie das bei unserer Beobachtung der Fall ist. Im übrigen ist das von uns beschriebene Krankheitsbild

durch den völlig abweichenden klinischen Verlauf und den abweichenden pathologisch-anatomischen Befund sowohl von der Osteomyeloidose als auch von der Polycythaemia vera klar abgetrennt.

Unsere Beobachtung könnte die durch zytogenetische Untersuchungsergebnisse gestützte Ansicht von einer gemeinsamen Stammzelle für die Erythropoiese, die Granulopoiese und die Megakaryozytopoiese weiter unterbauen [20, 21, 23] eine Ansicht, die u. a. aus dem Vorkommen des für die chronische myeloische Leukämie typischen Philadelphia-Chromosoms auch in Erythroblasten und Megakaryozyten abgeleitet ist. Eine solche gemeinsame Stammzelle wird auch von HAYNIZ und Mitarbeitern [6] anhand zytologischer und zytochemischer Untersuchungsergebnisse bei unreifelligen Leukosen diskutiert. Allerdings ist auch die Möglichkeit zu erwägen, dass Knochenmarkszellen – vor allem, da sie genetisch untereinander nahe verwandt sind – gleichartig anfällig gegenüber geschwulstauslösenden Noxen sind. Damit wäre z. B. denkbar, dass ein solches Agens bei allen Zellreihen gleichartige Veränderungen hervorruft, ohne dass eine gemeinsame Stammzelle unbedingt vorliegen muss.

Zur Frage der Therapie ist zu erwähnen, dass wir mit kleinen Dosen von Amethopterin wie sie von MORASCHKE [17] zur Behandlung von Erythroleukämien empfohlen werden und wie sie auch von uns mit gutem Erfolg bei einem Fall von Erythroleukämie eingesetzt werden konnten, in Kombination mit Prednison bei unseren Patienten keinen sichtbaren Erfolg hatten. Allerdings konnten wir die Behandlung nur 14 Tage lang durchführen. LUDKE [13a] hat bereits 1950 einen deutlichen Effekt des Folsäureantagonisten Aminopterin bei Erythroleukose beschrieben.

Zusammenfassung

Es wird über einen 66-jährigen Patienten berichtet, der das Krankheitsbild einer Panmyelose mit Panhämocytopenie bot. Bei der blutischen und autopsischen Untersuchung wurde eine schwere Hyperplasie des Knochenmarkes festgestellt, an der die Erythropoiese, die Granulopoiese und die Megakaryozytopoiese beteiligt waren. Alle drei Zellreihen wiesen überdies schwere zytologische Atypien auf. In der Milz fanden sich extramedulläre Blutbildungsherde. Die zytologischen und zytochemischen Befunde werden im Hinblick auf die allgemeine hämatologische Bedeutung solcher Fälle besprochen, und es werden diagnostische, differential-diagnostische und therapeutische Fragen gestreift.

Summary

This paper reports a case of malignant panmyelosis with panhemocytopenia, which occurred in a 66-years-old patient. At biopsy and autopsy the bone marrow revealed heavy hyper-

plasia of the blood forming parenchyma including erythropoiesis, granulopoiesis, and megakaryopoiesis as well. There were in addition, many cytological atypias in each of the three bone marrow cell strains. The cytological and cytochemical observations are discussed with respect to the general hematological importance of such cases, and problems of diagnosis, differential diagnosis, and therapy are briefly mentioned.

Literatur

1. BALDI, M., FUSCHIERI, H. H., FORNACE, K. and DIAMBER, W. The anemia of the Di Guglielmo syndrome. *Blood* 14: 334-363 (1959).
2. BERGMANN, H. und HARWERT, H.-G. *Praktische Hämatologie* (Thieme, Stuttgart 1967).
3. DIAMBER, W. Some speculations on the myeloproliferative syndromes. *Blood* 6: 372-373 (1951).
4. DI GUGLIELMO, G. Erythroleukämie. *Sci. med. Ital. (durch Ausgabe)* 3: 13-33 (1954).
5. DI GUGLIELMO, G. Die Erythroblastosen. In: HANSEN und HATTMANN Handbuch ges. Hämatol., Bd. III/1 (Urban & Schwarzenberg München/Berlin 1960).
6. HAYSON, F. G. J.; QUARLES, D. and DOLL, R. The cytology and cytochemistry of acute leukaemias (Her Majesty's Stationary Office, London 1964).
7. HAYSON, F. G. J. and QUARLES, D. Refractory sideroblastic anaemia and erythraemic myelosis: possible relationship and cytochemical observations. *Brit. J. Haemat.* 6: 381-387 (1960).
8. HEILMEYER, L. *Störungen der Hämsynthese* (Thieme, Stuttgart 1964).
9. HERRUYAL, R., HERRUYAL, H., QUERCI, O.; CUVY G. et DORNELLE, J. La pancytémie chronique (spinothégale avec érythroblastose, myélocytose et mégakaryocytose sanguines) *Nouv. Rev. franç. Hémat.* 1: 358-360 (1961).
10. LADNER, L. D. Über die selektive fermentzytochemische Darstellung neutrophiler myeloischer Zellen und Gewebeschatten im Paraffinschnitt. *Klin. Wochschr.* 42: 333 (1964).
11. LADNER, L. D. Fermenthistochemische Befunde bei chronischer Erythroblastose und akuter Erythrämie. *Klin. Wochschr.* 42: 795-976 (1963).
12. LEONERT, K. und OBERKIRCHNER, H. Pathologische Anatomie der sideroachroischen Anämie (Untersuchung von 4 Fällen) *Beitr. path. Anat.* 136: 68-89 (1967).
13. LÖFFLER, H. Zytochemischer Nachweis von unspitzenförmiger Esterase in Erythroblasten. *Proc. europ. Soc. Haemat.*, Wien 1961 vol. 8, p. 473 (Karger Basel/New York 1962).
14. LUDOX, H. Zur Klinik und Hämatologie der Erythromyelosen. *Acta haemat.* 6: 321-342 (1950).
15. LÖFFLER, H. und SCHUBERT, J. C. F. Zytochemischer Nachweis von Esteraseaktivität in den Angeräufchen (Moirschien) der Megaloblasten. *Klin. Wochschr.* 39: 1027-1028 (1961).
16. MÖRNER, H. Zytochemische Beobachtungen von Erythropathien unter besonderer Berücksichtigung von Glykogen und freiem Eisen. *Schweiz. med. Wochschr.* 91: 1209-1211 (1961).
17. MIZLER, H., TICALDINI, V. und SCHÄUBER, A. Unspezifische Esterasen bei Erkrankungen und Reaktionen des erythropoetischen Systems. *Proc. europ. Soc. Haemat.*, Wien 1961 vol. 8, p. 476 (Karger Basel/New York 1962).
18. MOSCHLER, S. Zeitgemäße Behandlung der Leukosen. *Schweiz. med. Wochschr.* 95: 268-274 (1965).
19. QUARLES, D. and HAYSON, F. G. J. Periodic-acid-Schiff positivity in erythroblasts with special reference to Di Guglielmo's disease. *Brit. J. Haemat.* 6: 26-33 (1960).

19. RAPPAFORT J.L.: Panmyelosis; in Tumors of the hemopoietic system. Atlas of tumor pathology Section III fascicle 8 (Armed Forces Institute of Pathology Washington, D.C. 1966).
20. TOCUM, I. M.; JACOB, P. A.; COURT BROWN, W. M.; BARRIE, A. G. and WILLIAMSON, E. R. D. Cytogenetic studies on bone marrow in chronic myeloid leukaemia. *Lancet* **i**, 844-846 (1963)
21. TRUJILLO J. M. and OWNO, S.: Chromosomal alteration of erythropoietic cells in chronic myeloid leukemia. *Acta haemat.* **29**: 311-316 (1963)
22. VERLOOF A. L. C.; BEERNOVA, J. and DIERCKAED-NJOO, A. Primary or essential siderochroic anaemias. *Acta haemat.* **27** 129-143 (1962)
23. WRAHO, J. FRIE III E. TJIO, J. H.; CANNON, P. P. and BASCHER, O. The distribution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. *Blood* **22**, 664-673 (1963)

Department of Medicine and Department for Pathological Anatomy
Intensive Care Unit, General Hospital Maribor

Fatal Peroral Iron Poisoning in a Young Woman

M. ČERNELČ, V. KUŠAR and S. JARŠEN

During recent years a considerable number of severe or fatal accidental poisonings by iron salts has been reported [1 2, 3 5 6 7 8, 12 13 14]. In the USA approximately 2000 cases of iron intoxication are encountered yearly with a death rate of 45 % [4]. In most cases children ingested tablets of ferrous salts, usually coloured or coated with chocolate. The exact dose of iron ingested could only be determined accurately in 36% of a group of 172 children [4]. The introduction of deferoxamine changed the treatment and improved the fatal outcome of iron poisoning [10]. The death rate is now lower than 10 % if proper therapy is started early enough. The normal low iron excretion in urine is increased by deferoxamine to levels exceeding one hundred times the normal values [10 15].

The majority of cases with iron poisoning reported were in children and it may be of interest to report a case of suicidal iron intoxication in an adult with a fatal outcome.

Case Report

A 25-year-old woman was admitted to the Psychiatric Department with the diagnosis of psychoneuroses. Her fiancé reported that he had found her in a semicomatose state vomiting brown and black masses which were suggestive of gastric hemorrhage. Thereafter the patient admitted to have ingested approximately 100 tablets 2 days previously because of conflicts in her family. On admission the patient was semicomatose and said with weak voice that she took two bottles of antianemic tablets about 32 h before. The local physician reported later that he found two empty bottles of antianemic tablets, containing 50 mg iron each, in the patient's room. The total dose taken was 10 g iron or 160 mg/kg body weight. The clinical findings were: dark brown appearance of skin similar to sun tanning. Feces of the 8th was found, but the reflexes on examinations of the extremities were normal. Skin temperature was 36.5°C, the blood pressure was not measurable, the pulse rate 130.




Fig 1 Myocardium. Sweden III Myocardial fibers with microscopic droplets of fat (appearing as black spots).

Hb 72.2% (11.55 g %), RBC 3,830,000, \bar{M} 0.95, WBC 49,000, bands 1 %, segs. 81 %, lymph. 12 %, monocy. 6 %. Blood urea 84 mg %, iron 480 μ g %. Stool examination for occult blood positive.

After infusion of Ringer solution with Dexamethasone, Rheomacrodex and antibiotic therapy the blood pressure rose to 70/60 mm Hg. The patient was then transferred to the Intensive Care Unit, where she died after admission.

Investigations (Intensive Care Unit) Blood urea 84 mg %, blood sugar 110 mg %, pH 7.133; 7.163; HCO_3^- 12.4 10.4 mEq/l, total CO_2 13.5 11.3 mEq/l, physio. bound CO_2 1 12 0.9 mEq/l, pCO_2 38.30 mm Hg, $\text{HCO}_3^-/\text{CO}_2$ 1 10.9 1 11.6. Electrophoresis Alb. 62.5 %, α -glob. 4.8 %, α_2 -glob. 6.4 %, β -glob. 8.8 %, γ -glob. 16.5 %.

Post mortem examination. The body is that of an adequately nourished woman. Both lungs show considerable degree of congestion and numerous hemorrhages especially on the anterior border. In the pleural cavities approximately 100 ml of hemorrhagic fluid were found. The heart, pericardium and thymus appeared normal and so did the gallbladder and pancreas. Lateral to both adrenals and under the capsules of the kidneys extensive hemorrhages were found. The kidneys appear pale with normal ureters; the bladder which is also normal, contains no urine. The reproductive organs are normal as are the brain and meninges. The stomach shows an area of congestion containing numerous small hemorrhagic spots with some edema. The stomach contains some millilitres of dark brown coffee-ground material. In the duodenal area there are abundant hemorrhages. The small intestine contains dark tarry material especially in the ileum. The large intestine shows areas of congestion and swelling with hemorrhagic spots. The liver is pale, flabby, greasy to touch, with areas of orange and yellow color. The spleen is normal in size, weight and consistence.

Histology. The heart shows fatty degeneration (fig. 1) as do also the epithelial cells of the tubules in the kidneys (fig. 2). In the liver widespread and uniform fatty change was found. The droplets of fat in the cells are confluent, so that no protoplasm can be seen (fig. 3).




Fig 2. Kidney Hematoxyline-eosine Numerous vacuolated tubular cells after extraction of fat.

Fig 3. Liver Hematoxyline-eosine Heavy parenchymatous degeneration of liver cells and deposition of fat.

Staining with Sudan III shows the fatty degeneration to be of higher degree than expected by the hematoxyline-eosine method. The main lesions occur in the gastro-intestinal tract. In the stomach minimal changes were found, but in the duodenal mucosa severe necrosis of

the epithelium edematous, so that no normal areas were encountered. In the deep layers the cell nuclei were colored pale or absent. The muscularis mucosae was edematous and thickened, the Brunner cells were weakly colored. It is of interest to note that in the tubules of kidneys and hepatic cells iron could not be demonstrated.

Discussion

REISMAN *et al* [9] studied the mechanism of the toxic action of iron in animals. By stomach or duodenal tube or by enemas dissociable iron salts were given. The lethal dose in dogs and rabbits was found to be approximately 150 to 200 mg iron per kilogram body weight. In the majority of the animals no histologic changes were seen in the intestinal mucosa, but in some instances intestinal bleeding from congested capillaries occurred. In children who died from iron intoxication, necrosis of the intestinal mucosa was encountered, although in some cases minimal necrotic changes were found. REISMAN estimates that the heavy intestinal necrosis in children is due to the corrosive effect of iron salts in substance while in the experiments with dogs and rabbits aqueous solutions have been used.

Poisoning with iron in adults is very rare. The patient reported passed at home of the three characteristic phases of iron intoxication: 1. Acute gastro-intestinal symptoms, 2. relative wellbeing, 3. fatal termination. She entered the hospital in the terminal phase of intoxication and died shortly after admission so that no therapy could be given. It appears that once the gastric mucosa is damaged, iron escapes from the gut into the tissues and leads to thrombosis of the submucosal veins. The numerous thromboses inhibit further iron absorption so that comparatively little iron is found in the liver and kidneys. It is difficult to come to another conclusion than that the extensive fatty changes in parenchymatous organs (liver, heart, kidney) cause the rapid fatal outcome. The liver is not able to maintain its detoxicating function, the heart becomes hemodynamically insufficient because of extensive fatty degeneration of its muscle fibers and the kidneys are damaged by the low blood pressure and fatty degeneration of tubular cells.

The cause of sudden death following relative wellbeing was obviously due to fatty degeneration of parenchymatous organs. Hyperventilation and pronounced acidosis, suggesting a disturbance in oxydative metabolism, was present. In a recent investigation WITZLEBEN and CHAFFEY [11] found extensive hepatic necrosis following

Prostatahypertrophie festgestellt wurde. Diese wurde zunächst konservativ behandelt; als es im April 1963 jedoch zu einer akuten Harnverhaltung kam, wurde eine Ausschaltung des Adenoms vorgenommen. Die histologische Untersuchung des Operationspräparates ergab keinen Hinweis auf Malignität. Nach der Operation war der Patient beschwerdefrei. Im Mai 1966 traten plötzlich am ganzen Körper blaue Flecken auf, ausserdem bemerkte der Patient eine ausgedehnte Blutung unter der Bindehaut. Einige Tage später kam es ausserdem zu einer Hämaturie, die so stark wurde, dass der Patient schließlich auf eine urologische Abteilung aufgenommen werden musste. Hier ergab die i.v. Pyelographie und die zystoskopische Untersuchung keinen Hinweis auf eine lokale Blutungsursache. Aus diesem Grund wurde nun eine Gerinnungsuntersuchung durchgeführt. Diese ergab eine schwere Gerinnungsstörung (siehe später), weshalb der Patient am 4. 7. 1966 zur weiteren Abklärung und Behandlung an die I. Medizinische Klinik verlegt wurde.

Die histische Untersuchung bei der Aufnahme an der I. Medizinischen Klinik ergab folgenden Befund: Reduzierter Allgemeinzustand, blasser Hautfarbe, an der Haut keine Zeichen einer hämorrhagischen Diathese. Herz und Lunge physikalisch unauffällig. Leber nicht vergrössert, Milz 1 QF unter dem Rippenbogen tastbar, keine Lymphknotenvergrösserung, Nierenlager nicht klopfempfindlich. Rektale Untersuchung: kein brennender Befund an der Prostata, erhebbar RR 170/90 mm Hg. Es bestand eine leichte Hämaturie.

Laboratoriumsbefunde: Senkung 70/46 mm, Serumweis 6,7 g%, Albumin 3,1 g%, Globulin 3,6 g%, Thymotribungsreaktion 1 E; Elektrophorese: Alpha₁- und Alpha₂-Globulinvermehrung, LAP 117 mE, Serumfibrinogen 0,42 mg%, Bromsulphalelektretention nach 45 min 2%, Cholesterin 240 mg%, Harnstoff-Stickstoff III 1 mg%, alkalische Phosphatase 3,1 m Mol E, saure Phosphatase 1,2 m Mol E. Blutbefund: Ery 5,9 Mill, Hb 75%, FI 0,96 Leukozyten 6.530, Unsegmentierte 5%, Segmentierte 74%, Eosinophile 2%, Basophile 2%, Monozyten 1%, Lymphozyten 16%. Harnbefund: Albumen positiv, Saccharum negativ, Urobilinogen 1/4, Sulfowisch positiv, im Sediment reichlich Erythrozyten.

Röntgenuntersuchungen: Thoraxröntgen: Linksherz mit beginnender Mitralisation, vermehrte Grundbeläufigkeit der Lungen. Kein Hinweis für blastomatoöse Veränderungen. Magen-Darm-Passage: normaler Befund. i. Pyelographie: Dünne Ausscheidung des Kontrastmittels in beiden Nieren mit vor allem rechts unvollständiger Darstellung des Hohlsystems. Unbehinderter Abfluss des Kontrastmittels in die nicht vollstommen zur Darstellung gebrachte Harnblase. Verdacht auf Anhebung des Blasenbodens bei Vergrösserung der Prostata. Skelettröntgen: Hochgradige Spondylitose mit multiplen Bandscheibendegenerationen und Osteochondrose im Bereich der Brustwirbelsäule. Mässige Osteoporose.

Gerinnungsuntersuchungen

Bei der ersten Untersuchung des Patienten konnten folgende Befunde erhoben werden (Tab. 1).

Als wesentliche pathologische Befunde wurde eine schwere Fibrinogenopenie bei gleichzeitiger Thrombopenie gefunden. Ferner bestand eine leichte Verminderung des Prothrombins und von Faktor V. Es war auch eine leichte Verminderung von Faktor VIII anzunehmen, da der Thromboplastinaktivierungstest unter Verwendung von Patientenplasma leicht pathologisch war. Eine vermehrte Fibrinolyse konnte mit dem Fibrinplattentest nicht nachgewiesen werden, die Enoglobulinzytzeit war bei der ersten Untersuchung normal, bei späteren Untersuchungen konnte jedoch gelegentlich eine verkürzte Enoglobulinzytzeit gefunden werden (Abb. 2).

Das gleichzeitige Vorkommen einer Fibrinogenopenie und einer Thrombopenie deutete mit grosser Wahrscheinlichkeit auf eine Verbrauchskoagulopathie. Zur Verifizierung dieser Diagnose wurde bei noch die biologische Halbwertszeit von jodmarkiertem humanem Fibrinogen bestimmt. Wie zu erwarten, war die Halbwertszeit des Fibrinogens bei dem Patienten mit 12 h deutlich verkürzt (Abb. 1). Die Halbwertszeit wurde noch kürzer (9 h)

Tabelle I Gerinnungsbefunde 24.6.1966

	Pat. H. L.	Normalwerte
Gerinnungszeit (Lee White) min	6	9
Blutungszeit (Duke) min	7 ¹⁰	-3
Thrombocytenzahl (Bacchar und Grawert)	90000	150000 250000
Thromboplastinzeit (Quick), %	68	75-110
Prothrombin (F II) (Duttson und Schaden) %	65	75-110
Proaccelerin (F V) (Duttson und Schaden), %	67	75-110
Fibrinogen (Claus) mg ¹⁰⁰	40	200-400
Partielle Thromboplastinzeit (Lundell) sec	77	50-70
Thromboplastinbildungszeit (Booe)		
Pat.-Pl.-Pl.-Serum	normal	
Pat.-Pl.-Normalserum	leicht path.	
Serumprothrombin nach 1 h, %	50	< 10
Englobulinhyalinst 1 h	über 8	über 12
Fibrinplatte	keine fibrinolytische Aktivität	

In die Fibrinolyse durch tägliche orale Verabreichung von 10 g Epsilon-Aminocapronsäure gebremst wurde. Wurde hingegen eine Dauerinfusion von Heparin verabreicht, kam es sofort zu einer deutlichen Verflüssigung der Fibrinogenhaltwertzeit, wobei allerdings der Normalwert nicht erreicht wurde. Damit war erwiesen, dass die beobachteten Gerinnungsveränderungen, vor allem die Fibrinogenopenie und Thrombopenie durch eine intravasculäre Gerinnung bedingt waren.

Beeinflussung der hämorrhagischen Diathese durch Heparin und weiterer Verlauf der Krankheit

Bei der Annahme einer Verbrauchskongulopathie infolge intravasculärer Gerinnung war zu erwarten, dass eine Unterbrechung des intravasculären Gerinnungsvorganges durch Heparin die Gerinnungsstörung beseitigen würde. Wie aus Abb. 2 zu entnehmen ist, kam es tatsächlich schon 12 h nach Beginn der Heparintherapie (1000 E Heparin/Stunde als Dauerinfusion) zu einem deutlichen Anstieg des Fibrinogens, das am 4. Tag nach Therapie begann einen Höchstwert von 410 mg% erreichte. Die Thrombocyten stiegen ebenfalls an, aber erst nach einigen Tagen und nicht in demselben Ausmaß wie das Fibrinogen. Gleichzeitig mit dem Anstieg des Fibrinogens und der Thrombocyten kam es zu einem Stillstehen der Blutungsneigung.

Der gute therapeutische Erfolg konnte aber nur so lange aufrechterhalten werden, als Heparin kontinuierlich laßändert wurde. Als aus technischen Gründen die Therapie mit Depotheparin subkutan fortgeführt wurde, kam es wiederum zu einem Abfall des Fibrinogens, was auch nicht auf so tiefe Werte wie vor der Therapie.

Der weitere klinische Verlauf war gekennzeichnet durch einen rasch zunehmenden Kraftverfall und Gewichtsverlust. Bei wiederholten rektalen Untersuchungen konnte schließlich an der Prostata ein Tumorfund erhoben werden, der dem Verdacht auf ein Prostatakarzinom zuelegte. Eine Probestrahlung zur Verflüssigung dieser Diagnose konnte




Abb. 1 Halbwertszeit von ^{125}I -Fibrinogen vor und während Therapie mit EACA 10 g tgl. bzw. Heparinderivinfusion (1000 E/h) Abzisse Zeit in Tagen, Ordinate Radioaktivität in % des 10-Minutenwertes.




Abb. 2 Einfluss der Heparintherapie auf Fibrinogen Spiegel und Thrombocytenzahl

— Fibrinogen in mg%
 ••••• Thrombocytenzahl

wegen der hämorrhagischen Diathese aber nicht durchgeführt werden. Die saure Phosphatase war bei wiederholten Kontrollen nur grenzwertig. Der Patient verstarb plötzlich unter dem Zeichen einer cerebralen Blutung am 3.8.1966.

Pathologisch-anatomischer Befund

Bei der Obduktion (Sekt. Prot. Nr. 1145/66, Obd. REUTER, Assistent) des Patienten fand sich ein Prostatakarzinom mit Befall der regionalen und paraaortalen Lymphknoten und aus-



Abb. 3. Fibrinthrombus in einem kleinen Lungengefäß. Mallory ($\times 300$).

gedenkten Knochenmetastasen in der Wirbelsäule. I. Leber und Lunge waren makroskopisch keine Metastasen nachweisbar. Als unmittelbare Todesursache war eine frische Massenblutung in die rechte Kleinhirnhemisphäre anzusehen. Weitere Zeichen einer schweren hämorrhagischen Diathese lagen in Form ausstretender Muskelfibrinungen im rechten Oberschenkel und verschiedenen subkutanen Hämatomen vornehmlich im Bereiche von Injektionsstellen vor.

Histologisch erwies sich das Prostatakarzinom als ein Adenokarzinom mit wechselndem Gehalt an doppelt-brechenden sudanophilen Tröpfchen im Plasma. Retroperitoneale Lymphknoten waren ausgedehnt von analogen Karzinomformationen durchsetzt, Nekrosen oder Fibrinabscheidungen fehlten dabei. I. den makroskopisch tumorfreien Lungen war im histologischen Schnitt eine geringgradige Lymphangiols carcinomatosa vor allem aber auch Tumorformationen in kleinsten Gefäßen und interalveolaren Kapillaren zu sehen vermischt und dabei unabhängig von den Tumorzellen gelegentlich auch Fibrinthromben (Abb. 3). Das Myocard ohne Auffälligkeiten, insbesondere die Gefäße mit freier Lichtung. Auch die Leber zeigte keine größeren Veränderungen, in den Sinusoiden keine Fibrinthromben. Die Kupferschen Sternzellen relativ gross und mit stark eosinophilen Plasma. Dieses zeigte bei der PAS-Reaktion eine deutliche Rotfärbung, die auch nach Diastasebehandlung bestehen blieb. Eisenfärbung negativ.

Der für diesen Fall wesentliche Befund war in den Nieren zu erheben. So gut wie alle Glomerula zeigten homogene eosinophile Ausgüsse in ihren Kapillarschlingen (Abb. 4). Diese gaben positive F. brinfärbung und waren stets von der Kapillarwand abgrenzbar. Sie waren demnach als hyaline oder Fibrinthromben anzusprechen. Schlingennekrosen fanden sich nicht. Größere und kleinere Nieren- und Markgefäße waren frei von Thromben.




Abb. 4 «Hyaline Thromben» in Schlingen von Nierenglomeruli. Mallory ($\times 400$).

Diskussion

Die grosse Häufigkeit thromboembolischer Ereignisse bei Patienten mit malignen Tumoren ist dem Kliniker und Pathologen wohl bekannt. Eine wesentliche Ursache der Thromboseneigung beim Tumorkranken stellt sicherlich die Hyperkoagulabilität dar die vor allem durch Vermehrung oder Aktivitätssteigerung verschiedener Prokoagulantien [13] (Fibrinogen, Faktor V und Faktor VIII) zustande kommt.

Klinisch äussert sich diese Thromboseneigung zumeist in Form von Makrothrombosen oder der sogenannten Thrombophlebitis migrans. Bei einer kleinen Zahl von Fällen führt die Hyperkoagulabilität aus bisher noch nicht genau bekannten Gründen jedoch zu einem anderen klinischen und pathologisch-anatomischen Bild. Es kommt zur Bildung zahlreicher Fibrinthromben in den kapillaren verschiedenen Organe, ein Zustandsbild, das als diffuse intravaskuläre Gerinnung bezeichnet wird. Dadurch kommt es zum raschen Verbrauch von Gerinnungsfaktoren, vor allem des Fibrinogens und der Thrombocyten, so dass eine Gerinnungsstörung entsteht, die vor allem durch eine Fibrino-

genopenie und Thrombozytopenie gekennzeichnet ist und nach ihrer Entstehung als Verbrauchskoagulopathie [6] bezeichnet wird.

Der vorliegende Fall weist alle charakteristischen Befunde einer solchen Verbrauchskoagulopathie auf Fibrinogenopenie, Thrombozytopenie, Verminderung von Faktor V und von Prothrombin. Auch die zeitweise nachgewiesene Fibrinolyse gehört zum Bild der Verbrauchskoagulopathie, da der Körper versucht, die Fibrinthromben durch Aktivierung der körpereigenen Fibrinolyse wieder zu beseitigen. Erwartungsgemäß war die Halbwertszeit des Fibrinogens deutlich verkürzt. Durch Gabe von Heparin konnte die Fibrinogenhalbwertszeit zumindest teilweise normalwert werden, was als Beweis dafür anzusehen ist, dass die intravaskuläre Gerinnung tatsächlich pathogenetisch im Vordergrund stand. Gleichzeitig führte die Heparinbehandlung, solange sie intensiv durchgeführt wurde, zur Beseitigung der ursprünglich bestehenden Gerinnungsstörung und der Blutungsneigung.

Auch das morphologische Substrat dieses Zustandsbildes konnte in diesem Fall eindeutig nachgewiesen werden. Es fanden sich Fibrinthromben in grosser Zahl in den Kapillaren der Niere und im geringeren Ausmass auch in der Lunge. Der Nachweis von Fibrinthromben bei der Autopsie gelingt auch bei sicheren Fällen von Verbrauchskoagulopathie nur selten, was wahrscheinlich darauf zurückzuführen ist, dass die aktivierte Fibrinolyse und die postmortale Autolyse die vorhandenen Fibrinthromben rasch weiter verändern.

Verbrauchskoagulopathien können prinzipiell bei jedem malignen Tumor [4 14 17] auftreten. Allerdings neigen bestimmte Karzinome, wie die Karzinome des Gastrointestinaltraktes [1 3 5 8] das Prostatakarzinom [5 15 16, 18, 19 21] und das Pankreaskarzinom [5 9] besonders häufig zu dieser Komplikation. Das Prostatakarzinom weist insofern eine Sonderstellung auf, als hier eine Defibrinierung nicht nur durch eine intravaskuläre Gerinnung, sondern auch durch eine Hyperfibrinolyse [10 20] zustande kommen kann, was durch den reichlichen Gehalt des Prostatagewebes an fibrinolytischen Fermenten erklärlich ist. Es scheint aber dass bei allen Fällen von Defibrinierungssyndrom beim Prostatakarzinom prinzipiell immer beide Vorgänge – nämlich Verbrauch und Hyperfibrinolyse – eine Rolle spielen, wobei einer der Mechanismen pathogenetisch im Vordergrund steht.

Wieso es gerade in bestimmten Karzinomfällen zur Verbrauchskoagulopathie kommt, ist noch nicht ausreichend geklärt. Es fällt aber auf dass diese Fälle gewisse pathologisch-anatomische und

klinische Gemeinsamkeiten haben. Pathologisch-anatomisch handelt es sich zumeist um Adenokarzinome. Es war in den bisher beschriebenen Fällen immer eine hämatogene Metastasierung nachzuweisen, wobei sich Metastasen stets in Knochen oder Lunge oder in beiden fanden. Lebermetastasen wurden hingegen so gut wie immer vermisst. Klinisch waren diese Fälle im allgemeinen durch einen besonders foudroyanten Verlauf charakterisiert, der wahrscheinlich als Ausdruck des Einsetzens einer massiven hämatogenen Metastasierung anzusehen ist. Innerhalb kurzer Zeit könnten aus den zirkulierenden Tumorzellen beträchtliche Mengen an thromboplastischen Substanzen freigesetzt werden wodurch die Clearancekapazität des RES und die körpereigenen Inhibitoren überspielt werden. Damit wären die Voraussetzungen für eine intravaskuläre Gerinnung gegeben.

Zusammenfassung

Es wird der Fall eines 71-jährigen Patienten mit einem Prostatakarzinom beschrieben, bei dem es akut zum Ausbrechen einer Blutungsneigung kam. Als Ursache wurde eine Verbrauchskoagulopathie festgestellt. Durch Gabe von Heparin konnten die Gerinnungsstörungen teilweise beseitigt und die ursprünglich verlängerte Fibrinogenabbauwertzeit verlängert werden. Bei der Autopsie wurde ein Prostatakarzinom mit regionären Lymphknotenmetastasen und hämatogenen Metastasen in den Knochen und der Lunge gefunden. Histologisch konnten in der Niere und der Lunge Fibrinthromben nachgewiesen werden.

Summary

A 71 years-old patient with metastatic prostatic cancer suddenly developed severe hemorrhagic diathesis. Fibrinogenopenia, thrombocytopenia, reduction of the factors II, V and VIII and a shortened half-life time of ¹²⁵I labeled fibrinogen were found. Diffuse intravascular clotting was suggested and heparin by continuous infusion was administered. This led to marked increase of fibrinogen and partial correction of the shortened half-life time of fibrinogen. At autopsy adenocarcinoma of the prostate with bone and lung metastases was found. Fibrin thrombi could be detected in the capillaries of the kidney and the lung.

Literatur

1. BAKER, R. L. and TYAN, M. L.: Haemorrhagic diathesis in carcinoma of the stomach case report. *Ann. intern. Med.* 49: 917 (1958)
2. DREYER, E.: Störungen der Blutgerinnung und ihre Behandlung. *Almanach für Blutkrankheiten*, S. 185 (1962)

3. FLEISCHMACKER, H.: Über die Herkunft der Plasmaschleimkörper. *Wien. Arch. inn. Med.* 3/ 96 (1911).
4. FOUNTAIN, J. R. and HOLMAN, R. L. Acquired fibrinogen deficiency associated with carcinoma of the bronchus. *Ann Intern. Med.* 52: 439 (1960).
5. FRICK, P. G. Acute hemorrhagic syndrome with hypofibrinogenemia in metastatic cancer. *Acta haemat.* 16: 11 (1956).
6. LARSEN, H. III, ROKA, L. and HEENE, D. The defibrination syndrome. *Thromb. Diath. haemorrh. Suppl.* 29: 97 (1966).
7. MACFARLANE, A. S. *In vivo* behaviour of ^{250}I Fibrinogen. *J. clin. Invest.* 42: 346 (1963).
8. MCKA, D. G. and WARE, G. H.: Disseminated thrombosis in colon cancer. *Cancer* 8: 970 (1955).
9. MCKAY, D. G.; MAXWELL, H. and HERTIG, A. T. Carcinoma of body of pancreas with fibrin thrombosis and fibrinogenopenia. *Cancer* 6: 662 (1953).
10. MANNROCK, R. und MÖRDER, M. H. Schwere hämorrhagische Diathese als erstes Zeichen eines metastatisierenden Prostatakarzinoms. *Med. Klin.* 60: 1993 (1965).
11. MERSKEY G. and JOHNSON, A. J. Diagnosis and treatment of intravascular clotting; in KOLLER, DICKERT and STREULI ed., Pathogenesis and treatment of thromboembolic diseases, p.555 (Schattner Verlag Stuttgart 1963).
12. MERMLEY G.; JOHNSON, A. J.; PIET, J. H. and WOLF, H. Pathogenesis of fibrinolysis in defibrination syndrome. Effect of heparin administration. *Blood* 24: 701 (1964).
13. MILLER, S. P. A. ALON, J. S.; STEFANO, T. and ZUCKERMAN, L. Coagulation disorders in cancer. I. Clinical and laboratory studies. *Cancer* 28: 1432 (1967).
14. MILLER, S. P. and DAVISON, T. The defibrination syndrome in cancer. Treatment of cancer with heparin. *N.Y.J. Med.* 67: 432 (1967).
15. PROCT, G. R.; SELIG, M. CLEFFTON, E. and WHITMORE, W. F. *J. amer. med. Ass.* 168: 840 (1956).
16. RAPAPORT, S. I. and CHAPMAN, CH. G. Occident hypercoagulability and acute hypofibrinogenemia in patient with prostatic carcinoma. *Amer. J. Med.* 27: 144 (1959).
17. ROYER, F. and RUTZ, K. D. The defibrination syndrome. *Arch. intern. Med.* 117: 17 (1966).
18. SEALE, R. A. JAMPOL, R. W. and BARON, J. A. Clotting defect in the presence of metastatic carcinoma of prostate. *Surg. Clin. North Amer.* 31: 1111 (1951).
19. SWAN, H. T.; WOOD, K. F. and DANIEL, O. D. Dangerous bleeding associated with carcinoma of prostate. *Brit. med. J.* 4: 495 (1957).
20. TAUBER, H. J., SEITZMAN, P. WHITMORE, W. F. and KRAVITZ, S. K. The hemorrhagic syndrome of metastatic prostatic cancer and its treatment. *J. clin. Invest.* 31: 666 (1952).
21. ZIM, E. und OTT, H. Klinische Gesichtspunkte zur Entstehung der erworbenen Fibrinogenämie und Fibrinogenopenie mit hämorrhagischer Diathese. *Acta haemat.* 12: 106 (1954).

Haematological Unit, Indian Council of Medical Research and Department of Haematology
School of Tropical Medicine Calcutta

A Rapid Clinical Method for the Estimation of Activity of Aconitase in Blood

S. K. GHOSH, SUBHILA SWARUP-MITRA and J. B. CHATTERJEA

The enzyme aconitase belongs to the class of hydrazase enzymes which add water to organic compounds without splitting. The reaction may involve an intermolecular oxydation reduction coupled with final hydration process. This is often a preliminary reaction step before starting biological oxydation.

The methods for the estimation of aconitase are based on the fact that it converts citrate to *cis*-aconitate which is further transformed into *dl* isocitrate. Citrate \rightleftharpoons *cis*-aconitate \rightleftharpoons *dl* isocitrate.

In a simple spectrophotometric method, the light absorption due to *cis*-aconitate at 240 nm wave length is measured as an index of the enzyme activity in presence of citrate or *cis*-aconitate as the substrate [1]. This procedure is unsatisfactory for direct estimation of enzyme activity in presence of haemoglobin or blood protein which has a high extinction coefficient at 240 nm wave length. The enzyme activity may also be measured from the amount of citric acid produced from *cis*-aconitic acid by the enzymatic reaction and determined colorimetrically as a pentabromoacetone derivative [2]. This method is accurate but not suitable for rapid clinical assay of blood aconitase.

While exploring the possibility of obtaining a reliable method suitable for rapid evaluation of the status of aconitase in human blood, a simple method was evolved. The principle of this method is as follows. The activity of the enzyme is determined colorimetrically by following the rate of reduction of the redox dye 2-6-dichlorophenol indophenol in presence of sodium citrate, pig heart extract (isocitric dehydrogenase), nicotinic adenine dinucleotide phosphate (NADP).

manganese chloride and phosphate buffer pH 7.4. The rate of reduction is followed in a Leitz photoelectric colorimeter at 610 nm wave length. A suitable substrate blank without citrate and NADP is run simultaneously to eliminate non-specific reduction of the dye. This method is modified from the spectrophotometric method employed by BARBAN and SCHULZE [3]. The unit of activity is taken as the rate of change of optical density per minute under the condition of the test.

Material and Method

Five ml of venous blood collected using heparin as the anticoagulant are used for colorimetric determination of activity of asconitase as detailed below. The same sample is also analyzed by standard spectrophotometric [4] method for the estimation of asconitase activity.

Colorimetric method

Immediately after collection, the blood is transferred to an ice bath; 0.5 ml of whole blood is dissolved in 4.0 ml of ice cold distilled water and kept in the ice bath for 10 to 15 min when the sample appears clear. Then 0.5 ml of 0.2 M phosphate buffer pH 6.8, is mixed with the solution and preserved in the ice bath till the end of the assay.

Into pyrex test tube (8" x 9"), the following reagents are added and maintained at 38° in water bath. Phosphate buffer pH 7.4, 0.2 M 1.0 ml, 0.06 M Sodium citrate 0.5 ml; distilled water 3.9 ml, manganese chloride 0.001 M 0.1 ml.

A blank reaction mixture tube is also prepared as follows. Phosphate buffer pH 7.4 M 1.0 ml, distilled water 4.4 ml, manganese chloride 0.001 M 0.1 ml.

Pig heart acetone powder extract in 0.1 M phosphate buffer of pH 7.4 containing 50-100 µg of protein/ml prepared and preserved at 4° C is used as source of isocitric dehydrogenase.

A NADP solution containing 2 mg of NADP (Sigma) per ml of distilled water is placed in test tube in ice bath.

A Leitz photoelectric colorimeter is adjusted to 100% transmittance against distilled water at 610 nm wave length. 0.1 ml of 2-6-dichlorophenol indophenol (0.033%) is taken in 1 cm² cuvette. Pig heart extract 0.1 ml, NADP solution 0.1 ml and 0.2 ml of blood solution (1 in 10 dilution) are added in succession to reaction mixture tube maintained at 38° C in water bath. The whole mixture is then poured into the cuvette containing the dye. This procedure ensures thorough mixing of the dye and the reactants. A stop watch is started after taking the initial (zero time) reading. Subsequent readings are taken at an interval of 1 min for 4 min. The above procedure is repeated with blank reaction mixture.

The rate of change of optical density (O.D.) is calculated for both the substrate and blank reaction mixtures from the linear part of the activity curve. The corrected value 'delta' (Δ) is obtained by subtraction of the value for blank activity from that of substrate activity.

All estimations are done in duplicate and the unit of enzyme activity is taken as the rate of change of O.D. per minute under the condition of the test.

The final enzyme activity is calculated as follows

$$\begin{aligned} \text{Corrected 'delta'} &= 0.0047 \\ \text{PVC (packed cell volume)} &= 32 \\ \text{Dilution factor} &= \frac{6 \times 10}{0.2} = 300 \end{aligned}$$

Table III. Units of aconitase activity in iron deficiency anaemia

Name	Hb g%	PCV %	Ret. %	WBC/mm ³	Enzyme activity/ ml blood/min
S. D.	8.09	23	7.4	7,700	0.55
G. R.	5.8	22	6.6	3,300	1.12
D. N.	5.2	19	4.0	8,200	0.53
J. N. D.	5.2	23	0.9	7,100	0.79
R. R.	8.7	30	1.9	6,300	0.65
A. P.	9.8	31	1.1	18,400	1.13
S. S.	5.5	27	1.5	6,800	1.27
P. C.	6.38	26	1.8	7,500	0
B. J.	6.38	24	5.5	11,900	0.65
H. S.	3.19	16	12.0	5,600	0.48

Values for activity of aconitase obtained colorimetrically in normal and iron deficiency subjects are shown in tables II and III

Comment

In the system employed the redox dye 2,6-dichlorophenol indophenol probably plays the following role: Citrate \rightarrow cis-aconitate \rightarrow di-isocitrate \rightarrow D-isocitrate + NADP \rightarrow oxalo-succinate + NADPH. NADPH + oxidized dye \rightarrow NADP + reduced dye. The reduced dye does not undergo spontaneous oxidation and the fall in optical density is used as a measure of the enzyme activity. The dye 2,6-dichlorophenol indophenol has also been employed in enzymatic assay of oxidized and reduced forms of NADP and diaphorase in colorimetric studies [5, 6]. The reducing effects of the substrate blank solution is due to non specific reducing substances likely to be present in blood lysates. The linearity curve shown in figure 1 is plotted after subtracting the blank value. Slope of the line or Δ expressed as the unit of enzyme activity per minute, by both spectrophotometric and colorimetric methods, gave comparable results as shown in table I. It would appear that for rapid clinical estimations, colorimetric method may be substituted for spectrophotometric method. This method is sensitive enough to detect differences in the enzyme activity of normal and anaemic subjects particularly those with iron deficiency anaemia [7].

Acknowledgement

Grateful thanks are due to K. K. MATHUR, All India Institute of Hygiene and Public Health, for statistical help.

Summary

A simple colorimetric method has been standardized for the rapid determination of aconitase activity in whole blood by using redox dye 2-6-dichlorophenol indophenol in the presence nicotian adenine dinucleotide phosphate isocitric dehydrogenase citrate and phosphate buffer pH 7.4. Comparison of the data on the same sample obtained colorimetrically and spectrophotometrically showed no statistically significant difference. Evaluation of the enzyme activity in blood of normal and iron deficient subjects showed a deficiency of aconitase in the latter group.

References

1. RACER, E. Spectrophotometric determination of aconitase as described by ASH-CHEE, B. C. in COLOWICK and KAPLAN's *Methods in Enzymology* vol. 1 pp. 695-696 (Academic Press, New York 1955).
2. NATILSON, S., FRATER, J. B. and LUDOVY, J. K. Microdetermination of citric acid. A new colorimetric reaction for pentabromocetone. *J. biol. Chem.* 175: 745-750 (1948).
3. BARBAX, S. and SCHUELE, H. O. Metabolism of tissue culture cells. The presence in HeLa cells of the enzymes in the citric acid cycle. *J. biol. Chem.* 222: 635-670 (1956).
4. REINSTEIN, D.; OTTOLENGHI, P. and DIBRENTI, O. F. Metabolism of erythrocyte XIII. Enzyme-activity in the reticulocyte. *Canad. J. Biochem. Phys.* 34: 222-235 (1956).
5. SLATER, T. F. and SEWTER, B. A colorimetric method for estimating the pyridine nucleotide content of small amounts of animal tissue. *Nature Lond.* 253: 454-456 (1962).
6. MARLER, H. R. Diaphorases in *methods in enzymology*. Ed. COLOWICK, S. P. and KAPLAN, N. H. vol. 2 pp. 707-711 (Academic Press, New York 1955).
7. SWARUP, S., GHOSH, S. K. and CHATTERJEA, J. B. Aconitase activity in iron deficiency. *Acta haemat.* 27: 53-61 (1967).

Book Reviews

R. DYREAGER und K. JENSEN: *Quantities and Units in Clinical Chemistry*. Munksgaard, Copenhagen 1967

In den letzten Jahren hat sich die klinische Chemie immer mehr zu einem selbständigen Fach entwickelt. Eine Vielzahl von körpereigenen Stoffen werden mit immer komplizierteren Apparaten unter teils komplexen Versuchsbedingungen analysiert. Ein echter Fortschritt ist aber nur dann gewährleistet, wenn eine auf der ganzen Welt einheitliche Terminologie in bezug auf die analysierten Stoffe und Ausdrucksformen in bezug auf Größen und Einheiten verwendet wird. Welche praktische medizinischen Fortschritt die Wahl einer richtigen Einheit mit sich bringen kann, hat der Übergang von g/100 ml auf mEq/Liter bei den Plasma-Elektrolyten gezeigt. Ähnliches muss auch auf allen anderen Bereichen angestrebt werden. Das Buch von DYREAGER und JENSEN bietet nicht nur Ansätze zu einer solchen einheitlichen Terminologie der Mass-Einheiten, sondern legt ein weitgehend vollständig ausgearbeitetes System vor. Das Buch soll von jedem gelesen werden, der sich mit wissenschaftlichen Fragen jeder Art auseinandersetzt. Nur dann ist zu hoffen, dass unverständliche und zweideutige Mass-Einheiten wie g% aus der Literatur verschwinden.

R. ROSTROFF, Bern

R. WARTZ: *Actualités en transfusion sanguine*. 2^e cours européen de transfusion sanguine organisé par le Conseil de l'Europe Strasbourg 1966. Masson, Paris 1967 184 S., 24 Abb., 50 Tab. Preis 46 F

Seit einiger Zeit organisiert der Europarat alljährlich einen Kurs für Transfusionskunde zu welchem die Mitgliederländer des Rates jeweils 1-2 jüngere Spezialisten dieses Fachgebietes delegieren. Der zweite Kurs fand vom 3.-14. Mai 1966 unter Leitung von Prof. R. WARTZ im Blutspendenzentrum Strasbourg statt. Die praktischen Kurseinheiten wurden umrahmt von 11 Übersichtsreferaten, gehalten von den führenden Fachleuten Frankreichs. Der vorliegende Band verringert diese Referate und vermittelt dadurch einen ausgezeichneten Überblick, namentlich über die immunhämatologischen Aspekte der Bluttransfusion.

A. HÄGG, Bern

Primates in Medicine. Vol. 1 First Holloman Symposium on Primate Immunology and Molecular Genetics. Ed. by C. H. KRAVCHYN. Karger Basel/New York 1967 XVI + 99 p., 33 fig., 28 tab. Price sF 16.50. US \$ 4.00/30 s.

The book contains contributions from eight research groups which were presented at the Symposium held on September 28/30, 1966, at the Aeromedical Research Laboratory of the Holloman Air Force Base, New Mexico (USA). Simultaneously with the increase of knowledge on human immuno-genetic systems, the study of such systems in non-human primates is gaining growing interest. Six out of the eight studies are dealing with this subject. MOON-JAKOWSKI and WICKER are giving survey on human-type and simian-type and cross-immune-type of blood groups in primates. MASLOVSKAYA *et al.* are presenting new data on the nature of Rh-antigens, obtained with the method of I 123 and Rh₀ (D) uptake on the red cells. WICKER *et al.* are reporting on the complex relationship of the chimpanzee C-c E-F system to the human Rh-Hr system. POULIN's paper is dealing with the structural similarities between immunoglobulins of human, chimpanzee and other non-human primates and ALEPA is presenting evidence that chimpanzees were contain at least four G₂- and two I₂-factors, known to be nonantigenic determinants of human γ G-immunoglobulins. Finally GOODMAN reports on his immunological investigations on proteins of primates

which – besides other interesting results – have revealed extensive transferrin polymorphisms in *Macaca mulatta*, chimpanzees and gorillas. Out of the two remaining studies, one by HOFFMAN and GOTTLEB deals with hemoglobin variants of chimpanzees and gibbons, the other by HERRALL, is an investigation on non-toxic immune-suppressive agents (performed not on primates but on mice). The Symposium has provided valuable informations on current researches in primate immunology and molecular genetics. Each of the studies gives lot of ideas and suggestions for further investigations which will also interest scientists working exclusively in human serology.

R. BÜTLER, Bern

J. GENOT: Des «Baetli-Syndrom» im Kindesalter VIII+133 S., 31 Abb., 14 Tab. Enke Stuttgart 1968. Preis DM 96.

Der Autor bemüht sich um eine Klärung des Begriffes «Baetli-Syndrom». Neben der Anbahnung symptomatischer Formen, insbesondere bei Nierendysplasie, hält er an der Existenz einer primären, erblichen Form fest. Er beschreibt im Detail die klinischen Symptome und den Verlauf bei 15 Patienten, die er hier darstellt. Durch Bestimmen erythrocytärer leukocytärer und thrombocytärer Antikörper wird versucht, einen Beitrag zur Ätiologie des Syndroms zu liefern. Auch die Rolle der Milz im Sinne einer Dysplasie und die Zellplasmaglykose werden erörtert. Die spätere Mitbeteiligung der Leber im Sinne einer Zirrhose wird ebenfalls z.T. auf Autoaggression zurückgeführt. Trotz den vielfältigen Untersuchungen bleiben viele Theorien in dieser äusserenden Betrachtung eines schwierigen Problems spekulativ.

J.L. VIER, Basel

J. M. COLLETTE, J. JANET and E. SCHOFFELEERS: New Trends in Basic Lymphology. Proceedings of Symposium held at Charleroi (Belgium) on 11 to 13 July 1966. Experientia, Supplementum 14 Birkhäuser Basel 1967 233 S. Preis F 48.

The papers on the rather young specialty of lymphology presented in the Symposium at Charleroi are reproduced in extenso in this volume. They concern the structure and microstructure of the lymphatic vessels, the properties and permeabilities of the lymphatic endothelium, the contractility of human lymphatics, the problems of lymphaticovenous communications, the effects of lymphatic stasis and the various methods for exploration of lymphatic structure and function.

There is no question that such booklet serves as a valuable source of information to the basic scientist as well as the clinical investigator interested in lymphology.

F. FÄHR, Zürich

Proceedings of the 10th Congress of the European Society of Haematology Strasbourg 1968, Part I Hauptvorträge, 312 Seiten, Preis sFz./DM 75.- Part II Kurzvorträge (2 Teile, 814 und 774 Seiten) Preis für beide Teile: sFz./DM 370.-

Traditionsgemäss erscheinen die Beiträge des 10. Kongresses der Europäischen Gesellschaft für Hämatologie in sorgfältig ausgestatteter Buchform. Der erste, bereits vor Jahresfrist veröffentlichte Teil enthält die Hauptreferate. Der Band ist für jeden hämatologisch orientierten Arzt und Biochemiker ein wertvolles Quellenwerk, welches auf knappem Raum neuere Aspekte in sorgfältig reifigten Übersichten über zentrale Probleme der Hämatologie zusammenfasst. Die Arbeiten von SADOVY über Methoden der Untersuchung von Makromolekülen in Lösung und diejenige von KARAT über Struktur und Heterogenität von Antikörpern zeigen die Bedeutung und Fruchtbarkeit interdisziplinärer Zusammenarbeit zwischen Kliniker und Biochemiker. Weitere, durchwegs originell dargestellte Beiträge behandeln die Geographie hämatologischer Erkrankungen, Probleme der Blutgerinnung, Fibrinolyse und Serologie, sowie neuere Aspekte der Leukämieforschung. Von besonderem praktischen Interesse ist die Arbeit von LAWOWICK und CERNY über die vergleichende Hämatologie verschiedener Tiergattungen, welche häufig für die experimentelle Forschung herangezogen werden.

or chronic renal insufficiency can be associated with a haemorrhagic disorder. In the same year SALEMAN and NERI [5] and CASTALDI *et al.* [6] investigated the dynamic platelet functions in the haemorrhagic diathesis of uraemia. This paper which is a continuation of that presented in 1966 describes the haemostatic mechanism in 19 cases of uraemia and deals mainly with platelet adhesiveness.

Material and Methods

Patients. The haemostatic mechanism was investigated in 19 uraemic patients who showed signs of a haemorrhagic disorder (tendency to epistaxis, spontaneous haematomas) at some stage of the disease. At the time of the examination 5 of these patients showed cutaneous-mucosal haemorrhages (purpura haematomata, haemoptysis). All these patients had severe renal impairment with high blood urea levels (over 150 mg/100 ml) markedly reduced glomerular filtration rate and ischaemia. A few of them were treated by peritoneal dialysis and the others were on the waiting list for renal transplantation.

Methods. The platelet function was investigated using the following tests:

1. Bleeding time: Owston's method [7] was used. In our hands the normal values were between 5 and 7 min. The bleeding time is determined by the vasoconstriction, platelet adhesiveness, aggregation and viscous metamorphosis.

2. Platelet adhesiveness: We used BORCHOREVNIK's test which measures platelet adhesiveness *in vivo* [8]. Two platelet counts are made: one in venous blood and another in the blood flowing from a 1 cm long and 1 mm deep skin incision in the forearm (the same incision was also used for the bleeding time test by Owston's method). The difference between the two counts indicates the number of platelets adherent to the margins of the incision. The normal values represented as a percentage of the venous blood platelet count were, in our experience between 20% and 48%, with an average value of 34% [9].

3. The difference between the maximal amplitudes (mm) of the thromboelastographic curves in platelet-rich and platelet-poor plasma expressed as $ma_1 - ma_2$. The $ma_1 - ma_2$ value depends on the thrombodynamic function of the platelets which determines their participation in syneresis. For normal platelet counts the $ma_1 - ma_2$ value varies between 30 mm and 35 mm.

4. Clot retraction: This test measures the retractive function of platelets.

5. Prothrombin consumption test: Normal results are more than 25 sec. Results below this limit are abnormal and, if one can be sure that there is no deficiency of any plasma factor which takes part in the generation of the intrinsic activator, they would indicate deficiency of platelet factor 3.

Results

Results are shown in table I. The prothrombin consumption test was abnormal in 17 out of 19 patients (89.4%) with an average time of 20.3 sec which is below the normal limit of 25 sec. This was, therefore, an almost constant finding. BORCHOREVNIK's test showed decreased adhesiveness in 11 out of 19 patients (57.9%). The average value of 18.8% was much below the normal value of $34\% \pm 7\%$, and the differ

Table 1. Chronic renal failure

Patient	No. of platelets per mm ³ × 1000	Bleeding time min	TEG ma ¹ -ma ² mm	Platelet adhesiveness mm in 10 sec %	Clot retraction	Prothrombin consumption index
1 F.L.	230	4	44	30	N	-
2 D.F.	269	>20	39.5	20	N	21
3 A.A.	100	27	-	44	III	19
4 V.S.	298	15	29	8	N	-
5 D.C.	179	27	-	9	N	14
6 E.B.	90	-	-	22	N	18
7 P.S.	185	>20	45	0	N	15
8 J.T.	138	4	40	17	N	21
9 D.C.	118	3	40	18	N	16
10 A.B.	115	>20	42	11	N	15
11 J.M.	381	-	-	22	N	-
12 S.P.	310	5	-	0	N	31
13 L.B.	350	5	-	30	N	-
14 E.R.	540	15	34	15	N	30
15 J.O.	315	4	36	8	N	23
16 J.V.	285	5	26	43	N	21
17 O.D.	285	>15	46	36	N	19
18 C.C.	255	7	31	15	N	17
19 D.L.	265	>15	34.5	17	N	24
Mean	236	>12	31.2	18.8		20.5

ence was statistically significant. This difference is well represented in figure 1 where a comparison is made between normal adhesiveness and adhesiveness in uraemia. The bleeding time was prolonged (over 7 min) in 9 out of 17 cases (52.9%). The thromboelastographic index ma¹-ma², which represents the thrombodynamic function of the platelets, was abnormal in 2 cases. Clot retraction was always normal. The platelet count was within normal limits (average 236,000/mm³ against the normal average of 262,000/mm³) except in one case where it was below 100,000/mm³.

Discussion

The above reported results show impairment of, at least, two platelet functions (1) deficiency in the plasma of platelet factor 3 and (2) deterioration in the dynamic function of platelet adhesiveness. In addition, CASTALDI has demonstrated impaired platelet aggrega-




Fig 1 Comparison between the platelet adhesiveness in uraemia (obliquely striped rose) and that in 50 normal controls (solid columns)

tion. Thus, it is logical to accept that a true 'uraemic thrombopathy' does exist and is the cause of the haemorrhagic diathesis in chronic renal insufficiency. Platelet adhesiveness and aggregation become active during the first stage of haemostasis and their failure has a serious effect on early haemostasis. This is well demonstrated by the rapid commencement of bleeding and its long duration when the bleeding time test is performed. Although the bleeding time is not always prolonged, there is another characteristic feature of the abnormal test which is always present in cases of diminished adhesiveness. In normal subjects there is a time interval of 30-45 sec between the time the incision is made and the time when bleeding begins and forms a drop of blood sufficiently large to be drawn into a pipette. In cases of diminished adhesiveness this time interval is reduced to 5-10 sec. The possible cause of this phenomenon could be either absence of adhesive platelets to occlude bleeding vessels mechanically or the fact that abnormal platelets do not carry serotonin which contributes to the early vasoconstriction. In view of this observation, the axonal reflex postulated as the earliest haemostatic response appears to be much less important than dynamic platelet functions and, especially the first of these in chronological order i.e. adhesiveness. On the other hand, deficient generation of intrinsic thromboplastin impairs coagulation of the plasma which, in normal conditions, follows and reinforces the early phase of haemostasis.

Analysis of the correlation between the platelet adhesiveness, prothrombin consumption, thrombodynamic function and bleeding time in uraemia shows that

(a) Out of 13 uraemic patients with an abnormal prothrombin consumption the platelet adhesiveness was decreased in 8 and normal in 5. Two other patients with a normal prothrombin consumption showed decreased adhesiveness. Thus, these two tests of platelet function agreed in 8 and disagreed in 7 cases. Figure 2 shows a slight correlation between deficient prothrombin consumption and decreased adhesiveness but the number of tests is too small to attempt to express it in mathematical terms as an index of correlation (r) or covariation (p). The average values for both prothrombin consumption (20.3 sec) and adhesiveness (18.8 %) are below the normal limit.

(b) Comparison of the platelet adhesiveness with the thrombodynamic function shows that (1) Out of 9 cases with diminished adhesiveness the thrombodynamic function was normal in 8 and abnormal in 1. (2) out of 4 cases where adhesiveness was within normal limits the thrombodynamic function was normal in 3 and abnormal in 1. Thus, there is a considerable difference in the way these two platelet




Fig. 2. Correlation between platelet adhesiveness and the prothrombin consumption. The area divided into squares represents the normal range. Circles (O) indicate 'pairs of values' of adhesiveness and the prothrombin consumption. The cross (x) represents the average 'pair of values'.

functions are affected adhesiveness is often unimpaired but the thrombo-dynamic function is usually normal.

(c) Finally the platelet adhesiveness and the bleeding time are compared in figure 3 which shows that (1) out of 11 cases of diminished adhesiveness the bleeding time was prolonged in 6 and normal in 5 (2) out of 6 cases with normal adhesiveness the bleeding time was normal in 3 and prolonged in the other 3. It is possible that decreased adhesiveness was compensated in some cases by vasoconstriction which participates in the haemostatic mechanism. The average adhesiveness was 18.8% and the average bleeding time 12 min. There was therefore some correlation between decreased adhesiveness and a prolonged bleeding time.

On the other hand, the synxeresis and clot retraction which are related to the so-called thrombodynamic function of the platelets were usually normal obviously these platelet functions are independent of the others.

Very little is known about the pathogenesis of the platelet defect in uraemia. We can only report that decreased adhesiveness and aggregation are not apparently related to low haematocrit values so fre-




Fig. 3. Correlation between platelet adhesiveness and the bleeding time. The area divided into squares represents the normal range. Circles (O) indicate 'pairs of values' in adhesiveness and the bleeding time. The cross (x) represents the average 'pair of values'.

quently found in uraemia [10-11] and that HELLM [12] has suggested that urea may interfere with platelet aggregation induced by ADP the meticulous investigations of SALZMAN and NERI [5] refute this hypothesis.

SALZMAN and NERI [5] and CASTALDI *et al* [6] using different techniques, obtained results similar to ours. SALZMAN investigated platelet adhesiveness *in vitro* (by this technique normal values are between 25 % and 60 %) in 24 patients and found marked reduction to between 0 % and 19 % in 21 of them. He found impaired adhesiveness in 7 out of 11 cases of gastrointestinal haemorrhage associated with uraemia. Like us, he observed some correlation but not full agreement, between deficient adhesiveness and reduced prothrombin consumption. In his opinion, deficient adhesiveness is an important factor in the uraemic haemorrhagic disorder and in the prolonged bleeding time.

CASTALDI *et al* [6] investigated the haemostatic mechanism in 19 cases of renal disease, 12 of which had haemorrhagic manifestations in 5 of the latter they found platelet adhesiveness *in vitro* of less than 20 % (the normal range with their technique was between 20 % and 70 %). The bleeding time by Ivy's method, was more than 15 min in all patients who were bleeding, and in only one who had no clinical signs of a haemorrhagic disorder. Platelet aggregation was also abnormal in the cases with a haemorrhagic tendency.

Thus, both our investigations and those of other authors show a defect in the adhesiveness, in addition to the well known diminished prothrombin consumption, which is probably related to the haemorrhagic tendency and prolonged bleeding time in uraemic nephropathy. It seems, therefore, that a deficiency of platelet adhesiveness together with a deficiency of platelet factor 3 may possibly be an important factor in the uraemic haemorrhagic diathesis. The thrombodynamic function, on the other hand, is usually normal.

Conclusions

In chronic renal insufficiency a decreased prothrombin consumption is the most frequent finding which indicates a deficiency of platelet factor 3. There is frequently diminished platelet adhesiveness which explains the prolonged bleeding time in some cases. The bleeding time is often prolonged. The thrombodynamic function is usually normal.

Summary

The bleeding time, platelet adhesiveness *in vivo*, thrombodynamic function of platelets, clot retraction and prothrombin consumption were investigated in 19 cases of chronic uraemia associated with a haemorrhagic diathesis at some stage of the disease. A decreased prothrombin consumption as a result of deficiency of platelet factor 3 was found in almost all the cases, as well as very frequently a diminution in the platelet adhesiveness, and often a prolonged bleeding time. It is suggested that impaired platelet adhesiveness and a deficiency of platelet factor 3 play an important role in the uraemic haemorrhagic disorder.

References

1. REIDMAN D. Hemorrhages in the course of Bright's disease, with special reference to the occurrence of a hemorrhagic diathesis of nephritic origin. *Amer. J. med. Sci.* 191: 709 (1907).
2. KIDLEBLACK, B.: Bleeding tendency in chronic renal failure. *Acta med. scand.* 157: 174 (1957).
3. ALTSCHULER, G., MARCUS, A. J. and ULLMAN, H. C. Platelets and platelet phosphatides in uremia. *Blood* 16: 1439 (1960).
4. CASTILLO C. y GARCÍA SAN MIGUEL, J.: Plaquetopatías adquiridas secundarias producidas por hemostoligias. *Med. Clin.* 48: 17 (1967).
5. SALZMAN E. W. y NERI, L. L. Adhesiveness of blood platelets in uremia. *Thromb. Diath. haemorrh.* 13: 84 (1966).
6. CASTALDI, P. A., ROZENCWEG, M. C. and STEWART J. H.: The bleeding disorder of uremia. *Lancet* ii: 66 (1966).
7. OWEN, P. A. Physiopathologie du temps de saignement. *Nouv. Rev. franç. Méd. S.* 380 (1965).
8. BORCHERSYON, C. P. A method for measuring platelets adhesiveness *in vivo*. *Acta med. scand.* 161: 157 (1960).
9. GARCÍA SAN MIGUEL, J. La adhesividad plaquetaria en la clínica. Tesis (1967).
10. CASPARI, E. A. Effect of red blood-cells and adenosine on platelets adhesiveness. *Lancet* ii: 1273 (1965).
11. HARRISON, M. J. II and MITCHELL, J. R. A. The influence of red blood-cell on platelet adhesiveness. *Lancet* ii: 1163 (1966).
12. KILLICK, A. J. The adhesiveness of human blood platelets *in vitro*. *Scand. J. clin. Lab. Invest.* 12: suppl. 51 (1960).

Medizinische Universitätsklinik Innsbruck
(Vorstand: Prof. Dr. H. BRAUNSTEINER)

Zur Diagnose monozytärer Leukämien mit zytochemischen Methoden¹

F. SCHMALZL und H. BRAUNSTEINER

Neuere zytochemische Untersuchungen über die Herkunft der normalen Blutmonozyten haben die Theorie der myelogenen Abstammung dieser Zellen bestätigt [4, 14, 30, 31]. Mit der Klärung dieses Problems eng verbunden, ist die seit SCHILLING und NAEGEL diskutierte Frage der Monozytenleukämien [3, 8, 22, 26, 28, 35]. Dem vielfach als «typische Monozytenleukämie» bezeichneten Typ SCHILLING für den eine unmittelbare retikulohistiocytäre Abstammung der leukämischen Zellen bisher angenommen wurde, steht die sogenannte «myeloische Monozytenleukämie» Typ NAEGEL, gegenüber deren Zellen von zahlreichen Autoren als Paramyeloblasten aufgefasst werden. Mischtypen [8] zwischen diesen Formen wurden beschrieben.

Diese Unterscheidungen wurden anhand panoptischer und phasenkontrastmikroskopischer Untersuchungsverfahren getroffen [3, 8, 22, 25, 28]. Mit der Anwendung zytochemischer Verfahren ist eine einfache und klare Differenzierung der Monozytenleukämie gegen über anderen Hämoblastosen möglich geworden [4, 7, 11, 14, 17].

Material und Methodik

Der vorliegenden Arbeit liegen die Ergebnisse von Untersuchungen an 5 Fällen monozytärer Leukämien zugrunde. Es wurden Ausstriche von peripherem Blut und von Knochenmarkpunktionen verwendet. Die Resultate wurden zum Teil mehrfach kontrolliert.

Diese Untersuchungen wurden mit Unterstützung des Fonds «Kampf dem Krebs» durchgeführt.

Zur Durchführung gelangten folgende zytochemische Reaktionen

1. Unspezifische Esterase mit α -Naphthyl-Acetat als Substrat (α -N-E). Wir verwendeten hierbei die von LÖRZEL angegebene Methode die wir gering modifizierten [16, 30]

2. Unspezifische Esterase mit Substraten der Naphthol-AS-Reihe (N-AS-E). Es sind dies unterschiedlich substituiert Derivat des β -Naphthols, wie Naphthol-AS-Naphthol-AS-D- und Naphthol-AS-EG-Acetat (N-AS-A). Diese Substrat geben übereinstimmende Resultate. Für den Nachweis der Hemmkreis der N-AS-E wurde Natriumfluorid (NaF) in der Konzentration von 1,5 mg/ml dem Puffer zugegeben [6, 16]

3. Naphthylamidase. Wir wählen diese unspezifische Bezeichnung, um jene Ferment zu kennzeichnen, die bei zytochemischen Nachweisverfahren Amide des β -Naphthylamins mit L-Leucin, D,L-Alanin oder D,L-Methionin spalten [1, 27, 29, 32] und die mit der echten Leucinaminopeptidase nicht identisch sind [5]. Geringe offenbar substratbedingte Unterschiede im Verteilungsmuster des Enzyms lassen sich bei Verwendung der verschiedenen Substrate feststellen. Wir verwendeten für die vorliegenden Untersuchungen L-Leucyl- β -Naphthylamid HCl mit der etwas modifizierten Technik nach SCHMIDT und KATZENSCHNIG [29, 32]

4. Die Darstellung der Naphthol-AS-D-Chloroacetat-esterase (N-AS-D-CLE) erfolgte nach der von MOLOVY et al. [21] angegebenen Methode

5. Saure Phosphatase wurde in Anlehnung an die Methode von BARKE und ANDERSON [2] nachgewiesen

6. Bei der Darstellung der alkalischen Phosphatase [9] und

7. der Myeloperoxidase [10] folgten wir den Angaben von KARLOW

8. Die PAS-Färbung erfolgte nach HORCHOW [25] die

9. Sodaschwarz B-Färbung nach SACHS und STORCK [33]. Kernfärbungen wurden entweder mit saurem Hämalaun nach MAYER oder mit der DNS-Färbung nach FICHTENS durchgeführt.

Ergebnisse

Die Ergebnisse unserer Ferment- und histochemischen Untersuchungen an normalen Blut- und Knochenmarksausstrichen stimmen mit den Ergebnissen anderer Autoren weitgehend überein [7, 11, 14, 16, 17, 21, 30]. In der Tabelle I sind die Befunde der verschiedenen zytochemischen Reaktionen an leukämischen Monozyten zusammengefasst.

Unter den aufgeführten Fermentnachweisen zeigten insbesondere die sogenannte unspezifische Esterase und die Naphthylamidase auffällige Reaktionsergebnisse in den leukämischen Zellen (Tab. I).

Die Aktivität der unspezifischen Esterase war sowohl mit dem Substrat α -Naphthyl-Acetat wie auch mit den Substraten der Naphthol-AS-Reihe sehr hoch. Die hohe Aktivität der N-AS-E wurde durch NaF 1,5 mg/ml; in den normalen und leukämischen Monozyten vollständig gehemmt [6, 30].

Die Naphthylamidase nachgewiesen mit den Substraten L-Leucyl- β -Naphthylamid HCl, liess in allen 5 untersuchten Leukämien eine deutliche Aktivität erkennen.

Naphthol-AS-D-Chloroacetat Esterase war bei Fall 1 in mäßigem Ausmass in den leukämischen Zellen nachweisbar. In den 4 anderen

Fällen fanden sich nur gelegentlich Spuren dieses Fermentes in den monozytären Zellen.

Sudanschwarz B-positive Phospholipide liessen sich in allen 5 Fällen in guttem Ausmass feststellen. Peroxydase ebenfalls nur in geringem Ausmass, fand sich nur in einem Fall, die anderen enthielten kaum Peroxydaseaktivität in den leukämischen Zellen. Wir ziehen die Sudanschwarzfärbung der Peroxydasereaktion vor, da die Sudan schwarzfärbung in jüngeren, weniger ausdifferenzierten Zellen der myelischen Reihe die noch keine Peroxydase enthalten, bereits eine positive Reaktion gibt.




Abb. 1 Esteraseaktivität bei verschiedenen Leukämieformen. a) A5-E, b) und c) A5-E, d) A5-E, e) A5-E, f) A5-E. Fermentaktivität durch 1,5 mg/ml NaF gehemmt. a) A5-E, d) A5-E, e) A5-E, f) A5-E. Stark positiv: Monozytenleukämie (a) und d). Weniger stark positiv: Promonozyten-Leukämie (b) und c). A5-E durch NaF in den leukämischen Zellen gehemmt (selber Fall wie a) und b). f) deutliche A5-E-Aktivität in Paraneublasten. a) 1100, b) 1100, c) 1100, d) 1800, e) 1800, f) 1800.

Tabelle I Angaben über weisses Blutbild, alkalische Neutrophilenphosphatase und Verhalten in den untersuchten Fällen von Monosytenleukämie 0 keine \pm unsichere,

	Leukosyten pro mm ³	Monosytoide Zellen in %	Index der alkalischen Leukosyten- phosphatase	α -Naphthyl- Acetate Esterase
Normale Blutmonosyten				++ bis +++
Fall 1 Pat. R. 23 J	3 400	48%	108	++ bis +++
Fall 2; Pat. L. 60 J	8 100	38%	40	++ bis +++
Fall 3 Pat. B. 39 J	12 000	56%	96	++ bis +++
Fall 4; Pat. W. 44 J	187 000	93%	307	+ bis +++
Fall 5 Pat. A. 72 J	12 400	70%	43	+ bis +++

Der Gehalt an saurer Phosphatase war in allen Fällen beachtlich hoch. Alkalische Phosphatase wurde in den leukämischen Zellen nicht gefunden. Die Indices der alkalischen Phosphatase der Neutrophilen sind in Tabelle I zusammengefasst. Sie waren sehr unterschiedlich hoch zum Teil wurden die hohen Werte durch bestehende Infekte bedingt.

PAS-positive Substanzen waren in allen Fällen, wenn auch in unterschiedlichem Ausmass, feststellbar. In 4 Fällen war die Anfärbung diffus und mässig stark. Ein Fall zeigte neben einer diffusen zytoplasmatischen Anfärbung in zahlreichen Zellen Granula, die teils fein, teils grob waren und sich manchmal in grossen Plaques darstellten.

Auf Grund der Anfärbung bei den zytochemischen Reaktionen liessen sich die 5 Fälle in zwei Gruppen unterscheiden. Während Fall 1

ten der leukämischen Monozyten bei den verschiedenen cytochemischen Nachweisreaktionen:
 + schwache ++ mäßig starke +++ sehr starke Reaktion

Naphthol-AS- Acetol Tartrate	N-AS-2 + 1,5 mg/ml NaF	Naphthylamidase	saure Phosphatase	alkalische Phosphatase	Naphthol- AS-D-Chloro- Acetol Tartrate	Nucleotidase D	PAS	Peroxidase
++	++	+	++	0	0	0	++	0
+++	+	+++	+++		+	+	+	+
++	++	+	++	0	0	0	++	0
bis	++	bis	bis		bis	bis	++	++
+++	+	+++	+++		++	+	+	+
++	/	/	++	0	0	0	++	0
bis			bis		bis	bis	++	++
+++			+++		+	+	+	+
++	++	+	+	0	0	0	0	0
bis		bis	bis			bis	bis	bis
+++		++	+++			+	+	+
+	++	0	++	0	0	0	0	0
bis	++	bis	bis		bis	bis	bis	bis
+++	+	++	+++		+	+	+	+
+	++	0	++	0	0	0	0	0
bis	++	bis			bis	bis	bis	
+++	+	++			+	+	+	

2 und 3 eine hohe Aktivität der unspezifischen Esterase in den leukämischen Monozyten und Monozytenvorstufen zeigen, wiesen die beiden anderen Fälle einen deutlich niedrigeren Gehalt auf. Dieser geringere Fermentgehalt kann mit einer gewissen Berechtigung als Zeichen einer mangelnden Ausdifferenzierung betrachtet werden. Tatsächlich waren in den beiden letzten Fällen zahlreiche unreife Zellen im peripheren Blut feststellbar.

Um die Reaktionsintensität in den einzelnen Zellen einer Population besser zu erfassen, wurden jeweils 500 Zellen ausgezählt und je nach der gefundenen Reaktion in 4 Klassen eingeteilt (Tab. II). Besonders bei der Esterasereaktion zeigte sich deutlich, wie in den Fällen 1, 2 und 3 die stärker positiven Formen überwiegen, während in den Fällen 4 und 5 die Mehrzahl der Zellen schwächer reagiert.

Tabelle 1/ Reaktionsstärke in den leukämischen Monozyten bei verschiedenen Bausteinen:
 0 keine + angedeutet bis schwache ++ mäßig starke

	α-Naphthyl- Acetat Esterase				Naphthol-AS- Acetat Esterase			
	0	+	++	+++	0	+	++	+++
Fall 1 Pat. R. 25 J	0	+	21	75	0	+	40	58
Fall 2 Pat. L. 60 J	0	5	27	68	0	5	30	62
Fall 3: Pat. B. 39 J	0	2	29	69	0	5	37	52
Fall 4 Pat. W. 44 J	0	12	38	50	0	42	46	12
Fall 5 Pat. A. 72 J	0	22	0	15	0	53	42	5

Diskussion

Normale Blutmonozyten sind auf Grund neuerer Untersuchungen in ihrer baustein- und enzymzytochemischen Ausstattung weitgehend charakterisiert. Ihre eindeutige Identifizierung in Ausstrichen von Blut und Knochenmark, sowie in Exsudaten und Infiltraten ist mit verfeinerten zytochemischen Methoden möglich [4 12, 14 15 29 36]. Die Theorie der Herkunft der Monozyten aus dem Knochenmark wurde mit diesen Methoden erneut untermauert, und die Abgrenzung dieser Zellen gegenüber dem retikuloendothelialen System erlaubt [4 14 30 31].

Es erscheint nun naheliegend, diese zytochemischen Eigenschaften auch als diagnostische Kriterien für die Erkennung der Monozytenleukämie heranzuziehen [11 12, 14 17 20 30]. In Tabelle I sind die wesentlichsten kennzeichnenden Befunde zusammengefasst, die bei der zytochemischen Untersuchung normaler Blutmonozyten feststellbar sind. Ein entsprechendes Verhalten der leukämischen Zellen muss erlangt werden, um die Diagnose einer Monozytenleukämie oder falls es sich um jüngere Zellen mit noch nicht so ausgeprägter zytochemischer Ausstattung handelt, - einer Promonozytenleukämie zu stellen.

Unspezifische Esterase

Das Ausmass der mit den Substraten Naphthol AS-Acetat und α-Naphthyl Acetat feststellbaren Esteraseaktivität in den verschiedenen

und enzymcytochemischen Nachschleverfahren. Jeweils 500 Zellen wurden klassifiziert. +++ sehr starke Reaktion. x nicht durchgeführt.

Naphthol-AS-Acetat Esterase + 1,5 mg/ml NaF	Naphthyl- amidase	Naphthol-AS-D- Chloracetat Esterase	Sudan- schwarz B
0 + ++ +++	0 + ++ +++	0 + ++ +++	0 + ++ +++
20 60 0 0	10 16 22 52	12 70 18 0	96 4 0 0
x	x		
/ / / /	/ / / /	79 21 0 0	92 8 0 0
12 63 0 0	10 44 37 9	71 29 0 0	59 41 0 0
18 82 0 0	23 54 19 4	93 2 0 0	95 5 0 0
5 95 0 0	32 47 18 3	89 11 0 0	69 39 2 0

Zellformen stimmt nicht immer überein [14 30] Besonders ausgeprägt sind die Unterschiede bei verschiedenen hämatologischen Erkrankungen. So enthalten z. B. Plasmocytomzellen [18 24] Erythroblasten bei erythraemischer Myelose [13 30] bei Perniciosa [19] und bei toxischen Knochenmarkstörungen [30] und in Einzelfällen, was vielleicht zu wenig beachtet wird, auch Paramyeloblasten mehr α Naphthylacetat Esterase als Naphthol AS-Acetat Esterase




Abb. 2 Naphthylamidase-Reaktion: a) stark positiv: Monocytem b) Promonocyteleukämie mit z. T. schwach positiven Zellen. 1000

Ein spezifisches Kriterium zur Erkennung der Monozyten wurde mit der Feststellung der fast vollständigen NaF-Hemmbarkeit der \backslash AS-E in diesen Zellen und ihren Vorstufen gegeben [6]. In anderen Zellen des Blutes und Knochenmarks, mit Ausnahme angereifter Megakaryozyten, ist diese Esterase kaum hemmbar [30]. Für die Erkennung monozytärer Leukämien legen wir demzufolge mehr Wert auf die hohe durch NaF-hemmbarkeits Aktivität der \backslash AS-E als auf eine hohe α -N-E, die auch bei anderen Erkrankungen feststellbar ist. Die von uns bisher gesehenen Monozyten und Promonozytenleukämien lassen neben einer hohen α -N-E tatsächlich auch eine hohe, durch NaF fast vollständig hemmbare, \backslash AS-E erkennen. Im Gegensatz dazu wurde die mäßig starke \backslash AS-E leukämischer Promyelozyten und Plasmazytomzellen durch NaF kaum gehemmt, ebenso die geringe \backslash AS-E der Myeloblasten- und Paramyeloblastenleukämie (Tab. I).

Naphthylamidase

Unter den Zellen des peripheren Blutes zeigen die Monozyten bei Verwendung des Substrates *L*-Leucyl- β -naphthylamid die stärkste zytochemisch nachweisbare Aktivität [32]. Diese bleibt den Monozyten auch in Exsudaten, in Hautfesterpräparaten [29] und in Ergüssen [eigene Beobachtung] erhalten. Retikulumzellen enthalten viel Promyelozyten mäßig viel und die übrigen Blut- und Knochenmarkszellen enthalten wenig Naphthylamidase [1, 27, 32 eigene Beobachtungen].

Bei Monozytenleukämien liess sich das Ferment unter Verwendung von Leucin- β -naphthylamid in unterschiedlicher Intensität in den leukämischen Zellen nachweisen. Im Durchschnitt war die Aktivität mäßig hoch [1]. In einigen Fällen fielen manche Zellformen durch ihren hohen Fermentgehalt auf. Sehr junge Zellformen – Monoblasten – enthielten ebenso wie Myeloblasten keine Fermentaktivität.

Naphthol-AS-D-Chloroacetal Esterase

Dieses Ferment ist, von den stark positiv reagierenden Gewebsmastzellen abgesehen, für die Zellen der neutrophilen Reihe spezifisch. Basophile und Eosinophile enthalten in der Regel keine entsprechende Fermentaktivität [16, 30]. Die in den Monozyten manchmal nach-



Abb. 3. Naphthol-AS-D-Chloroacetat Esterase () nicht fermenthaltige leukämische Monozyten neben positivem neutrophilen Segmentkernigen (b) und () z.T. deutlich positive leukämische Monozyten () neben angedeutet und schwach positiven (b) sowie stark positiver Promyelozyt (b) und Neutrophile () b) und () selber Fall wie () und () der Abb. 1 1000 \times

weisbare geringe Aktivität wurde ebenso wie die Peroxydasereaktion der Monozyten, als Beweis für die enge genetische Beziehung der Monozyten zu den Zellen der neutrophilen Reihe angesehen [14]

Drei der beobachteten Monozytenleukämien (Nr 3 4 5) ließen keine Aktivität des Ferments in den Zellen erkennen. Der Fall 2 enthielt nur in vereinzelten Zellen eine angedeutete Aktivität. Hingegen waren die leukämischen Zellen des Falles 1 z.T. stark positiv unterschieden sich allerdings deutlich von der sehr ausgeprägten Reaktionsintensität der wenigen vorhandenen reifen Promyelozyten, von denen sie sich im übrigen auch morphologisch völlig unterschieden. Eine positive Korrelation zwischen dem Vorkommen reifer Promyelozyten im Blut und Knochenmark und stark N AS-D-E positiven Monozyten konnten wir nicht feststellen.

Ähnlich den normalen Promyelozyten weisen auch die Zellen der Promyelozytenleukämien einen hohen Behalt an N AS-D-Cl E auf

Myeloblasten und Paramyeloblastenleukämien enthalten, wenn überhaupt, eine sehr niedrige Aktivität des Fermentes.

Sudanschwarz B-Färbung

Übereinstimmend zeigten in allen Fällen die leukämischen Zellen einen geringen oder keinen Gehalt an Sudanschwarz-anfärbbaren Substanzen. Bei den wenigen festgestellten stärker positiven Zellen dürfte es sich um Promyelozyten gehandelt haben. Die leukämischen Monozyten stimmten in ihrem Verhalten mit normalen Blutmonozyten überein, die in der Regel eine geringe Anfärbbarkeit mit Sudanschwarz B erkennen lassen. Im Gegensatz dazu weisen Promyelozytenleukämien eine deutlich größere Anzahl positiver Zellen und auch einen stärkeren Reaktionsgrad der Einzelsellen auf.

Für die Auswertung zytochemischer Reaktionen an hämatologischen Präparaten wurde in Anlehnung an die score-Technik zur Be-




Abb. 4 Sudanschwarz B-Färbung a) z.T. angedeutet positiv und b) ölig negativ. Im linken Monocyten. Eine Anfärbung zeigen in c) ein eosinophiler Granulozyt und in d) ein neutrophiler Myeloblast. 1000 \times

urteilung der alkalischen Neutrophilenphosphatase mehrfach eine ähnliche Technik verwendet [20-34]. Es scheint uns für diese Fälle allerdings zweckmäßiger die Reaktionsintensität einer bestimmten Zellpopulation aufgeschlüsselt nach Reaktionsklassen in Prozenten anzugeben wie wir es in Tab. II durchgeführt haben. Diese Darstellung gestattet eine bessere Beurteilung der gefundenen Aktivität und des Grades der Ausdifferenzierung der leukämischen Zellen unter der doch wahrscheinlichen Annahme, dass der Fermentgehalt der zunehmenden Differenzierung parallel geht. Bei reaktiven Monozyten im Rahmen von Stammzellenleukämien sind die Monozyten durch eine hohe Stammzellen durch eine fehlende oder sehr geringe Esteraseaktivität gekennzeichnet. Es fehlen Zwischenstufen, die hingegen bei Monozytenleukämien vorhanden sind [14]. LEDER [14] entwickelte neuerdings die Theorie, die bisher als «jüngere» und deshalb fermentärmere Zellformen angesehenen leukämischen Zelltypen z.B. «Myeloblasten» im Endstadium von Monozytenleukämien, seien das Resultat einer Entdifferenzierung der ursprünglich gewucherten Monozyten, etwa analog dem Vorgang der Entdifferenzierung bei Karzinomzellen. Ein Beweis für diese Ansicht steht noch aus.

Zusammenfassung

Auf Grund zytochemischer Untersuchungen lässt sich das Krankheitsbild der Monozytenleukämie eindeutig begrenzen. Die gewucherten Zellen leiten sich von im Knochenmark gebildeten Blastomonozyten ab. Die Diagnose der Monozytenleukämie erfolgt auf Grund folgender zytochemischer Kriterien: 1. Der hohe Gehalt der leukämischen Zellen an unspezifischer Esterase bei der Verwendung von Naphthol-Acetat als Substrat. Substrate der Naphthol-AS-Reihe sind besser geeignet als α -Naphthyl-Acetat, das ebenfalls auch bei Paraneuroblasten eine positive Reaktion gibt. 2. Die Hemmbarkeit der starken Esteraseaktivität durch NaF (1,5 mg/ml) unter Verwendung der Substrate der Naphthol-AS-Reihe. 3. Eine mäßige bis starke Aktivität der Naphthylamidase in den leukämischen Zellen. 4. Die geringe Anfärbbarkeit mit Sodaschwarz B 5. Eine in der Regel geringe Aktivität der Naphthol-AS-D-Chloroacetat Esterase in den leukämischen Monozyten.

Summary

Monozytic leukaemia can be clearly distinguished on the basis of cytochemical studies. The hyperplastic cells are derived from monocytes formed in the bone marrow. The following cytochemical criteria determine the diagnosis of monozytic leukaemia: (1) The high level of unspecific esterase in the leukaemic cells when naphthol acetates are used as substrate. Substrates of the naphthol-AS series are more suitable than α -naphthyl acetate, which occasionally gives positive reaction also in paraneuroblast. (2) Inhibition

of the marked esterase activity by NaF (1.5 mg/ml) when naphthol-AS substrates are used (3) Moderate to marked naphthyl amidase activity in the leukaemic cells; (4) Poor staining with Sudan black B (5) Usually limited naphthol-AS chloroacetate esterase activity in leukaemic monocytes.

Literatur

- 1 ACKERMAN G.A.: Histochemical demonstration of aminopeptidase activity in the cells of the blood and bone marrow from various hematological disorders. *Nature, Lond.* 197 189 (1963)
- 2 BARKA, T. and ANDERSON, P.J.: Histochemical methods for acid phosphatase using hexazonium pararosanilin as coupler. *J. Histochem. Cytochem.* 10 741 (1962)
- 3 BELLERU, H.W.; DALAND, G.A. and PARAKE, P.: Histocytic and monocytic leukemia. A clinical, hematological, and pathological differentiation. *Cancer* 8 237 (1953)
- 4 BRÄUNSTEDER, H. und SCHMALZ, F.: Das Problem der Monocyten. *Dtsch. med. Wochschr.* 92 456 (1968)
- 5 DUBOIS, F.; BAILLY, S.; SANDROUWER, F. und BRÄUNSTEDER, H.: Spaltung von L-Leucyl- β -Naphthylamid-HCl durch Leukocyten. *Klin. Wochschr.* 42 794 (1964)
- 6 FISCHER, R. und SCHMALZ, F.: Über die Hemmbarkeit der Esteraseaktivität in Blut monocyten durch Natriumfluorid. *Klin. Wochschr.* 42 751 (1964)
- 7 FISCHER, R.; LOBBACKER, P. und KLOVER, C.: Untersuchungen zur cytochemischen Differenzierung von leukämischen Erkrankungen am Schnittpräparat. *Virchow's Arch. path. Anat.* 337 523 (1964)
- 8 HITTMANN, A.: Die myeloische Monocytenleukämie (Monocytenmyelose); in HANSEN und HITTMANN Handbuch der gesamten Histologie Bd. IV/2 (Urban & Schwarzenberg, München/Berlin 1963).
- 9 KAPLOW L.S.: A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow. *Blood* 10 1023 (1955)
- 10 KAPLOW L.S.: Simplified myeloperoxidase stain using benzidine dihydrochloride. *Blood* 26 215 (1962)
- 11 LAMBERG, K. und RAUEN-SEK, P.: Zur Zytochemie der Blutzellen. *Dtsch. med. Wochschr.* 87 1913 (1962)
- 12 LEDER, L.D.: Zur Erkennung leukämischer Monocyten im Schnittpräparat. *Beitr. path. Anat.* 131 207 (1963)
- 13 LEDER, L.D.: Fermenthistochemische Befunde bei akuter Erythraämie und chronischer Erythroblastose. *Klin. Wochschr.* 43 795 (1965)
- 14 LEDER, L.D.: Der Blutmonocyt (Springer Berlin/Heidelberg/New York 1967)
- 15 LEDER, L.D. und NICOLAS, R.: Fermenthistochemische Untersuchungen zur Gewebe der Makrophagen an Hautfestschnitten. *Frankf. Z. Path.* 73 228 (1963)
- 16 LÖFFLER, H.: Zytochemischer Nachweis von unspezifischer Esterase in Ansmachen. Beiträge zur Technik und Ergebnisse im Blutausstrich des Menschen. *Klin. Wochschr.* 39 1220 (1961)
- 17 LÖFFLER, H.: Hinweise zur Unterscheidung unreifer Leukämien mit cytochemischen Methoden. *Dtsch. med. Wochschr.* 86 1531 (1963)
- 18 LÖFFLER, H.: Unspezifische Esterase und saure Phosphatase bei Plasmonyomen. *Blut* 15 330 (1967)
- 19 LÖFFLER, H. und SCHUBERT I.C.F.: Cytochemischer Nachweis von Esteraseaktivität in den Nagehäutchen (MORCHLEV) der Megaloblasten. *Klin. Wochschr.* 39 1027 (1961)
- 20 LOMBARDY P.; LAFITE, F.; BOURDIER, J.; TUILLET P. T.; VIER, J. et BOUVER, M.: Contribution à l'étude cytochimique des leucémies aigües d'après les cellules monocytoides. *Nouv. Rev. franç. Hémat.* 7 711 (1967)

21. MOWLEY W. C., McPHERSON, A. and FLECHSMAN, L.: Esterase activity in leukocytes demonstrated by the use of naphthol-AS-D-chloroacetate substrate. *J. Histochem. Cytochem.* 8, 200 (1960)
22. NAEGLI, O. *Blutkrankheiten und Blutdiagnostik* (Springer Berlin 1923)
23. PEARSE, A. G. E. *Histochemistry Theoretical and applied* (Churchill, London 1961).
24. QUARLENO, D., TORRELLI, U., SAULTI, S. and MARCHI, C. Cytochemical and autoradiographic investigations on normal and myelomatous plasma cells. *Acta haemat., Basel* 38, 13 (1967)
25. RABKOVITZ, Y. and SCHREK, R. Monocytic cells of normal blood, Schilling and Naegeli leukemia, and leukemic reticuloendotheliosis in slide chambers. *Blood* 20: 453 (1962)
26. REISCHAU, H. und SCHILLING, V. Über eine neue Leukämie durch echte Übergangsformen (Spänozytenleukämie) und ihre Bedeutung für die Selbständigkeit dieser Zellen. *Munch. med. Woch.* 69: 1961 (1913)
27. RUTENFRANZ, A. M. und ROSALES, C. L. A histochemical method for the demonstration of leucocyte naphthylamidase using two substrates: alanyl- and methoxyl-4-methoxy-2-naphthylamide. *Brit. J. Haemat.* 1: 593 (1966)
28. SCHILLING, V. Klinik der Reticuloendotheliosen und Monosytosen. *Z. ges. inn. Med.* 5, 506 (1950)
29. SCHWALZ, F. und BRACHWITZER, H. Zytochemische Untersuchungen zur Entwicklung der grossen mononukleären Zellen des Knochenmarks. *Acta haemat., Basel* 38, 281 (1967)
30. SCHWALZ, F. und BRACHWITZER, H. Zytochemische Darstellung von Esteraseaktivitäten in Blut und Knochenmarksmustern. *Klin. Woch.* 46, 642 (1968).
31. SCHWALZ, F. und BRACHWITZER, H. On the origin of monocytes. *Acta haemat. Basel* 39: 177 (1968)
32. SCHWARTZ, J. C. F. und HATENOESER, F. Der cytochemische Nachweis der Leucinaminopeptidase in menschlichen Blut- und Knochenmarksmustern in Zyto- und Histochemie in der Hämatologie. 9 Freiburg Symp. (Springer Berlin/Göttingen/Heidelberg)
33. SKEELAN, H. L. and STORRY, C. W. An improved method of staining leucocyte granules with Sudan black B. *J. Path. Bact.* 59: 336 (1947)
34. SOGI, R. H. Die zentriologische Bedeutung zytochemischer Untersuchungen an Leukozyten. *Schweiz. med. Woch.* 96, 634 (1966).
35. SOY, C. M. and DICK, F. W. Monocytic leukemia. *Amer. J. Med.* 20: 388 (1956)
36. WELTJ, H. R. Histochemical studies of leukocytes from an inflammatory exudate. V. Alkaline and acid phosphatases and esterases. *Acta haemat., Basel* 30: 159 (1963).

which with acute terminal blastic crisis, chronic lymphoid leukemia (6), reticular (9) and lymphoid (3) disseminated sarcomatous diseases, Hodgkin's disease (12) and plasmacytoma (6). All these patients have been studied out of phases of hematologic or clinical remissions, generally in the first days after the admission in our Clinic. Moreover 8 patients with epithelial neoplasms and 9 with systemic lupus erythematosus have been studied.

Since the anti-I serum used in our researches has been obtained from O-group patient, all the subjects included in this study were selected belonging to this erythrocyte group.

2) *In vitro*-interaction between *Mycoplasmas* and erythrocyte I antigen. The red cells of two normal O-group I-positive subjects have been suspended, after three preliminary washings, in sterile saline at 2% concentration, and incubated, respectively for 80 min to 22°C and for 24 h to 4°C with the following human *Mycoplasma* strains: *Mycoplasma pneumoniae* (Eaton agent) (FH strains) *Mycoplasma fermentans* (PG. 18) *Mycoplasma hominis* type 1 (PG. 21) and type 2 (PG. 27) *Mycoplasma orale* (Patt strain). They have been grown (3-5 days at 37°C, for *M. pneumoniae* 10 days) in PPLO fluid medium (ALTROCCI *et al.*, 1966), then centrifuged 1 h at 12 000 rpm, and finally resuspended in saline at 100-fold concentration.

At the end of these two incubation periods, the red cell suspensions have been washed three times with sterile saline, resuspended in the same medium at 2% concentration, and were tested with the anti-I serum, adding 0.1 ml of the red cell suspension to 0.1 ml of the serum. The degree of the I positivity of erythrocyte suspensions after the incubation with *Mycoplasmas* has been compared with that of the same suspensions before the addition of these micro-organisms.

3) *Interaction between M. pneumoniae and I antigen in vivo.* We have selected for this study the hamster infection with *M. pneumoniae* [7]. At first, we must remember that starting researches, performed for testing the behaviour of I antigen in the normal hamster red cells, have always shown (100% of the experiments) : marked I-positivity in the erythrocytes of these animals.

We have infected, in two different experiments, 4 hamsters, intranasal route (ml 0.1 x 2) previous Nephrotic sarcoma, with *M. pneumoniae* FH strain (10^6 CFU/ml). Two animals were sacrificed in the 10th day for isolating on agar the infecting agent; and 2 respectively in 20th day for measuring the specific complement fixing antibodies.

For all the sacrificed animals we have performed long pathology evaluation agar titration, at tenfold dilutions, of infecting agent, I-antigen research in the red cells, serum cold agglutinin [FELLER and HILLERMAN] and CF antibodies measurement [3, 1], reticulocyte count and Ht determination.

Results

All the red cells of patients suffering from leukemia or other malignancies have presented a strong I positivity. We could not show any difference, with both types of incubation, between these erythrocytes and those from controls. As registered in table I we have always

Coating the serum we have used from O-group patient, we have examined, both for (1) and (2) all O-group red cells. It has been said [15] that *Mycoplasmas* are more active toward I antigen from A-group subjects. Nevertheless, the same AA. admitted the possibility of an interaction (of biophysical and/or enzymatic order) [4] between *Mycoplasmas* and O-group cells.

The specificity of this phenomenon was demonstrated through the lack of agglutination of hamster red cells by both anti-A and anti-B serum.

Table I. Intensity of I-positivity of red blood cells of normal subjects, patients suffering from leukemia, malignancies and systemic lupus erythematosus

Groups	No. of cases	Anti-I serum agglutination	Intensity
Normal subjects	10	positive	+++
Acute leukemia	15	positive	+++
Chronic myelogenous leukemia	11	positive	+++
Chronic lymphoid leukemia	6	positive	+++
Reticulosarcoma	9	positive	+++
Lymphosarcoma	3	positive	+++
Hodgkin disease	12	positive	+++
Plasmacytoma	6	positive	+++
Epithelial neoplasias	3	positive	+++
Systemic lupus erythematosus	9	positive	+++

observed an I positivity with 3+ intensity comparable to that of controls. The same results were obtained in epithelial neoplasias and systemic lupus erythematosus.

The red blood cells of normal subjects, after the two different incubation periods with the Mycoplasmas, have shown neither a fall nor a loss of I positivity. The intensity of the agglutination by anti-I serum has been equal both for the red cells incubated and for those not incubated with Mycoplasmas (table II).

Although the infection by *M. pulmonis* in hamster has been documented by the pathological findings in the lungs, by the isolation (in 10th day) of Mycoplasma, and by the content in CF antibodies (in 20th day) of the sera of the animals, we have not been able to show any change of the normally high I-positivity in the hamster red cells. The research of cold agglutinins has been negative: the reticulocyte count and the Ht value have not shown any difference in respect to the controls.

DISCUSSIONS and CONCLUSIONS

Our results about the eventual loss of I antigen in red blood cells of patients affected by leukemia or other systemic and malignant conditions, and about the capacity of Mycoplasmas to inactivate I antigen *in vitro* or *in vivo* have been negative. They do not agree with the conclusions of McGINNIS *et al.* [12], SCHMIDT *et al.* [14-15] BARRILE *et al.* [4]. On the other hand, during the development of our work,

Table II. I-positivity of normal red blood cells before and after incubation with *Mycoplasma* strains *in vitro*

Normal red blood cells samples examined	Mycoplasma strains tested	Red blood cells incubated at 22°C for 60 min and at 4°C for 24 h	
		Intensity of I-positivity before incub.	after incub.
1	<i>M. pneumoniae</i> (FH)	+++	+++
	<i>M. fermentans</i> (PG 18)	+++	+++
	<i>M. hominis</i> 1 (PG 21)	+++	+++
	<i>M. hominis</i> 2 (PG 27)	+++	+++
	<i>M. orale</i> (Patt)	+++	+++
2	<i>M. pneumoniae</i> (FH)	+++	+++
	<i>M. fermentans</i> (PG 18)	+++	+++
	<i>M. hominis</i> 1 (PG 21)	+++	+++
	<i>M. hominis</i> 2 (PG 27)	+++	+++
	<i>M. orale</i> (Patt)	+++	+++

our data have been confirmed by the results of other authors [8, 13-10]

It is not easy actually to find an explanation for these opposite results. From the technical point of view the most accurate works appear those of DUOOS *et al* [8] SALMON *et al* [13] and above all, by FEIZI and HARDISTY [10] who have performed a quantitative study of I antigen in red cells, and [at least FEIZI and HARDISTY] have tested both leukemic and control red cells against three different anti-I sera (whose two with high titer)

An interesting observation [10] is related to the different capacity of the various anti-I sera to detect a partial loss of I antigen (as, for example, that of some types of newborn red cells, I-cord). However it is not probable that this explanation may also partially justify the different results. On one hand it is clear that all the anti-I sera are able to show the complete loss of I antigen and/or its lack in the rare 'Y' cells in adult subjects [10]. On the other hand, the loss of I antigen in leukemic red cells [12-14] has been observed with high concentrations of anti I serum (1-2)

In our work, we could not perform a quantitative titration of anti-I reactivity of the various red cells examined, because of the low titer of the serum. Nevertheless, the intensity in the agglutination with 1-2 serum dilution clearly showed the normal presence of I antigen in the red cells. On the other hand, the technique followed by us is the same of the authors, who, on the contrary have obtained positive results. The

Table III Behaviour of I-positivity related with other tests, in hamsters infected by *Mycoplasma pulmonis*

Testing criteria	Normal hamsters sacrificed	Hamsters infected with <i>M. pulmonis</i>	
		Sacrif. 10th day	Sacrif. 20th day
Lung pathology	best	1) Interstitial pneumonia 2) Interstitial pneumonia	1) healing lesions 2) healing lesions
Agar titration of <i>M. pulmonis</i> (CFU/ml)	n. d.	1) 2.10^7 $1.8.10^6$ 2) 1.10^7 ; $0.5.10^6$	1) $1.5.10^6$; 1.10^6 2) 0 2.10^6
I-positivity	+++	1) +++; +++ 2) +++; +++	1) +++; +++ 2) +++; +++
Cold agglutinins	n. d.	1) absent 2) absent	1) absent 2) absent
Specific CF antibodies	n. d.	1) <10 <10 2) 10; <10	1) 40 80 2) 40; 40
Reticulocytes, / ∞	17-22%	1) 20 20 2) 19 23	1) 19 18 2) 17; 18
Hematocrit, %	40-42	1) 38; 43 2) 40 43	1) 40; 43 2) 41 42

Expressed as the reciprocal of the highest serum dilution still able to show complete absence of hemolysis with 4-8 units of antigen and 2 full units of complement.

discrepancies with the results of these authors, obtained with *in vitro* incubation between *Mycoplasmas* and I positive red cells are - nevertheless - partial. They concern *M. pulmonis* (active, following American authors, in determining I negativity of erythrocytes) and *M. fermentans* (only slightly active). Of other 3 strains tested by us, *M. hominis* 1 has been inactive also in their experiments, *M. hominis* 2 variably inactive or slightly active, *M. orale* not tested. Contrarily to SCHMIDT *et al.* [14] we have not previously disrupted *Mycoplasmas* in these experiments by freezing and thawing twice. It is not easy to say how this difference may have contributed to give a different result.

More recently during the writing of our work, FEIZI and DARRELL [9] have reported that the treatment of OI red cells with two different strains of *M. pulmonis* did not affect the activity of any of three anti I sera tested either after overnight incubation at 4°C, or after incubation at 22°C. These data agree with our results.

Also the experiments concerning the behaviour of I antigen *in vivo* after a documented *Mycoplasma* infection have given conflicting results. On one hand, American authors [16-12] have recently noted

that the activity of the erythrocyte I agglutininogen was (only) transiently reduced following *M. pneumoniae* infection in 5 of 27 volunteers, without signs of hemolytic anemia. On the other hand, FRIZY and DARRILL [9] have found that the red cells from patients with *M. pneumoniae* infection (1st 3rd 7th week) reacted with the anti-I serum in a manner indistinguishable from the normal cells.

We have obtained similarly negative results in *M. pneumoniae* infection in the hamster.

However it must be stressed that we cannot say at present, whether so conflicting results, in the whole, may depend also from the eventually different antigenic distribution of various I positive red cells, and/or from the different source of anti I antibody in human sera tested (a natural agglutinin in I negative patient or a cold agglutinin from patients who had suffered or not for a *M. pneumoniae* infection). Also SMITH *et al.* [16] admit that the greater sensitivity of the cold agglutinin anti I reagent than the iso-anti I reagent in detecting these antigenic changes may have been due to basic differences in molecular structure of anti I cold agglutinins found in cold agglutinin disease and iso anti-I cold agglutinins.

In conclusion, our data bring us to exclude both the changes in I-positivity of leukemic red cells and the interaction between I-antigen and *Mycoplasmas*. It cannot be excluded that *Mycoplasmas* are the principal microbial candidates for the triggering of autoimmune conditions [8]. Nevertheless, our actual results bring us to consider with relative scepticism, also from this point of view, the possibility of an etiological relationship between *Mycoplasmas* and leukemia.

Summary

The red cells of patients affected by leukemia and other systemic or malignant diseases do not show the loss of I antigen after two different types of *in vitro* incubation with anti-I serum. Normal red cells, incubated *in vitro* with five different human *Mycoplasma* strains, retain their normal I-positivity.

M. pneumoniae infection in hamsters does not change the I positivity of the red cells. The results of some authors, who showed the loss of I antigen in leukemic red cells and its interaction *in vitro* with *Mycoplasmas*, are discussed in relation with our negative results.

References

1. ALTUCCI, P. SAPPAL, U.; VIZALE, P. DE VARGAS, F. I. *Mycoplasma* nella patologia umana. Contributo personale allo studio della casistica respiratoria. *Med. clin. oper.* 36: 313 (1966).

2. ALTUCCI, F., CORAGGIO, F.; COTO, V.; DE VARGAS, F. and VARONE, G. L.: Isolation of Mycoplasmas from patients with leukemia and other diseases. *Acta haemat.* 40: 9-17 (1968).
3. BAKIR, M. F.: Mycoplasma (PPLO) leukemia and autoimmune disease; in *Methodological approaches to the study of leukemias*, p. 171 (1965).
4. BAKIR, M. F.; SCHMIDT, P. J.; MCGOWAN, M. H.; RUCOS, D. B. and GRABOWSKI, M. W.: Mycoplasma PPLO antigen I and leukemia. *Bact. Proc.* 110 (1965).
5. CHAIKOC, R. M. et al.: Growth of Eaton PPLO in broth and preparation of CF antigen. *Proc. Soc. exp. Biol., N.Y.* 110: 684 (1962).
6. DACH, S. V.: *The hemolytic Anemias*, p. 342 (Grune & Stratton, New York 1962).
7. DAJANI, A. S.; CLYDE, W. A. and DESERT, F. W.: Experimental infection with Mycoplasma Pneumoniae (Eaton agent). *J. exp. Med.*, p. 1071 (1963).
8. DOON, S.; RUPPE, S.; COLOMBINI, P.; MARTY, Y. and OTTAVIO, E.: I antigen in leukemic patients. *Nature Lond.* 207: 1329 (1965).
9. FEIZI, T. and DARRILL, Y. H.: Failure to demonstrate blocking of I antigen by M. pneumoniae *in vivo* and *in vitro*. *Nature Lond.* 211: 1199 (1966).
10. FEIZI, T. and HARDISTY, R. M.: I antigen in leukemic patients. *Nature Lond.* 210: 1066 (1966).
11. MARSH, W. C.: Anti I-A cold antibody defining the I-I relationship in human red cells. *Brit. J. Haematol.* 7: 200 (1961).
12. MCGOWAN, H. H.; SCHMIDT, P. S. and CARBONE, P. P.: Close association of I blood group and disease. *Nature Lond.* 202: 606 (1964).
13. SALMOY, C. H.; SALMOY, D.; MARDON, C. et BERTHELE, J.: Etude quantitative de l'antigène I dans les érythrocytes des sujets atteints de leucémie aigüe. *Nouv. Rev. franç. Hémat.* 6: 563 (1966).
14. SCHMIDT, P. J.; BAKIR, M. F. and MCGOWAN, M. H.: The I blood group, PPLO and leukemia. *Blood* 24: E34 (1964).
15. SCHMIDT, P. J.; BAKIR, M. F. and MCGOWAN, M. H.: Mycoplasma and blood group I association with neoplastic disease. *Nature Lond.* 203: 371 (1965).
16. SETHI, C. B.; MCGOWAN, M. H. and SCHMIDT, P. J.: Changes in erythrocyte I agglutinogen and anti I agglutinins during *M. pneumoniae* infection in man. *J. Immunol.* 99: 333 (1967).
17. WINGER, A. S.; VOGEL, L. S.; COHEN, L. and FELDMAN, S.: *Ann. Intern. Med.* 44: 221 (1956).

separately were prepared for histological and chromosomal study and the remaining tissue was then transplanted into syngeneic hosts.

3. *Thymus from mice exposed to thigh-shielded irradiation.* Eight weeks following the first in series of thigh-shielded irradiation, mice were killed and pieces of the thymus implant prepared for histological, chromosomal and transplantation study as mentioned above.

4. *Virus-induced lymphomas.* Four 7 and 10 weeks after inoculation of virus into the intracranial implant in the thymectomized and irradiated recipients the animals were killed and pieces of the thymic implants prepared for histological, chromosomal and transplantation study as mentioned above.

b) In a separate set of experiments, chromosomal analysis and histological examination were performed on 11 virus-induced disseminated lymphomas. No transplantation was performed on these animals since other experiments have shown that the disseminated lymphomas are readily transplantable [unpublished data].

Results

1. *Thymus from normal controls.* The chromosome pattern of thymus cells from 7 normal control mice of various ages is shown in table I. A metaphase of a normal thymus cell is shown in figure 1. Occasional cells contain only 39 chromosomes and a few cells have an extra chromosome. Although an attempt was made to count only cells that appeared intact, the possibility cannot be excluded that the missing and extra chromosomes are artefactual, due to excessive hypotonic treatment.

2. *Thymus from mice exposed to leukemogenic whole-body irradiation* (table II). Eight weeks after irradiation the thymic lobes were very small. Two were histologically classified as atrophic, indicating lymphocytic depletion [7]. The small size of these lobes made it dif-

Table I. The chromosome pattern of normal untreated mice

Sex	Age weeks	No. cells with indicated chromosome number		
		39	40	41
F	6	1	38	
F	10		42	
F	21	1	36	1
M	20	2	36	1
M	20		41	
M	20	1	29	1
M	21	1	35	

Table II. The chromosome patterns and transposition behaviour of thymus cells during the development of radiation-induced lymphomas

Weeks after X-ray	Mouse No.	Histol. classif.	Results of transpl.	No. cells with indicated chromosome number						Structural chromosome aberrations	Fluor. interpretation normal	Fluor. interpretation reciprocal	deficiency normal
8	1	Atrophy		2	6	1					x		
	2	LGT		1	6	1				+	x		
	3	Normal		1	12							x	
	4	Normal		2	11					+	x		
	5	LGT		2	2	9	1			+	x	x	
	6	Atrophy		2	1	8				+	x	x	
14	1	LGT		1	1	24	2	1					
	2	LGT		2	17	2	1						
	3	LGT		3	24	1	3						
	4	IL		1	4	17	2			+			
	5	IL	+	2	2	13	1						
	6	IL		2	7	16	4			+			
20	1	LGT		1	1	11	2						
	2	IL		1	2	17	1						
	3	IL	+	4	7	4							
	4	IL	+	1	2	1	10						
	5	IL	+	1	4	13							
	6	IL		3	9								
	7	IL	+	1	2	28	2	1		+			
	8	IL		1	2	12		1					
	9	IL	+	1	2	1	16	2	1				
	10	IL		1	2	1	13	2					

LGT lymphoma confined to thymus, IL invasive lymphoma.

difficult to obtain good chromosome preparations and only relatively few metaphases could be examined. Occasional morphological aberrations were observed and in one atrophic lobe (No. 6) 7 of 15 cells showed aneuploidy. All of the implanted thymic lobes gave a negative transplantation test at 8 weeks after irradiation.

Fourteen weeks after irradiation all the lobes exhibited histological signs of tumour, either as lymphomas confined to the thymic lobe or as invasive lymphoma. Only one, however, gave a positive take after transplantation. All these lobes showed numerical aberrations in chromosome pattern (fig. 2) and some chromatid breaks were observed. Four of the 6 animals were classified as definitely abnormal.

At 20 weeks all lobes examined were histologically lymphomatous. Though the number of metaphases examined is small in some of the lymphomas, it is obvious that all tumours analyzed at 20 weeks had substantial proportions of aneuploid cells. Two out of 10 lobes were classified as definitely abnormal. Six of 36 cells from one mouse (No. 9) had chromosome numbers in the tetraploid range. Only occasional breaks were observed in these groups.

Five out of 10 lobes gave a positive transplantation test (table II). All of these were invasive lymphomas in a macroscopically and microscopically early stage. Mice No. 2 exhibited slight dissemination to distant organs. Thus no correlation was found between specific morphological features and positive transplantation tests of the thymomas developing after irradiation. Nor was there a correlation between transplantation behaviour and the first appearance of numerical or morphological abnormalities in the chromosome patterns.

3. Thymus from mice exposed to thigh-shielded irradiation. Following irradiation with the thighs shielded the thymus undergoes characteristic histological alterations instead of the atrophy preceding the tumour development following leukemogenic whole-body irradiation. The thigh shielded irradiation is attended by rapid recovery and hyperplasia of the thymus that becomes populated by small dense thymocytes [7]. Good spreading of the chromosomes is very difficult to obtain from these cells and a total of 40 acceptable metaphases could be obtained from 4 mice. The number of the chromosomes of these cells are presented in table III showing no major deviations from the mode of 40. No structural abnormalities were observed and the transplantation tests were all negative.

4. Virus-induced lymphomas (table IV). Four weeks after the inoculation of leukemogenic virus all of the three implants available for

Table III The chromosome pattern of thymus cells following thigh-shielded irradiation of the mice

No. cells with indicated chromosome number				Final interpretation		
38	39	40	41	normal	equivocal	definitely abnormal
2	4	33	1		x	

The table includes the chromosome counts of thymus cells from 4 mice

histologic examination were neoplastic. Two of these gave positive transplantation tests. Occasional aneuploid cells occurred but no convincing chromosomal aberrations were encountered. One of 4 were considered equivocal.

Seven weeks after virus-inoculation all implants were neoplastic and exhibited histological evidence of invasive lymphoma although in an early stage of development. One of these, No. 1 had about 30 of the cells in the hyperdiploid range. Because of the very small size of this tumour few metaphases could be examined. The other animals in these groups showed occasional loss of chromosomes but no major numerical or morphological aberrations occurred. Because of the small number of metaphases accessible to analysis the majority of these cases were classified as 'equivocal'. All tumours gave positive takes after transplantation.

Ten weeks after virus-inoculation the tumours were histologically still in an early stage of development. Two of the lymphomas were still non-invasive. The chromosome counts indicate numerical aberrations in most of the cases, except for No. 3 and possibly No. 2. One tumour No. 5 had some missing chromosomes and one tetraploid cell and occasional chromatid breaks were observed. Four of the 5 tumours were classified as 'equivocal'. Three implants, of which 2 were histologically classified as lymphoma confined to the implant, yielded positive transplantation takes. One invasive lymphoma with 5 out of 16 cells in the hyperdiploid range was negative after transplantation.

The chromosome pattern of virus-induced, disseminated lymphomas in the terminal stage of the disease is demonstrated in table V. The counts indicate numerical abnormalities in all cases and 9 of the 11

Laboratory of Blood Coagulation, Department of Medicine and the ENT Department,
University of Louvain

**Double Blind Evaluation of the Haemostatic Effect
of Adrenochrome Monosemlearbazone, Conjugated Oestrogens
and Epilgonaminocaproic Acid after Adenotonsillectomy**

M. VERSTRAETS, J. VERMYLEN and J. TYBERGHEIN

Evaluation of the haemostatic effect of agents designed to reduce blood-loss is beset with numerous difficulties. Patients with a chronic haemorrhagic diathesis often bleed intermittently haemorrhage ceasing or diminishing regardless of the drug administered. If the alleged beneficial effect of a haemostatic agent is tested when normal haemostasis is challenged, it must be ascertained that the severity of bleeding and underlying mechanism leading to it are similar in the different individuals. This latter requirement implies that traumatized persons or patients subjected to the multiple variants of surgery cannot be considered as valid test material for this purpose.

A more uniform challenge to haemostasis is a well standardized bleeding time but even in the best hands it is difficult to make a uniform cut through the skin, due to the natural anatomical variations in vessel size. Because of other variables also, numerous cuts (e.g. 20 in the rabbit's ear) have to be made to ensure statistical validity [11]. Reproducible results are also very difficult to obtain in man [13].

In view of these drawbacks we chose adenotonsillectomy as a test situation wherein the mechanical trauma is fairly standard and large enough to permit pharmacologically induced reduction in blood loss, if any, to be measured. Furthermore a large number of individuals can be included in the trial and as only healthy children are involved, the subjects can be considered as constituting a fairly homogenous group. The type of operation selected also offers the possibility of assessing blood-loss.

Three substances commercially available as haemostatic agents were evaluated in double blind trials using measured blood-loss as criterion in children subjected to adenotonsillectomy. The order of allocation of the test substance or placebo was randomly determined.

Methods

The experiments reported herein were performed in collaboration with the ENT department of the University Hospital of Louvain, Belgium. The subjects involved were all patients admitted to this department the night before operation and discharged 10 h after surgery. The technique used for tonsillectomy and adenoidectomy did not vary substantially among the different surgeons of the University department where all the operations were performed. Minor variations could not influence the results as a control group was included in the series. No premedication was given; the child remained awake during the operation and was briefly anaesthetized with ethyl chloride. The adenoids were removed using the Volkmann curette and tonsillectomy performed by means of the Stadeltoeng. 80% of the children studied were subjected to both operations.

In the trial with adrenochrome monosemicarbazone, loss of blood through aspiration or ejection, was ascertained gravimetrically. Previously weighed dry gauze sponges, doctors' and nurses' blouses and bedlinen were used and the quantity of blood-loss determined by immediate re-weighing. The blood lost during the following 10 h was assessed using the same gravimetric method. The incidence of saliva and other ejected material in the weight difference can be disregarded because a large control group underwent similar treatment.

In the trials with conjugated oestrogens and with epilone-amino-caproic acid, total blood loss was determined by placing all the ejected blood, tampons, towels, doctors' and nurses' blouses and bedlinen used for one child in a blood-loss monitor. The instrument used was the Perdometer (A.B. Lars Ljungberg, Stockholm). The blood containing materials were collected in a tank containing 40 l of water and haemolysing agent. The blood was washed out by rotary washing mechanism and haemolyzed. The blood-containing solution was filtered and pumped continuously through a photometer that measured the light absorption due to haemoglobin content. Since this is proportional to the amount of blood present, the quantity of blood lost can be immediately ascertained by a conversion table that takes into account the patient's preoperative haemoglobin value. The objection that swallowed blood is not taken into account can be disregarded because the same procedure was used for both the treated and control groups. The measurement of very small amounts in the Perdometer is not reliable below 10 ml of blood due to uneven distribution of fluids in the instrument (40 l) but above this figure, the correlation with the measured value is good. The average error of the instrument in test determinations of known amounts of blood was 3% [14]. Haemoglobin was determined by the method of DRABKIN.

Adrenochrome monosemicarbazone (1-methyl-2,3-dihydro-3-hydroxyindole-5,6-quinone) (Adrenocyl® Labas; Adrenocin® SE Macgregill Co.) is one of the first derivatives produced during the oxidation of epinephrine; the semicarbazone of adrenochrome is stable substance. Vials containing 5 mg active substance or placebo were prepared. The water soluble conjugated oestrogens (Premarin® Ayerst; Equigyn® Torndac) were used. Each vial contained 20 mg natural oestrogen in the dried state or placebo. The epiloneamino-caproic acid-vials (EACA) were Epilapron® Kabi, Stockholm, containing 5 ml active substance at 40% (w/v).

The kind cooperation of the doctors and nurses of the ENT Department (Head Prof. Dr. FR. CHAMPE) is gratefully acknowledged.

Results

Adrenochrome

Vials with adrenochrome monosemicarbazone (5 mg) or placebo, identical in appearance, were prepared and numbered at random by the manufacturer and administered according to the double blind technique. The key indicating the content of each vial was kept in a sealed envelope which was not opened until the trial had been completed. A total number of 100 children took part in the trial of which 6 were eliminated at the end of the study because of incomplete data. Placebo was administered to 47 children and adrenochrome monosemicarbazone to the remaining 47 cases. Each patient received the night before amygdalotomy 5 mg adrenochrome intramuscularly and a second identical dose approximately half an hour before operation. This dose is considered to be high for children with an average weight of 22.3 kg.

In this trial, blood-loss was measured by a gravimetric method. The mean difference in weight of the linen before and after operation was 60 g (SD 21) in the adrenochrome-treated group and 58 g (SD 28) in the placebo-treated group. Both groups were similar in weight and height (table I).

Conjugated Oestrogens

This trial also was conducted strictly according to the double blind method, the sequence of substances given to the patients being determined by random allocation. All vials were similar in appearance. The content of one vial (20 mg) was injected intramuscularly approximately half an hour before the operation. At all 200 children were involved in this trial upon completion of the study, 27 cases (15 treated with conjugated oestrogens and 12 with placebo) had to be rejected for a variety of reasons likely to invalidate the results (loss of part of the linen, spitting of blood in the toilet or children leaving the ENT department before 5 p.m.). After disclosure of the code-key it appeared that, of the remaining 173 children, 85 received the test substance and 88 the placebo material.

The results of measured blood-loss are given in table I. Both groups of patients were identical in weight and height, no difference in blood loss could be found.

Table I

	Monosemicarbazone of adrenochrome	Placebo
Number of children in the trial	47	47
Mean blood loss	58 g (SD 28)	60 g (SD 21)
Mean height	115 cm (SD 0.12)	112 cm (SD 0.18)
Mean weight	22.2 kg (SD 7.7)	22.2 kg (SD 9.7)
	Conjugated oestrogen	Placebo
Number of children in the trial	85	88
Mean blood-loss	85.4 ml (SD 37.8 ml)	89.8 (SD 37.0)
Mean height	117 cm (SD 16.1 cm)	115 (SD 15.7)
Mean weight	22.6 kg (SD 8.4)	21.2 kg (SD 8.08)
	EACA (2 g i.v.)	
Number of children in the trial	25	
Mean blood-loss	89.0 ml (SD 36.6)	
Mean height	121.5 cm (SD 15.08)	
Mean weight	23.9 kg (SD 6.8)	
	EACA	Placebo
	≤ 15 kg: 4 g i.v.	
	> 15 < 30 kg: 8 g i.v.	
	> 30 kg: 12 g i.v.	
Number of children in the trial	51	36
Mean blood-loss	60.3 ml (SD 17)	87.2 ml (SD 40.0)
Mean height	119 cm (SD 16.2)	125 cm (SD 15.4)
Mean weight	22.5 kg (SD 7.3)	22.6 kg (SD 8.5)

Epsilon-Amino-Caproic Acid

Vials containing 5 ml EACA at 40% were available. The content of one vial (2 g) was injected intravenously 30 to 60 min before operation in 25 children. There was no control group however the children involved in this trial were not preselected. The results of blood-loss are compared with the blood-loss obtained in the 88 control children, operated in identical circumstances. No difference was noted in measured blood-loss 89.0 ml (SD 36.6) in the treated group 89.8 ml (SD 37.0) in the control group of the previous trial.

As the possibility that the EACA dose was insufficient could not be excluded, it was decided to initiate a new trial whereby the EACA dose was increased and adapted to the weight of the child. The following doses of EACA were administered intravenously 30 to 60 min before the operation in children less than 15 kg 4 g EACA between

15 and 30 kg 8 g EACA over 30 kg 12 g EACA. A few instances of vomiting were observed after injection of the drug

As the EACA dose had to be adapted according to the weight of the child, this part of our investigation was not a double blind but still a controlled not stratified study. Each patient involved in the study was allocated to the EACA or placebo group according to serial numbering before the trial started each number was listed at random in one of the two groups. As a significant difference in blood loss was observed after treatment of 67 children (31 in the EACA group, 36 in the control group) this trial was not continued with the remaining 33 of the 100 children initially envisaged. Both groups were similar with respect to weight and height. The blood loss in the EACA treated group was 60.3 ml (SD 17) and in the control group 87.2 ml (SD 40.0 ml) this difference is highly significant ($P < 0.001$)

Discussion

The alleged haemostatic effect of conjugated oestrogens is based on the work of SCHIFF and BURN [17]. These authors have demonstrated a progressive change from the sol to the gel state of mucopolysaccharides in the ground substance around small vessels and in the arterial walls. This polymerization of the mucopolysaccharides was observed in hamsters, monkeys and men following intravenous administration of conjugated oestrogens.

Detailed reports concerning the impact of conjugated oestrogens on blood coagulation are rare and often conflicting. An elevation of fibrinogen [12], prothrombin and factor V and a decrease of antithrombin [6] have been described but these findings could not be confirmed by other investigators [7-9]. It is possible however that capillary oozing could be shortened by action of oestrogens at the vascular or extravascular level without being influenced by the intravascular coagulation factors. An attentive study of the clinical reports is rather disappointing as the effect of conjugated oestrogens on haemostasis is based on clinical judgment only except in two trials conducted according to the double blind method which however were both negative [7-9].

It is beyond doubt that epinephrine from which monosemicarbazone of adrenochrome is derived has a vasoconstrictor effect on the microcirculation. The direct relationship between the decreased flow

of blood within these vessels and its alleged function in lessening blood loss is less clear. As epinephrine is readily oxidized to adrenochrome which itself is also unstable, a more suitable agent for clinical use was developed: the monosemicarbazone of adrenochrome which is said to be stable when administered by mouth or by injection [4].

Numerous studies have been published on monosemicarbazone of adrenochrome claiming its increased capillary resistance and usefulness in reducing haemorrhage after oral or parenteral administration. Unfortunately the enthusiastic clinical reports on its haemostatic role in man originate from clinical impressions and/or uncontrolled clinical trials. The only reported double blind clinical trial failed to confirm previous favourable reports: in this trial the observation of the duration of bleeding after dental extraction was made by the patient himself, thus exposing the evaluation method to criticism because of the ill-defined subjective criterion [5]. In another controlled trial the same drug had no statistically significant effect on capillary resistance as measured by a negative pressure method. No apparent difference in the incidence of post-operative hyphaema in a series of forty pairs of patients, one of each pair receiving monosemicarbazone of adrenochrome by mouth, was observed [18].

Different fibrinolysis inhibitors are commercially available, some of them being extracted from tissue. The polypeptide isolated from bovine lung (Trasylo[®] Bayer) or pancreas (Iniprol[®] Choay) are inhibitors of trypsin, plasmin and plasminogen activator. Synthetic fibrinolysis inhibitors are the aminoacids ϵ -amino-caproic acid (EACA), Transamino-methyl-cyclohexane-carboxylic acid (AMCHA or tranexamic acid: cyclocapron) and para-aminomethyl benzoic acid (PAMBA).

It has been demonstrated beyond reasonable doubt in controlled studies that synthetic fibrinolysis inhibitors can diminish bleeding from areas with increased local fibrinolytic activity as for instance in the urinary tract [1, 8, 16] and uterus [10, 15, 20]. The effective oral dose required is approximately 400 mg/kg EACA or between 60–90 mg/kg AMCHA.

Activators of the fibrinolytic system are present in almost all tissues as shown by the experiments of Astrup and Parham [3]. After adenotonsillectomy haemorrhage at the adenoid and tonsil bed may be sustained because of the local activity of tissue activators, premature dissolution of local clots prolonging bleeding or provoking renewed blood-loss. It is a fair assumption to relate the haemostatic value of

15 and 30 kg 8 g EACA over 30 kg 12 g EACA. A few instances of vomiting were observed after injection of the drug.

As the EACA dose had to be adapted according to the weight of the child, this part of our investigation was not a double blind but still a controlled not stratified study. Each patient involved in the study was allocated to the EACA or placebo group according to serial numbering before the trial started each number was listed at random in one of the two groups. As a significant difference in blood loss was observed after treatment of 67 children (31 in the EACA group, 36 in the control group) this trial was not continued with the remaining 33 of the 100 children initially envisaged. Both groups were similar with respect to weight and height. The blood-loss in the EACA treated group was 60.3 ml (SD 17) and in the control group 87.2 ml (SD 40.0 ml) this difference is highly significant ($P < 0.001$).

DISCUSSION

The alleged haemostatic effect of conjugated oestrogens is based on the work of SCHIFF and BURR [17]. These authors have demonstrated a progressive change from the sol to the gel state of mucopolysaccharides in the ground substance around small vessels and in the arterial walls. This polymerization of the mucopolysaccharides was observed in hamsters, monkeys and men following intravenous administration of conjugated oestrogens.

Detailed reports concerning the impact of conjugated oestrogens on blood coagulation are rare and often conflicting. An elevation of fibrinogen [12], prothrombin and factor V and a decrease of anti-thrombin [6] have been described but these findings could not be confirmed by other investigators [7-9]. It is possible however that capillary oozing could be shortened by action of oestrogens at the vascular or extravascular level without being influenced by the intravascular coagulation factors. An attentive study of the clinical reports is rather disappointing as the effect of conjugated oestrogens on haemostasis is based on clinical judgment only except in two trials conducted according to the double blind method which however were both negative [7-9].

It is beyond doubt that epinephrine from which monosemicarbazone of adrenochrome is derived has a vasoconstrictor effect on the microcirculation. The direct relationship between the decreased flow

8. JOHNSON, J. F. Changes in plasma prothrombin, acryglobulin and antithrombin concentration following intravenous administration of oestrogens. *Proc. Soc. exp. Biol.* **51** 92 (1957).

9. MCGOVERN, J. J.; BUCKER, J. P.; GOLDBERG, R. and ESTES, J. W. The effect of conjugated oestrogens in the coagulation mechanism. *J. Amer. med. Ass.* **175** 1011-1012 (1961).

10. McNICOL, G. P.; FLETCHER, A. M.; ALKJAERUNG, N. and SENERY, S. Impairment of hemostasis in the urinary tract. The role of urokinase. *J. Lab. clin. Med.* **58** 34 (1961).

11. NELSON, L. M. Intravenous promastin as a hemostatic agent. *Canad. Med. Ass. J.* **68** 1185 (1960).

12. NELSON, L. and RYBO, G. Treatment of menorrhagia with epsilon aminocaproic acid. A double blind investigation. *Acta obst. gynec. scand.* **44** 467-473 (1965).

13. F. UWER, L. J. ROSEMAN, J.; DEMOUAT, G. et PERRANT, A. Etude statistique du temps de saignement moyen humain. *Arch. Int. Pharmacodyn.* **67** 390 (1942).

14. PHILLIPS, L. L. Etiology of afibrinogenemia. Fibrinogenolytic and fibrinolytic phenomena. *Ann. N. Y. Acad. Sci.* **73** 678-684 (1959).

15. ROSEMAN, J. *Art of bleeding* (Thomas, Springfield, Ill. 1934).

16. RISTAD, H. Measurement of blood-loss during surgery. *Lancet* **i** 1304 (1963).

17. RYBO, G. Plasminogen activators in the endometrium. II. Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood-loss. *Acta obst. gynec. scand.* **45** 429-450 (1966).

18. SACK, E.; SEAST, T. M.; GETTLE, R. L. and HICSON, B. Reduction of post prostaticectomy bleeding by epsilon-aminocaproic acid. *New Engl. J. Med.* **266** 541 (1962).

19. SCHWARTZ, M. L. and BULL, H. F. The effect of intravenous oestrogens on ground substance. *Arch. Otolaryng.* **73** 44 (1961).

20. SWAN, H. T.; NUTT, A. B.; JOWETT, G. H.; FRASCHER, W. J. and BLACKBURN, E. K. Monocarbonylisation of adrenochrome (Adrenocortyl) and cataract surgery. Effect on capillary resistance and incidence of hyphaema. *Brit. J. Ophthalm.* **45** 415-422 (1961).

21. TRAJER, S.; KOCACIOGLU, M. and McELFISH, A. E. Value of systemic hemostatic drugs. "Double blind" evaluation of agents used to increase coagulation during tonsillectomy and adenoidectomy. *Arch. Otolaryng.* **70** 72 (1959).

22. VERMYLEN, J.; VERMAEREN-DEGERS, M. L.; FLEURY, P. and VERSTRAETE, M. A double blind study of the effect of tranexamic acid in essential menorrhagia (to be published, 1968).

Department of Pathology and Clinical Laboratories, St. Barnabas Hospital, Minneapolis, Minn.

Reticulohistiocytic Origin of the Blood Basophil in Human Marrow

E. M. SCHLESISER

Since EHRICH [1] described two types of mast cells the Blutmastzelle and the Gewebsmastzelle their origin and histochemistry have been studied. Because of the structural, chemical and functional similarities between the cells SELVZ [2] states the blood basophil represents the circulating form of the tissue mast cell system. However LEVY and SCHUBERT [3] BRAUNSTEINER [4] BRAUNSTEINER and PAKESCH [5] SHELLY and JUDLIN [6] and WENQVIST [7] showed structural differences between the blood basophil and the tissue mast cell. While the genesis of the blood basophil has remained conjectural UADWITZ [8] derives the cell from a Basophiloblast.

It is the purpose of this communication to present morphological evidence of a direct reticulohistiocytic origin of the blood basophil in human bone marrow. For this study Hodgkin's disease was found to be particularly appropriate. Frequently the basophils are increased in the circulating blood and the bone marrow in this condition besides, the genesis of the blood basophil could be more easily studied than in leukemic marrows containing large quantities of undifferentiated and pleomorphic cells.

Material and Method

The cell studies were made on male 28 years old, who had generalized Hodgkin's disease. The peripheral blood basophils ranged from 8 to 14% determined by the method of SCOTT [9]. From the body of the sternum marrow units (Marrowbriquets) were separated. The marrow unit imprint technique was employed [10, 11]. The preparations were stained by dual staining procedure namely Wright blood stain with Toluidin blue O. aqueous

solution superimposed. The latter forms chemical union with the acid mucopolysaccharides in the granules giving them the specific metachromatic appearance.



Fig 1 Reticuloendothelial syncytium. (a) Primitive reticulolymphoid cell (kleine lymphoide Retikulumzelle of Roux) (b) Early developmental stage of the blood basophil. (c) Advanced developmental stage of the blood basophil.

Fig 2. (a) Histiocytes. (b) Variants of developmental stages of the blood basophil. Note the 'cytoplasmic tail' containing various amounts of granules of different size and degree of metachromasia.

Results

In the reticulohistiocytic syncytium (fig 1) the earliest recognizable developmental stage of the blood basophil is a small reticulolymphoid cell *kleine lymphoide Retikulumzelle* of ROSS (fig 1a). The nucleus is round and often slightly notched and more or less eccentrically located. It has a reddish-purple color and several various sized bluish-purple nucleoli. The narrow cytoplasm ranges from light blue to colorless and may contain small metachromatic granules. The cell boundary is demarcated by a condensation of the cytoplasm. This primitive cell differentiates within the syncytium into a blood basophil without going through a blast stage (fig 1b-c). One to several basophils in various maturation stages may be present in a syncytium. The cells retain a histiocytic nucleus which becomes indented, lobulated and more or less overlaid by granules of different size and degrees of metachromasia. Various developmental stages are presented in fig 2b. The pear-shape results from a 'cytoplasmic tail' in which the granules tend to concentrate. This morphological feature appears to be characteristic of the developing basophil. According to these morphologic findings it is inferred that the blood basophil is a histiocyte.

Summary

The genesis of the blood basophil in human bone marrow as seen in marrow wash imprint preparations is presented. A direct origin from reticulohistiocytic syncytia could be demonstrated. The progenitor of the blood basophil is a small reticulolymphoid cell *kleine lymphoide Retikulumzelle* of ROSS. It is inferred that the blood basophil is a histiocyte.

References

1. EHRICH, P. Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukozyten. *Arch. Anat. Physiol.* 3: 166 (1879).
2. SILVER, H. *The Mast Cells*, p. 361 (Butterworth, Washington, D.C. 1963).
3. LEVINTHAL, A. and SCHUBERT, J. G. F. Untersuchungen über die azurophilen Myelozytenstadien der Gewebeschleimzellen im menschlichen Knochenmark. *Frankf. Z. Path.* 7: 578 (1959).
4. BRÄUTERINGER, H. *Physiologie und Pathophysiologie der weissen Blutzellen* (Thieme, Stuttgart 1959).
5. BRÄUTERINGER, H. and FÄRBER, F. Elektronenmikroskopische Untersuchungen der Granula menschlicher Leukozyten. *Acta haemat., Basel* 27: 136 (1977).
6. SMELL, W. B. and JENSEN, L. Functional cytology of the human basophil in allergic and physiologic reactions. *Blood* 19: 708 (1962).

- 7 WISQVIST G. Electron microscopy of the basophilic granulocyte. *Ann. N.Y. Acad. Sci.* 173, 352 (1963)
- 8 UNOWITZ, E. Sandoz Atlas of Haematology, p. 49 (Sandoz, Basel 1952)
- 9 SCHLICHTER, E. M. Technique for determination of the differential leukocyte ratio and total leukocyte count. *Minnesota Med.* 45, 914 (1962)
- 10 SCHLICHTER, E. M. Method for making imprints and direct smears from gross marrow units. *Amer. J. Path.* 9, 8 (1945) Techn. Sect.
- 11 ROSE, K. Das menschliche Knochenmark; 3rd ed., p. 11 (Thieme, Stuttgart 1960).

Results

In the reticulohistiocytic syncytium (fig 1) the earliest recognizable developmental stage of the blood basophil is a small reticulolymphoid cell "kleine lymphoide Retikulumzelle" of ROSEN (fig 1a). The nucleus is round and often slightly notched and more or less eccentrically located. It has a reddish-purple color and several various sized bluish-purple nucleoli. The narrow cytoplasm ranges from light blue to colorless and may contain small metachromatic granules. The cell boundary is demarcated by a condensation of the cytoplasm. This primitive cell differentiates within the syncytium into a blood basophil without going through a blast stage (fig. 1b-c). One to several basophils in various maturation stages may be present in a syncytium. The cells retain a histiocytic nucleus which becomes indented, lobulated and more or less overlaid by granules of different size and degrees of metachromasia. Various developmental stages are presented in fig 2b. The pear shape results from a "cytoplasmic tail" in which the granules tend to concentrate. This morphological feature appears to be characteristic of the developing basophil. According to these morphologic findings it is inferred that the blood basophil is a histiocyte.

Summary

The genesis of the blood basophil in human bone marrow as seen in marrow smears prepared by the method of ROSEN is presented. A direct origin from reticulohistiocytic syncytia could be demonstrated. The progenitor of the blood basophil is a small reticulolymphoid cell "kleine lymphoide Retikulumzelle" of ROSEN. It is inferred that the blood basophil is a histiocyte.

References

1. EHRICH, P. Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukozyten. Arch. Anat. Physiol. 3: 166 (1879).
2. SELYE, H. The Mast Cells, p. 361 (Butterworth, Washington, D.C. 1963).
3. LÖNNERT K. and SCHLESINGER J. C. F. Untersuchungen über die sauren Mucopolysaccharide der Gewebestellen des menschlichen Knochenmark. Frankf. Z. Path. 69: 578 (1959).
4. BRÄNNSTEDER, H. Physiologie und Pathobiologie der weissen Blutzellen (Thieme, Stuttgart 1959).
5. BRÄNNSTEDER, H. and PARKER, F. Elektronenmikroskopische Untersuchungen der Granula menschlicher Leukozyten. Acta haemat., Basel 17: 136 (1957).
6. SEITZ, W. B. and JUDEN, L. Functional cytology of the human basophil in allergic and physiologic reactions. Blood 19: 208 (1962).

- 7 WILQVIST G. Electron microscopy of the basophilic granulocyte. *Ann. N.Y. Acad. Sci.* 103: 352 (1963).
- 8 UNDAERTZ, E. *Bondou Atlas of Haematology*, p. 49 (Sandoz, Basel 1952).
- 9 SCHULMANN, E. M. Technique for determination of the differential leukocyte ratio and total leukocyte count. *Minnesota Med.* 45: 914 (1962).
- 10 SCHULMANN, E. M. Method for making imprints and direct smears from gross marrow smita. *Amer. J. Path.* 9: 8 (1943) Techn. Sect.
- 11 ROSA, K. *Das menschliche Knochenmark*, 3rd ed., p. 11 (Thieme Stuttgart 1960).

Istituto di Clinica Pediatrica dell'Università di Roma (II Cattedra)
di Chimica Biologica dell'Università di Urbino

Neonatal Hemolysis Due to a Transient Severity of Inherited Pyruvate Kinase Deficiency¹

M. BOSSI, M. D'AGHÀ and G. FORNAINI

In recent years many works have shown the high occurrence and severity of the hemolytic diseases in the newborn period. In many cases, such as those due to an isoimmunization, to a bacterial and viral infection, to genetically determined metabolic deficiencies, to hemoglobinopathies, to morphological modifications of the cell, the etiology and pathogenesis are fairly known; in other cases, the causes of the hemolytic episode are unknown. The latter forms may be ascribed to some morphological or functional transient disturbances of the cell.

However it might be that a transient state of deficiency is responsible for the hemolytic episode also in the subjects bearing an inherited defect and particularly in those cases in which some inborn errors of erythrocyte metabolism are present. Such a possibility is confirmed by the present case of hemolytic disease in a newborn infant being heterozygous for pyruvate kinase deficiency. In this subject the hemolytic state is determined by a transient severity of the genetic deficiency.

Case Report

M.P. Proposita. At 4 days age the patient's colouring became pallid and he demonstrated icterus, vomiting and slight splenomegaly. Examination of peripheral blood provides the

The following abbreviations have been used: *G-6-PD* glucose-6-phosphat dehydrogenase; *6-P-GD* phosphogluconat dehydrogenase; *PK* pyruvate kinase; *G-6-P* glucose-1-phosphat; *6-P-G* 6-phosphogluconate; *GSH* reduced glutathione; *APH* acetyl-phenylhydrazine; *ATP* adenosine-5-trisphosphat; *RBC* red blood cells; *WBC* white blood cells; *WEP* Whole erythrocyte population.

The present work has been carried out with CNR funds.

following data: RBC 2,600,000, Hb 11%, reticulocytes 4%, slight aniso-polychytosis, small number of macrocytes and normoblasts, no spherocytes, WBC 7,200, serum bilirubin 16.8%. Coombs test negative. The red cell osmotic fragility was normal before incubation and markedly increased after incubation at 37°C for 24 h. The autohemolysis was not corrected by adding glucose, and slightly decreased by adding glucose and ATP. The subject was not transfused and was treated with cortisone and albumin.

24 h after crisis RBC 2,600,000, reticulocytes 7%, bilirubin 16.6%; 48 h after crisis RBC 2,800,000, reticulocytes 9%, bilirubin 15.4%; 5 days after crisis RBC 2,800,000, reticulocytes 14%, bilirubin 12.4. 10 days after crisis both icterus and splenomegaly disappeared and the hand-feeding was well accepted. RBC, 3,900,000, reticulocytes 9%, bilirubin 9.3%; 20 days after crisis RBC 3,900,000, reticulocytes 3%, bilirubin 5.8%; 30 days after crisis RBC 4,200,000, reticulocytes 2%, bilirubin 4.1.

The examinations of the subjects used as controls were normal, for the referred experiments, from a pathological point of view or from hematologic tests.

Researches were always been carried out parallelly on the pathological subject and on controls bearing approximately the same age.

Materials and Methods

Blood was collected with siliconeated syringe and heparin added. After centrifugation the plasma and buffy coat were removed by suction and the red cells washed three times with isotonic buffered NaCl solution at pH 7.4. The packed cell volume of these suspensions was determined by centrifugation at 3,000 rpm for 60 min in hematocrit tube. The hemolysates were prepared by treating washed cells with two volumes of cold distilled water. The ghosts were then removed by centrifugation at 30,000 $\times g$ for 30 min and the supernatant collected. All procedures were carried out at +2°C.

Young and old erythrocytes were prepared from resuspended washed cells according to MARAS and JOHNSON's method [1], which is based on the principle that young erythrocytes are more resistant to hypotonic hemolysis than are older erythrocytes.

The glucose utilization by intact erythrocytes was determined according to previously described procedure [2] and the reduced glutathione stability according to BROTHIE [3] in presence of $5 \cdot 10^{-3}$ M glucose.

G-6-PD and 6-P-OD determinations were performed according to KORNBERG and HORNIGER [4] and HORNIGER and SCHNEIDER [5] following GADGE and MCLAREN' suggestions [6] to remove the 6-P-GD interference on 6-P-G derived from G-6-P. Pyruvate kinase determinations were performed according to BUCHER and PYLEMERIS [7] and Triose P isomerase determinations according to BERNHARDT [8].

Glucose was determined with glucose oxidase [9], lactic acid according to BARKER [10] GSH according to OSTRICHT and PHILLIPS [11] hemoglobin concentration with DRABKIN' method [12].

In experiments of erythrocyte separation on the basis of different osmotic resistance young-cells are those lysed after hemolysis with 0.30% NaCl for 15 min at +2°C; old cells are those hemolyzed with 0.46% NaCl under the same conditions. The number of cells was determined by hemolysis achieved by given concentration of NaCl , taking the extent of hemolysis in water tube as equal to 100%.

In the GSH content is expressed in mg/100 ml of packed erythrocytes. The values of glucose uptake and the level of enzyme activities are referred as μ moles of metabolized substrate per hour and per ml of packed erythrocytes.

Substrates, enzymes and coenzymes were products of Sigma and Biochemica Boehringer other chemicals of Merck. Spectrophotometric determinations were carried out with Optica

CF4 spectrophotometer high speed centrifugations have been done on Lauder LRA refrigerated centrifuge

Results

We have assayed in the erythrocytes of the propositus the GSH content and stability glucose uptake and the levels of those enzyme activities showing most frequently a genetic deficiency. The results are shown in table I and compared to normal values of newborn and adult subjects. The glucose-6-phosphate dehydrogenase 6-phosphogluconate dehydrogenase and triose-phosphate isomerase activities showed normal values the GSH content is slightly decreased, but the stability test is normal as expressed in per cent values. On the contrary glucose uptake (46, the normal values) the synthesis of lactate (48 the normal values) and the pyruvate kinase activity (18 the normal values) are markedly decreased.

These metabolic alterations and laboratory findings indicate therefore that the hemolytic episode of the propositus is due to a PK deficiency. The slight decrease of GSH content may be referred to the marked lowering of glucose uptake.

We have assayed PK activity also in the young and old erythrocytes which were separated by hypotonic hemolysis. Also in both of these

Table I Erythrocyte metabolic activities of the propositus, and of normal newborns and adults

Metabolic activities	Propositus	Normal subjects Newborn	Adults
Reduced glutathione { before APH	63	74 \pm 5.8	72 4.6
{ after APH	5.	61 \pm 7.2	9 5.7
Glucose uptake	1.8	3.4 \pm 0.4	2.6 0.3
Lactate synthesis	1.7	3.6 \pm 0.7	4.5 0.6
G-6-P dehydrogenase	73	72 \pm 8.3	56 6.1
6-P-G dehydrogenase	60	63 \pm 7.4	43 3.6
Pyruvate kinase	26	196 \pm 31	153 \pm 17
Triose-P-isomerase	4000	4,00 \pm 6.0	4900 3.7

The reduced glutathione content is expressed in $\mu\text{g}/100$ ml packed erythrocytes. The glucose uptake lactate synthesis and enzyme activities are referred as $\mu\text{moles of metabolized substrate hour ml packed erythrocytes}$. The values for normal subjects are the means of literature and personal data.

fractions the enzyme activity was low being 47 units in the young cells and 19 units in the old ones.

The clinical course and the very low level of PK activity of the propositus raised the possibility of an homozygous state of the defect. Therefore we have assayed erythrocyte PK activity also in the relatives of the propositus in those cases where the enzyme activity was decreased, glucose uptake also has been determined. Table II and figure 1 show the results of the investigations performed on the relatives. The defect of PK is present in the erythrocytes of the paternal branch whereas the maternal branch is unaffected. In the affected subjects the defect appears to be in the heterozygous state the PK activity ranged between 44-70% the normal values. Glucose uptake and lactate synthesis were slowly decreased in two subjects only (case No 10 and No 16)

Table II. Erythrocyte pyruvate kinase activity and glucose utilization in the family members of the propositus

Subjects Case No.	Pyruvate kinase	Glucose utilization cross uptake	lactate synthesis
1	84	2.7	4.8
2	168	—	—
3	153	—	—
4	108	2.5	4.5
4	138	—	—
5	174	—	—
5	142	—	—
6	68	2.6	4.8
7	160	—	—
8	149	—	—
9	93	2.7	4.5
10	71	2.1	3.4
11	134	—	—
12	172	—	—
13	165	—	—
15	147	—	—
16	87	2.0	3.1
17	150	—	—
18	144	—	—
19	161	—	—

The values are referred as μ moles of metabolized substrate/hour/ml packed erythrocytes. The relationship of the reported cases is elucidated in figure 1




Fig 1 Pedigree of propositus family in which members were tested by the pyruvate kinase activity

As it is reported in literature Ph. deficiency is highly heterogeneous as concerns the activity level [13-16]. Since in some heterozygous subjects the activity is much lower than in homozygous subjects, the propositus could fall within this group. However it is also possible that the severity of the defect was related to the newborn state. The results reported in figure 2 are consistent with the latter hypothesis.




Fig 2. Pyruvate kinase activity in erythrocyte fractions of different age obtained from the propositus at different time intervals after crisis.

The erythrocyte pyruvate kinase activity of the propositus has been assayed during 40 days at different time intervals on the whole erythrocyte population and on the young and old erythrocyte fractions. The results are reported in the figure 2 as per cent of similar cell preparations obtained from newborns of the same age. In the old erythrocytes the enzyme activity is very low at every time. The enzyme from the WEP in which the reticulocyte count is very high, shows high levels of activity at the 5th and 10th day this increase is also present and progressive in the following period of observation during which blood reaches normal pictures. In the young erythrocytes the enzyme shows marked modifications with aging the activity rises rapidly during the first 20 days and then becomes stable at a level (66% the normal) which is the mean value in the heterozygous subjects.

Discussion

Many authors [17-19] have demonstrated that some transitory modifications of glucose-6-phosphate dehydrogenase induce neonatal hemolysis. Our present results show that this may be also for pyruvate kinase in the propositus the transitory state of deficiency comes out to be a greater extent of the inherited trait. The low levels of the enzyme activity could account for a homozygous state. A rather long time interval is necessary for observing the disappearance of the transitory state of the defect thus, in the young cells the enzyme level reaches values which are typical for the heterozygous state only after more than 20 days from the hemolytic episode.

Few evidences have been provided that a transitory state of deficiency affecting both normal or genetically altered enzymes, may determine hemolysis. Many reasons may account for this. The hemolysis in the neonatal period has been considered only recently from a biochemical point of view. In few cases the biochemical features have been investigated during the hemolytic episode also in these cases those parameters have been examined which are usually affected by genetic mutations. In most cases, where transfusions are made, the biochemical assays are performed a long time after the crisis and therefore it is possible to detect only the metabolic inherited defects in their typical expressions.

Many authors [20-27] have incriminated some endogenous factors other than the genetic defect for the hemolytic episode in newborn

with G-6-PD deficiency. The hemolysis, which is known to affect approximately 5 % of infants bearing this defect [27] has been shown to be independent of the degree of the deficiency; moreover no known hemolytic agents could be demonstrated to determine the episode. For these cases the additional, independent genetic factor might be a transient state of deficiency.

The mechanisms determining the transient states of deficiency are unknown. However the occurrence of this condition is probably related to the features of the newborn's erythrocyte which are very different from those of the adult [28]. The newborn's red blood cells, besides for the HbF, differ from the adult's ones as concerns electron microscopic appearance and chemical composition of the membrane, carbohydrate uptake and the activity levels of several enzymes. On this subject it must be remembered that the marked vulnerability of newborn's cells to damage from hydrogen peroxide [29-30] and from oxidizing agents [31-35] may be ascribed to the lowered levels of glutathione peroxidase [30] and catalase [36] activities.

As regards the mechanisms of hemolysis due to Ph. deficiency this may be framed in the general problem of that hemolysis which related to metabolic defects. It has been established that the process leading to sequestration and destruction of erythrocytes in the reticuloendothelial system, is determined by a progressive failure in energy production [37-43] and in the maintenance of the reductive state [44-49] of the cell. Both these processes are related to glucose utilization which is the only fully active metabolic process in the mature circulating cell. Energy production occurs by ATP resynthesis at the pyruvate kinase and phosphoglycerate kinase steps; the maintenance of the reductive state is linked with reduced pyridine nucleotides synthesis through the dehydrogenase reactions of the Embden Meyerhof Parnas pathway and of the oxidative shunt. Thus, all the erythrocyte defects leading to modifications of either process may induce the hemolytic episode.

As concerns pyruvate kinase, when the defect is partial, that is, in the heterozygous state, the damage is generally asymptomatic, probably because of two reasons: 1. Pyruvate kinase shows high levels of activity [41-42-50] and may work sufficiently even when it is partially damaged. 2. the possible compensatory mechanism for ATP synthesis by the Rapoport Luebering cycle [51-52]. In fact the enzymes of this cycle (phosphoglycerate kinase, diphosphoglyceromutase, diphosphoglycerate phosphatase) regulate the glycolytic resynthesis of ATP. The transformation of 1,3-diphosphoglycerate into 3-phosphoglycerate may

occur through the phosphoglycerate kinase reaction with coupled ATP resynthesis or through diphosphoglyceromutase and diphosphoglycerate phosphatase reactions with release of inorganic phosphate.

In those cases where a total defect is present the pyruvate kinase activity is so low as to block the glycolytic process, as it is clear from the decreased glucose uptake. This damage leads to a decreased ATP and pyridine nucleotides synthesis and the alterations occur (cell shape, permeability phospholipid, cholesterol and coenzyme turnover allosteric properties of Hb oxidation of Hb and of structural and enzyme proteins) determining the lysis.

Summary

A case of hemolysis in a 4 days old infant is reported which is due to a transient severity of a heterozygous pyruvate kinase deficiency. Assays performed on the whole erythrocyte population during the crisis revealed normal levels of glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and triose-phosphate isomerase. A low decrease of GSH content without any modifications of its stability. A marked decrease of pyruvate kinase activity (18% the normal values) and of glucose uptake (50% the normal values). The pyruvate kinase activity has been followed during 40 days from the beginning of the hemolytic episode on the whole erythrocyte population and on young and old cell fractions. It has been demonstrated that in the young cells the enzyme activity increases progressively till reaching a level (86% the normal values) which is peculiar of the heterozygous state of the defect.

References

1. MALKIN, P. A. and JOHNSON, A. B. Relationship between the age of human erythrocytes and their osmotic resistance: basis for separating young and old erythrocytes. *J. clin. Invest.* 37: 1342 (1956).
2. FORMICA, G.; LEONCINI, G.; LUCIATTO, L. and SEVERI, G. Glucose metabolism in human erythrocytes from normal and sickle cell sensitive subjects. *J. clin. Invest.* 41: 1446 (1962).
3. BEUTLER, E. The glutathione instability of drug sensitive red cells: method for the in vivo detection of drug sensitivity. *J. Lab. clin. med.* 49: 87 (1957).
4. KOROSCHKO, A. and HORRICKER, B. L. Glucose-6-phosphate dehydrogenase. *Methods in Enzymology* vol. 1 p. 323 (Academic Press, New York 1955).
5. HORRICKER, B. L. and BARRINGTON, P. Z. Phosphogluconic acid dehydrogenase from yeast. *J. Biol. Chem.* 233: 571 (1958).
6. GLOCK, G. E. and McLEAM, P. Further studies on properties and assay of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver. *Biochem. J.* 51: 400 (1953).
7. BOCHER, T. and FLECKNER, G. Pyruvate kinase from muscle. *Methods in Enzymology* vol. 1 p. 435 (Academic Press, New York 1955).
8. BOCHER, G. Triosephosphate isomerase from calf muscle. *Methods in Enzymology* vol. 1 p. 587 (Academic Press, New York 1955).

9. KARLAK, N.O. Enzymatic determination of free sugars. *Methods in Enzymology* vol. 3, p. 107 (Academic Press, New York 1957).
10. BARBER, S.B. and SCHNEIDER, W.H. Colorimetric determination of lactic acid in biological material. *J. Biol. Chem.* 132: 535 (1941).
11. GRUBERT, R.R. and PHILIPS, P.H. A modification of the nitroprusside method of analysis for glutathione. *Arch. Biochem.* 30: 217 (1951).
12. DARRER, D.L. A simple technique for a large scale crystallization of human oxyhemoglobin. Isoelectric transformation of hemoglobin and myoglobin in the crystalline state. *Arch. Biochem.* 21: 224 (1949).
13. VALENTINE, W.N., TAMAKA, K.R. and MIWA, S. Specific erythrocyte glycolytic enzyme defect (pyruvate-kinase) in three subjects with congenital non spherocytic hemolytic anemia. *Trans. Am. Soc. Phys.* 74: 100 (1961).
14. HYLM, M. and VERDINE, G.H. Non spherocytic hemolytic anemia and changes in phosphoglycerate and phosphopyruvate metabolism of the red blood cell. Xth Congr. Int. Soc. Haemat., Stockholm 1964.
15. KOTLER, R., BUCKLEY, R., JONES, R.J., RIGGS, D.A., VAN BELLINGHUSEN, P. and THOMPSON, P. Pyruvate-kinase: molecular differences between human red cell and leukocyte enzyme. *Cold Spr. Harb. Symp. quant. Biol.* 29: 213 (1964).
16. JOLLET, A., DERRAY, J., BORTIN, P., BRACLY, J. et D'ASOGLY, U. cas d'anémie hémolytique par déficit en pyruvate-kinase. *Arch. franc. Pédiat.* 22: (1965).
17. VILLO, C., TOSOLLA, A.M.: Ittero neonatale con difetto transitorio della glucosa-6-fosfato deidrogenasi eritrocitaria. *Pediatria* 67: 527 (1961).
18. CASTRO, D., VOLPATO, S. et SCARPA, P.: Patologie eritrocitarie neo-natale per difetto en glucosa-6-phosphat deidrogenase. *Ann. Ped.* 32: 625 (1962).
19. OKOJOLE, A. Erythrocyte glucose-6-phosphate dehydrogenase. A study of the enzyme activity in children. *Amer. J. Dis. Child* 107: 180 (1964).
20. PANIZOS, I. L'ictère grave du nouveau-né associé à une déficience en glucose-6-phosphate dehydrogénase. *Bull. Neonat.* 2: 167 (1960).
21. DOXIADIS, S.A., FERIAS, P., VALARI, T. and MANTROKALOS, N. Glucose-6-phosphate dehydrogenase deficiency: a new aetiological factor of severe neonatal jaundice. *Lancet* i: 297 (1961).
22. DOXIADIS, S.A. and VALARI, T. The clinical picture of glucose-6-phosphate dehydrogenase deficiency in early infancy. *Arch. Dis. Child* 39: 343 (1964).
23. VALARI, T., FERIAS, P. and DOXIADIS, S.A. Kernicterus in full-term infant without isoimmunization (4 cases). *Proc. roy. Soc. Med.* 54: 331 (1961).
24. SCHITTINI, F., MELORE, T., COMA, G. and MELA, G. Red cell survival in jaundice newborn children with erythrocyte-enzyme deficiency. *Lancet* ii: 1012 (1963).
25. CAPPE, F.P.A., GELLES, H.M., JOLLY, H. and WOLLINGER, S.M. Glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Nigeria. *Lancet* ii: 370 (1963).
26. FLATZ, G., SRINIVAN, S. and KORNBERG, V. Neonatal jaundice in glucose-6-phosphate dehydrogenase deficiency. *Lancet* i: 1382 (1963).
27. FERIAS, P.H., DOXIADIS, S.A. and VALARI, T. Neonatal jaundice in glucose-6-phosphate dehydrogenase deficient infants. *Brit. med. J.* ii: 1339 (1962).
28. FORDANO, G. Biochemical modifications during erythrocyte lifespan (A review). *Ital. J. Biochem.* 16: 257 (1967).
29. GORDON, H.H., WITOWSKY, H.M. and CORUCCATI, M. Studies of tocopherol deficiency in infants and children. I. Hemolysis of erythrocytes in hydrogen peroxide. *Amer. J. Dis. Child* 90: 603 (1953).
30. GROSS, R.T., BRACCI, R., REDOLPH, V., SCHROEDER, E. and KÖRNER, J.A. Hydrogen peroxide toxicity and desoxidation in the erythrocytes of newborn infants. *Blood* 29: 481 (1967).
31. CORUCCATI, M. and HARTMAN, A.F. Methemoglobinemia in young infants. *J. Pediatr.* 33: 421 (1948).

52. GAMER, C.: Die hämolytische Frühgeburtenanämie mit spontaner Innenkörperbildung. Ein neues Syndrom, beobachtet an 14 Fällen (The hemolytic anemia of premature infants with spontaneous Heinz body formation. A new syndrome observed in 14 cases) *Heiv paediat. Acta* 8: 491 (1953).
53. ALLISON, A.C.: Danger of vitamin K to newborn (letter to the editor) *Lancet* ii: 689 (1955).
54. KRAVITZ, H., ELEGANT D.L., KAMEN, E. and HADAN, B.M.: Methemoglobin values in premature and mature infants and children. *Amer. J. Dis. Child* 91: 1 (1956).
55. BROWN, A.K.: Peculiarities of erythrocytes of the newborn in kernicterus, p. 54. Ed. A. SAs (Kortrak, Toronto 1961).
56. JONES, P.H.E. and McCAMON, R.A.: Enzyme activities in the blood of infants and adults. *Biochem. J.* 45: 464 (1949).
57. HOFFMAN, E.G. and RAPOPORT S.: Triphospho-pyridin-nucleotid, Flavinadenindinucleotid, Coenzym A und Thiamin-phyrophosphat im Hämolytaten von Kaninchen-Erythrocyten. *Z. physiol. Chem.* 304: 157 (1956).
58. LÖNN, G.W., WALLER, H.D., HARGIS, O., SCHLÖSSL, B. und MILLER, A.A.: Zur Biochemie der Alterung menschlicher Erythrocyten. *Klin. Wochschr.* 36: 1008 (1958).
59. NAKAO, M., NAKAO, T. and YAMAZAKI, S.: Adenosine triphosphate and maintenance of shape of human red cells. *Nature Lond.* 187: 945 (1960).
60. NAKAO, M., NAKAO, T., YAMAZAKI, S. and YOSHIZAKA, H.: Adenosine triphosphate and shape of erythrocytes. *J. Biochem.* 49: 487 (1961).
61. NAKAKA, H.R., VALLEY, W.N. and MITRA, S.: Pyruvate kinase deficiency hereditary non-spherocytic hemolytic anemia. *Blood* 19: 267 (1962).
62. POWELL, R.D. and DE GOWDE, R.L.: Relationship between activity of pyruvate kinase and age of the normal human erythrocytes. *Nature, Lond.* 205: 507 (1965).
63. BRON, F., RAMOT, B., ZWANG, E. and DABON, D.: Enzyme activities in human red blood cells of different age groups. *Israel J. med. Sci.* 2: 291 (1966).
64. JAKOB, J.H., ENGEL, L.F. and ALLEN, D.W.: Oxidative hemolysis and precipitation of hemoglobin. I. Heinz body anemias as an acceleration of red cell aging. *J. clin. Invest.* 39: 1818 (1960).
65. JACOB, H.S. and JAKOB, J.H.: Effect of sulphydryl inhibition on red blood cells. I. Mechanism of hemolysis. *J. clin. Invest.* 41: 779 (1962).
66. JACOB, H.S. and JAKOB, J.H.: Effect of sulphydryl inhibition in red blood cells. II. Studies in vivo. *J. clin. Invest.* 41: 1514 (1962).
67. HILL, A.S., HART, A., CARTWRIGHT, G.E. and WITKOWSKY, M.M.: The role of non-hemoglobin proteins and reduced glutathione in the protection of Hemoglobin from oxidation in vivo. *J. clin. Invest.* 43: 17 (1964).
68. JACOB, H.S., INGRAM, S.H. and JAKOB, J.H.: Oxidative hemolysis and erythrocyte metabolism in hereditary acatalasia. *J. clin. Invest.* 44: 1187 (1965).
69. JACOB, H.H. and JAKOB, J.H.: Effects of sulphydryl inhibition on red blood cells. III. Glutathione in the regulation of the hexose monophosphate pathway. *J. biol. Chem.* 241: 4243 (1966).
70. GRAPMAN, R.G., HEINENHART, M.A., WALTERS, A.M., HURLOCK, F.M. and GARROD, B.W.: Erythrocyte metabolism. V. Levels of glycolytic enzymes and regulation of glycolysis. *J. clin. Invest.* 41: 1249 (1962).
71. RAPOPORT S. and LUXERBURG, J.: The formation of 2,3-diphosphoglycerate in rabbit erythrocytes: the existence of diphosphoglycerate kinase. *J. biol. Chem.* 183: 507 (1950).
72. RAPOPORT S. and LUXERBURG, J.: Glycerate 2,3-diphosphatase. *J. biol. Chem.* 189: 683 (1951).

Authors' addresses: Dr. M. BOMBI, Istituto di Clinica Pediatrica, Università di Roma, Rome; Prof. G. FORNARDI and Dr. M. DACCÀ, Istituto di Chimica Biologica, Università di Urbino, Urbino (Italy).

Libri

Surp
Advances in Transplantation. Proceedings of the 1st International Congress of the Transplantation Society Paris, 27-30 June 1967 Hrg. J. DAZMUT J. HANSEN and G. MATR. Munksgaard, Copenhagen 1968. 786p. Preis £ 18/0/0, D/M 145.00, dKr 270.-

Die Forschungen auf dem Gebiete der Gewebe- und Organtransplantation machten in den letzten Jahren außerordentlich große Fortschritte. Die neuen Erkenntnisse ergaben sich aus Arbeiten verschiedener Spezialitäten, wie Immunologie, Biochemie, Genetik, Innere Medizin und Chirurgie. Es erwies sich deshalb als notwendig, dass sich die Forscher aller Spezialitäten, die an den Zervorgeschäften beteiligt sind, regelmäßig treffen. Aus diesem Grunde fand vom 27. - 30. Juni 1967 in Paris der 1. Internationale Kongress der Transplantations-Gesellschaft statt. Zuerst wurden an sieben Meetings allgemeine Themen behandelt wie: Der Mechanismus der Transplantationsabstoßung - Immunsuppressive Methoden - Genetische Probleme der Transplantation - Transplantationsentstehung - Organtransplantation - Knochenmarktransplantation - Krebs als Transplantat. Danach folgten verschiedene Übersichtsreferate, u.a.: Betrachtungen zum Abstammungsmechanismus - Spenderauswahl für Organtransplantationen - Biologische Probleme bei Transplantationen - Immunsuppressive Substanzen. Weitere Referate befassten sich mit Transplantationen von Niere, Leber, Herz, Lunge, Pankreas und Gehirn.

Die im Kongressband niedergelegten Ergebnisse sind nur für den an Transplantationsproblemen speziell interessierten Mediziner bestimmt. Derjenige, der sich über Transplantationen allgemein orientieren möchte, sollte nicht zu diesem Buch greifen. Dem Spezialisten dagegen bietet es eine große Fülle von neuen Erkenntnissen.

R. TROLES, Basel

Varia

VIIth International Congress of Clinical Pathology

The VIIth International Congress of Clinical Pathology will be held in Montreal, July 13th to 19th, 1969 under the joint auspices of the Canadian Association of Pathologists, the Canadian Society of Clinical Chemists and the Canadian Association of Medical Bacteriologists.

Scientific program: Monday July 14 Symposium I Mycoplasmas Symposium II Enzyme Tests. Tuesday July 15 Symposium III Complications of Extra-Corporeal Perfusion and Cardiac Surgery Symposium IV Standards, International Surveys and Quality Control Symposium V Immunofluorescence in Diagnosis. - Thursday July 17 Symposium VI Restrictive Lung Disease; Symposium VII Hospital Infections; Symposium VIII Neuropathology. - Friday July 18 Symposium IX: Labor Errors in Metabolism Symposium X Cytology; Symposium XI Haemolytic Disease of the Foetus and Newborn. Saturday July 19 Symposium XII Future of Laboratory Medicine.

Enquiries regarding the Congress can be directed to VII International Congress of Clinical Pathology P.O. Box 8, Station 'G' Montreal 18 (Canada)

Pathologisches Institut der Universität Köln (Direktor Prof. Dr. M. Eder) und II. Medizinische Universitätsklinik und Poliklinik Mainz (Direktor Prof. Dr. F. Schmölzer)

Über den Nachweis der Thiaminpyrophosphatase («Golgi-phosphatase») in Blut und Knochenmarkszellen¹

R. FISCHER und H. H. HENCKESEN

NOVIKOFF und GOLDFISCHER [17] haben eine enzymzytochemische Methode angegeben, mit der in den Zellen zahlreicher Gewebe im Bereich der Golgzone ein deutlicher Reaktionsausfall feststellbar war. Bei diesem auf dem Gomori-Prinzip basierenden Nachweisverfahren dienten verschiedene Nukleotiddiphosphate sowie Thiaminpyrophosphat als Substrate, die bei annähernd neutralem pH von einer «Golgi-Phosphatase» hydrolysiert wurden. Die Annahme einer solchen spezifischen Enzymlokalisation in den lamellären und vesikulären Strukturen des Golgiapparates konnte in der Folgezeit bestätigt werden [2, 5, 13, 15, 16, 20].

Bei den vorliegenden Untersuchungen sollte das Vorkommen und die Lokalisation der Thiaminpyrophosphatase in den Zellen des Blutes und Knochenmarks geprüft werden. Die Klärung dieser Frage erschien vor allem deshalb von Interesse, weil sich gerade in jüngster Zeit wichtige Hinweise für die funktionelle Bedeutung des Golgiapparates bei der Granulabildung in den Zellen des hämatopoetischen Systems ergeben haben [3, 7, 23].

Material und Methodik

Als Untersuchungsmaterial dienten Blut- und Knochenmarksausstriche von 30 gesunden Personen bzw. von Patienten mit nicht-hämatologischen Erkrankungen. Außerdem wurden 20 Fälle verschiedener Leukämien untersucht.

Mit Unterstützung durch die Deutsche Forschungsgemeinschaft. Anzugeschie vorgetragen auf der 12. Tagung der Deutschen Gesellschaft für Hämatologie, Berlin 1966.

Die Ausstriche wurden luftgetrocknet und anschließend fixiert. Unter den in Vorversuchen getesteten Fixierungsmitteln ergab die Vorbehandlung mit Formalin-Calciumchlorid oder Formalin-Calciumacetat (5 Min., 4°C) die besten Resultate.

Nach der Fixierung wurden die Ausstriche in Aqua dest. gespült und erneut luftgetrocknet.

Die Inkubation erfolgt 1 Std. bei 37°C in dem von NOVITSKY und GOLDSCHMIDT [17] angegebenen Medium: 20 ml 0,01 M Thiaminpyrophosphat, 8 ml Aqua dest., 40 ml 0,2 M Tris-Maleat Puffer pH 7,2, 12 ml 0,03 M Bleinitrat und 20 ml 0,025 M Manganchlorid.

Nach der Inkubation wurden die Präparate mehrmals in Aqua dest. gespült, anschließend für 1–2 Min. in verdünnte Ammoniummolybdatlösung eingestreut und erneut gewässert. Die Kerngegenfärbung erfolgt mit Mayers Hämalaun. Elodecken in Glycerinobjektive.

Die Spezifität der Thiaminpyrophosphatase-Aktivität wurde durch folgende Kontrollreaktionen geprüft: a) Weglassen des Substrates oder Hitzeinaktivierung b) Zusatz von folgenden Inhibitoren zum Inkubationsgemisch: 0,01 M Uranylnitrat, 0,01 M Natriumfluorid, 0,01 M Zysteinchlorid. Nach Weglassen des Substrates, Hitzeinaktivierung sowie nach Zusatz von Uranylnitrat war keine Enzymaktivität feststellbar. Dagegen blieb die Aktivität der Thiaminpyrophosphatase durch die Inhibitoren der sauren Phosphatase (Natriumfluorid) und der alkalischen Phosphatase (Zysteinchlorid) unbeeinträchtigt.

Neben der Pappenheim-Färbung kamen als Ausstrichpräparate der untersuchten Fälle in parallel durchgeführte Untersuchungen außerdem folgende enzymzytochemischen Nachweisverfahren zur Anwendung: Naphthol-AS-D-Chloroacetat Esterase [14], Naphthol-AS-Acetate-Esterase [12], saure Phosphatase [4], alkalische Phosphatase [11].

Ergebnisse

In der Entwicklungsreihe der *neutrophilen Granulozyten* zeigen Myeloblasten und frühe Promyelozyten nur eine geringe Aktivität der Thiaminpyrophosphatase, deren Reaktionsprodukt hier in einem kleinen umschriebenen, perinukleären Zytoplasmabezirk lokalisiert ist (Abb. 1a). Mit der weiteren Differenzierung zu Promyelozyten fällt eine deutliche Vergrößerung der Aktivitätszone auf die relativ scharf begrenzt in der Nähe der beginnenden Kerneinsenkung liegt (Abb. 1b und c). Das Reaktionsprodukt zeigt in den Promyelozyten häufig eine ring- bzw. schalenförmige Anordnung, deren Mitte etwa der Lage der Zentriolen entspricht (Abb. 1b). Auch im Myelozytenstadium findet sich zumeist eine deutliche Fermentaktivität, deren Ausdehnung im Vergleich zu den Promyelozyten etwas abgenommen hat (Abb. 1d und e). Noch deutlicher wird die Abnahme der Enzymaktivität bzw. die Verkleinerung der Reaktionszone mit der weiteren Ausreifung der neutrophilen Granulozyten. Während in den Metamyelozyten häufig noch einzelne Bleisulfidniederschläge zu beobachten sind (Abb. 1f) war in den stab- und segmentkernigen Neutrophilen in der Regel keine sichere Enzymaktivität mehr nachweisbar.

Die Aktivitätszone der Thiaminpyrophosphatase in den Promyelozyten entspricht der im panoptisch gefärbten Präparat erkennbaren Lokalisation der beginnenden Azurgranula-




Abb. 1 Nachweis der Thiaminpyrophosphatase in Zellen des menschlichen Knochenmarks: a) Myeloblast, b) und c) Promyelocyten, d) und e) Myelocyten, f) Metamyelocyt, g) eosinophiler Myelocyt, h) und i) Plattenzellen. Relativ scharflokalisierte Reaktion in einem perizukleären, der Golgizone entsprechenden Bezirk. $\times 1400$.

tion. Eine abhebbare, zunächst auf einen perizukleären Bezirk beschränkte Reaktion zeigt im frühen Promyelocyten auch der cytochemische Nachweis der Naphthol-AS-D-Chloroazetat-Esterase (Abb. 2) oder anderer an die Leukozytengranula gebundener Enzyme (Peroxydase, Naphthol-AS-Acetat-Esterase, saure Phosphatase).

Der Reaktionsausfall in den eosinophilen Granulozyten stimmt im Prinzip mit den geschilderten Befunden an den Zellen der neutrophilen Entwicklungsreihe überein. Im allgemeinen fällt der Nachweis der Thiaminpyrophosphatase in den Eosinophilen jedoch etwas kräftiger aus als in den entsprechenden neutrophilen Zellen. Besonders deutlich tritt die charakteristische zirkuläre Orientierung der Aktivitätszone in den eosinophilen Promyelocyten und Myelocyten hervor



Abb. 2. Darstellung der *Naphthol-AS-D-chloroacetat-Esterase* in frühen Promyelozyten mit einem zunächst auf einen perinukleären Bezirk (Goldbraune f) beschränkten Reaktionsprodukt (a und b) das sich bei der weiteren Differenzierung der Zellen auf größere Abschnitte ausdehnt (c) und schließlich das Zytoplasma völlig ausfüllt (d) Promyelozyten-Leukämie. $\times 1400$.

(Abb. 1g) Außerdem war im Gegensatz zu den enzymnegativen stab- und segmentkernigen Neutrophilen auch in den reifen eosinophilen Leukozyten gelegentlich noch eine geringe Aktivität der Thiaminpyrophosphatase in Form einzelner punktförmiger Granula zwischen den beiden Kernsegmenten nachweisbar.

Durch eine besonders starke Thiaminpyrophosphatase-Aktivität fallen die in den Knochenmarksaustriichen nachweisbaren *Megakaryozyten* auf. Das Reaktionsprodukt ist in den Vorstufen mit noch unsegmentiertem Zellkern in einer deutlich ausgeprägten perinukleären Zone lokalisiert (Abb. 3a). Besonders bei stärkerer Vergrößerung ist hier eine lamelläre und granuläre Anordnung feststellbar. Mit zunehmender Kernlappung und Ausdifferenzierung der Megakaryozyten dehnt sich die Aktivitätszone über größere Anteile des Zytoplasmas aus (Abb. 3b und c). Neben unregelmäßigen Verdichtungen des Reaktionsproduktes lassen sich netzförmige Strukturen oder granuläre bzw. feinvakuoläre Reaktionsniederschläge in kettenförmiger Anordnung feststellen.

Sowohl in den Zellen der *Erythrozytose* als auch in den *Lymphozyten* im peripheren Blut und Knochenmark war mit der von uns ange-



Abb. 3. Deutliche Aktivität der Thiaminpyrophosphatase in Megakaryozyten. Das Reaktionsprodukt ist in einer perinukleären Zone (a) mit zunehmender Kernabspaltung in einem größeren Zytoplasmabereich (b) z.T. in netzförmiger bzw. feinkörnlicher Anordnung (c) erkennbar $\times 900$

wandten Technik kein sicherer Reaktionsausfall der Thiaminpyrophosphatase nachweisbar. Eine zumeist deutliche Enzymaktivität

in einer umschriebenen, etwa der perinukleären Aufhellung entsprechenden Zone fand sich dagegen in den *Plasmazellen* des Knochenmarks (Abb 1h und i) *Monozyten* des peripheren Blutes zeigten eine insgesamt schwache Reaktion im Bereich der Kerneinhuchtung.

Bei den untersuchten *Leukasen* entsprach die Aktivitätsverteilung der Thiaminpyrophosphatase weitgehend dem Differenzierungsgrad der Zellen. So zeigten unreifere myeloische Leukämien je nach ihrer Differenzierungstendenz zu promyelozytären Zellen eine unterschiedlich entwickelte Golgi-phosphataseaktivität. Auch in den neutrophilen und eosinophilen Promyelozyten und Myelozyten der chronischen Myelose bestand, ähnlich wie in den entsprechenden Zellen des normalen Knochenmarks, eine deutliche Enzymaktivität. Die Zellen lymphatischer Leukämien wiesen keine zytochemisch nachweisbare Aktivität der Thiaminpyrophosphatase auf.

Diskussion

In der seit langem geführten Diskussion über die Existenz und die funktionelle Bedeutung des in enger struktureller und funktioneller Beziehung mit dem endoplasmatischen Retikulum stehenden Golgiapparates konnte inzwischen eine weitgehende Klärung herbeigeführt werden [Überichten 9 und 21]. Vor allem die neueren Ergebnisse der Elektronenmikroskopie haben gezeigt, dass Strukturen des Golgisystems, allerdings in sehr unterschiedlicher Ausprägung eine obligatorische Komponente der tierischen Zellen darstellen. Zur lichtmikroskopischen Darstellung des Golgiapparates hat sich in jüngster Zeit besonders der von Novikoff und Goldfischer [17] eingeführte zytochemische Nachweis einer Nukleondiphosphate bzw. Thiaminpyrophosphat hydrolyzierenden Phosphatase bewährt, deren spezifische Lokalisation in Strukturen des Golgisystems inzwischen durch zahlreiche licht- und elektronenmikroskopische Untersuchungen an verschiedenen Geweben bestätigt worden ist [2 5 13 15 16 20].

Die vorliegenden Ergebnisse zeigen, dass die zytochemische Lokalisation der Thiaminpyrophosphatase auch in den Zellen des hämatopoetischen Systems mit der aus elektronenmikroskopischen Untersuchungen bekannten Anordnung des Golgiapparates völlig übereinstimmt. In der neutrophilen Granulozytopoese findet sich das Maximum der Enzymaktivität im Promyelozyten- und Myelozytenstadium

während in den reifen Neutrophilen mit der angewandten Methode keine nennenswerte Reaktion mehr nachweisbar war. Auch elektronenmikroskopisch zeigt der in Myeloblasten nur spärlich ausgebildete Golgiapparat in den Promyelozyten und Myelozyten eine deutliche Vergrößerung, um sich mit der weiteren Ausreifung bis auf einige rudimentäre Zysternen wieder zurückzubilden [1 3 6, 22]. Entsprechende Übereinstimmungen ergeben sich auch in der eosinophilen Entwicklungsreihe.

Der besonderen Ausprägung des Golgiapparates im Promyelozyten und Myelozytenstadium muss in Übereinstimmung mit den allgemeinen Vorstellungen über die funktionelle Bedeutung dieses Zellorgans eine wichtige Rolle bei der Granulabildung zugesprochen werden, die in enger räumlicher Beziehung zu Strukturen des Golgikomplexes steht [1 3 7 23]. So entwickeln sich beispielsweise in den neutrophilen Vorstufen im Knochenmark des Kaninchens die azurophilen Granula durch Ausstülpung und nachfolgende Aggregation von Mikrobälchen an der konkaven, d. h. der dem Zentriol zugewandten Fläche des Golgiapparates, während die im Myelozytenstadium auftretenden «spezifischen» Granula durch Abschnürung und Konfluenz von Golgibälchen an der konvexen Begrenzung entstehen [3]. In Übereinstimmung mit diesen elektronenmikroskopischen Befunden stehen die Ergebnisse autoradiographischer Untersuchungen, bei denen nach Inkorporation von ^3H -Lysin der intrazelluläre Fluss der markierten Aminosäure von Strukturen des endoplasmatischen Retikulums über den Golgikomplex in die neugebildeten Granula verfolgt werden konnte [7].

Tatsächlich lässt sich auch lichtmikroskopisch in frühen Promyelozyten im Bereich der zytochemisch darstellbaren Golgiposphatase nicht nur im panoptisch gefärbten Präparat der Beginn einer azurophilen Granulation nachweisen, sondern auch eine zunächst auf diese Zone beschränkte Aktivität bestimmter an die Leukozytengranula gebundener Enzyme wie der Peroxydase oder der Naphthol-AS-D-Chloroazetat Esterase (Abb. 2) feststellen. Eine ähnliche Lokalisation der sauren Phosphatase und anderer hydrolytischer Enzyme [1 23] liefert zudem einen weiteren Beleg für die Lysosomennatur der Leukozytengranula sowie Hinweise für die Bedeutung des Golgikomplexes bei der Entstehung «primärer» Lysosomen überhaupt. Dabei ist die saure Phosphatase jedoch im Gegensatz zu der Nukleosiddiphosphate oder Thiaminpyrophosphat hydrolisierenden «Golgiposphatase» nicht in den lamellären Strukturen des Golgiapparates selbst lokalisiert.

sondern in den benachbarten lysosomalen Granula anzutreffen [16, 17]

Eine besonders auffällige Aktivität und Verteilung der Thiaminpyrophosphatase liess sich bei unseren Untersuchungen in den Megakaryozyten des Knochenmarks feststellen. Sie entspricht auch hier den elektronenmikroskopischen Befunden eines sehr stark ausgeprägten Golgiapparates, der bereits in den Megakaryoblasten im perinnukleären Zytoplasma eine grosse, aus mehreren herdförmigen glatten Membranen und vielen Mikrobälchen aufgebaute Zone bildet. Unter wesentlicher Beteiligung des Golgiapparates entstehen in den Megakaryozyten aus Eiweissbausteinen der Grundsubstanz die verschiedenen Vorstufen des Granulomers und der Demarkationsbälchen der Thrombozyten [10, 18, 19]

Auch in den Zellen des hämatopoetischen Systems kommt somit dem Golgiapparat eine wesentliche Bedeutung im Rahmen «sekretorischer» Leistungen zu wie sie etwa von den Plasmazellen oder Geweben mit einer starken Eiweissynthese bereits seit längerem bekannt ist. Durch die Thiaminpyrophosphatase-Reaktion ergibt sich nicht nur die Möglichkeit, die Struktur des Golgiapparates in den Zellen des Blutes und Knochenmarks mit einer den klassischen Immunprägnationsverfahren überlegenen enzymzytochemischen Methode darzustellen sondern auch seine Variabilität unter funktionellen Bedingungen wie etwa bei den Transformationsvorgängen der Blut lymphozyten *in vitro* [8] zu erfassen. Vor allem durch die Kombination mit anderen Enzymnachweisen werden darüber hinaus auch auf zytochemischer Basis weitere Hinweise auf die Bedeutung des Golgi-komplexes bei der zellulären Differenzierung der blutbildenden Systeme möglich sein.

Zusammenfassung

Der zytochemische Nachweis der Thiaminpyrophosphatase in Zellen des Knochenmarks zeigt eine unterschiedlich starke Enzymaktivität, deren Lokalisation mit der via elektronenmikroskopischen Untersuchungen bekannten Anordnung und Grösse des Golgiapparates übereinstimmt. In der neutrophilen und eosinophilen Entwicklungreihe zeigen Promyktozyten und Myelozyten das Maximum der Enzymaktivität. Durch eine besonders ausgeprägte Reaktion der Golgiapphosphatase sind die Megakaryozyten gekennzeichnet. Ausserdem ist eine ziemlich deutliche Enzymaktivität in den Plasmazellen feststellbar. Der Thiaminpyrophosphatase und der besonderen Ausprägung des Golgiapparates in bestimmten Knochenmarkszellen muss eine wichtige Rolle bei den sekretorischen Leistungen dieser Zellen, vor allem bei der Granulabildung, zugesprochen werden.

Summary

Cytochemical demonstration of thiamine pyrophosphatase in bone marrow cells reveals different degrees of enzyme activity according to the arrangement and size of the Golgi apparatus known from electron microscope studies. Among the neutrophils and eosinophils, maximum activity is found in the promyelocytes and myelocytes. Megakaryocytes are characterized by particularly marked Golgi phosphatase reaction. Fairly marked activity is also generally seen in the plasma cells. The presence of thiamine phosphatase and the particular development of the Golgi apparatus in certain bone marrow cells must play an important part in the secretory activity of these cells, especially formation of the granula.

Literatur

1. ACKERMAN, G. A. Histochemical differentiation during neutrophil development and maturation. *Ann. N.Y. Acad. Sci.* 113: 557-563 (1964).
2. ALLEN, J. M.: The properties of Golgi-associated nucleoside diphosphatase and thiamine pyrophosphatase. I. Cytochemical analysis. *J. Histochem. Cytochem.* 11: 529-541 (1963).
3. BASTON, D. W. and FARGNAR, M. G. Origin of granules in polymorphonuclear leukocytes. *J. Cell. Biol.* 29: 277-301 (1966).
4. BAREA, T. and ANDERSON, P. J. Histochemical methods for acid phosphatase using hexazonium pararosaniline as coupler. *J. Histochem. Cytochem.* 10: 741-753 (1962).
5. BARNOW, K. D. and TROCHAY, T. O. Histochemistry of acid phosphatase and thiamine pyrophosphatase during axon reaction. *Amer. J. Path.* 40: 637-652 (1962).
6. BESSA, M. and TERRY, J. P. Electron microscopy of human white blood cells and their stem cells. *Int. Rev. Cytol.* 12: 199-241 (1961).
7. FEDORKO, M. E. and FRISCH, J. G. Cytoplasmic granule formation in myelocytes. *J. Cell Biol.* 29: 307-316 (1966).
8. FISCHER, R. and OSOBY, A. Zytochemie des Lymphocyten *in situ*. *Klin. Wochschr.* 44: 733-738 (1966).
9. GIEBOMANN, E. Funktionelle Morphologie der Zelle. In: HEMMERLEN's Handbuch d. Inn. Med., Bd. II/1 (Springer Berlin/Heidelberg/New York 1968).
10. JONES, O. P. Origin of megakaryocyte granules from Golgi vesicles. *Anat. Rec.* 138: 105-112 (1960).
11. KAPLOW, L. S.: A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow. *Blood* 10: 1023-1029 (1955).
12. LÖFFLER, H. Zytochemischer Nachweis von unspezifischen Esterasen an Amastochen. *Klin. Wochschr.* 39: 1220-1227 (1961).
13. MACK, G. A. and BRADLEY, S. Localization of thiamine pyrophosphatase activity in the Golgi apparatus of mollusc, *Helix aspersa*. *J. Cell Biol.* 18: 73-85 (1965).
14. MOLOWAY, W. C., McPHERSON, K. and FLEISCHMAN, L. Esterase activity in leukocytes demonstrated by the use of naphthol ASD-Chloroacetate. *J. Histochem. Cytochem.* 8: 200-207 (1960).
15. NOVIKOFF, A. B. Cytochemical staining methods for enzyme activities their application to the rat parotid gland. *Jewish med. Hosp. Bull., N.Y.* 6: 70-93 (1962).
16. NOVIKOFF, A. B. and EMMER, E. Pathological changes in cytoplasmic organelles. *Fed. Proc.* 21: 1130-1142 (1962).
17. NOVIKOFF, A. B. and GOLDSTONER, S. Nucleosidediphosphatase activity in the Golgi apparatus and its usefulness for cytological studies. *Proc. nat. Acad. Sci.* 67: 802-810 (1961).

18. SCHULTZ, H.: Submikroskopische Beiträge zur Orthologie und Pathologie der Thrombocyten. *Verh. dtsch. Ges. inn. Med.* 66: 832-848 (1960).
19. SCHULTZ, H.: Die Erneuerung der Thrombocyten im elektronenmikroskopischen Bild. *Verh. dtsch. Ges. Path.* 50: 239-247 (1966).
20. SRANIVAYARAJA, T. R. and BOCKHE, G. H.: The thiamine pyrophosphatase technique as an indicator of the morphology of the Golgi apparatus in the neurons. *Acta histochem.* 27: 155-178 (1963).
21. STUTZ, A.: Funktion des Golgi-Apparates in pflanzlichen Zellen, in *Funktionelle und morphologische Organisation der Zelle* Bd. II, Sekretion und Exkretion, pp. 89-111 (Springer Berlin/Heidelberg/New York 1963).
22. WATANABE, Y.: Observations of white blood cells with electron microscope. *J. Electronmicrosc.* 5: 46-57 (1957).
23. WITZEL, B. K.; HORN, R. G. and SPICER, S. S.: Cytochemical localization of non-specific phosphatase activity in rabbit myeloid elements. *J. Histochem. Cytochem.* 11: 812-814 (1963).

Research Hematology Laboratory Peter Bent Brigham Hospital and Harvard Medical School, Boston, Mass.

Serum Lactic Dehydrogenase Activity in Refractory Anemia¹

D. S. ROSENTHAL, A. T. SKARIN and W. C. MOLOVEY

Serum lactic dehydrogenase activity (LDH) is markedly elevated in patients with untreated megaloblastic anemias secondary to folic acid or Vitamin B₁₂ deficiency and this activity rapidly falls with appropriate therapy [1-4]. The serum LDH levels in the anemias of iron deficiency and bone marrow aplasia are normal but levels in hemolytic anemias are frequently elevated [3]. Over the past several years we have been following a group of patients with refractory anemias, some with ineffective erythropoiesis and demonstrating sideroblasts, others presenting with Di Guglielmo's syndrome. It is often difficult to distinguish morphologically the megaloblastoid changes in these cases from that noted in pernicious anemia or folate (FA) deficiency. In this paper results of studies on the behavior of serum LDH and LDH isozymes will be reported.

Methods and Materials

There were 9 patients in this series, all characterized by severe anemia, low reticulocytes, variable red cell morphology in the peripheral blood and bone marrow showing marked erythroid activity with reversal of the myeloid to erythroid ratio. Red cells were of varying degrees of immaturity ranging from proerythroblasts with normal maturation to population of primitive erythroid precursors associated with multi-nucleated dysplastic normoblasts. Megaloblastic like changes were frequently noted. In 7 of the 9 cases Prussian Blue stain demonstrated ringed sideroblasts and generally increased iron deposition in phagocytic histiocytes. In some cases there was an increased number of promyelocytes and myelocytes, but striking absence of monocytemyelocytes and other myeloid changes usually associa-

ted with B_{12} or folate deficiency. Over several months, 3 patients progressed to overt acute granulocytic leukemia and expired. Six patients were refractory to therapy, two of which required frequent transfusions (table I). Serum LDH activity was measured by the methods of WROBLEWICK [2] and the percentage of serum LDH isoenzyme ('Heart' type) by the method of DAWSON *et al.* [6].

Results

There were no significant differences in the LDH levels or the percent of LDH isozymes in the serum of a group of 15 normal controls compared to the patients with refractory anemia (fig 1). The mean serum LDH level for normals was 221.5 units and for the patients 241 units.

Discussion

The extremely high serum LDH level reported in megaloblastic anemias associated with B_{12} and FA deficiency was not present in patients with refractory anemia characterized by increased iron and ringed sideroblasts. These findings are in agreement with observations made by HOFFBRAND *et al.* [7]. The elevated serum LDH activity in megaloblastosis has been presumed to come from either increased hemolysis or directly from cell breakdown in the bone marrow [2, 3].




Fig 1 Serum LDH and LDH isoenzyme activity in 9 patients with refractory anemia and 15 normal controls.

Table 1 Clinical and laboratory data in nine cases of refractory anemia

Case No	Age/Sex	L/D	Lat anem	Death	Hb g %	Hct %	WBC	Retic %	Bone marrow	Folds acid ng	B ₁₂ pg	F pg	LDH u.u	H %
1	67 ♂	+	11/30/64		7.5	24	2850	1.4	Ringed siderobl.	300	849	197	277	91
2	72 ♀	+	12/7/63		9.8	25	8600	2.2	Ringed siderobl.	3.3	689	120	312	91
3	74 ♂	+	6/28/68		8.2	25	3000	2.3	Ringed siderobl.	22.5	671	224	222	68
4	80 ♂	-	7/1/68	10/19/68	8.5	27	7200	1.8	Ringed siderobl.	90	1823	-	340	-
5	56 ♀	+	10/31/68		7.5	25	3500	2.5	Ringed siderobl.	17.2	681	249	228	84
6	67 ♂	+	11/30/68		8.8	28	4000	0.4	Ringed siderobl.	3.6	303	100	142	91
7	42 ♀	-	12/28/68	5/31/67	10.0	32	1450	5.0	Iron F	-	-	171	225	75
8	45 ♀	-	1/10/67	5/19/67	6.0	19	2000	1.8	Iron F	11.9	745	117	241	100
9	46 ♂	+	9/13/67		9.6	28	7000	3.2	Ringed siderobl.	40	2080	172	290	-
									Normal values	7-15.9	200-2000	50-150	221.5	84

+ Irregular, clonal
 Confronted in acute
 Wroblewski units

This increase has been attributed to an absolute increase in LDH₁ and LDH₂, the two electrophoretically fast LDH isoenzymes [3] found in adult red cells. In the refractory anemias there are probably two defects: an 'ineffective' type of erythropoiesis of marked degree and hemolysis resulting from increased destruction of defective red cells in the bone marrow [8]. The normal serum LDH levels in these 9 patients is of diagnostic importance and raised the question as to the source of elevated LDH activity in megaloblastic anemias.

Our observations suggest that the ineffective erythropoiesis in cases of refractory anemia may not be due to abnormal cellular proliferation, but rather to an accumulation of immature red cells with decreased destruction within the bone marrow. On the other hand, the ineffective erythropoiesis in megaloblastosis may be a result of rapid destruction of immature red cells with release of LDH from the marrow. Recent evidence of 'ineffective' granulocytopoiesis raises the alternative possibility that much of the elevated serum LDH activity may be derived from the myeloid elements in the megaloblastic bone marrow [9, 10].

Acknowledgements

The authors are grateful to Miss Ann Rowe for valuable technical assistance, and to the Hematology Laboratory (Tufts) Boston City Hospital, where these patients were followed and to the Thorndike Memorial Laboratory Boston City Hospital for performing the serum B₁₂ and folic acid levels.

Summary

Normal serum levels of LDH and its isoenzymes were found in 9 cases of refractory anemia. The red cell activity and morphology in these cases was often indistinguishable from that seen in pernicious anemia. The source of elevated LDH activity in megaloblastosis due to B₁₂ and folic acid deficiency may therefore not be derived from the increased erythroid activity but rather the increased myeloid elements which are not present in refractory anemia.

References

1. ANDERSSON, N. The Activity of lactic dehydrogenase in megaloblastic anemia. *Scand. J. Haemat.* 1: 212 (1964).
2. ELIAS, B. A. and FLAEGGE, A. F. Source of elevated serum enzyme activities in patients with megaloblastic erythropoiesis secondary to folic acid deficiency. *Brit. med. J.* 1: 626 (1963).
3. POLONETSKY, J. A. and LEXIA, E. Serum lactic dehydrogenase activity and isoenzyme pattern in some hematological diseases. *Acta med. scand.* 117: 115 (1963).

4. STEED, I., KOCHEWAR, S.; ZALCERY, R. and HOOVERSTRATEK, B. Mechanism of serum LDH elevation in megaloblastic anemia. *Blood* 30: 876 (1967).
5. WROBLEWICKI, F. and LADUE, J. S.: Lactate dehydrogenase activity in blood. *Proc. Soc. exp. Biol., N.Y.* 90: 210 (1964).
6. DAWSON, D. M., GOODFREED, T. L. and KAPLAN, N. O. Lactic dehydrogenase functions of the two types. *Science* 143: 929 (1964).
7. HOFFBRAND, A. V.; KREIDBERGER, S. and BUTTERWORTH, P. J. Serum lactic dehydrogenase activity and folate deficiency in myelodysplasia and other hematological disorders. *Brit. med. J.* i. 377 (1968).
8. BALDOW, M., FUCHSBERG, H. J.; FUTAKI, K. and DAMENITZ, W. The anemia of the De Geyfickens syndrome. *Blood* 14: 334 (1959).
9. LEE, Y. K. and SULLIVAN, L. W. Marrow granulocytic reserve in pernicious anemia. *Clin. Res.* 4: 312 (1966).
10. FERTILLIZ, P. E., KAPLAN, S. S. and FORD, S. C. Significance of changes in serum aspartate activity in megaloblastic anemia. *New Engl. J. Med.* 277: 16 (1967).

Departments of Clinical Pathology and Medicine,
American University of Beirut

Cytogenetic Studies in Acute Leukemia¹

F. P. KHOURI, M. J. SHAHID and S. YENIKOMSHIAN

The discovery of a specific chromosomal abnormality in chronic myeloid leukemia [1-7, 8] has led to a revival of interest in the karyotyping of human tumors. In this respect the acute leukemias have received special attention, at least partly because of the difficulties frequently encountered in classifying them on cytological grounds alone.

The present report deals with the results of cytogenetic studies on bone marrow aspirates from 7 consecutive patients admitted to the American University Hospital with the diagnosis of acute leukemia.

Materials and Methods

Six patients were males and one was female. The age range was 16-83 years, with only one patient (LCP-3) above the age of 45 years. Four had received no treatment prior to karyotyping: one (LCP-14) had prednisolone for one month, another (LCP-18) had nitrogen mustard for 7 days, 2 months prior to the examination, and a third patient (LCP-7), the only female in the group, was on both prednisolone and 6-mercaptopurine at the time of the investigation.

As to the cytological type 3 of the patients had myeloblastic, three lymphoblastic and one monoblastic leukemia. The criteria used in differentiating these types have been described in detail by Harnock *et al.* [9]. Features of diagnostic importance were cellular and nuclear morphology, nuclear:cytoplasmic ratio, the presence of certain cytoplasmic inclusions such as Auer rods, as well as cytochemical reactions of the leukemic cells.

Sternal bone marrow aspiration was performed on every patient at the time of admission. A small portion of the aspirate was used for cytological examination following colonization with the Romanowsky stains, and for cytochemical reactions [9]. The rest was utilized in the

cytogenetic studies using slight modification of the method of Tjio and Whang [11], without prior *in situ* culturing (direct marrow preparations). At the same time peripheral leucocyte counts were made and smears prepared for differential counts and for cytochemical studies.

Table I contains the pertinent clinical and hematological data.

Results

The results of the chromosome studies are shown in table II. In 4 of the patients all available plates were suitable for analysis, and all showed an entirely normal chromosome constitution. In the fifth patient (LCP 18) most of the plates were found to be normal only 3 were hypodiploid, with a random loss of one or more chromosomes.

Distinct abnormalities were present in the marrow aspirates from 2 patients. The first, LCP 3, an 83-year-old male with myeloblastic leukemia, had not received any treatment prior to the study. Smears from his bone marrow showed numerous pleomorphic blasts with frequent mitoses, and several macroblasts and binucleate cells. Very few megakaryocytes could be seen. Cytogenetic studies revealed the presence of 2 cell-lines: a major line with a chromosome count of 41 (fig 1) and a minor near-tetraploid line of cells with 82 chromosomes. None of these latter were of adequate quality for accurate analysis.




Fig 1. Case LCP-3. Chromosome constitution of hypodiploid bone marrow cell. Note missing Y chromosome, extra D and deficiencies in groups C, E and G.

Table 1 Clinical and hematological data

Patient	Age years	Sex	Duration of symptoms prior to autopsy	Treatment prior to autopsy	Leucocyte count	Peripheral blood	Sternal marrow
LCP-3 Case 218156	83	M	3 weeks	None	22,000	Myeloblasts: 73% Promyelocytes: 3% Myelocytes: 4% Metamyelocytes: 4%	Numerous plasmotomable blast cells Allison's frequent A number of myeloblasts and blastocytic blast-like cells Erythrocytes markedly hypochromic Very few megakaryocytes
LCP-6 Case 221803	19	M	4 weeks	None	104,000	Lymphoblasts: 82% Lymphocytes: 9%	Numerous lymphoblasts and few mature lymphocytes Granulocytes and erythrocytes depressed
LCP-7 Case 200619	30	F	8 months	Quarantinization predominant	8,550	Myeloblasts: 81% Promyelocytes: 1% Myelocytes: 1%	Numerous plasmotomable blast, some having Auric bodies. Allison's frequent Erythrocytes relatively active normoblastic. Lymphocytes common.

Table I (continued)

Patient	Age years	Sex	Duration of symptoms prior to examination	Treatment prior to karyotyping	Leucocyte count	Peripheral blood	Sternal marrow
LCP-8 Case 222744	45	M	6 months	Vitamin Prednisolone Boriprostacycline	31,000	Myeloblasts: 80% Promyelocytes: 1% Myelocytes: 1%	Numerous blast cells, many having eccentric pale granules. Absence of caulocal. Erythropoiesis markedly depressed
LCP-13 Case 225899	16	M	1 week	None	210,000	All cells classified as lymphoblasts	Numerous lymphoblasts and im- mature lymphocytes. Granulopoiesis and erythropoiesis markedly depressed.
LCP-14 Case 226010	26	M	3 months	Prednisolone 1 month	2,500	Monoblasts and Promonocytes: 81% Neutrophils: 18%	Numerous monoblasts, promono- cytes and monocytes. Granulopoiesis markedly depressed. Erythropoiesis relatively active
LCP-18 Case 229125	23	M	3 months	Nitrogen mustard 7 days, 2 months earlier	1,950	Lymphoblasts: 20% Lymphocytes: 25%	Numerous lymphoblasts, Absence few Granulopoiesis relatively active. Erythropoiesis depressed.

Table II Results of chromosome studies on sternal marrow aspirates

Patient	Diagnosis	Total cells analyzed	40	41	44	45	46	Chromosome count	Marker chromosome	Remarks
LCP-3	AML	17		13				4 (near tetraploid)	-	Two abnormal cell lines
LCP-6	ALL	12					12		-	Normal karyotype
LCP-7	AML	17				7	10		2 No. 11	Two abnormal cell lines
LCP-8	AML	14					14		-	Normal karyotype
LCP-13	ALL	5					5		-	Normal karyotype
LCP-14	A. monocytic L.	10					10		-	Normal karyotype
LCP-18	ALL	12	1		1	1	94		-	Normal karyotype

Normal karyotype. Missing 1C, Missing 1 No. 2 1 No. 17 Missing 1C, 1D 1 No. 16, 2F Y
 ALL Acute lymphoid leukemia, AML Acute myeloid leukemia.

The second patient, LCP 7 was a 30-year-old female with myeloblastic leukemia. Marrow smears showed numerous pleomorphic blasts, some with Auer bodies. Mitoses were frequent among them. Cytogenetic studies showed two abnormal cell-lines, one with 46 chromosomes and the second with a count of 45. Examples of both lines are shown in figures 2 and 3.

Discussion

To date, several hundred cases of acute leukemia have been studied cytogenetically. In some the studies were performed on direct bone marrow preparations; in others peripheral blood leukocyte cultures were used alone or in combination with the bone marrow preparations. The advantages of direct marrow methods over leukocyte cultures have been stressed by HUNGERFORD *et al.* [4] and more recently by KROON JENSEN [6]. Although marrow specimens in the absence of *in vitro* culturing often yielded fewer mitoses for analysis, the culturing of peripheral leukocytes has frequently resulted in the loss of abnormal cell lines, or in the preferential growth of some cell lines over others. Or if phytohemagglutinin was used in the culture, this stimulated normal lymphocytes to proliferate and predominate the cultured cell population.

Even where no culture methods were used, a variable number of patients with acute leukemia were found to have no demonstrable chromosomal aberrations. In the remaining cases, various abnormalities have been encountered. The overall incidence of these as reported in the world literature was approximately 60% [2] although REISMAN *et al.* [9] were able to demonstrate abnormal cell lines in all specimens studied during the active phase of the disease in children. In our present series only 2 of the 7 patients had karyotype changes in their marrow cells.

The chromosome groups most frequently affected were groups C and G and less commonly groups D, E and F. Both of our cases had deficiencies in group G and an extra member in group D. In addition, case LCP 3 had deficiencies in groups C and E, and one of the lines of case LCP 7 had a missing E.

In contrast with the specific abnormality present in chronic myeloid leukemia, no characteristic chromosome pattern has been established for any type of acute leukemia. In general, it has been found that in lymphoblastic leukemia the abnormal cell lines are usually hyper-



Fig. 2. Case LCP 7. Chromosome constitution of the cell line with 46 chromosomes. Note abnormally short? No. 11 deficiency in group G, and extra D.



Fig. 3. Case LCP 7. Chromosome constitution of hypodiploid line. Pattern as in Figure 2, but in addition, member of pair No. 17 is missing.

diploid, while in the acute myeloid type the abnormal cells are often hypodiploid. An exception to this is the small group of elderly patients with acute myeloid leukemia in whom SANDBERG *et al.* [10] found 2 abnormal lines—one hypodiploid and the other hyperdiploid. Our case LCP 3 appears to have many features in common with this group.

In conclusion, despite the small size of the series studied our findings are in agreement with the reports in the literature, namely that cytogenetic abnormalities are not demonstrable in many cases of acute leukemia, and if present, they are not of specific diagnostic significance.

Summary

Cytogenetic studies are reported on direct bone marrow preparations from 7 patients with acute leukemia. Abnormalities were present in 2 patients with myeloblastic leukemia, one of whom was receiving cytotoxic drug therapy at the time of the examination. The remaining patients, including 3 with lymphoblastic leukemia, had no demonstrable chromosome changes. The above findings are compared with results of similar investigations carried out elsewhere.

References

1. BAIRD, A. G.; COHEN-BROWN, W. M.; BOCKTON, K. E.; HARRISON, D. G.; JACOB, P. A. and TOOTH, I. M. A possible specific chromosome abnormality in human chronic myeloid leukemia. *Nature Lond.* 180: 1163 (1960).
2. HAYMON, F. G. J. and HANNOUDA, F. Cytogenetic and metabolic observations in leukemias and allied states; in HAYMON's *Current research in leukemia*, pp. 55-76 (University Press, Cambridge 1965).
3. HAYMON, F. G. J., QUILTERO, D. and DOLL, R. The cytology and cytochemistry of acute leukemias. *Spec. Rep. Ser. med. Res. Council, Lond.*, No. 304 (1964).
4. HENDERFORD, D. A. and NOWELL, P. C. Chromosome studies in human leukemia. III. Acute granulocytic leukemia. *J. nat. Cancer Inst.* 29: 345 (1962).
5. KROMOLOU, K. A., MITOS, W. J. and DANKER, W. Chromosomal aberrations in acute leukemia. *Blood* 25: 610 (1965).
6. KROM JOWEK, M. Chromosome studies in acute leukemia. II. A comparison between the chromosome patterns of bone marrow cells and cells from the peripheral blood. *Acta med. scand.* 182: 157 (1967).
7. NOWELL, P. C. and HENDERFORD, D. A. Chromosome studies on normal and leukemic human leukocytes. *J. nat. Cancer Inst.* 23: 85 (1960).
8. NOWELL, P. C. and HENDERFORD, D. A. A minute chromosome in human chronic granulocytic leukemia. *Science* 132: 1497 (1960).
9. RICHMAN, L. E.; MITANI, M. and ZILLER, W. W. Chromosome studies in leukemia. I. Evidence for the origin of leukemic stem lines from aneuploid ancestors. *New Engl. J. Med.* 270: 591 (1964).
10. SANDBERG, A. A., ISHIMURA, T., KIKUCHI, Y. and CROWWHITE, L. H. Chromosomal differences among the acute leukemias. *Ann. N.Y. Acad. Sci.* 113: 663 (1964).
11. Tjo, J. H. and WHANG, J.-. Chromosome preparations of bone marrow cells without prior *in vivo* culture or *in vivo* colchicine administration. *Stain Technol.* 37: 17 (1962).

Authors' address: Drs. FARID P. KHOURI, MUNIR J. SHARAF and STEPHAN YEHOUDERIAN American University Hospital, Beirut (Lebanon).

A Trial of Slow Release Ferrous Sulphate (Ferrogradumet®) in Prevention of Iron Deficiency in Pregnancy

R. W. BURLEIGH, L. POLLER and H. WACKS

We have attempted to assess the effectiveness of a slow release ferrous sulphate tablet given once daily as opposed to conventional ferrous sulphate given three times daily in the prevention of anaemia.

An ideal situation for the study of such preparations arises during pregnancy which results in iron deficiency in a considerable proportion of patients when prophylactic iron is not administered. A controlled trial has, therefore, been performed of slow release ferrous sulphate with folic acid supplement, studied in parallel with a conventional ferrous sulphate tablet and folic acid. A large number of ante natal patients attending a general maternity hospital has been followed.

Method

The effectiveness of the slow release iron in the prevention of anaemia was evaluated by means of two large parallel groups of ante-natal patients. It was found advisable to use alternate clinics for the selection of patients for the two groups. Two booking clinics every week are held at this hospital. They were identical in all respects.

The series covered initially all patients attending the booking clinic for the first time over a three-month period (September 1963–December 1963). Details were recorded of age, parity, gravidity and previous illnesses. Initial tests included haemoglobin, examination of a blood film and urine bacteriology.

Routinely haemoglobin readings are expressed grams per cent. For convenience in the analysis percentage haemoglobin figures were used 100% = 14.6 g with the conventional cyanmethaemoglobin standard.

All patients were given 3 months supply of slow release ferrous sulphate (Ferrogradumet) and folic acid, or combined conventional ferrous sulphate/folic acid. The former group took one tablet daily containing 105 mg elemental iron and one 5 mg folic acid tablet, and the latter group took one tablet three times daily giving a total of 180 mg elemental iron daily and an equivalent dose of folic acid.

Normal patients were not seen again until 30 weeks in the ante-natal clinic following general practitioner care.

From the 30th week of gestation onwards each patient had regular haemoglobin check (capillary finger prick cyanmethaemoglobin) at least once every 4 weeks, although in some cases the haemoglobin was repeated weekly or fortnightly.

If the haemoglobin was below 10.2 g (70%) venous specimen was taken for absolute values. If the venous haemoglobin was found to be less than 10.2 g routine serum iron, B₁₂ and folate were advised. In some cases marrow aspiration was performed.

All patients had haemoglobin estimation just prior to delivery and, in nearly all cases within 48 h *post partum*. During the ante-natal period, not was taken of urinary infection, toxæmia, bleeding, hyperemesis and various complications as well as the number of abortions, stillbirths, live births, premature and multiple births and perinatal deaths.

Finally the need for parenteral iron *pre* or *post partum* or any change in the regime of slow release ferrous sulphate to any other form of iron was noted.

Subjective data were not included, e.g. whether the patients said they were taking their tablets, whether they suffered nausea or constipation. It was assumed that with such large numbers this would be reflected in the haemoglobin level.

Results

Of 472 patients in the trial, 228 received slow release ferrous sulphate and folic acid and 224 were given folic acid and ferrous sulphate in conventional combined form. The mean parity of the slow release group was 1.5 and 1.6 with the conventional group. The mean age was 26 years in both groups.

Ten patients were lost from each group because of confinement at another hospital, abortions, etc. The percentage of patients given parenteral iron was identical at (11.4%) in both groups. Nine additional patients were lost from the slow release iron group because they were changed to other oral iron preparations at some stage during the trial.

The effect on haemoglobin levels was as follows. The mean haemoglobin figure after delivery was 79.3% for the slow release groups and 78.7% for the other group. The weekly mean haemoglobin levels are seen in table I. Patients who were anaemic had more frequent estimations of their haemoglobin their results were analysed separately (table II). There were 54 patients with initial haemoglobin of less than 10.2 g in the slow release ferrous sulphate series and 60 patients in the conventional series. Their mean haemoglobins at delivery were 81.1% and 80.3% respectively. There was no significant difference in the speed of response of anaemic patients to the two preparations when analysed on a weekly basis using students 't test' (table II). The gross incidence of anaemia in the two groups seemed to be very close and there was no significant difference between the groups.

Table I Mean Hb levels, %

Weeks	14	28	29	30	31	32	33	34	35	36	37	38	39	40	Post partum
Slow release ferrous sulphate	79.6	76.5	78.9	78.0	77.9	78.5	78.12	78.7	80.2	80.2	80.4	81.7	81.7	81.2	79.3
	Mean of 37th-40th week levels = 81.3%														
Ferrous sulphate folic acid	82.6	78.6	78.9	77.9	78.3	77.9	79.3	79.3	81.5	80.4	80.1	80.3	81.5	80.5	78.7
	Mean of 37th-40th week levels = 80.5%														

Table II Mean Hb levels (%) of patients with 10.2 g and under at initial reading (excluding patients given parenteral iron)

Weeks	Initial	28	29	30	31	32	33	34	35	36	37	38	39	40	Post partum
Slow release ferrous sulphate	68.5	70.9	78.5	77.8	78.1	74.9	73.5	78.2	77.8	78.9	79.8	79.7	80.5	79.1	80.8
Ferrous sulphate folic acid	68.2	71.0	72.3	72.4	72.2	72.7	74.7	73.0	73.9	77.3	76.3	78.4	78.9	78.3	79.6

The incidence of complications of pregnancy was as follows. In the slow release iron group urinary infections 19 (8.3 %) antepartum haemorrhage 2, hyperemesis 1 in the conventional iron group urinary infections 17 (6.9 %) antepartum haemorrhage 4 hyperemesis 1. Premature births were 7 and 11 respectively and the number of ante-natal admissions for various causes was 38 in the slow release iron, and 45 in the other group.

Discussion

At the start of the trial the two groups of patients appeared identical. Their ages and parity were similar. During the trial obstetrical complications, were similar. There was no increase in the number of premature births, abortions or stillbirths. Ante-natal admission rates were similar in the two groups and the number of patients who had hospital admission for investigation of anaemia was insignificant.

The incidence of non-responsive anaemia in patients treated with prophylactic iron and folic acid is of interest. In both series this was 11.4 %. There is thus a hard core of cases in whom anaemia was not prevented by a prophylactic regime. Similar figures have been reported in the literature. HENDERSON [2] found that regardless of the combination of oral agent used approximately 10 % of patients remained anaemic. CHAMBLISS [1] in a survey in Oxford found an incidence of anaemic of 12 % in spite of prophylactic iron therapy.

It appears that the one tablet daily regime of the administration of slow release iron is as effective clinically as giving iron three times daily in conventional form. As the amount of elemental iron is less in the slow release tablets it must be assumed that absorption is more efficient. It does not appear however that this regime is significantly better clinically in the prevention of anaemia.

If the patients' acceptability of the new preparation had been superior to conventional iron it might be assumed that the mean haemoglobin would have been maintained at a higher level or that the incidence of anaemia would have been less due to the elimination of cases unable to tolerate conventional ferrous sulphate.

The analysis of the anaemic cases showed that the two preparations were equivalent in their long term effects, no significant difference being found in the two groups at term. Although the differences were not significant the results do perhaps suggest that the response to slow release ferrous sulphate may have been more rapid and this is also

suggested by the higher number of anaemic patients in the conventional ferrous sulphate group who required parenteral iron. Similar accelerated response has been suggested by Israëlis and Cook [3] in the treatment of established anaemia. This trial however was not designed to assess the speed of response of established anaemias.

Conventional ferrous sulphate is used on a large scale in hospitals in this country and is consequently extremely cheap. The cost of a combined conventional ferrous sulphate/folic acid tablet for a 28 week course per patient is 4/6d. The preparations of slow release ferrous sulphate (Ferrogradumet®) used in this study is much more expensive, the current cost for a 28 week course at the best hospital price being over 30/ per patient. There might be a case for routine use of the slow release ferrous sulphate if substantial benefit could be shown. In the present study we have found no significant benefit in the prevention of anaemia in pregnancy as distinct from the treatment of established anaemias.

Acknowledgment

We are grateful to Abbott Laboratories for some statistical assistance with the trial and for supplies of Ferrogradumet® and Dr A. ARROWood Resident Clinical Pathologist, for help in the early stages of the study.

Summary

A trial of the effectiveness of a slow release, once daily preparation of ferrous sulphate has been performed in the prevention of anaemia in pregnancy. The control group consisted of a parallel large series of pregnant women given conventional ferrous sulphate three times daily. There was no significant difference in the incidence of anaemia, side-effects and complications in the two groups. The once daily regime was as good as, but no better than conventional ferrous sulphate in the prevention of anaemia, although there may be more rapid response in patients with established anaemia.

References

1. CARROWAY, M. A controlled clinical trial of prophylactic folic acid and iron in pregnancy. *J. Obstet. Gynaec. Brit. Comm.* 72, 191 (1965).
2. HIZENBACH, F. A.: Anaemia of pregnancy. *Obstet. Gynec.*, N.Y. 24, 752 (1964).
3. ISRAËLIS, M. C. G. and COOK, T. A. New preparations for oral iron therapy. *Lancet* ii, 654 (1965).

Authors' address: Drs. R. W. BORLEN, L. POLLER and H. WACHS, Widdington Hospital, Department of Haematology West Didsbury Manchester 20 (England)

I. Medizinische Klinik der Johann-Wolfgang-Goethe-Universität Frankfurt am Main
(Direktor: Prof. Dr. W. Sarnitz)

Untersuchungen über den Einfluss von Natrium-Oleat auf die Aggregation menschlicher Thrombozyten

A. M. EIRLY, H. DÖPFENSGREUT und E. BÖHLE

Die Bedeutung der Blutfette für die Entstehung von Thrombozyten aggregaten im Zusammenhang mit Störungen der Hämostase und der Mikrozirkulation ist in den letzten Jahren zunehmend diskutiert worden. Besondere Beachtung verdienen hier die unveresterten Fettsäuren des Plasmas (UFS) die sowohl unter physiologischen als auch unter pathophysiologischen Bedingungen erheblichen Konzentrationsänderungen unterliegen. Über den Einfluss erhöhter Konzentrationen von langkettigen unveresterten Fettsäuren, speziell von Ölsäure auf die Plättchenaggregation liegen allerdings widersprüchliche Angaben vor [1 5 15 16]. Nach eigenen Beobachtungen bewirken sowohl der Zusatz von Ölsäure oder Natrium-Oleat zu Blut *in vitro* als auch eine Erhöhung der Konzentration der unveresterten Fettsäuren *in vivo* eine Desaggregation von Erythrozytenaggregaten [9 10 13]. In der vorliegenden Arbeit wurde untersucht, ob der Zusatz von Natrium-Oleat zu plättchenreichem Plasma eine Aggregation der Thrombozyten *in vitro* bewirkt, und ob verschiedene Konzentrationen von Natrium-Oleat eine ADP induzierte Thrombozytenaggregation verstärken oder abschwächen können.

Material und Methode

Nachternblut gesunder Probanden beiderlei Geschlechtes zwischen 17 und 41 Jahren wurde durch Punktion der V. can. cubitalis gewonnen, wobei die ersten 2 ml verworfen wurden.

Herrn Prof. Dr. W. Sarnitz zum 60. Geburtstag

Das Blut wurde in silikonierten Gläsern aufgefangen, in denen so viel Natrium-Zitrat-Lösung vorlag, dass eine Endkonzentration von 3,6% im Blut erreicht wurde. Plättchenreiches Plasma wurde durch 20 min dauerndes Zentrifugieren des Blutes bei 500 g, plättchenfreies Plasma durch 20minütiges Zentrifugieren des plättchenreichen Plasmas bei 2000 g erhalten. Die Extinktionsmessungen wurden mit einem Eppendorf-Fotometer mit dem Filter 578 durchgeführt. In Abänderung der von Bower [4] beschriebene Methode wurde die Durchmischung des plättchenreichen Plasmas mit Natrium-Oleat bzw. Natrium-Oleat und ADP durch Klappen der Gläsern und Küvetten ersetzt. In der Originalmethode [4] wird das plättchenreiche Plasma durch Rotieren eines Stäbchens geführt (stirring). Die infolge der verwendeten hohen Umdrehungszahl des Rührstäbchens von 1000 U/min verursachte mechanische Belastung der Thrombocyten ist gross genug, um einen Teil der Plättchen zu zerstören [3]. Die dabei freierwerdenden Substanzen, insbesondere ADP können selbst eine Aggregation der Thrombocyten auslösen. In einer Mitteilung von Gross *et al.* [14] wurde die Bowersche Originalmethode ebenfalls so verändert, dass keine mechanische Alteration der Thrombocyten mehr eintritt.

Nach Zusatz der einzelnen Substanzen zum plättchenreichen Plasma (PRP) wurden die Gläsern mit Parafilm verschlossen und zunächst 20mal gekippt. Die Extinktionen wurden dann in einminütigen Abständen gemessen, beginnend jeweils 60 sec nach Substanzangabe. 15 sec vor jeder folgenden Ableseung wurde die Küvette wiederum 5mal gekippt. So konnte bei ausreichender Durchmischung des Plasmas eine Sedimentation der Thrombocytenaggregate vermieden werden [8]. Parallel zu jedem untersuchten plättchenreichen Plasma wurde ein Kontrollplasma des gleichen Probanden mitgeführt, dem ausser der Testsubstanzen ein gleiches Volumen physiologischer Kochsalzlösung zugegeben wurde.

Alle Versuche wurden bei Zimmertemperatur (20 bis 22°C) und unmittelbar im Anschluss an die Blutentnahmen vorgenommen. Sämtliche Zusätze zum Plasma erfolgten in Form von 0,1 ml Lösung der entsprechenden Substanzen in physiologischer Kochsalzlösung. Dabei wurden die Konzentrationen dieser Lösungen so gewählt, dass 0,1 ml mit 5 ml Plasma die angegebenen Konzentrationen, bezogen auf Plasma, ergaben. Natrium-Oleat (Riedel-de-Haen AG Seehse) wurde in 0,9% NaCl gelöst. Als aggregationsauslösende Substanz wurde das Trinatriumsalz des Adenosin-5-Diphosphats der Fa. C.F. Boehringer und Söhne, Mannheim, in einer Endkonzentration von 2×10^{-4} M/l verwendet. Die Lösung wurde täglich neu hergestellt. Alle Geräte, die mit Blut oder Plasma in Berührung kamen, wurden nach den üblichen Vorschriften sterilisiert. Die Genauigkeit der Extinktionsmethode ergab bei Wiederholungsmessungen eine maximale Abweichung von nur 2,6% [8]. Ein Schema der Versuchsabläufe zeigt Abb. 1




Abb. 1 Schema des Ablaufs der Versuche

Ergebnisse

1 Einfluss von Natrium-Oleat auf die Aggregation von Thrombocyten in plättchenreichem Plasma

Jeweils 8 plättchenreiche Plasmen wurden auf 10 20 40 80 und 160 mg% Natrium-Oleat Konzentration gebracht. Parallel zu jedem Messwert wurde ein Kontrollversuch mit physiologischer Kochsalzlösung mitgeführt. Die Beobachtungsdauer betrug 5 Minuten nach Zugabe von Natrium-Oleat bzw. physiologischer Kochsalzlösung zu plättchenreichem Plasma. In Vorversuchen [8] hat es sich ergeben, dass eine längere Beobachtungsdauer nicht erforderlich ist.

Die Abb. 2 zeigt den Extinktionsverlauf 8 verschiedener plättchenreicher Plasmen nach Natrium-Oleat Zusatz von 20 mg%. Die Extinktionskurven der Kontrollversuche mit physiologischer Kochsalzlösung verliefen deckungsgleich mit den eingezeichneten Kurven. Wie in allen folgenden Abbildungen sind auch hier die Extinktionen der plättchenreichen Plasmen abzüglich der Extinktionswerte der jeweiligen plättchenfreien Plasmen aufgeschrieben worden. Die unterschiedlichen Ausgangshöhen der Kurven sind Ausdruck der in den verschiedenen Plasmen der einzelnen Probanden erhaltenen verschiedenen Anzahl von Blutplättchen. Aus der Abb. 2 ist ersichtlich, dass nach Zugabe von 20 mg% Natrium-Oleat zu plättchenreichem Zitratplasma keine Extinctionsveränderung gegenüber den entsprechenden NaCl-Kontrollversuchen erfolgte. Analog dazu verliefen auch die Untersuchungen mit 10 40, 80 und 160 mg% Natrium-Oleat. In keinem der insgesamt 40 untersuchten plättchenreichen





Abb. 2. Die Wirkung von Natrium-Oleat (20 mg%) auf die Aggregation der Thrombocyten in FRP. Die Extinktionskurven der NaCl-Kontrollversuche verliefen deckungsgleich mit den eingezeichneten Kurven. Die Ziffern 1-8 bezeichnen die verschiedenen Plasmen.

Das Blut wurde in silikonierten Gläschen aufgefangen, in denen so viel Natrium-Zitrat-Lösung vorlag, dass eine Endkonzentration von 3,8% im Blut erreicht wurde. Plättchenreiches Plasma wurde durch 20 min dauerndes Zentrifugieren des Blutes bei 500 g, plättchenfreies Plasma durch 20minütiges Zentrifugieren des plättchenreichen Plasmas bei 2000 g erhalten. Die Extinktionsmessungen wurden mit einem Eppendorf-Fotometer mit dem Filter 578 durchgeführt. In Abänderung der von Born [4] beschriebenen Methode wurde die Durchmischung des plättchenreichen Plasmas mit Natrium-Oleat bzw. Natrium-Oleat und ADP durch Klappen der Gläschen und Küvetten ersetzt. In der Originalmethode [4] wird das plättchenreiche Plasma durch Rotation eines Schälchens geführt (stirring). Die infolge der verwendeten hohen Umdrehungszahl des Rührstäbchens von 1000 U/min verursachte mechanische Belastung der Thrombocyten ist gross genug, um einen Teil der Plättchen zu zerstören [3]. Die dabei freiwerdenden Substanzen, insbesondere ADP, können selbst eine Aggregation der Thrombocyten auslösen. In einer Modifikation von Gans *et al.* [14] wurde die Bornsche Originalmethode ebenfalls so verändert, dass keine mechanische Alteration der Thrombocyten mehr eintritt.

Nach Zusatz der einzelnen Substanzen zum plättchenreichen Plasma (PRP) wurden die Gläschen mit Paraffin verschlossen und zunächst 20mal gekippt. Die Extinktionen wurden dann in einminütigen Abständen gemessen, beginnend jeweils 60 sec nach Substanzzugabe. 15 sec vor jeder folgenden Ableseung wurde die Küvette wiederum 5mal gekippt. So konnte bei ausreichender Durchmischung des Plasmas eine Sedimentation der Thrombocytenaggregate vermieden werden [8]. Parallel zu jedem untersuchten plättchenreichen Plasma wurde ein Kontrollplasma des gleichen Probanden mitgeführt, dem anstelle der Testsubstanzen ein gleiches Volumen physiologischer Kochsalzlösung zugegeben wurde.

Alle Versuche wurden bei Zimmertemperatur (20 bis 22° C) und unmittelbar im Anschluss an die Blutentnahmen vorgenommen. Sämtliche Zusätze zum Plasma erfolgten in Form von 0,1 ml Lösung der entsprechenden Substanzen in physiologischer Kochsalzlösung. Dabei wurden die Konzentrationen dieser Lösungen so gewählt, dass 0,1 ml ad 5 ml Plasma die angegebenen Konzentrationen, bezogen auf Plasma, ergaben. Natrium-Oleat (Riedel-de-Haen A.G. Seelze) wurde in 0,9% NaCl gelöst. Als aggregationsauslösende Substanz wurde das Trisnatriumsalz des Adenosin-5-Diphosphats der Fa. C.F. Boehringer und Söhne, Mannheim, in einer Endkonzentration von 2×10^{-4} M/l verwendet. Die Lösung wurde täglich neu hergestellt. Alle Geräte, die mit Blut oder Plasma in Berührung kamen, wurden nach den üblichen Vorschriften silikoniert. Die Genauigkeit der Extinktionsmethode ergab bei Wiederholungsmessungen eine maximale Abweichung von nur 2,63% [8]. Ein Schema der Versuchsanlage zeigt Abb. 1.



5 min nach ADP Zusatz ist im allgemeinen das Maximum der Thrombozytenaggregation erreicht (Abb.3) So wie am Beispiel dieses Einzelversuches mit einer Natrium-Oleat Konzentration von 20 mg%, gegenüber der Kontrolle mit NaCl-Zusatz zu plättchenreichem Plasma dargestellt (Abb.3) wurden für jeden Einzelversuch entsprechende Kurven aufgezeichnet, so dass für jede Natrium-Oleat Konzentration jeweils 8 Kurvenpaare erhalten wurden. Aus diesen 8 Kurvenpaaren wurden Mittelwerte errechnet und graphisch aufgetragen (Abb.4 und 5)

Die Abb.4 zeigt die arithmetischen Mittelwerte der Extinktionen 8 verschiedener plättchenreicher Plasmen nach ADP Zugabe.

Bei Zusatz von Natrium-Oleat in einer Konzentration von 10 mg lagen die Extinktionswerte nach ADP Zugabe geringgradig höher als bei den Kontrollversuchen, was einer Verringerung der Thrombozytenaggregation entspricht.




Abb.4 Kurven der arithmetischen Mittel der Extinktionswerte (E) je 8 verschiedener PRP nach ADP-Zugabe ($x \cdot 10^{-4}$ M/l). — Plättchenreiche Plasmen mit Natrium-Oleat in einer Konzentration von 10 mg% (a) 20 mg% (b) 40 mg% (c), 80 mg% (d), 160 mg% (e). — Vergleichsproben der gleichen Plasmen, die NaCl anstelle von Natrium-Oleat enthalten. Natrium-Oleat bzw. NaCl wurden bei $t = 0$ min clupestetiert, ADP bei $t = 5$ min.

Plasma wurde durch Natrium-Oleat Zusatz eine Extinktionsänderung gefunden. Auch mikroskopisch waren nach Natrium-Oleat Zusatz bis 80 mg% keine Thrombozytenaggregate nachzuweisen lediglich bei einer Plasmakonzentration von 160 mg% Natrium-Oleat waren vereinzelt Thrombozytenaggregate zu finden.

2. Einfluss verschiedener Natrium-Oleat Konzentrationen auf die ADP induzierte Thrombozytenaggregation

Jeweils 8 plättchenreiche Plasmen wurden auf 10 20 40 80 und 160 mg% Natrium-Oleat Konzentration gebracht. 5 min nach dem Zusatz von Natrium-Oleat zu den plättchenreichen Plasmen wurde ADP Lösung zupipettiert. Wie sich aus Vorversuchen ergab, ist es unerheblich, ob zunächst ADP und dann Natrium-Oleat dem plättchenreichen Plasma zugesetzt wird oder ob umgekehrt vorgegangen wird [8]. Die Wirkung von Natrium-Oleat auf eine ADP-induzierte Aggregation von Thrombozyten ist aus dem Vergleich zu den in jedem Fall mitgeführten Kontrollversuchen (Zusatz von physiologischer Kochsalzlösung anstelle von Natrium-Oleat Lösung) ersichtlich. Es sollte so nachgewiesen werden, ob eine ADP-induzierte Thrombozytenaggregation durch Zusatz von Natrium-Oleat in verschiedenen Plasmakonzentrationen verstärkt oder vermindert wird.

Wie Abb 3 zeigt, kommt es innerhalb der ersten beiden Minuten nach Zusatz von ADP zu plättchenreichem Plasma zu dem bekannten Extinktionsabfall (Absinken der optischen Dichte). Gleichzeitig lassen sich schon makroskopisch Thrombozytenaggregate nachweisen.




Abb. 3. Änderung der Extinktion eines PRP nach ADP-Zusatz (2×10^{-3} M/l). o-o-o PRP mit Natrium-Oleat in einer Konzentration von 20 mg%. O-O-O PRP mit NaCl anstelle von Natrium-Oleat. Natrium-Oleat bzw. NaCl wurden zur Zeit 0 zupipettiert, ADP 5 sek später.




Abb. 5. Extinktionsdifferenzen zwischen Mess- (Natrium-Oleat-) und Kontroll- (NaCl-) Plasmen in Abhängigkeit von den geprüften Natrium-Oleat-Konzentrationen. Die schwarzen Quadrate geben die Mittelwert der Extinktionsdifferenzen an. Ordinate: Unterschiede der optischen Dichte zwischen Mess- und Kontrollplasma, gemessen in Einheiten der Extinktionskala des benutzten Gerätes.

tistische Signifikanz sowohl für die desaggregierende Wirkung von Natrium-Oleat in Konzentrationen von 10 und 20 mg %, als auch für die aggregierende Eigenschaft von Natrium-Oleat Konzentrationen über 40 mg %, ist aus der Abb. 5 deutlich ersichtlich (Zeichentest) eine weitergehende statistische Prüfung hatte sich deshalb erübrigt.

Discussion

Der Ölsäure, als einer einfach ungesättigten C_{18} -Fettsäure, kommt deswegen besondere Bedeutung zu, weil sie von den im Plasma vorkommenden unveresterten Fettsäuren den höchsten Anteil ausmacht [19]. In menschlichem Plasma, das bei einem pH von 7,4 eine große Pufferkapazität besitzt, sind die unveresterten Fettsäuren nahezu vollständig dissoziiert, da Fettsäuren als Essigsäure-analoge Carbonsäuren einen pK (wässrige Lösung) von 4,7 bis 5,0 aufweisen. Der Zusatz von Natrium-Oleat zu Blut in Konzentrationen bis 120 mg % verändert den pH des Blutes bzw. Plasmas nicht [12]; die Wirkungen auf Erythrozyten [13, 12, 10] und Thrombozyten sind demnach dem Fettsäureanion zuzuschreiben.

Aus den vorliegenden Ergebnissen geht hervor, dass Zusatz von Natrium-Oleat zu Plasma in Konzentrationen bis 40 mg/100 ml eine partielle Desaggregation von Plättchenaggregaten bewirkt. Hohe Konzentrationen von Natrium-Oleat über 40 mg % verstärken demgegenüber die ADP-induzierte Thrombozytenaggregation. Diese

Befunde stehen teilweise im Widerspruch zu den Ergebnissen anderer Autoren. Hierfür dürften an erster Stelle methodische Unterschiede verantwortlich sein. Von HOAK *et al.* [16] sowie MAHADEVAN *et al.* [18] wurde nachgewiesen, dass Natrium-Oleat sowohl auf gewaschene Thrombozyten als auch auf Thrombozyten in plättchenreichem Plasma aggregationsfördernd wirkt. Relativ niedrige Natrium-Oleat Konzentrationen (bis 60 mg / l) aggregierten nach weiteren Feststellungen jedoch lediglich gewaschene Thrombozyten, nicht aber Blutplättchen in Plasma [16]. Die gleichen Verfasser konnten weiterhin nachweisen, dass die aggregierende Wirkung des Natrium-Oleates auf gewaschene Thrombozyten durch vorherigen Zusatz von ausreichend Albumin nahezu aufgehoben werden kann. ARDLIE *et al.* [1] fanden bei niedrigen Oleat Konzentrationen weder eine aggregierende Wirkung des Natrium-Oleates in plättchenreichem Plasma noch eine Beeinflussung der ADP induzierten Plättchenaggregation. Die Anwesenheit von Serumalbumin ist offenbar bei *in vitro*-Untersuchungen über die Plättchenaggregation von entscheidender Bedeutung, da dem Plasma zugesetzte Ölsäure bzw. Natrium-Oleat nicht frei vorliegt, sondern an Albumin gebunden wird [11-16]. Auch die unveresterten Fettsäuren des Plasmas *in vivo* sind an Albumin gebunden. «freie» Ölsäure (ohne Bindung an Plasmaalbumin) kommt *in vivo* praktisch nicht vor. Die fehlende aggregierende Wirkung von Natrium-Oleat in Konzentrationen unter 40 mg % auf im Plasma suspendierte Thrombozyten dürfte daher Folge einer Symplexbildung zwischen dem Albumin und dem Oleat Anion sein, so dass es nicht zu einer direkten Beeinflussung von freiem, nicht an Albumin gebundenem Natrium-Oleat auf die Blutplättchen kommt.

Unter diesen Gesichtspunkten sind auch die Ergebnisse von HOAK *et al.* zu erklären, die das Auftreten von Thromben in den Lungen von Versuchstieren nach intravenösen Injektionen von Albuminlösungen mit hohen Natrium-Oleat Konzentrationen beschrieben [15-16]. Möglicherweise bestand bei der grossen Menge von zugesetztem Natrium-Oleat zur injizierten Albumin-Lösung keine quantitative Bindung der Fettsäureanionen an das Albumin, so dass freies, nicht gebundenes Natrium-Oleat direkt auf die Plättchen einwirken konnte. Ähnliche Vorbehalte wie für die Arbeiten von HOAK *et al.* gelten auch für die Ergebnisse von ZANDEN [20] und DAY [6], die nach Natrium-Oleat Infusionen bei Tieren eine Thrombopenie beobachteten.

Intravital erfolgt der Anstieg der Konzentration der unveresterten Fettsäuren bei Stresszuständen beim Rauchen und während

des Hungers relativ langsam und auf das gesamte Plasmavolumen verteilt. Bei der therapeutischen Anwendung von Heparin und Heparinoiden kommt es zu einem relativ schnellen Anstieg der unveresterten Fettsäuren im Plasma, wobei die Fettsäuren quantitativ an Albumin gebunden sind. Die durch Heparininjektionen ausgelöste Erhöhung der Konzentration an unveresterten Fettsäuren übersteigt jedoch im allgemeinen nicht 40 mg% und liegt demnach in einem Konzentrationsbereich, der nach den vorliegenden Ergebnissen eine leichte desaggregierende Wirkung auf Thrombozytenaggregate aufweist.

Die partiell desaggregierende Wirkung von Natrium-Oleat in Konzentrationen bis 40 mg% auf ADP induzierte Thrombozytenaggregate zeigt eine auffallende Parallelität zu der früher beschriebenen desaggregierenden Wirkung von Natrium-Oleat auf Erythrozytenaggregate [13]. Während jedoch für Erythrozytenaggregate bei höheren Konzentrationen die desaggregierende Wirkung zunimmt, ist dies bei Thrombozytenaggregaten nicht der Fall (s. Abb. 5). Die Ursache der thrombozytendesaggregierenden Wirkung von Natrium-Oleat in geringen Konzentrationen und der aggregationsfördernde Effekt von hohen Konzentrationen von Natrium-Oleat konnten bisher nicht gefunden werden. Bei Erythrozytenaggregaten erfolgt die Desaggregation über eine Abrundung der Zellen (bikonvexe Erythrozyten). Der Nachweis eines entsprechenden oder ähnlichen Mechanismus für die Thrombozytendesaggregation nach Zusatz geringer Konzentrationen von Natrium-Oleat gelang mit den üblichen Methoden (Phasenkontrastmikroskop) nicht.

Der Hemmung der Aggregation der Thrombozyten kommt im Zusammenhang mit der Prophylaxe und der Therapie thromboembolischer Erkrankungen und möglicherweise auch bestimmter Schockzustände eine besondere Bedeutung zu, da die Zusammenlagerung der Thrombozyten einen massgeblichen pathogenetischen Faktor dieser Erkrankungen darstellt. Nach DEUTSCH [7] BÖHLE *et al.* [2] ZWEIFLER [21] und anderen Autoren ist weiter die Möglichkeit zu diskutieren, dass arteriosklerotischen Frühveränderungen über eine Minderung der Thrombozytenaggregation zu begegnen ist. Die vorliegenden Untersuchungen mit Natrium-Oleat ergaben eine leicht desaggregierende Wirkung auf Thrombozytenaggregate bei physiologisch denkbaren Konzentrationen. Den Salzen anderer unveresteter Fettsäuren (z. B. Palmitinsäure, Stearinsäure) wird eine aggregationsfördernde Wirkung auf Thrombozyten nachgesagt [5 16 17 18]. Dabei wurden aller

dinge relativ hohe Fettsäurekonzentrationen untersucht. Angesichts der Tatsache, dass Natrium-Oleat ein bivalentes Verhalten in Beziehung auf die Thrombozytenaggregation zeigt, erscheinen entsprechende Untersuchungen mit niedrigen Konzentrationen anderer Fettsäuren angezeigt.

Zusammenfassung

Mit einer Modifikation der Bornschen Methode zur Messung der Thrombozytenaggregation wurde die Wirkung verschiedener Konzentrationen von Natrium-Oleat sowohl auf Thrombozyten als auch auf ADP-induzierte Thrombozytenaggregate untersucht. Es ergab sich, dass Natrium-Oleat Konzentrationen bis 80 mg/100 ml Plasma keine Aggregation der Thrombozyten verursacht. Die Wirkung von Natrium-Oleat auf bereits bestehende Thrombozytenaggregate ist verschieden. Während niedrige physiologisch deutbare Konzentrationen bei 40 mg% eine leichte Disaggregation von Thrombozytenaggregaten bewirken, führen Natrium-Oleat-Konzentrationen über 40 mg% zu einer Verstärkung der bereits vorhandenen Thrombozytenaggregation.

Summary

Aggregation of platelets has been studied *in vitro* by a modification of Born method. It could be shown, that addition of sodium-oleat to platelet rich human plasma does not cause platelet aggregation in concentrations up to 80 mg%. When platelets in plasma had been aggregated by ADP before, the addition of sodium oleate in concentrations up to 40 mg% leads to a partial disaggregation of the platelet aggregates, while higher concentrations enhance the aggregation of platelets.

Literatur

1. ARDRE, N. G., KIDDOON, R. L., GLEW, G. and SCHWARTZ, C. J. Fatty acids and *in vitro* platelet aggregation. *Austral. J. exp. Biol. med. Sci.* 41: 103-110 (1965).
2. BÖCKL, E.; RAUKE, J., HARTMUTH, E. und BERTSCH, K. Untersuchungen über die Agglutination der Blutplättchen nach Zufuhr verschiedener Nahrungsfette. *Klin. Wochr.* 43: 555-562 (1965).
3. BORN, G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature Lond.* 194: 927-929 (1962).
4. BORN, G. V. R. and CAHILL, M. J. The aggregation of blood platelets. *J. Physiol.* 162: 159-178 (1963).
5. CONNOR, W. E.; HOAR, J. G. and WALKER, E. D. The role of lipids in thrombosis. In *Pathogenesis and treatment of thromboembolic diseases*, pp. 193-208 (Schattauer Stuttgart 1965).
6. DYER, H. J.; FEWELL, W. and SOLOVY, L. A. Thrombosis in the dog produced by single rapid infusions of long chain saturated fatty acids. *Amer. J. med. Sci.* 253: 113-123 (1967).
7. DAUTMAN, E. Die Antikoagulantien in der Therapie der peripheren arteriellen Durchblutungsstörungen. *Wien. klin. Wochr.* 76: 151-153 (1964).

8. DÖRRSCHNEIDER H.: Untersuchungen über den Einfluss des Natriumoleates der Ölsäure als Vertreter der unversättigten Fettsäuren des Plasmas auf die Aggregation menschlicher Thrombozyten. Inaug. Diss. Mainz (1968)
9. ESKLY A. M. Untersuchungen über Wirkung und Wirkungsmechanismus verschiedener oberflächenaktiver Substanzen und Pharmaka auf Erythrocytenaggregate die Elektroperchenabgangsgeschwindigkeit, die Viskosität und den Hämatokrit menschlichen Blutes. *Arztl. Forsch.* 2/ 323-334 (1967)
10. ESKLY A. M. Wirkung und Wirkungsweise unversättigter Fettsäuren auf die Viskosität des Blutes. Proc. 1st int. Conf. on Hemorheology. Reykjavik/Island 1966 (Pergamon Press, im Druck).
11. ESKLY A. M., GRAMBLICH, F. und MÜLLER, H. E.: Die Verteilung von 131 Iod-markierter Ölsäure zwischen Plasma und Erythrocyten. *Blut* 1/ 264-290 (1965).
12. ESKLY A. M.; GRAMBLICH, F. und MÜLLER, H. E. Über den Einfluss von Lipiden, insbesondere von unversättigten Fettsäuren auf den Mechanismus der Elektroperchenabgangsgeschwindigkeit. *Klin. Wochschr.* 17 943-946 (1965).
13. ESKLY A. M. und MÜLLER, H. E. Aggregation und Desaggregation von Erythrocyten. *Acta haemat.*, Basel 3/ 323-334 (1966)
14. GAGOS, R.; NIEHMEYER, G. und REUTER, H. Untersuchungen über die Aggregation menschlicher Blutplättchen. I. Standardisierte Methoden zur quantitativen Bestimmung der Aggregation. *Klin. Wochschr.* 45: 931-939 (1967)
15. HOAK, J. C., CORSON, W. E. and WARDER, E. D. Thrombogenic effects of albumin-bound fatty acids. *Arch. Path.* 8/ 136-139 (1966)
16. HOAK, J. C., WARDER, E. D. and CORSON, W. E. Platelets, fatty acids and thrombosis. *Circulat. Res.* 20- 11 17 (1967)
17. KERR, J. W.; FURIE, R.; MACAULEY, I. and BROOKE-STEWART, B. Platelet-aggregation by phospholipids and free fatty acids. *Lancet* 8/ 1296-1299 (1963).
18. MARADYAN, V.; SOVA, H. and LEONARD, W. O. Effects of saturated and unsaturated fatty acids on blood platelet aggregation *in vitro*. *Proc. Soc. exp. Biol., N.Y.* 12/ 82-85 (1966).
19. SCHLAGE, W.; BÖCKE, E.; BRÜCKE, R.; TIECKE, R. und ULLRICH, B. Gaschromatographische Untersuchungen der Serumfettstufen des Menschen. III Die Fettsäuren der Cholesterolester der Phospholipide und Triglyceride, sowie der unversättigten Fettsäuren bei Gesunden und Arteriosklerotikern. *Klin. Wochschr.* 43. 739-753 (1960).
20. ZACHAR, G. Transient thrombopenia after intravenous injection of certain fatty acids. *J. Epid. Res.* 5. 578-584 (1964).
21. ZWISLOCK, A. J. Impairment of platelet function and thrombus growth in reserpine-treated rabbits. *J. Lab. clin. Med.* 70- 16-22 (1967)

Second Medical Unit, Evangelismos Hospital, Athens

The Effect of Adrenergic Blockers on the Action of Adrenaline on the Factor VIII Activity in the Plasma

C. GARDIKAS, C. LYBERATOS, J. PYROVOLAKIS and A. PAPAYANNIS

The observation of INGRAM [4] that the intravenous infusion of adrenaline brings about a considerable elevation of the factor VIII activity in the plasma of normal subjects, was confirmed by other workers [3, 7]. According to INGRAM, isopropylnoradrenaline and noradrenaline have no similar effect. The mechanism of this action of adrenaline remains unexplained.

AHLQVIST [1] has first shown that the various actions of the sympathomimetic drugs are mediated through two special receptor groups, the α and β receptors. Adrenaline acts on both types of receptors, noradrenaline on the α , whilst isopropylnoradrenaline almost exclusively on the β receptors. Various agents block selectively the action on the α or the β receptors. Thus, tolazoline, phentolamine, benzodioxane, dibenamine and phenoxymetamine are α -adrenergic blocking agents, whilst dichloroisoprenaline, pronethalol and propranolol are β adrenergic blocking agents.

The present paper describes investigations on the effect of α - or β -adrenergic blocking agents on the action of the adrenaline on the factor VIII activity in the plasma.

Material and Methods

Experiment 1. Two normal adult males were used. (a) Adrenaline was administered i. v. (160 μ g in 10 ml of 5% glucose in 10 min). Before and 5 min after the end of the infusion venous blood was collected. (b) Two days later phentolamine (Regitine®), as a α -adrenergic blocker was given by i. v. infusion (10 mg in 200 ml of 5% glucose in 30 min). On the 20th minute of the phentolamine infusion adrenaline was administered as described above in

10 min through veins of the other arm. Five min after the end of the infusion venous blood was collected.

Experiment II. Ten normal adult males were used. (a) Adrenaline was administered as described in part (a) of experiment I. Before and 5 min after the end of the infusion venous blood was collected. (b) Two days later and for three consecutive days the subjects received orally propranolol (Inderal®) 60 mg daily divided into 4 six-hourly doses. On the fourth day immediately after the morning propranolol dose adrenaline was injected as described in part (a) of experiment I. Five min after the end of the adrenaline infusion venous blood was collected.

Assay of factor VIII. Samples of 9 ml of venous blood taken with siliconized needles and glass syringes were mixed with 1 ml of trisodium citrate ($\text{Na}_3\text{C}_6\text{H}_5 \cdot 2\text{H}_2\text{O}$ 3.8 g/100 ml) in siliconized glass test tube. After centrifugation for 15 min at 300 rpm the plasma factor VIII concentration was assayed immediately by the method described by BLOOM and MACFARLANE [2]. As reference standard mixed pool of plasma from 10 normal donors stored in 1 ml amounts at -30°C was used.

Results

As the tables I and II show neither Regitine® and α -adrenergic blocker nor propranolol, a β -adrenergic blocker inhibit the effect of adrenaline on the factor VIII activity of plasma.

The present experiments support the view that the action of adrenaline on the factor VIII activity of the plasma is not mediated through the special receptor groups, as special adrenergic blockers do not inhibit this action. Thus, the mechanism of the rise of factor VIII activity in the plasma produced by adrenaline remains obscure.

Table I. The effect of Regitine® on the action of adrenaline on the factor VIII activity

Experiment	Factor VIII activity in the plasma (% of normal)		
	before adrenaline	after administration of adrenaline	adrenaline + regitine
1	98	185	197
2	102	212	208
3	114	265	253
4	94	206	220
5	108	228	222
6	115	301	307
7	96	183	194
8	101	216	209
9	100	192	202
10	107	227	220

The figures represent the mean value of 3 determinations.

Table II. The effect of propranolol on the action of adrenaline on the factor VIII activity

Experiment	Factor VIII activity in the plasma (% of normal)		
	before adrenaline	after administration of adrenaline	adrenaline + propranolol
1	96	214	220
2	102	176	190
3	112	233	228
4	98	206	210
5	98	197	191
6	102	230	203
7	110	198	211
8	98	265	262
9	108	179	188
10	102	221	214

The figures represent the mean value of 3 determinations.

Discussion

The present experiments show that neither phentolamine, an α -adrenergic blocker nor propranolol a β -adrenergic blocker inhibit the effect of adrenaline on the factor VIII activity. These results are in agreement with the findings of McCLURE *et al.* [6] that α -adrenergic blockade with phentolamine did not prevent elevation of factor VIII after adrenaline infusion. On the other hand INGRAM [5] found that pronethalol a β -adrenergic blocker inhibits the elevation of factor VIII brought about by adrenaline infusion. No plausible explanation for the discrepancy of these findings can be given.

Acknowledgement

A grant from the Royal Hellenic Research Foundation is gratefully acknowledged.

Summary

Phentolamine an α -adrenergic blocker and propranolol, β -adrenergic blocker do not inhibit the effect of adrenaline on the factor VIII activity in the plasma.

References

1. AUGUSTY, R. E. A study of adrenotropic receptors. *Amer. J. Physiol.* **153**: 586 (1948).
2. BOOS, R. and MACFARLANE, R. G. *Human blood coagulation and its disorders* 3rd ed., p. 404 (Blackwell, Oxford 1962).
3. EKENHED, O. Changes in the activity of antihæmophilic A factor and in the bleeding time associated with muscular exercise and adrenaline infusion. *Scand. J. clin. Lab. Invest.* **15**: 539 (1963).
4. IVORAM, G. I. C. Increase in antihæmophilic globulin activity following infusion of adrenaline. *J. Physiol.* **156**: 217 (1961).
5. IVORAM, G. I. C. *Dissertation in Bævnæts Hemophilias*, p. 243. University of North Carolina (Chapel Hill 1964).
6. McCLELLAN, P. D., IVORAM, G. I. C. and JONES, R. V. Platelet changes after adrenaline infusions with and without adrenaline blockers. *Thromb. Diath. hæmorrh.* **13**: 196 (1965).
7. SOLOS, A. Observations on the effect of adrenaline and related substances on blood coagulation phenomena. Thesis, Athens (1962).



Fig. 2. Agar gel electrophoresis in citrate buffer pH 6.0. At the top and the bottom: haemoglobin of the parents of the propositus. In the center: haemoglobin of the propositus and of the other two children, homozygous carriers of $\beta\delta$ -thalassaemia. Total absence in these three subjects of haemoglobin A_2 and presence of haemoglobin F only.

S. Conetto (II-1, table I, fig. 1) the father of the propositus was healthy subject which showed haematologic picture typical of microcythaemia and a haemoglobin pattern with an elevated level of haemoglobin F (10%) and normal level of haemoglobin A_2 (2.02%). Acid elution test showed quite an heterogeneous intracellular distribution of haemoglobin F.

A. Domenica (II-2, table I, fig. 1) the mother of the propositus and first cousin of the father was a healthy woman with haematologic microcythaemic picture and haemoglobin pattern with elevated haemoglobin F (7.50%), normal haemoglobin A_2 (2.30%), and heterogeneous intracellular distribution of haemoglobin F.

A. Gregorio (I-1, table I, fig. 1) paternal grandfather of the propositus, was healthy microcythaemic subject with the same haemoglobin characters of the son (haemoglobin F 9.55%, haemoglobin A_2 1.87%) and the same heterogeneous aspect of its intracellular distribution of haemoglobin F.

Discussion

Both the parents and the paternal grandfather of the patient observed presented the haematologic abnormalities typical of microcythaemia (or thalassaemia) with high level of haemoglobin F and heterogeneous erythrocytic distribution of haemoglobin F. These data



Fig. 3. Cellulose acetate electrophoresis, glycine buffer pH 8.8. From the top to the bottom the father of the propositus Cooley disease patient the three sisters, homozygous carriers of $\beta\delta$ -thalassaemia. Total absence of haemoglobin A_2 and haemoglobin A_1 in the three homozygous subjects.

are typical of F microcythaemia. The three children show a microcythaemic haematologic picture and their haemoglobin is only haemoglobin F. These data suggest that the children are homozygous for F microcythaemia. From the clinical point of view the propositus was the only one to present a slight anaemia with moderate hepatosplenomegaly the other two sisters are in good health, and have no history of illness.

This is the third family reported in the literature in which cases of homozygosity for F microcythaemia have been found. In the first family [20] the propositus was a 31 year-old woman with slight pallor and marked hepatosplenomegaly in the second case [22] the condition was discovered accidentally in a 9-year-old boy. Thus, all these observations agree in showing that the homozygous condition for F microcythaemia causes the subjects to be far less severely affected than the homozygous carriers of A_2 -microcythaemia.

The same tendency towards a milder clinical picture is also found in the patients with double heterozygosity for A_2 - and F microcythaemia.

The cases so far observed include 8 patients with severe Cooley's disease [1 8 16 17] and at least 7 other patients with a much less serious disease (microcytic constitutional anaemia or thalassaemia intermedia) [5 17-19]. In another series [12 22] most of the 21 patients were moderately affected.

These data show that the F microcythaemia is a microcythaemia variant which interacts with classical A_2 microcythaemia and besides this, they offer the documentation of new variants of genetic basis of the thalassaemia intermedia: that is the homozygosity for $\beta\delta$ -microcythaemia with high F and the double heterozygosity for this microcythaemia variant and classical A_2 microcythaemia.

The present patients and the two of the literature had haemoglobin F only. Homozygosity for F microcythaemia is thus the third homozygous condition so far described, in which there is a complete absence of haemoglobin A_1 and haemoglobin A_2 , the other two being homozygous condition for haemoglobin Lepore and homozygous condition for hereditary persistence of foetal haemoglobin and the second condition in which haemoglobin F only is found (the other being homozygosity for high F gene). This proves that in the three families so far described the $\beta\delta$ -microcythaemia genes completely suppress β - and δ -chain synthesis.

There are, till now only few cases which can supply informative data on the activity of the structural genes β and δ in this variant of microcythaemia. The three present and the two preceding homozygotes [10 21 22] and the double heterozygote for B_s haemoglobin and $\beta\delta$ -microcythaemia [14] show a complete inactivity of locus δ . As for locus β in the 5 homozygotes for F microcythaemia and in the 2 double heterozygotes for haemoglobin S and F microcythaemia [4 6] such locus has proved to be completely inactive in 6 cases and partially functioning in 1 case [4]. It would appear that in F microcythaemia, likewise in A_2 microcythaemia, locus β is in most instances suppressed and rarely partially functioning: as for locus δ on the contrary the observations are not sufficient to prove a constant and complete inactivity. A larger number of cases is necessary for the final interpretation of the genic effects of this microcythaemic mutation.

In $\beta\delta$ -microcythaemia with high F locus γ appears affected in a characteristic way: there is, in the heterozygote state, an evident hyperactivity which has such a constant uniformity as to appear genetically determined. On the contrary the resulting haemoglobin F is irregularly distributed in the erythrocytes - like in the other forms of

microcythaemia – a fact that would suggest a compensatory mechanism. Therefore the compensatory hyperactivity of locus γ is typically evident in the F microcythaemia heterozygote, but not in the A_2 -microcythaemia heterozygote. Moreover in the $\beta\delta$ -microcythaemia homozygote the hyperactivity of locus γ often reaches a much higher functional level than in the classical β -microcythaemia with high A_2 homozygote thus considerably reducing the severity of clinical manifestations.

This consideration and the equality of the haemoglobin picture of homozygous carriers of F microcythaemia and of hereditary persistence of haemoglobin F brings to the fore the problem of relationships between microcythaemia and hereditary persistence of haemoglobin F. The similarity between the two conditions is highly suggestive. It is however clear that the two conditions cannot be based on the same genetic alteration. While in homozygous F microcythaemia state the degree of haemoglobinization is always below the normal range (so that the haematological picture of microcythaemia is always present) in homozygous state for high haemoglobin F gene the normal haemoglobin level reveals that loci γ are both fully functioning.

Therefore in F-microcythaemia any future hypothesis on the basic genetic mechanism shall have to take into account not only the total or partial suppression of the products of the two adjacent structural genes β and δ but also the partial and characteristic persistence of activity of structural gene γ which is constant and typical in this microcythaemia variant.

Summary

In family of Sicilian origin the parents, who are first cousins to each other are both carriers of $\beta\delta$ -thalassaemia (or microcythaemia) with high haemoglobin F (F-thalassaemia) and their three children are homozygous carriers of F-thalassaemia. Clinically only the proband shows slight anaemia and moderate hepato-splenomegaly. His two sisters are apparently healthy. As the two preceding observations of literature, this family proves that the activity of normal β and δ genes is completely suppressed in F-thalassaemia, and that the homozygous condition produces much less severe disease than the homozygosity for β -thalassaemia with high haemoglobin A_2 genes.

References

1. ZIEGLER, W. W., ROSSIGNOL, A. R. and BOOKER, C. R. Reciprocal relationship of hemoglobins A_2 and F in beta chain thalassaemias, key to the genetic control of hemoglobin F. *Blood* 17: 393 (1961).

2. FERRELL, PH., STAMATOYANNIDIS, G. and KARAKIS, A. Hereditary persistence of fetal haemoglobin and its combination with alpha- and beta-thalassemia. Proc. 8th Congr. europ. Soc. Haemat., Wien 1961 (Karger Basel/New York 1962)
3. SILVESTROTTI, E.; BIANCO, I. BRANCATI, C. Presenza di microcitemia con quota normale di emoglobina A₂ quota elevata di emoglobina F in una famiglia calabrese (Terza varietà di microcitemia) Policlinico, Sez. ped. 71 1343 (1964).
4. RUSSO, G. and MIOLELLA, P.; Sickle cell haemoglobin and two types of thalassemia in the same family Acta haemat., Basel 28 329 (1962)
5. POLONA, P. and MOTTA, L. On incidence of thalassemia and abnormal hemoglobins in the eastern part of Sicily First results. Proc. 9th Congr. europ. Soc. Haemat. Lido on 1963 p. 530 (Karger Basel/New York 1963).
6. SILVESTROTTI, E. BIANCO, I. Un caso di malattia microdepreanocitica e Hb S varietà di microcitemia con quota normale di Hb A₂ quota elevata di Hb F (Terza varietà di malattia microdepreanocitica) Progr. med., Napoli 20 1 (1964)
7. BERTETTI, A. ROMA, U. BERGONZI, AL. T. thalassemia eterozigot con Hb F elevata ed Hb A₂ normale. Haemat. ital. 9 99 (1966)
8. SILVESTROTTI, E. BIANCO, I. Microcitemia con abbondant Hb F ed Hb A₂ normale in tre famiglie pugliesi. Policlinico, Sez. ped. 41 1381 (1965)
9. SILVESTROTTI, E. BIANCO, I. e MURATORE, F. Frequenza dei vari tipi di microcitemia di emoglobine normali nella provincia di Lecce Progr. med., Napoli 21 211 (1965)
10. QUATTRO, N. BRANCATI, P. COENZO, R. DE ROSA, L.; DIAS, E.; SILVESTROTTI, E. VENTRUTO, V. Il problema sociale medico della microcitemia e delle altre emoglobinopatie in Campania. Atti Giornat. di Studio della microcitemia Ferrara 23-24 ottobre 1963. Ist. Ital. Med. Soc. Roma, p. 5.
11. KALAMON, E. FERRELL, PH. and STAMATOYANNIDIS, G. Types of thalassemia-trait carriers as revealed by a study of their incidence in Greece. Brit. J. Haemat. 8 5 (1962).
12. STAMATOYANNIDIS, G. FERRELL, PH. and PAPAYANNIDIS, T. G. Genetic and hematologic study of F-thalassemia. 3rd Int. Congr. hum. Genet. Chicago 1966. Abstracts, pp. 95-96.
13. WRIGHT, D. J. Biochemical phenotypes of thalassemia in the American Negro populations. Ann. N. Y. Acad. Sci. 129 450 (1964)
14. COENZO, R. E. and MOTULSKY, A. G. Absence of the delta chain synthesis in ($\delta\delta$) thalassemia (F-thalassemia) Blood 26 54 (1966)
15. FLATZ, G.; FOX, C. and SENGDAH, S. Haemoglobinopathies in Thailand. I. A study of patients with the thalassemic syndrome and their families. Brit. J. Haemat. 11 16 (1965)
16. WOLFF, J. A. Interacting thalassemia with normal A hemoglobin and elevated or normal fetal hemoglobin levels. 4 Ann. Intern. Med. Soc. Haemat. Blood 18 807 (1961)
17. WOLFF, J. A. and LOCANTO, V. G. Heterogeneity of thalassemia major. Amer. J. Dis. Child 105 254 (1963)
18. GARNICA, T. G. NATHAN, D. G. and GARDNER, F. H. Thalassemia trait, genetic combinations of increased fetal and A₂ hemoglobins. New Engl. J. Med. 270 1212 (1964)
19. FERRELL, PH. Forms of thalassemia, in CLOMIS Symposium on Abnormal Hemoglobins in Africa, p. 71 (Blackwell, Oxford 1964).
20. BRANCATI, C. Primo caso di omozigote per la varietà di microcitemia con quota normale di emoglobina A₂ quota elevata di emoglobina F Progr. med., Napoli 1 223 (1965)
21. BRANCATI, C. and BIANCHI, C. Homozygous $\beta\delta$ -thalassemia ($\beta\delta$ -microcytharæmia) Nature Lond. 212 262 (1966)
22. FERRELL, PH. Thalassemia: Clinical and patho-physiological considerations. Trans. roy. Soc. trop. Med. Hyg. 61 164 (1967)
23. FRASER, G. R. and STAMATOYANNIDIS, G. KATTAKIS, C. LOCKWOOD, D. In A-

- BRAND, B.; MITCHELL, C.; ZANNO-MARCOLLA, L.; CHIORELLI, G.; FERRAR, P. and MONTUORI, A. F. Thalassemias, abnormal hemoglobins and glucose-6-phosphate dehydrogenase deficiency in the Arta area of Greece. Diagnostic and genetic aspects of complete village studies. *Ann. N.Y. Acad. Sci.* 119: 415 (1964).
24. BRANCO, I.; SCHILLERO, G.; GRAZIANTI, B.; DE FEO, G.; SAVORITO, N. Ricerca sulla frequenza di beta-microcitemia di emoglobine abnormali nella popolazione della Sicilia sud-orientale. *Progr. med., Napoli* 22: 827 (1967).
25. SILVERSTEIN, E.; BRANCO, I.; MICCIZOLINI, M.; MODIANO, G.; VALLINOTTI, E. Studio biochimico, elettroforetico e spettrofotometrico dell'emoglobina di malati di anemia microcitetica costituzionale di morbo di Cooley. *Progr. med., Napoli* 13: 705 (1957).
26. ROSSIGNOL, A. R.; ROSSIGNOL, M.; HARRISON, A. P. and ZIEGLER, A. W. A new technique for differentiation of hemoglobins. *J. Lab. clin. Med.* 30: 745 (1957).
27. GRAZIANTI, B.; DE FEO, G. La determinazione quantitativa delle emoglobine normali ed abnormali mediante elettroforesi su acetato di cellulosa. *Progr. med., Napoli* 22: 643 (1967).
28. SVETKEY, K.; COHENOFF, A. L. and SVETKEY, L. Studies on abnormal hemoglobins. I. Their demonstration in sickle-cell anemia and other hemologic disorders by means of alkali-denaturation. *Blood* 6: 413 (1951).
29. KLEINHAUER, E.; BRÄUN, H. and BEYER, K. Demonstration of fetal hemoglobin in dem Erythrocyten eines Blausüchtigen. *Nach. Wehr* 35: 637 (1957).
30. SILVERSTEIN, E.; BRANCO, I. and GRAZIANTI, B. The hemoglobin picture in Cooley disease. *Brit. J. Haemat.* 14: 301 (1968).
31. COHENOFF, A. L. Some important considerations in the quantitative determination of Hb F. *Int. Symp. comp. Hemogl. Structure* Tokyo, 11-13 April, 1966, p. 45.

Department of Hematology (Dir: Prof. P. FARRERAS) Internal Medicine Clinic (Dir: Prof. A. PEDRO-PONS) Faculty of Medicine, University of Barcelona, Barcelona

Complete Remission in Chronic Lymphocytic Leukemia

Report of Case

P. PARDO E. SIMÓ M. RIBAS-MUYDÓ and P. FARRERAS

Patients with chronic lymphocytic leukemia have usually a long survival either spontaneously or with treatment, but lymphocytic infiltration of the bone marrow and blood lymphocytes persist in the majority of cases throughout the course of the disease.

We report a patient with chronic lymphocytic leukemia in whom complete clinical and hematological remission, proven by even cytochemical and lymphographic techniques, developed after therapy with cyclophosphamide and prednisone. After the complete remission it was impossible to find any feature which let us suspect the persistence of chronic lymphocytic leukemia. As this is an unusual case not often reported in the literature we think it might be worth to report it.

Case Report

A 53 years old, married, railroad employé, born in Pedalbes (Huesca), Spain. Family history was not significant. At the age of 24 he suffered pleuritis of unknown etiology. At the age of 35 ocular surgery for strabismus. Since then he has complaint of frequent upper respiratory infections.

His present illness began at the age of 53 (February 1961) with bronchitis, progressive blindness and taste and severe pain of the left eye followed by amaurosis. A diagnosis of glaucoma was made. At this time an hemogram revealed no anemia, 15,770 leukocytes with 96% lymphocytes and numerous Gumprecht cells.

Physical examination revealed an apparently healthy man with amaurosis of the left eye and generalized lymphadenopathy of medium size in cervical, axillary and inguinal regions.

Laboratory analyses (24 II 61): E.S.R. 11 mm at the first hour; red blood cell count 4,565,000; hemoglobin 13.6 g%; total leukocyte count 15,770 with juvenile forms 1 %.

segmented neutrophils 3%, lymphocytes 96% and many Gumprecht cells. Myelogram hypoplastic erythropoiesis of about 8% of the total cellularity 80% of infiltrating mature lymphocytes and some lymphoblasts, scattered myelocytes and metamyelocytes. No megakaryocytes. Total proteins 5.6 g%, albumin 3.08 g%, globulin 1.24 g%. Uric acid 0.55 mg%. Platelet count 230,000. Due to the good general condition of the patient no specific treatment was given.

Three months later (3 VI.61) the leukocyte count rose to 147,070 and an enlarged spleen was detected 4 cm under the left costal margin. Treatment was started with 150 mg cyclophosphamide and 10 mg prednisone per os daily and was given for 3 months. 1 September 1961 the spleen was not palpable and the leukocyte count had dropped to 14,080. Treatment was reduced to 200 mg cyclophosphamide i.m. weekly and 5 mg prednisone per os daily.

During this time he suffered from frequent upper respiratory infections. A basocellular epithelioma infiltrating the left preauricular region and spinocellular epithelioma on the right temporal region also developed.

After year of treatment (8.VI.62) with cyclophosphamide and prednisone the peripheral leukocyte count was 11,900 with 57% lymphocytes. The bone marrow aspirate revealed 20% lymphocytes. On physical examination the liver was still palpable 3 cm below the right costal margin and axillary lymph nodes were still felt. The same treatment was prescribed.

1 May 1964, three years after beginning of treatment, the patient was in good condition. On physical examination only the liver was palpable 2 cm below the costal margin neither splenomegaly nor lymphadenopathies were detected. Red blood cell count was 5,200,000, Hb 14.7 g% and the leukocyte count was 8,250 with 22% lymphocytes. Treatment with cyclophosphamide 50 mg and prednisone 5 mg per os every other day was continued. 1 December 1964 the liver was no longer palpable. Analysis of peripheral blood was normal and treatment was stopped.

1 July 1966 physical examination was normal. The erythrocyte count was 5,300,000 with 16.1 g% Hb, the leukocyte count was 7,370 with 36% lymphocytes; only 15% of these lymphocytes presented PAS reaction. The bone marrow aspiration was normal with 5% lymphocytes.

1 July 1967 the patient was asymptomatic and physical examination was entirely normal. The hematological data remained within the normal limits. Less than 10% of the peripheral lymphocytes presented PAS reaction. The bone marrow aspiration revealed normal erythro- and leukopoiesis, presence of megakaryocytes and 12% of lymphocytes. The lymphography in July 1967 failed to reveal enlarged retroperitoneal lymph nodes.

1 March 1968 the patient is still in good clinical condition. Neither hepato-splenomegaly nor lymphadenopathies are palpable. Nevertheless, peripheral blood leukocyte count has risen to 13,500 with 32% lymphocytes. Bone marrow aspiration reveals 30% lymphocytic infiltration. Treatment with cyclophosphamide 50 mg and prednisone 5 mg every other day is recommenced.

DISCUSSION

Chronic lymphocytic leukemia has always been considered the less malignant of all types of leukemia. Patients with long survival are common. Our case, however has remained in complete remission for at least 3 years with no clinical or laboratory features of chronic lymphocytic leukemia.

In the available literature we have found very few cases where the complete remission of chronic lymphocytic leukemia had been satis-

factorily proven. REICH [1] published in 1959 a case of complete remission after radiotherapy of the spleen (1 700 r) and blood transfusions. The patient persisted on complete remission for 5 years. DURANT and FINKBEINER [2] published in 1964 a revision of 250 cases of chronic lymphocytic leukemia, lymphosarcoma and leuko-lymphosarcoma. These authors comment the difficulties encountered in some cases to differentiate chronic lymphocytic leukemia and lymphosarcoma. From the 250 cases only one achieved complete remission during 3 years after treatment with prednisone and TEM. In 1955 a case of remission in a female treated with radiotherapy was published by SCHOTT [3]. However there is no mention of the myelogram during the remission phase. Recently, TEN HAN *et al* [4] have described 6 cases of complete remission among 202 patients with chronic lymphocytic leukemia and leukolymphosarcoma. The lymphocytic infiltration in bone marrow of these cases during remission ranged however between 15 and 20 % which is over the upper limit for normal adults.

In our case the diagnosis of chronic lymphocytic leukemia seems unequivocal for he had generalized adenopathy liver and spleen enlargement, white cell count of 147 000 with 96 % lymphocytes and many Gumprecht cells, bone marrow infiltration with mature lymphocytes and some lymphoblasts. The leukocytosis of 13 560 with 52 lymphocytes and the 30 % lymphocytic bone marrow infiltration after 3 years of clinical and hematological remission confirms the diagnosis of chronic lymphocytic leukemia.

We consider a complete remission to be present when there are no clinical or laboratory signs which could detect the disease. These criteria are consistent with the published criteria of BISEL [5] for complete remission of acute leukemia. We suggest two further criteria to accept the complete remission of chronic lymphocytic leukemia (1) The PAS reaction of the peripheral lymphocytes should be positive in less than 20 % as is in normal subjects (2) the lymphography should be normal.

In our patient complete remission during 3 years can be proved by the following data (1) No clinical symptoms of disease (2) no palpable adenomegaly, no hepatosplenomegaly (3) red blood cell count 5 300 000 Hb 102 white blood cell count 7 370 with 36 % lymphocytes (4) the lymphocyte content of the bone marrow is less than 15 (5) less than 20 % of the peripheral lymphocytes show a PAS reaction (6) the lymphography is normal.

The maintenance dose of cyclophosphamide and prednisone even when the patient was in good condition has probably played a role in the evolution of this patient, but as TIN HAN *et al* [4] comment, factors other than treatment might mediate in such cases. In accordance with these authors it is also possible that the frequency of complete remission in chronic lymphocytic leukemia might be increased significantly if patients were treated earlier and with a maintenance dosage of proven effective drugs in a long term therapy.

At the Department of Hematology of the University of Barcelona we have only seen this single case of complete remission among 68 cases of chronic lymphocytic leukemia in a period of 10 years.

Summary

The authors report a case of chronic lymphocytic leukemia which attained clinical and hematological remission during 3 years after treatment for 3 years with cyclophosphamide and prednisone. A review of the literature has revealed very few cases of complete remission in chronic lymphocytic leukemia. The authors suggest two further criteria of complete remission in chronic lymphocytic leukemia: the PAS peripheral lymphocytes should not exceed 20% and the lymphography should be normal.

References

1. REXES, G. Apparent recovery in chronic lymphocytic leukemia. *J. Amer. med. Ass.* **176** 169 (1959).
2. DOLANT, J. R. and FENIMORE, J. A. "Spontaneous" remission in chronic lymphatic leukemia? *Cancer* **17** 105 (1964).
3. SCHOTT, M. Ten-year recovery from chronic lymphocytic leukemia. *Brit. med. J.* **ii** 877 (1955).
4. TIN HAN, ESTRELL, E. Z. and SORAL, J. F. Complete remission in chronic lymphocytic leukemia and leukolymphosarcoma. *Cancer* **20** 243 (1967).
5. BASK, H. F. Criteria for the evaluation of response to treatment in acute leukemia. *Blood* **11** 676 (1956).

Authors addresses: DR. F. Pardo, E. Somo and P. Farreras, Department of Haematology Internal Medicine Clinic, University of Barcelona, Barcelona (Spain). Dr. MANUEL RILAS-Mitoco, Blood Research Laboratory Massachusetts General Hospital, Boston, Mass. 02114 (USA).

Second Chair of Medicine University of Salamanca (Prof. G. ROZMAN) School of Hematology University of Barcelona (Prof. P. FARRERAS)

Acute Erythromyelosis after Benzene Poisoning

C. ROZMAN, S. WOESNER and J. SAEZ-SERRASIA

In 1965 we published 20 cases of aplastic anemia induced by chronic benzene poisoning [1]. Malignant neoplastic disorders of the bone marrow: acute leukemia or less often chronic leukemia have been found in patients with prolonged exposure to benzene containing environments [2, 3]. There are more than 100 of such cases referred to in the literature [3]. Rare cases of erythromyelosis (erythremia in its pure form or as erythroleukemia) have been found associated with long contacts with benzene: the latter form being more common than the former [3-13]. The rarity of this cases has prompted us to report a patient with acute erythromyelosis after chronic benzene poisoning.

Case Report

A 58-year-old varnisher was seen in January 1968, with a previous history of workase during 30 years in a closed environment rich in benzene.

In November 1967 after a short flu with low fever the patient noticed onset of dyspnea after effort, lassitude and paresthesia. A blood count performed in early January showed normochromic anemia with 2,500,000 RBC/mm³. On examination hepatosplenomegaly was found. Chest roentgenogram was normal. In two separated occasions 500 ml of whole blood were given, without improvement in the patient's condition.

A hematological study performed on the 15th of February showed the following data: RBC 1,480,000/mm³; hemoglobin 25; Hbg 27 µg; Reticulocytes 1,500/mm³; Platelets 11,000/mm³; Leukocytes 11,000/mm³: myeloblasts 1%, promyelocytes 3%, neutrophilic myelocytes 2%, metamyelocytes 7%, young neutrophils 4%, segmented neutrophils 41%, lymphocytes 21%, monocytes 1%, 3 erythroblasts per 100. Very marked anisopoikilocytosis: some erythrocytes with crenated edges.

Bone marrow: Proerythroblasts 14%, basophil erythroblasts 40.0%, polychromatophil erythroblasts 19.0%, orthochromatic erythroblasts 17.2%, myeloblasts 0.8%, promyelocytes 5.8%, metamyelocytes 1.2%, reticulum cells 4.6%. Marked morphological changes of the erythroblasts were found mainly in the nuclei. Giant polyploid forms, diploerythroblasts, atypical mitoses and in some cells cytoplasmatic vacuoles were seen (fig. 1-3). There were



Fig 1 Giant and small polyploid erythroblasts with 4 and 5 nuclei.

no atypia in the white cell series. The number of megakaryocytes was scarce. Most erythroblasts showed an intense diffuse PAS-positivity of the cytoplasm. Some erythroblasts had PAS-positive granules. Perl's stain showed 70% sideroblasts without ring forms.

The course of the illness was growing worse, without response to the therapy. The patient died on the 24 of February of massive intestinal hemorrhage.

Comment

Clinically and experimentally it has been shown that benzene exerts its toxicity upon the erythroblastic mitoses resulting in giant erythroblasts, polyploid mitoses and arrested mitoses in metaphase [11-12, 14]. The finding of diploerythroblasts in marrow medular aplasia identifies benzene as the most probable causal agent [15].



Fig 2. Group of young erythroblasts with vacuoles in the cytoplasm.

Fig 3. Three 'diploerythroblasts' with nuclei arranged like coffee beans.

The above named anomalies and the history of prolonged exposure to benzene have lead us to consider this substance as the causative agent. On the other hand the other clinical and hematological findings are similar to the non benzene produced erythremias. The ferrokinetic and erythrokinetic findings [1] and the PAS-positivity of the erythroblasts, as shown in our case are similar in both types of erythremia. There are a number of blood diseases, like thalassemia, iron-deficiency anemia and hemolytic disease of the newborn which show some PAS-positivity in the erythroblasts, but this is more intense in the

acute erythremia (DI GUIGLIEMO'S disease) and offers an important clue to its diagnosis [16]

Summary

A case of acute erythromyelosis is reported after 30 years exposure to benzene. Nuclear abnormalities were found in the erythroblasts, which showed marked PAS-positivity in their cytoplasm, like in other types of erythremia.

References

1. ROZMAN, C.; RUBIA-MENDO, M.; WOLFFER, S. y CORDERO-LATORRE, F. Estudio clínico hematológico de 43 casos de anemias aplásicas, con particular atención a las de origen benzénico (20 casos). *Med. Cha.* 41: 10-22 (1965).
2. VILLANI, E. C. and SARTI, G. Benzene and leukemia. *New Engl. J. Med.* 271: 872 (1964).
3. GODELL, A.; CAYROL-CLAU, A. et BELLARD J. Les leucémies benzéniques de la région parisiennne entre 1950 et 1963 (Etude de 50 observations). *Nouv. Rev. franç. Hémat.* 7: 465-480 (1967).
4. DEMOLE-REICHEN, R. et DELCROIX R. Un nouveau cas d'érythro-leucémie. Etude anatomoclinique. *Acta haemat.* 2: 350 (1949).
5. GALAVOTTI, B. and THORP, F. M. Erythroleukemic myelosis in benzene poisoning. *Brit. J. Indust. Med.* 7: 79 (1950).
6. PALLARD, F.; GEORGE, P.; PLATONIC, J. L. et F. VIE-GELLY J. Un cas d'anémie érythroblastique mortelle chez un ouvrier exposé au benzol. *Arch. mal. prof.* 11: 264 (1950).
7. AUCANT, R. et DUBUTTE, B. Sur une observation de maladie de Di Guglielmo. *Sang.* 21: 676 (1952).
8. MARCIAL, G. A propos de la communication de R. AUCANT et B. DUBUTTE. *Sang.* 21: 682 (1952).
9. NISSEN, N. I. and OWSEN, A. B. Erythromyelosis. Review and report of a case in benzene (benzol) worker. *Acta med. scand.* 143: 56-71 (1953).
10. MARTI, H. R. und FETTER, H. Akute Erythraemie; Diagnose und Differentialdiagnose eines klinisch und autopsisch beobachteten Falles. *Schweiz. med. Woch.* 47: 1231 (1957).
11. DI GUIGLIEMO, D. and LASAGNOLI, A. Inhibition of mitosis and regressive changes of erythroblasts in acute erythropathy caused by occupational benzene poisoning. *Acta haemat.* 19: 144-147 (1958).
12. MÜSCHER, P., WERTHEIMANN, A. und LÖNN, H. Erythromyelose-ähnliche Hämopathie als Folge einer Benzolintoxikation. *Acta haemat.* 25: 308 (1961).
13. KUBIL, P., BEUTNER, H. E. und SCHWENTHALER, W. Erythroleukämie nach chronischer Benzolintoxikation. Untersuchung der Ferro- und Erythrocytenkernmetik mit radioaktivem Eisen und Chinon. *Schweiz. med. Woch.* 97: 368-373 (1967).
14. ROMANELLI, E. G., GORDI, F., FICORANI, D., TROTTAT, N. et COLONCHI, R. Effets du benzène sur la mitose érythroblastique. Investigations à la microcinématographie en continu de phase. *Acta haemat.* 26: 281-302 (1961).
15. ROZMAN, C., WOLFFER, S. y DE DIEGO-SALDANO, T. Valor de los llamados diplocitoblastos en el diagnóstico de la paroxismitis benzénica. *Sangre* 11: 205-206 (1966).
16. QUARLES, D. and HAYMON, F. H. J. Periodic-acid-Schiff positivity in erythroblasts with special reference to Di Guglielmo disease. *Brit. J. Haemat.* 6: 26 (1960).

Authors' address: Drs. C. ROZMAN, S. WOLFFER and J. SATE-SERRANA, Escuela de Hematología, Clínica Médica Universitaria, Facultad de Medicina, Casanova 143, Barcelona 11 (Spain).

Erratum

In der Arbeit SCHENKOWSKY SCHWARTZ: Zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymph (Vol. 39 Nr. 5, 1968) wurden leider die beiden Abbildungen vertauscht.

Therapie der Leukosen und malignen Lymphome

In Wien findet vom 24. - 26. März 1969 eine internationale Arbeitstagung über Chemotherapie und Immuntherapie der Leukosen und malignen Lymphome statt. Leitung: Prof. Dr. H. FLEISCHMANN. Ankünfte: Doz. Dr. A. STACHA, Ludwig Boltzmann-Institut für Leukämieforschung und Hämatologie, A-1140 Wien, Heinrich Collin-Strasse 30.

International Society of Blood Transfusion

At the meeting of the ISBT Executive Committee which took place in Moscow from the 25th February to the 1st March, 1968 it was decided that the Society could offer a few travel grants to help some young scientists to go to the VIIth International Congress of Blood Transfusion, Moscow August 1-23, 1969. The total amount of money available for travel grants is \$ 4000 which will be divided among a few candidates up to the age of 35 years, actively engaged in research, to assist them in paying for their travel expenses.

Applicants shall apply to Dr E. FREESTRUP, Blood Bank, Ryghospitalet, 9 Blegdamsvej, 2100 Copenhagen (Denmark) furnishing the Committee with 4 copies, abstracts or reprints of the paper to be submitted, a complete curriculum vitae (including the age of the applicant) and a letter of recommendation from the applicant's chief or head of the research programme, as well as some information about the applicant's possibility of obtaining financial support from other sources. The applications should be sent before the 1st of February 1969.

Department of Medicine, The University of Adelaide,
The Queen Elizabeth Hospital, Woodville, South Australia

Measurements of Protein Synthesis by Lymphocytes *in vitro* in Diseases of the Lymphoid Tissues

J. W. M. LAWTON and I. J. FORBES

In earlier studies [8, 9] measurements showed reduced globulin synthesis by lymphocytes from peripheral blood in a variety of disease states. Of particular interest were low values in a few cases of chronic lymphatic leukaemia and macroglobulinaemia, suggesting that the reduced rate of immunoglobulin synthesis commonly found in these conditions [17] may be associated with measurable metabolic deficiency in the circulating lymphocytes.

Studies were therefore undertaken to extend these preliminary observations. The activity of lymphocytes was measured in medium containing autologous plasma and in plasma-free medium, to investigate the possibility that circulating substances may inhibit protein synthesis by lymphocytes in disease states. Parallel measurements were made of the effect of phytohaemagglutinin on protein synthesis. Lymphocytes were studied from normal subjects, and from patients with chronic lymphatic leukaemia, lymphoma (unclassified) and lymphosarcoma, macroglobulinaemia, multiple myeloma and infectious mononucleosis.

Materials and Methods

Normal subjects were healthy laboratory workers, medical practitioners, students, and blood donors. Diagnosis of chronic lymphatic leukaemia (CLL) was made on blood count of more than 9,000 lymphocytes/mm³ and the finding of non-follicular lymphocytic infiltration of the bone marrow [5]. Multiple myeloma was diagnosed by γ - or β -2S band of paraprotein on serum electrophoresis which was not precipitated from the serum by ethanol [15] associated with an infiltration of the bone marrow by plasma cells. In macroglobulinaemia the paraprotein was precipitated from the serum by ethanol, and was associated with

infiltration of the bone-marrow by abnormal cells of the lymphocyte series. The category *Tymphoma* (unclassified) was made up of a small group of patients with lymphocytic infiltration of the bone marrow but without diagnostic changes in the lymph node blood or bone marrow. Diagnosis of lymphosarcoma was made from histological sections. Diagnosis of infectious mononucleosis was made in the presence of characteristic symptoms and signs, and the presence of atypical lymphocytes in the blood [6]. Heterophile agglutinins [12] were present in 6 cases, absent in 3 and not tested for in one case. The heterophile antibodies were not absorbed by guinea-pig kidney suspension [5] in 3 cases and were absorbed in one case.

Culture of lymphocytes. Venous blood, 40–50 ml where possible was collected into heparin (25 IU/ml) and dextran 0.5%. After the erythrocytes had sedimented for 1 h at 37°C, the supernatant plasma was taken and centrifuged at 800 g for 15 min. The sedimented leucocytes were resuspended in half the volume of plasma and incubated at 37°C for 1 h in a glass column packed with cotton wool. The lymphocytes were eluted from the column with the other half of autologous plasma, washed twice with BSS and suspended in Eagle's medium supplemented with non-essential amino acids [1]. From each blood sample 12 × 1.0 ml cultures were prepared in 4 groups, so that each determination was made in triplicate. The composition of the cultures is shown in table I. A small volume of the lymphocyte suspension was dispensed separately for the determination of the lymphocyte count (Coulter Counter Model D) and for making a smear for a differential leucocyte count. Cultures were incubated at 37°C for 24 h then frozen.

Measurement of protein synthesis. Cultures were frozen and thawed three times and centrifuged at 10 000 g for 15 min to remove cell debris. To each plasma-free supernatant was added 0.25 ml of standard human pooled serum. The protein was precipitated in 5% trichloroacetic acid, washed three times, dissolved in NH_4OH and plated at infinite thickness on 2 cm planchets for counting in an end-window gas-flow Geiger-Müller counter.

Total protein concentration of plasma was estimated by the method of Wolfrom *et al.* [20].

Calculation of results. Net counts per minute (CPM) were obtained by subtracting the CPM of protein in cultures containing puromycin, 60 µg/ml. These samples gave counts very little above background for the counter (15–20 CPM). Mean net CPM of triplicates was converted to mean net CPM/10⁶ cells.

The following 4 correction factors were applied

1. Correction for the efficiency of the counter

Table I Composition of standard cultures

Group	Cell suspension ml	Autologous plasma ml	PHA ml	¹⁴ C-leucine solution ml	Final ¹⁴ C-leucine concentration µCi/ml
Plasma free	0.5	0	0	0.5	0.5
Plasma free + PHA	0.5	0	0.06	0.5	0.5
25% plasma	0.5	0.25	0	0.25	0.25
25% plasma + PHA	0.5	0.25	0.06	0.25	0.25

L-Leucine ¹⁴C(U) specific activity 150 mCi/m-mole, Radiochemical Centre Amersham (England)




Fig. 1 Effect of increasing population density in 25% plasma medium. Simultaneous triplicate 1 ml cultures of lymphocytes from the same subject were set up with increasing numbers of lymphocytes. Protein synthesis was measured after incubation for 24 h (cpm counts per minute).

2. Correction for the ^{14}C -leucine concentration to standard ^{14}C concentration of 0.5 $\mu\text{Ci}/\text{ml}$. It was shown that the CPM in newly synthesized protein were directly proportional to the concentration of radioactive substrate.

3. Correction for the amount of carrier protein to correspond to the amount (15.5 mg) in 0.25 ml of standard pooled serum, by reference to standard curve.

4. Correction for population density in plasma-containing cultures to give the theoretical incorporation in culture containing 1×10^6 cells/ml, using the graph shown in figure 1 (No such correction was necessary for plasma-free cultures where the incorporation was directly proportional to the number of lymphocytes per ml up to density of 16×10^6 lymphocytes per ml).

Results

1 Protein synthesis in plasma free medium

Mean total synthesis. The basal (unstimulated) synthesis by normal lymphocytes in plasma-free medium was measured in 28 healthy adults. The mean incorporation was not significantly different from the normal in all clinical groups: CLL, lymphoma, lymphosarcoma, macroglobulinaemia, multiple myeloma and infectious mononucleosis (table II).

PHA stimulation of protein synthesis by normal lymphocytes. The stimulation by PHA is expressed as a ratio incorporation with PHA/incorporation without PHA. The effect of PHA in increasing protein synthesis by normal lymphocytes in plasma-free medium was highly significant ($P < 0.001$). The values for PHA stimulation under these culture conditions ranged from 0.7 to 3.5 with a mean of 1.87 (table II).

ing autologous plasma. Also, in order to use radioactive substrate as economically as possible, the incorporation of ^{14}C -leucine into all of the soluble proteins was measured, rather than into the portion which was precipitated by sodium sulphate solution. The fraction of the radioactive proteins in the globulin fraction is quite variable in normal subjects and is usually substantially less than half of the total. The results in the present study are therefore not directly comparable with the previous measurements.

These studies have provided further evidence that circulating lymphocytes may have a reduced capacity to synthesize protein in diseases involving lymphoid tissues.

Measurements of protein synthesis in plasma-free medium alone showed low activity by lymphocytes from all of the disease categories studied except multiple myeloma. However the mean total synthesis in any disease group was not significantly lower than the control mean, nor was the difference significant when the data from all categories was pooled.

The addition of 25 % of autologous plasma to the medium significantly enhanced protein synthesis by normal lymphocytes. This effect is probably due to better nutrition, as unidentified substances in plasma are necessary for optimal growth of other mammalian cells *in vitro* [7]. ASKROOS [1] found hydrocortisone to be the factor in serum which was necessary for maximal antibody synthesis by rabbit lymph-node fragments *in vitro* but hydrocortisone has been shown to inhibit protein synthesis by human peripheral lymphocytes [16].

No evidence was found of inhibitory substances in the plasma of subjects with CLL, lymphoma and lymphosarcoma. The mean values for plasma stimulation of protein synthesis by lymphocytes in these conditions were actually higher than the normal mean, although they did not reach the level of statistical significance. These findings are of interest in view of the suggestion of VON HALLAUER [19] that CLL serum contains substances which stimulate cell growth.

Although the mode of action of PHA and the significance of the response to it are not yet known, it is a useful substance to bring out differences in lymphocytes from different sources. When the adjuvant effects of plasma and PHA were both utilized it was possible to show significant deficiencies in the capacity of lymphocytes to synthesize protein. Significantly low activity was seen in lymphocytes from subjects with lymphoma, lymphosarcoma, macroglobulinaemia and infectious mononucleosis. Lymphocytes from patients with CLL showed

the same trend and when only the untreated cases were considered the mean incorporation was significantly lower than the normal.

The low total protein synthesis by the circulating lymphocytes in lymphoma, lymphosarcoma and macroglobulinaemia seems to be related to the poor immunological function reported in these so-called lymphoproliferative disorders [3 4 10 17]

Significantly low values for PHA stimulation in medium containing plasma were found in 2 cases of lymphosarcoma. In chronic lymphatic leukaemia one estimation was above the normal range and 3 were below. The degree of stimulation by PHA was found to be significantly low in infectious mononucleosis, omitting one case in which the diagnosis was doubtful. The low stimulation in infectious mononucleosis agrees well with the lack of increase of RNA synthesis in response to PHA [13]. RUSK also noted that unstimulated lymphocytes in infectious mononucleosis synthesized RNA at 10 times the rate of normal blood lymphocytes under the same conditions. This finding is not compatible with the results in our series where incorporation of

C-leucine into protein was not elevated. The reason for this discrepancy is not readily apparent. It may be due to a difference in the stage of the disease between the two series: more than 60% of the lymphocytes in RUSK's cases were morphologically atypical whereas a much lower proportion of such cells was found in the blood of the subjects of this study.

The cause and significance of these abnormalities of protein synthesis are not understood. Further qualitative characterization of the deficiencies is necessary. It is also necessary to consider the population dynamics of the disorders, for the lymphocytes are a heterogeneous population, at least with respect to immunoglobulin synthesis [18] and each immunologically competent cell normally synthesizes antibodies of only one or two specificities [11 2]. The changes in the total protein synthesis may reflect changes in the proportions of various types of cell, or changes affecting each cell of the whole population. The derangement could conceivably be initiated at the level of formation of stem cells, in the thymus, or in the peripheral lymphoid tissues. It seems likely that the disturbance in infectious mononucleosis is self limited, occurring in peripheral lymphoid tissues. The disturbance may be at a similar level in lymphosarcoma, and it has been argued that the abnormalities of immunoglobulin synthesis in CLL may also be explained by a failure of terminal immunologic determination at this level [14].

Acknowledgements

We are grateful to Miss PEONY WOOD for skilled technical assistance. This research was supported by a grant from the National Health and Medical Research Council of Australia.

Summary

Measurements were made of protein synthesis *in vitro* by lymphocytes from normal subjects and from patients with chronic lymphatic leukaemia, lymphoma (unclassified) and lymphosarcoma, macroglobulinaemia, multiple myeloma and infectious mononucleosis. Protein synthesis was significantly stimulated by both plasma and phytohaemagglutinin in all groups. When the lymphocytes were cultured in medium containing 25% autologous plasma and PHA, significant differences between the normal and disease groups were observed. The degree of stimulation by phytohaemagglutinin in medium containing 25% plasma was significantly low in the lymphosarcoma and infectious mononucleosis groups. In interpreting these findings it is necessary to take into account the functional heterogeneity of the circulating lymphocytes.

References

1. ANDERSON, C. T. The requirement for hydrocortisone in antibody forming tissue cultivated in serum-free medium. *J. exp. Med.* 119: 1027-1049 (1964).
2. ATTARDE, G., COMTE, M., HORIMATA, K. and LEXVRE, E. S. Antibody formation by rabbit lymph node cells. IV. The detailed methods for measuring antibody synthesis by individual cells, the kinetics of antibody formation by rabbits and the properties of cell suspension. *J. Immunol.* 92: 379-390 (1964).
3. BARR, M. and FARLEY, C. H. Circulating antibodies in reticulosis. *Lancet* 1305-1310 (1961).
4. BACON, J. I. and BEZLER, L. H. Alteration of blood group antigens in leukemic lymphocytes. *J. clin. Invest.* 41: 1582-1589 (1963).
5. D. VINOGRAD, I. Serologic diagnosis of infectious mononucleosis. *J. Amer. med. Ass.* 74: 289-295 (1937).
6. DOWNEY H. A. L. and SICKELA, C. A. Acute lymphadenoma compared with acute lymphatic leukaemia. *Arch. intern. Med.* 37: 82-112 (1923).
7. EAGLE, H. Metabolic controls in cultured mammalian cells. *Science* 117: 4-31 (1961).
8. FORREST, I. J. and HENDERSON, D. W. Globulin synthesis by human peripheral lymphocytes *in vitro* measurements using lymphocytes from normals and patients with disease. *Ann. intern. Med.* 65: 69-79 (1966).
9. FORREST, I. J. and TIERNEY, L. J. Synthesis of protein by human lymphocytes *in vitro*. I. Clinical studies. *Amer. Ann. Med.* 41: 304-310 (1965).
10. LANE, D., PILLEY, F., KELLY, W. D. and GORD, R. A. A comparative study of the incidence of energy in patients with carcinoma, leukaemia, Hodgkin disease and other lymphomas. *J. Immunol.* 87: 335-338 (1962).
11. NODAL, G. J. V. Antibody production by single cells. *Brit. J. exp. Path.* 39: 44-51 (1958).
12. PILL, J. R. and BRUNELL, W. W. The presence of heterophile antibodies in infectious mononucleosis. *Amer. J. med. Sci.* 183: 90-104 (1957).
13. R. BEN, A. D. Lymphocyte RNA synthesis in infectious mononucleosis: the response to phytohaemagglutinin *in vitro*. *Blood* 73: 602-605 (1966).

14. SAOR, R. E. and FORMES, I. J. A case of multiple autoimmune disease, lymphoid proliferation and hypergammaglobulinaemia. *Blood* 31: 536-548 (1968)
15. SAUTER, A. A simple chemical test for distinguishing myeloma globulins from macroglobulins. *J. lab. clin. Med.* 63: 1054-1060 (1964)
16. SMITH, J. L. and FORMES, I. J. Use of human lymphocytes in studies of drug action. *Nature, Lond.* 215: 538-539 (1967).
17. SOLOMON, A., WALDMAN, T. A. and FAREY, J. L. Metabolism of normal 6.6S gamma-globulin in normal subjects and in patients with macroglobulinaemia and multiple myeloma. *J. lab. clin. Med.* 62: 1-17 (1963)
18. VAN FURTER, R. The formation of immunoglobulins by human tissues *in vitro*. Doctoral thesis, University of Leiden (1964)
19. VON HALLATER, C. Über den Nachweis leukocytyrer Reinstoffe im leukämischen Menschenblut. *Z. ges. exp. Med.* 76: 577-586 (1931)
20. WOLKOW, W. Q., COWY, C., CALVERT, E. and ICHIBA, F. Rapid procedure for the estimation of total protein, true albumin, total globulin, α globulin, β globulin and γ globulin in 1.0 ml of serum. *Amer. J. clin. Path.* 18: 723-730 (1948)

II Anatomisches Institut der Freien Universität Berlin (Direktor Prof. Dr. med. W. SCHWABE)

Über den Abbau von Zellen im Knochenmark des Menschen und der Ratte

D. GRAF HEYERLING

Der Abbau von Erythrozyten und Erythroblasten in den phagozytierenden Retikulumzellen des Knochenmarks ist bereits sorgfältig untersucht worden [2, 3, 4, 5]. Auch Kerne und Fortsätze von Megakaryozyten wurden in diesen Zellen gefunden [36-38]. Es fehlen jedoch genaue Angaben darüber, welche Zellen ausserdem noch in den phagozytierenden Retikulumzellen abgebaut werden und wie dieser Vorgang morphologisch erfolgt. Bei der elektronenmikroskopischen Untersuchung dieser Frage zeigte sich darüber hinaus, dass der intrazelluläre Abbau von Zellen im Knochenmark bei Mensch und Ratte zu morphologisch verschiedenen Abbauprodukten führt.

Material und Methode

Menschliches Knochenmark wurde durch Sternapunktion gewonnen. Ein Teil der Patienten litt an hämatologischen Erkrankungen, während bei einer zweiten Gruppe zunächst der Verdacht auf eine solche Erkrankung bestand, der dann bei sich und elektronenmikroskopisch nicht bestätigt wurde. Das Knochenmark der Ratte wurde am Femur von 6 Tieren eines Wistar-Kyushu-Stammes entnommen. Das Gewebe wurde sofort in einer 1 OsO₄-Lösung in Michaelis-Puffer mit Saccharosezusatz bei pH 7,4 und 4°C für 1½ Std. fixiert. Stufenweise Entwässerung in Aceton und Einbettung in Micropal. Zum Nachweis der sauren Phosphatase erfolgt die Fixierung in 2,5 Glutaraldehyd in 0,1 M Caedylat-Puffer pH 7,4. Weitere Behandlung nach der Vorschrift von SUMM und FARRAR [39]. Das Inkubationsmedium enthielt 0,01 M γ -Glycerolphosphat, 0,004 M Pb (Cl)₂ in 0,05 M Acetatpuffer bei pH 4,9. Die Inkubationszeit betrug 1 Std. bei 37°C. Anschliessend Nachfixierung in 1 OsO₄-Lösung in Michaelis-Puffer. Entwässerung und Einbettung wie oben. Die Schnitte wurden mit einem LKB-Ultratom hergestellt und mit Uranylacetat und Bleicitrat nachkontrastiert. Aufnahmen mit einem Siemens Elmiskop I.

Befunde

Bei der elektronenmikroskopischen Beurteilung von Phagozytosevorgängen muss die geringe Dicke der Schnitte berücksichtigt werden, um Fehldeutungen zu vermeiden. Die Ausläufer der phagozytierenden Retikulumzellen des Knochenmarks reichen oft weit zwischen die benachbarten Zellen. Um eine extrazellulär gelegene Zelle nicht fälschlicherweise als Phagosom anzusehen muss deshalb eine eingeschlossene Zelle nicht nur vollständig von einer Membran der phagozytierenden Zelle umgeben sein, sondern auch Veränderungen in ihrer Feinstruktur die für einen Abbau sprechen, erkennen lassen. Nur bei der Enzymreaktion unterscheidet sich diese Einschlussmembran schon durch ihren Niederschlag von der äußeren Zellmembran. In den phagozytierenden Retikulumzellen des Menschen und der Ratte konnten wir Zellen der roten Reihe, isolierte Normoblastenkerne neutrophile Granulozyten (Abb. 1a) Lymphozyten, Plasmazellen (Abb. 1b) und Thrombozyten nachweisen. Da der Abbau hämoglobinhaltiger Zellen bereits mehrfach untersucht wurde [31] braucht hier nicht näher darauf eingegangen zu werden. Das markanteste Zeichen dieses Abbaus ist das Auftreten von Einschlusskörpern mit Ferritin-Granula [24] (Abb. 2) Ferritinhaltige Einschlüsse sind auch in unserem Material häufig zu finden.

Alle Einschlusskörper enthalten das Reaktionsprodukt (Bleiphosphat) der sauren Phosphatase. Wenn eine phagozytierte Zelle noch keine deutlich ausgeprägten Zeichen des Abbaus aufweist, so liegt der Bleiphosphat-Niederschlag der umgebenden Membran innen an (Abb. 2). Die äußere Zellmembran der phagozytierenden Retikulumzelle ist stets frei von Niederschlägen. Wenn deutliche Abbauerscheinungen in der eingeschlossenen Zelle erkenntlich sind, liegt das Reaktionsprodukt der sauren Phosphatase auch innerhalb des Phagosoms. Kleine Einschlüsse können vollständig von dem Niederschlag ausgefüllt sein.

Die Einschlussmembran kann der phagozytierten Zelle dicht anliegen (Abb. 1b) oder einen mehr oder weniger breiten Spaltraum zum Phagosom freilassen (Abb. 1a, 3). Dieser Spaltraum erscheint weitgehend elektronenoptisch leer (Abb. 3) oder mit einem amorphen Material geringer Elektronendichte ausgefüllt.

Im Kern der phagozytierten Zelle treten Veränderungen auf, bevor andere Abbauerscheinungen deutlich werden. Das Nukleoplasma verliert sein typisches Aussehen und wird pyknotisch (Abb. 1a)

- 37 WEINBAUM, G. Lysosomes. *New Engl. J. Med.* 273, 1084-1090 (1965).
- 38 WITZEL, B. J., SEICER, S. S. and HORN, R. G.: Fine structural localization of acid and alkaline phosphatases in cells of rabbit blood and bone marrow. *J. Histochem. Cytochem.* 15, 311-324 (1967).
- 39 YAMAKAWA, I.: Glycolipids of mammalian red blood cells. in 16. Colloq. Gen. physiol. Chem. Mosbach 1965 (Springer Berlin/Heidelberg/New York 1966).

University of Louvain, Department of Medicine (Head Prof. J. VANDERBOECK)
Laboratory of Coagulation (Head Prof. M. VERSTRAETE)

Investigations on the Fibrinolytic System in Liver Cirrhosis¹

G. TYTGAT², D. COLLEN³, R. DE VREEKE and M. VERSTRAETE

For nearly half a century various observers have reported increased fibrinolytic activity in the blood of patients with liver cirrhosis. However the fibrinolytic activity was frequently measured by the auto-digestion time of clots of total or diluted blood or plasma of the patient. This decreased lysis time, often due to low amounts of lyzable fibrin substrate, should be interpreted as 'pseudofibrinolytic activity' as long as the lytic activity cannot be measured on a standard substrate not variable from patient to patient.

Nevertheless in some well documented cases of cirrhosis, true increased plasma fibrinolytic activity has been demonstrated. This enhanced blood proteolytic activity may be a cause of spontaneous bleeding or may encourage bleeding from esophageal varices or surgical wounds [5, 8, 11]. Particularly patients subjected to portocaval shunt operations have an increased tendency to operative and postoperative bleeding [9].

According to FLETCHER *et al.* [7] the increased fibrinolytic activity in the cirrhotic patients may be due to a failure of hepatic clearance mechanisms for plasminogen activator and not to deficient plasma fibrinolytic inhibitors. This latter statement is in contradistinction with the studies of several authors [3, 11, 12, 17] indicating that the fibrinolysis in cirrhosis may also be related to decreased serum plasmin inhibitors.

This work was supported in part by the Fonds voor Geschiedkundig Wetenschappelijk Onderzoek, Belgium.

Aspirant van het Nationaal Fonds voor Wetenschappelijk Onderzoek.

Navorsingsstagiair van het Nationaal Fonds voor Wetenschappelijk Onderzoek.

This discordance prompted us to study both hypotheses in a group of 25 cirrhotic patients in different stages of evolution of the disease. The present investigation involved the assay of various fibrinolytic parameters before and after activation of the fibrinolytic system by nicotinic acid.

Materials and Methods

Reagents. Saline (0.07 M)-phosphate (0.06 M) buffer pH 7.3 (S.P. buffer) [10]. - Glycerol-phosphate buffer containing equal volumes of glycerol and S.P. buffer - Fibrinogen Bovin (Puriet, Amsterdam) lot 57 (protein 78.2% clottable fibrinogen 62.5%, NaCl 16.9%) dissolved freshly before use, in concentration of 25 mg/7 ml S.P. buffer - Thrombin (Topostase Roche) 20 NIH units per ml S.P. buffer stored at 20°C. - Plasmin chloroform activated bovine fibrinolysin (Parke, Davis and Co.) 1,900 Loomis units/vial, diluted in 650 ml glycerol-phosphate buffer and stored at -20°C, is diluted adequately with the same solvent before use so that 0.10 ml plasmin lyses the standard clot (formed by mixing 0.35 ml S.P. buffer 0.25 ml fibrinogen solution and 0.10 ml thrombin) in a 9-11 minute range. This plasmin working solution is kept on ice during the whole procedure and discarded when the lysis time of the standard clot exceeds 11 min.

Fibrinolytic activity was measured in the plasma and in the euglobulin fraction, on unheated bovine fibrin plates, prepared according to ARRATTE and MULLINIX [1]. For statistical evaluation the individual values of lysed surface were converted into fibrinolytic activity by reading on linear reference curve constructed from plots of log lysed surface on bovine fibrin plate versus log sample concentration. This reference curve was obtained from pool of fibrinolytic active euglobulin precipitates, reconstituted with veronal buffer into number of 'activator' levels. Similar curves for individual cirrhotic precipitates showed slopes comparable to that of the reference curve.

Astiplasmin assay (according to JOHNSON [10] with slight modifications) 0.1 ml of serum dilutions (1/25, 1/50 and 1/100) in S.P. buffer are transferred to a testtube at room temperature. 0.15 ml of the plasmin working solution is added. The tubes are mixed gently and kept at room temperature for 10 min.

Consequently are added S.P. buffer 0.40 ml, fibrinogen 0.25 ml, thrombin 0.10 ml. Immediately after adding thrombin, a time reading device is started, the reagents are mixed by mechanical swirling for about 10 sec and the tube is transferred to a water bath at 37°C. Along with each series of serum dilutions reference clot is made containing 0.10 ml plasmin dilution and buffer up to 0.65 ml. Fibrinolytic endpoints, indicated by the rising of all air bubbles into the upper half of the test mixture, are read visually or in the lysis recorder [4]. All determinations are performed at least in duplicate. The astiplasmin content of the serum is calculated from a plot on log-log paper the lysis times being plotted against the reciprocal of the final serum concentrations. A line is drawn joining the two dots with lysis times adjacent to the reference time. On this line the serum dilution, producing lysis time equal to the reference time is looked for. As 0.10 ml plasmin dilution contains per definition 1 plasmin unit, the reciprocal of the serum concentration which prolongs the lysis time of 0.15 ml plasmin to the time of 0.10 ml plasmin (reference time) inhibits 0.5 plasmin units. Divided by two, this reciprocal of the serum concentration gives conventionally the astiplasmin content of the sample.

Experimental groups. Nicotinic acid was administered in two series of 25 subjects. The cirrhotic group consisted of 25 hospitalized patients, in whom the diagnosis of hepatic cirrhosis, in different stages of evolution was documented by physical examination, laboratory findings, laparoscopy and proved in all of them by liver biopsy: none of the patients was taking corticosteroids, but some were under intermittent diuretic treatment. The

control group consisted of 15 laboratory personnel and hospitalized psychosomatic patients without any known physical or biochemical abnormality. Mean age (controls 48 years; cirrhotics 50 years), mean body weight (controls 63 kg; cirrhotics 66 kg), mean cholesterol value (controls 238 mg%; cirrhotics 208 mg%) mean hemoglobin value (controls 14 g%; cirrhotics 13.2 g%) and sex ratio (5 males, 1 female) were comparable. Nicotinic acid (100 mg) was rapidly injected i.v. to the recumbent person in the mid-afternoon. Under these conditions, diurnal changes were assumed to operate uniformly [6].

Venous blood was sampled just before and 15, 30 and 60 min after the i.v. administration. The tourniquet was applied during about 15 sec before puncture of an antecubital vein. The blood was collected directly in glass tubes for preparation of serum and in pre-cooled siliconized tubes, containing potassium oxalate (H_2O) 2.5% (1 part for 10 parts of blood) for fibrinolytic determinations. Serum was pipetted off after clotting of the whole blood for 2 h at 37°C. After centrifugation at 4°C for 10 min and 4,000 g the plasma and the serum were stored in polystyrene tubes at 20°C until used. Serum from 20 healthy donors was obtained in similar manner and mixed in equal proportions for constituting serum pool, used for preliminary investigation of the reproducibility of the antiplasmin assay.

Results

Determination of *in vivo* Plasminogen Activator Clearance

The fibrinolytic activity in the euglobulin fraction, measured on unheated bovine fibrin plates, will be considered according to SHEARY *et al.* as blood plasminogen activator activity [20]. Figure 1 shows the individual values of euglobulin fibrinolytic activity before (sample 0) and 15 min (sample 1), 30 min (sample 2) and 60 min (sample 3) after nicotinic acid administration.

As there is no linear correlation between lysed surface and activator




Fig. 1. Euglobulin fibrinolytic activity measured on bovine fibrin plate before and 15, 30 and 60 min after intravenous injection of 100 mg nicotinic acid, in control subjects and cirrhotic patients.

content, it is necessary for statistical analysis to compute these lysed surfaces shown in figure 1 into activator concentration by reading from a linear reference curve (plotting $\log \mu\text{m}^2$ lysed surface versus \log activator activity). After calculation of the mean activator activity in the different samples of both groups these mean data are expressed in percentage of the mean activator activity in the control group before nicotinic acid injection. These calculated mean values are for blood samples 0, 1, 2 and 3 respectively 100, 206, 152 and 187% for control subjects and 66, 403, 274 and 154% for cirrhotic patients. The lower mean value found in the cirrhotic patients, before nicotinic acid injection, is not statistically different from the mean control value ($0.05 < P < 0.10$). The increase in euglobulin fibrinolytic activity from sample 0 to sample 1 is statistically significant for both series ($P < 0.001$) the mean increase being higher for the cirrhotic patients in comparison to the control subjects ($P < 0.001$). After the 15 minute sample, the euglobulin lytic activity declined progressively to base-line values, more rapidly for the control subjects than for the cirrhotic patients.

As the *in vivo* disappearance rate of plasminogen activator is an exponential function of activator concentration with respect to time [7] the 50% *in vivo* decay time of euglobulin fibrinolytic activity can be calculated from the formula $\log Y = \log A + bx$ and $T_{1/2} = \log 2/b$. The calculated mean *in vivo* 50% disappearance time of activator is 19.8 min for these control subjects who clearly responded to nicotinic acid injection and 24.5 min for the total group of 25 cirrhotic patients ($0.002 < P < 0.01$). The 50% *in vivo* activator decay is 26.2 min for the 10 cirrhotic patients exhibiting the most serious coagulation abnormalities and clinical signs of severe hepatic decompensation. These findings indicate that the *in vivo* disappearance of plasminogen activator in the cirrhotic patients is significantly longer compared to that of the control subjects.

Antiplasmin Determination

The reproducibility of the antiplasmin assay has been preliminarily investigated. The mean of normal pool values, obtained over several weeks, is 360 antiplasmin units per ml serum, with a standard deviation of 25 units. Individual normal values vary from 210-510 units per ml, $\bar{x} = 344$, $s = 94$ and $n = 20$.




Fig. 2. Antiplasmin activity before and 15, 30 and 60 min after intravenous injection of 100 mg nicotinic acid in control subjects and cirrhotic patients.

The serum antiplasmin activity has been assayed before and after nicotinic acid injection in both experimental groups. The individual experimental results are summarized in figure 2, the mean values being for blood sample 0 1 2 and 3 respectively 311 263 271 and 296 units for the control persons and 192, 145 153 and 169 units for the cirrhotic patients. The mean antiplasmin content before fibrinolytic activation in the cirrhotic patients is significantly lower than in the control group ($P < 0.001$). Activation of the fibrinolytic system by nicotinic acid is associated in the 15 min blood sample with a decrease in serum antiplasmin content for both series, which is highly significant ($P < 0.001$) when evaluated with the method of paired comparison. The decrease in serum antiplasmin is maximal at the moment of maximal increase of euglobulin fibrinolytic activity. Subsequently the antiplasmin capacity rises steadily towards initial values, in association with a progressive decrease in euglobulin fibrinolytic activity.

In order to evaluate the importance of the decreased antiplasmin level in liver cirrhosis, a comparison was made between the fibrinolytic activity on fibrin plate in total cirrhotic plasma samples versus control plasma samples both with an identical fibrinolytic activity in the corresponding euglobulin precipitates. Indeed, the difference between plasma and euglobulin lytic activity is mainly based upon the elimination of the bulk of inhibitors (the still hypothetical anti-activator and the antiplasmins) in the euglobulin fraction. After plotting the various

plasma fibrinolytic activities versus the corresponding euglobulin fibrinolytic activities for both series, the correlation coefficient b between the plasma and euglobulin lytic activity measured on bovine fibrin plate, was calculated as 0.630 for cirrhotic patients and 0.268 for control subjects. The corresponding difference in slope between both regression lines is statistically significant ($0.02 < P < 0.05$) confirming the importance of the decrease in fibrinolytic inhibitors in explaining the susceptibility of the cirrhotic patients for induction of fibrinolytic activity in total plasma.

Discussion

Various observers have reported increased fibrinolytic activity in liver cirrhosis, measured by the autodigestion time of clots of total or diluted blood or plasma of the patient. In our experiments, the lytic activity before nicotinic acid injection was measured on a standard lysable fibrin substrate, not variable from patient to patient, and no evidence for enhanced plasminogen activator activity in the euglobulin fraction of 25 cirrhotic plasma samples was obtained (fig. 1). Nevertheless, patients with liver cirrhosis are prone to develop increased fibrinolytic activity in certain circumstances [8-9-19]. Many authors relate the increased fibrinolytic activity to the release of an increased amount of plasminogen activator in the cirrhotic plasma.

Our data confirm the known susceptibility of the patients with liver cirrhosis to develop increased fibrinolytic activity after stimulation of the fibrinolytic system (fig. 1). According to FLETCHER *et al.* [7] a major factor in the abnormal fibrinolytic response to nicotinic acid, is a failure of hepatic clearance mechanisms for plasminogen activator in liver cirrhosis. Calculating the activator concentration by assessment of the euglobulin lysis time, these authors find a mean *in vivo* 50% plasma activator clearance rate of 13 ± 5 min in control persons versus 53 ± 19 min in cirrhotic patients.

In our experiments blood plasminogen activator precipitated almost quantitatively in the euglobulin fraction, is measured on bovine fibrin plates. From our data the calculated mean *in vivo* 50% disappearance time of activator activity is 13.8 min for the control subjects, who clearly responded to nicotinic acid injection, and 24.5 min for the total group of 25 cirrhotic patients ($0.002 < P < 0.01$). Notwithstanding the methods in both studies differ the *in vivo* disappearance of plasminogen activator in the two control series is

strikingly similar. However, the prolongation of the *in vivo* decay of plasminogen activator in cirrhotic patients in comparison with control subjects is less pronounced in our study. As differences in patient material (our patients being scattered over a wider range of liver insufficiency) could provide a possible explanation for this discrepancy, we calculated the *in vivo* plasminogen decay in the 10 cirrhotic patients with the most seriously disturbed coagulation set and clinical signs of severe liver failure, but the 50% plasminogen decay time of 26.2 min in this group was still the half of the value found by FLETCHER [7]. The significantly longer *in vivo* disappearance time of plasminogen activator in cirrhotic patients, compared to control subjects, is according to FLETCHER [7] ascribed to insufficient hepatic clearance mechanisms of activator by the diseased liver. However, it has to be kept in mind that other still hypothetical mechanisms may be involved in explaining the differences in activator disappearance time after nicotinic acid injection, such as differences in possible renal clearing of activator activity, differences in continuous activator release during the declining part of the disappearance curve, differences in nicotinic acid metabolism, and differences in level and rate of release of anti-blood activator activity. The availability of purified blood plasminogen activator is required for exact activator clearance studies and for further elucidation of the mentioned hypothetical mechanisms.

The role of the fibrinolytic inhibitors in the genesis of the increased fibrinolytic activity in liver cirrhosis and the enhanced susceptibility to stimuli capable of inducing fibrinolytic activity is debated. According to FLETCHER *et al.* [7] assays of plasma antiplasmin, performed with a caseinolytic technique, revealed no significant difference between the normal and cirrhotic group. Studies of other authors however [3, 11, 12, 17] indicate that the fibrinolytic activity in liver cirrhosis may be related to a decrease in the plasmin inhibitors in serum, this finding being in agreement with the previously stated lowered levels of α_2 -globulins in cirrhosis [18]. We performed a serum antiplasmin assay in 25 cirrhotic patients according to the fibrin clot digestion method as proposed by JOHNSON [10]. Interference in the test by residual activator activity in the serum samples was considered as negligible if not existent both for reasons of prolonged clotting at 37°C of the blood and subsequent extensive dilution (250–1 000 times) of the serum sample. As autodestruction of plasmin occurs during the test, the error may be minimized by measuring serum inhibition after a relatively short incubation time (10 min) and by adding glycerol as a

stabilizer to the plasmin solution. Although the plasmin inhibition is not fully evolved this short preincubation time may be reliable as the bulk of serum antiplasmin activity resides in the α_2 -globulin fraction, which produces an immediate temperature independent inhibition of plasmin [13 15 16]. The mean antiplasmin content (192 U/ml serum) in the cirrhotic patients is substantially lower than the corresponding value in control subjects (311 U/ml serum) this difference being highly significant ($P < 0.001$) (fig 2). The importance of the decrease in fibrinolytic inhibitors (the still hypothetical anti activator and the antiplasmins) was evaluated by comparing the lytic activity in cirrhotic versus control plasma samples with an identical corresponding lytic activity in the euglobulin fraction where the bulk of fibrinolytic inhibitors is eliminated. Our finding of a significantly higher plasma fibrinolytic activity in cirrhotic plasma in comparison with control plasma for an identical euglobulin lytic activity supports the hypothesis that the susceptibility of the cirrhotic patients for induction of fibrinolytic activity in total plasma may be related to decrease in fibrinolytic inhibitors ($p < 0.05$). Decreased antiplasmin levels in cirrhosis are probably not only due to decreased hepatic synthesis but also to increased consumption in plasmin antiplasmin complex formation. Indeed it has been demonstrated that plasmin-antiplasmin complex may form a circulating reservoir of plasmin which is innocuous to other circulating proteins but forms a ready source of plasmin when required for the lysis of fibrin. The extent of such plasmin binding may be appreciated from the work of NAMINGA and GUST [14] who have shown that bound plasmin is present in a hundredfold greater concentration than free plasmin at a plasmin concentration of $10^{-1} M$.

There is a suspicion that not only the antiplasmin content but also the level of the still hypothetical inhibitor of blood plasminogen activator is decreased in liver cirrhosis. As it has repeatedly been shown that increased fibrinolytic activity is frequently the result of the presence of an activator of plasminogen and not of plasmin an inhibitor of this activator may have important physiological implications. However it has until now been impossible to measure such an inhibitor as the activator itself has not been isolated and purified.

Summary

Patients with liver cirrhosis are prone to develop increased fibrinolytic activity after *L.* as injection of nicotinic acid. This abnormal response is due to failure of hepatic clearing of plasminogen activator. The calculated mean is one 50% disappearance time of activator activity is 13.8 min for 25 control subjects and 24.5 min for 25 cirrhotic patients ($0.002 < p < 0.01$). Decreased antiplasmin levels in cirrhotics may potentiate this susceptibility of these patients to develop plasma fibrinolytic activity. This difference between the mean antiplasmin content (192 U/ml serum) in the cirrhotic patients and the corresponding value in the control subjects (311 U/ml serum) is highly significant. The decrease in fibrinolytic inhibitors is probably related with the finding of significantly higher fibrinolytic activity in total cirrhotic plasma in comparison with control plasma for an identical level of plasminogen activator activity in the corresponding globulin fraction of both cirrhotic and normal plasma ($0.02 < p < 0.05$).

References

1. ASTRUP T and MULLERITZ, S. The fibrin plate method for estimating fibrinolytic activity. *Arch. Biochem. Biophys.* 40: 346 (1952).
2. BAILEY N. T. J. Statistical methods in biology (The English Universities Press, London (1959)).
3. BEAUMONT J. L., BEAUMONT V. et DOMART A. Recherches sur l'activité fibrinolytique spontanée du plasma dans les cirrhoses du foie. *Ref. franç. Et. clin. biol.* 1: 667 (1956).
4. COLLIER, D.; TYTOGA G. and VANDERSTRAET, M. A semi-automated method for routine evaluation of fibrinolytic components. *J. clin. Path.* (In press).
5. DE NICOLA, P. and SOARIS, F. Fibrinolysis in liver diseases. Study of 109 cases by means of the fibrin plate method. *Thromb. Diath. haemorrh.* 2: 290 (1958).
6. FRANKLEY G. R., BALFOURTH, G. and FRANKLEY E. Evidence of diurnal fibrinolytic rhythm, with simple method of measuring natural fibrinolysis. *Clin. Sci. N.* 645 (1957).
7. FLETCHER, A. B., BODDERMAN, O. J., MOORE, H., ALVAREZ, N. and SANCHEZ S. Abnormal plasminogen-plasmin system activity in patients with hepatic cirrhosis: its cause and consequences. *J. clin. Invest.* 43: 681 (1964).
8. GROSS, C. E., MORENO, A. B. and ROCHELLO, L. M. Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and its inhibition by epsilon amino caproic acid. *Ann. Surg.* 153: 383 (1961).
9. GROSS, C. E., ROCHELLO, L. M. and PARKER, W. F. Coagulation defects in patients with cirrhosis of the liver undergoing portacaval shunts. *Amer. J. Surg.* 104: 512 (1962).
10. JONCOW, A. J. Blood coagulation, haemorrhage and thrombosis; edited by TOCANTINS, L. M., and KARL, L. A. (Grune & Stratton, New York/London 1964).
11. KWAAR, H. C., LO, R. and MC FADDEAN, A. J. S. Antifibrinolytic activity in primary carcinoma of the liver. *Clin. Sci.* 18: 231 (1959).
12. KWAAR, H. C., MC FADDEAN, A. J. S. and COOR, J. Plasma fibrinolytic activity in cirrhosis of the liver. *Lancet* i: 132 (1965).
13. MARY, R. D., COTTON, S. and JACKSON, H. Antiplasmin activity of electrophoretically separated human serum fractions. *J. clin. Path.* 19: 185 (1966).
14. NARAYANA, L. B. and GUPTA M. M. On the interaction of fibrinolysin (plasmin) with the inhibitors antifibrinolysin and soyabean trypsin inhibitor. *Arch. Biochem.* 108: 542 (1964).
15. NORMAN, F. S. Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma. *J. exp. Med.* 106: 53 (1938).

16. NORMAN, P. S. and HILL, M. B.: Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma. *J. exp. Med.* 103: 639 (1956).
17. O'CONNELL, R. A.; GROSS, C. E. and ROUMELLOY, L. M.: Role of inhibitors of fibrinolysis in hepatic cirrhosis. *Lancet* i. 990 (1964).
18. SATCHEL, R. S.; LEWIS, R. A. and GANTON, B. B.: Electrophoretic studies of the plasma proteins in virus hepatitis. *J. lab. clin. Med.* 44: 349 (1954).
19. SAWYER, W. D., FLETCHER, A. P.; ALKJAREMO, N. and SÖDERBY S.: Studies on the thrombolytic activity of human plasma. *J. clin. Invest.* 39: 428 (1960).
20. SÖDERBY S., LINDHOLTER, R. Z., FLETCHER, A. P. and ALKJAREMO, N.: Studies on enhanced fibrinolytic activity in man. *J. clin. Invest.* 38: 810 (1959).

Authors address: Drs. G. TYNDAL, D. COLLIER, R. DE VRIES and Prof. Dr. M. VERSTRAETE, University of Louvain, Department of Medicine, Laboratory of Coagulation, Louvain (Belgium).

Central Laboratory of the Blood Transfusion Service of the Swiss Red Cross, Berne

A Specific Inhibitor of Human Clotting Factor V

V LOPEZ, R. PFLUGSHAUPF and R. BÜTLER

In 1958 FERGUSON *et al.* [5] reported on a patient suffering from a heavy haemorrhagic diathesis due to the presence of an inhibitor of factor V. This inhibitor showed no species-specificity since it was found to inhibit bovine factor V as well. The therapeutic effect of ACTH suggested that this anticoagulant could have been of immunological origin although no direct proof for this assumption was offered.

We have observed a similar coagulation disorder in a 66-year-old woman. An inhibitor which was effective only against human factor V could be demonstrated in the plasma as well as in the serum of the patient.

Case Report

M. R. L. 1899, was admitted to the hospital on September 26th, 1963 because of right-side pleurisy. Prior to hospital admission she had been treated with chloromycetin, Tanderl® and Lederkys®. From her history it became clear that she had suffered from specific (tbc) lung infiltration already 40 years ago.

After a few days in the hospital the patient developed pericarditis. Tuberculostatic therapy was started. The treatment of thrombophlebitis of the right leg which developed early in 1963, was followed by prolonged Butazolidin® therapy. The patient's condition had improved significantly by November 13th, 1963 and she was discharged from the hospital; however 6 days later the patient had to be readmitted as an emergency with haematuria which had persisted for 2 days already. On the medial side of the right thigh and on the abdomen small to medium-size suffusions were visible. The patient was afebrile. A cystoscopy gave no evidence for mucous membrane lesions.

Laboratory findings: haemoglobin 34%, haematocrit 21%, bleeding time 3 1/2 min, clotting time 5 min, thromboplastin time determined according to Quack 33%, thrombocytes 136,000/mm³.

The patient received blood transfusions; in spite of serological compatibility she developed temperatures of 39.2° C after the fourth transfusion.

An analysis of the blood clotting system was performed on blood sample received on November 23rd, 1963 (table I). The most striking result consists in the pronounced reduc-

tion of factor V activity as measured by the one stage assay. Correspondingly the global tests of the intrinsic system (recalcification time, *hydrin* tolerance time, partial thromboplastin time and prothrombin consumption test) as well as thromboplastin time were all pathological. The moderately diminished factor XI activity was probably due to the low factor V content of the factor XI-substrate used.

The patient's history gave no indication of parahaemophilia: she never had bleeding episodes before although she was allergic to penicillin. Furthermore, hereditary coagulopathy seemed excluded by the absence of bleeding disorders in the patient's family. Thus, the presence of an inhibitor of factor V appeared probable.

The patient's blood was reexamined on December 4th, 1965 (table I). Factor V activity was still markedly reduced, and hyperfibrinogenemia had developed.

A search for auto- and iso-antibodies against red cells, for leucoagglutination, for cell nucleus antibodies, for rheumatoid factor activity and for antibodies against immunoglobulins gave negative results.

Special Investigations

1. Substitution experiments in Quick's thromboplastin test. The following incubation mixture was used: 0.1 ml citrated plasma (patient) and normal pooled plasma mixed in different ratios), 0.1 ml thromboplastin (Roche), 0.1 ml 0.4 M CaCl_2 . The results of substitution experiments using the patient's plasma (3:1-plasma) and normal plasma are shown in figure 1.

In a second series, cross-correction experiments were performed using different incubation times of the patient's plasma with normal plasma. In these experiments the plasma was diluted 1:10 with isotonic barbitol buffer (figure 2). The results obtained must be interpreted in terms of the presence of an anticoagulant inhibiting the prothrombin-conversion by the extrinsic activation mechanism. The activity of this anticoagulant appeared immediately but increased on prolonged preincubation.

2. Effect of the inhibitor on thromboplastin generation. As shown in figure 3, the thromboplastin generation test (TGT) [3], in which BaSO_4 -adsorbed patient's plasma and normal

Table I Clotting Investigations

	25-11-65	4-12-65	5-1-66	Normal range
Recalcification time, sec	450	840	115	90-180
<i>Hydrin</i> tolerance time sec	570	1,200	120	~ 300
Partial thromboplastin time (Apolectin) sec	300	510	95	70-120
Prothrombin consumption test, %	45	55	5	0-8
Thromboplastin time, sec	55	65	12	~ 15
Thrombin time sec	11	16	14	~ 10
Fibrinogen (Schultz), mg %	400	600	300	~ 300
Factor II activity sec	19	17	18	~ 19
Factor V activity %	5	3	60	70-120
Factor VII activity %	90		100	70-120
Factor VIII activity %	100	100	100	70-120
Factor IX activity %	100	100	—	70-120
Factor X activity %	100	—	100	70-120
Factor XI activity %	22	—		70-120




Fig. 1. Substitution experiments in Quick's thromboplastin test. *M.P.*, patient's plasma, *N.P.L.*, normal plasma.




Fig. 2. Cross correcting experiments with patient's plasma and normal plasma at different preincubation times. ●—● mixture of patient plasma and normal plasma; ○—○ normal plasma alone.

serum were used, is also influenced by the inhibitor. This experiment shows, furthermore, that the inhibitor is not or only poorly absorbed by BaSO_4 . It proved necessary to modify the standard conditions of the TGT whereby concentrated reagents (BaSO_4 -absorbed plasma and serum) were used in order to demonstrate the activity of the inhibitor.




Fig. 7 Activity of human and bovine factor V preparations. ●—● human factor V preparation ○—○ bovine factor V preparation.

shown in figure 5. They appear to demonstrate the presence of an anticoagulant directed against factor V. These findings also confirm that the inhibitor is present in both plasma and serum, and that it is effective upon incubation.

Patient's serum and normal plasma were preincubated for different periods of time in order to establish the interdependence of the inhibitory effect and preincubation time: the one-stage factor V assay was used. The results represented in figure 8 demonstrate that the inhibitory effect increases correspondingly with increasing incubation times.

4 *Inhibition experiments with factor V-preparations of bovine and human origin.* Factor V was prepared according to a slightly modified version of Owston's method [35]. The activity of the lyophilized product was tested as follows: 25 mg of factor V preparation of bovine origin and 100 mg factor V preparation of human origin, respectively, were dissolved in 1 ml barbitol buffer. Factor V activity was determined in dilutions prepared from these solutions. Both preparations were tested for activity of other clotting factors: only factor V activity could be demonstrated.

For demonstration of inhibitor activity both, bovine and human factor V-preparations were adjusted to equal activity as based on their respective activity curves (figure 7). 0.5 ml factor V-preparation (human or bovine) was preincubated with 0.05 ml of the patient's plasma for different lengths of time: the clotting activity was measured by determination of the thromboplastin time. As a control, the patient's plasma was substituted by factor V reagents. Results are shown in figure 8, demonstrating that the inhibitor is specifically directed against human factor V but not effective against bovine factor V. Furthermore, it appears from the shape of the curve that both preparations may have lost some of their activity during the test procedure.

5 *Stability of the anticoagulant.* The inhibitor showed no loss of activity after standing at +4°C or -20°C for several weeks. Incubation at 37°C for 24 h likewise caused no loss of activity. After 1 h at 60°C no decrease of activity was discernible; whereas at 70°C the activity disappeared after 30 min.

6 *Chemical and physicochemical properties of the anticoagulant.* The inhibitor was neither absorbable on aluminum-hydroxide nor on BaSO₄ [2]. It is not lipophilic since after shaking with ether it was still found in the water phase.




Fig. 2. Dependence of the inhibitor's activity against factor V preparations on preincubation time

- human factor V preparation + patient plasma
- human factor V preparation + factor V deficient plasma
- ×—× bovine factor V preparation + patient's plasma
- ×—× bovine factor V preparation + factor V deficient plasma




Fig. 3. Distribution of the inhibitor activity among electrophoretic fractions of the patient's serum.

In order to determine the electrophoretic mobility of the inhibitor 0.1 ml of the patient serum was applied to each of 15 paper strips. After electrophoresis, one strip was colored with amido black to localize the different fractions, and the 5 mm electrophoretic fractions thus localized were cut out in the remaining 14 strips. The paper cuttings were eluted during 12 h in barbital buffer at 4°C, whereby the amount of barbital buffer added was proportional to the protein content of the different fractions. Of each eluate 0.5 ml were

mixed with 0.1 ml of normal plasma, diluted 1:10 with isotonic barbital buffer during 30 min. Factor V activity was then assayed by the one-stage test. Figure 9 shows that the inhibitory activity was contained mainly in the γ -globulin fraction.

7. Immunoelectrophoretic investigations. The patient's serum was submitted to Ouchterlony immunodiffusion tests against human and bovine factor V-preparations, against normal pooled plasma as well as against a factor V-free plasma (factor V reagent). A weak but definite precipitation line formed between the patient's serum and human factor V preparation, whereas reaction of the patient's serum with normal plasma pool remained doubtful. No reaction was observed between the patient's serum and bovine factor V preparation, and no precipitation line was formed, as expected, between the patient's serum and factor V-free plasma. Due to the weak appearance of the precipitation line it was not possible to obtain a convincing photographic picture for reproduction.

Follow-up Studies

On December 18th, 1963, a new sample of extracted blood was tested. No alteration in the clotting defect was discernible. Factor V activity was still only 3% of normal values.

The patient's general condition was unchanged. After transfusion haematuria stopped for a few days, but then bleeding resumed. On December 20th, 1963, ACTH-therapy was started. A daily dose of 25 mg was given until January 8th, 1964. A few days after initiation of this therapy the general condition improved both objectively and subjectively; haematuria stopped and the thromboplastin time showed substantial improvement amounting to 60% by December 29th, 1963. On January 5th, 1964, the coagulation analysis was reassessed. With the exception of a slightly reduced factor V activity (60% of normal values) blood coagulation appeared normal (table 1). On January 9th, 1964, the patient went to the bathroom where she suddenly collapsed and died. An embolic obstruction of the pulmonary artery as well as thromboses of the left femoral and iliacal veins were revealed at autopsy.

Discussion

The appearance of haemorrhagic diathesis caused by the action of inhibitors of the clotting system is well known. This phenomenon may be due to either a raised activity of physiological inhibitors (e.g. antithrombins) or the appearance of (usually acquired) circulating anticoagulants (e.g. specific inhibitors of factor VIII). Circulating anticoagulants are most frequently directed against factors VIII and IX or against tissue thromboplastin; however specific inhibitors of most other clotting factors may be found as well [8].

Formation of circulating anticoagulants specifically directed against factor V appears to be very rare. In addition to the one case mentioned by FERGUSON *et al* [5] there exists only the observation reported by HORDER [9-10] in 1955. A critical evaluation of HORDER's case especially with regard to the genetic pattern of the haemorrhagic diathesis and to his interpretation of the experimental data leaves it very doubtful that a factor V inhibitor was present at all. We are inclined to agree with FERGUSON *et al* who concluded that HORDER described a case of parahæmophilia.

The case reported in this study is very similar in its characteristics to the one described by FERGUSON. As a result of the inhibition of factor V an impairment of the prothrombin-conversion by the intrinsic as well as by the extrinsic activation mechanisms occurs accordingly the recalcification time the hirudin tolerance time, the partial thromboplastin time, as well as the thromboplastin time are distinctly prolonged. Inhibition experiments with purified factor V preparations clearly demonstrate the factor V specificity of the inhibitor. However the inhibitor present in our case, contrary to the inhibitor of FERGUSON *et al.*, did not react with bovine factor V and therefore appears to be species-specific. Furthermore it may be concluded from inhibition experiments, that the inhibitor is exhibiting immediate as well as progressive activity. Evidence indicating that the inhibitor could be an antibody appears to be of particular interest. This concept is supported by the physicochemical properties (electrophoretic behaviour as a γ -globulin) by the effect of ACTH-therapy but mainly by the results obtained in immunochemical analyses. In fact the inhibitor behaved as a weak precipitin it must be considered, however that most precipitating antibodies form only after prolonged and powerful antigenic stimulation.

For a long time, most authors were inclined to believe that acquired circulating anticoagulants were antibodies [8]. Inhibitors found in multi-transfused haemophiliacs are classified as isoantibodies since these patients do not possess the corresponding antigens (factor VIII or factor IX, respectively). Inhibitors observed *post partum* often can be related to an iso-immunization. In this case, one must postulate group-specific differences in the antigenic structure of the clotting factor in question. However such differences have not as yet been demonstrated.

Inhibitors detectable in cases of collagen disease (e.g. in patients with *lupus erythematosus disseminatus*) but also during the course of other diseases, such as chronic glomerulonephritis, liver cirrhosis, tuberculous lymphadenitis, sepsis lenta, lues, pemphigus vulgaris, dermatitis herpetiformis, are likewise attributed to an immunologic origin. In all these cases, an autosensitization must be assumed. Indirect support for the concept of the antibody character of circulating anticoagulants in most instances may be gained from the patient's history or from the physicochemical behaviour of the inhibitor. Direct serological evidence has been presented only in a few cases occasionally precipitating antibodies against factor VIII or factor IX could be demonstrated

[4 6 11 12 18, 19] in other cases the inhibitor activity could be removed with a specific anti-immunoglobulin anti serum [2 16, 1 7]. To our knowledge an inhibitor with antibody activity directed against factor V has never been demonstrated before. In our case, the antibody may be of autoimmune origin although the question of aetiology has to remain open. Neither clinical nor serological evidence for a generalised autoimmune disease was found. The aetiological role of drugs in the induction of autoantibody formation has to be considered. As mentioned already the patient was allergic to penicillin. STEFANINI and DAMESHEK [17] reported on a patient with purpura SCHÖNLEIN HENOCH who developed a circulating anticoagulant directed against factor VIII after the administration of penicillin procaine simultaneously the clinical picture deteriorated. Dysproteinemia of the γ -globulin type observed in this patient was traced back by the authors to the presence of large amounts of the inhibitor although no direct proof for its antibody character was offered. An analogous case has also been described by NUSSEY and DAWSON [13].

Acknowledgement

We are greatly indebted to Dr H. VORRELL, Langrou, for putting blood samples as well as the case history and clinical data of his patient at our disposal.

Summary

A severe haemorrhagic diathesis in a 66-year-old woman was found to be due to circulating anticoagulant directed against clotting factor V. The inhibitor was species-specific and active immediately. Immunohistochemical studies presented evidence for the antibody character of the inhibitor.

References

1. ANDERSON, B. R. and TROUP S. B. γ G-antibody to human antihemophilic globulin (factor VIII). *J. Immunol.* 100: 175 (1968).
2. McDWELL, E., DEDMON K. W. E., DUKA, G. W. R., AUGUSTUS, R. and LLOYD, G. M. Antibody nature of the inhibitor to antihemophilic globulin (factor VIII). *N. rare Lond.* 210: 745 (1966).
3. NUSSEY, R. and DOUGLAS, A. B. The thromboplastin generation test. *J. clin. Path.* 6: 23 (1953).
4. CRADDOCK, C. O. and LAWRENCE, J. B. A report of the mechanism of the development and action of circulating anticoagulant in two cases. *Blood* 2: 505 (1947).

5. FERGUSON, J. H., JOHNSON, CH. L. and HOWELL, D. A. A circulating inhibitor (anti-AcG) specific for the labile factor V of the blood-clotting mechanism. *Blood* 13, 382 (1958).
6. FERGUSON, W. B.; EYENIK, R. H. and TYLER, F. H. L. Refractoriness in hemophilia to coagulation promoting agents. Whole blood and plasma derivatives. *Blood* 5, 401 (1950).
7. GLUCK, H. J. and HONO, R. J. A circulating anticoagulant in y1A-multiple myeloma its modification by penicillin. *J. clin. Invest.* 44, 1868 (1965).
8. HAMO, A., STRECHMANN, H. and BUTLER, R. Immuno-plasmapathien; in MACKENZIE und VORLÄNDER's Immunopathologie in Klinik und Forschung, 2nd ed., p. 270 ff. (Thieme Stuttgart 1961).
9. HÖRNER, M. H. Isolierter Faktor V Mangel, bedingt durch einen spezifischen Hemmkörper. *Acta haemat., Basel* 23, 235 (1955).
10. HÖRNER, M. H. und SOREL, G. Inhibitorstudien bei familiärem Faktor V Mangel. *Acta haemat., Basel* 16, 65 (1955).
11. HOCOCK, C. and FRANKLEY, M. E. The nature and action of circulating anticoagulants. *Acta haemat., Basel* 12, 1 (1954).
12. MITCHELL, F. L. and JONES, H. W. The detrimental effects of frequent transfusion in the treatment of patient with hemophilia. *Amer. J. med., Sci.* 206, 710 (1943).
13. NISNEY, A. M. and DAWSON, D. W. Haemophilia-Eike disease due to an auto-antibody. *Brit. med. J.* 61, 1077 (1957).
14. OUCHTERLOFF, O. Diffusion-in-gel methods for immunological analysis. *Progr. Allergy* vol. 3, p. 1 (Karger Basel/New York 1958).
15. OWSEN, P. A. In J. ROSEN's Klinische Methoden der Blutgerinnungsanalyse (Thieme, Stuttgart 1959).
16. SHELTON, S. S. The immunological character of acquired inhibitors of anti-hemophilic globulin (factor VIII) and the kinetics of their interaction with factor VIII. *J. clin. Invest.* 46, 147 (1967).
17. STEFANO, M. and DANESHMANN, V. The hemorrhagic disorders; 2nd ed., p. 339 (Grune & Stratton, New York/London 1962).
18. VERSTRAETE, M. et VANDEWEGH, J. L'hémophilie compliquée par la présence d'un anticoagulant dans le sang. *Acta clin. belge* 9, 291 (1954).
19. VERSTRAETE, M. and VANDEWEGH, J. Occurrence and mode of action of endogenous circulating anticoagulants. *J. lab. clin. Med.* 48, 673 (1956).

G W Hooper Foundation and Department of Medicine Section of Hematology and Immunology University of California Medical Center San Francisco, Cal., Department of Medicine The Permanente Medical Group, Kaiser Hospital, Oakland, Cal.

Another Family Showing the Interaction of the Genes for Hb G and Hb S¹

L. E. LIN INJO, A. C. WANG² and R. C. BURNETT

The combination of haemoglobin G α and haemoglobin S β is rare. PUGH *et al* [12] described a family in which this abnormality resulted in 4 major haemoglobins in one individual and in mild anaemia. To our knowledge, no other instance of Hb G α Hb S β combination has so far been reported. More frequent are instances of Hb G α combined with Hb C β , which also lead to the presence of 4 haemoglobin components and to mild haematological symptoms. SMITH and TORBERT [18] described 4 haemoglobin components in cases of Hb Hopkins 2 - Hb S and HALL CRAIG *et al* [5] in cases of Hb S - Hb Stanleyville 11. Hb Hopkins 2 and Hb Sta II are also abnormal in the α -chains. Family studies in such cases revealed that the mutants of the α and β -chains were inherited independently of one another. The study of such exceptional families is essential to understand the mode of inheritance of haemoglobin abnormalities and to obtain a better idea of the arrangement of the genetic loci in the chromosomes. The more families that are studied, the better one can calculate the probable relative location of the genes.

We therefore believe it important to report another case of Hb G α combined with Hb S β . It provides more data on the clinical and haematological expression of such an interaction and on the chromo-

This work was supported by Research Grant HE 10486-01 by the University of California ICMRT Hooper Foundation, San Francisco Medical Center with Research Grant TW 00144 from the Office of International Research, and by Training Grant HT-05677 all from the National Institutes of Health, US Public Health Service.

Postdoctoral Fellow (No. PF-407) from the American Cancer Society

somal relationship of the genes responsible for abnormal haemoglobins in an additional family

Methods

Haematologic examinations were conducted according to standard methods. Haemoglobin electrophoresis was performed on starch gel [19] and on agar gel [15]. Alkaline denaturation of haemoglobin followed the method of STOKES *et al.* [17] with 2% of the total amount of haemoglobin taken as the upper limit of normal. The solubility test was performed by the method of ITANO [9]. Haemoglobin components were quantitatively analyzed on diethylaminoethyl (DEAE) cellulose column chromatography by the method of HUMMAN and DORY [7]. Polypeptide chains of haemoglobin were studied on starch gel electrophoresis in an urea-barbital system at pH 8.0 [4]. Fingerprinting of peptides was performed by BLOOMBERG's [2] modification of INGRAM's method [8].

Isolation of peptides. Peptides for amino acid analysis were isolated on Whatmann 33AM filter paper by one-dimensional electrophoresis followed by descending chromatography as described by INGRAM [8]. Additional purification was achieved by descending chromatography in butanol, acetic acid, and water solvent (4:1:5 upper layer 24 h). After each step of separation, guide strips were cut from both sides of the paper and dipped in ninhydrin to locate the position of the band containing the peptide to be isolated. This region was then eluted with solvent of ethanol, acetic acid and water (50:0.15:49.85) pH 3.8, and the eluate was evaporated to dryness in a desiccator.

Amino acid analysis. The isolated peptides were hydrolyzed in 6 *N* HCl under reduced pressure at 110°C for 20 h, and the amino acids were analyzed on Spico automatic amino acid analyzer (Model 120 C).

Case Report

H. E., the proband, was 43-year-old Negro man who complained of prolonged tiredness. Upon examination he was somewhat pale but normotensive and otherwise physically normal, without enlarged spleen or liver. Repeated blood examinations revealed mild anaemia with slight microcytosis. Haematological findings, when the patient was examined again on September 21, 1967 after repeated iron therapy were as follows: Hb 12.3 g per 100 ml, RBC 5.40 million/mm³, PCV 39.0%, MCV 72.2 μ m³, MCH 22.8 μ g, MCHC 31.5, reticulocytes 2.1%. WBC and platelet counts normal. The peripheral blood smear showed slight anisocytosis and poikilocytosis with few target cells. Sickling of the erythrocytes took place, although not readily when they were deprived of oxygen. Alkali-resistant haemoglobin was 0.5% of the total amount of haemoglobin. Acid elution for Hb F was negative. Serum bilirubin was not increased. Haemoglobin electrophoresis revealed 4 components: (1) Hb A, (2) haemoglobin component with the mobility of Hb S, (3) component with the mobility of Hb A₂, and (4) slower haemoglobin component more cathodic than Hb A₂ and resembling Hb B₂ (Fig. 1).

Examination of the patient's wife, 2 daughters, and 3 sons disclosed the following: S. E., the 32-year-old Negro wife, was physically and haematologically normal. Her haemoglobin electrophoretic pattern was also normal, she showed no increase of fetal haemoglobin and her Hb A₂ level was not elevated. The 2 daughters, QJ and QJ, 15 and 14 years old, were physically normal. Their peripheral blood showed slight microcytosis, anisocytosis, and poikilocytosis and contained few target cells. Results of the sickling test were positive, but sickling did not take place readily. The pattern of haemoglobin electrophoresis in these 2 daughters was identical to the father's, again consisting of 4 haemoglobin components




Fig. 1 Starch gel electrophoresis in tris-EDTA-boric acid buffer pH 8.6 of the haemolysates of patient and family

(Fig. 1) Hb F was not increased. All 3 sons were physically normal. C.E., the eldest, 17 years old, was haematologically normal and had normal haemoglobin pattern on electrophoresis, normal Hb A_2 level, and no increase of Hb F. K.E., the 11 year-old second son had a haemoglobin pattern like that of the father and two sisters. It consisted of 4 haemoglobin components, but their quantitative distribution differed (see 'Further Haemoglobin Studies') and his erythrocytes did not sickle. M.E., the 10-year-old youngest son had normal electrophoretic haemoglobin pattern without increase of Hb F or Hb A_2 . The haematological findings in all members of the family are listed in table 1. After prolonged oral iron therapy haematological studies were repeated in all members of the family but they were found to be essentially unchanged.

Further Haemoglobin Studies

Electrophoresis Haemoglobin findings on starch gel electrophoresis have already been presented (Case Report). On agar gel electrophoresis, the haemolysate of the patient and the 2 daughters, whose red blood cells




Fig. 2. Agar gel electrophoresis in citric acid-sodium citrate buffer pH 6.2 of patient haemolysate compared with that of his son K. E. and standard Hb A + S. Note that there is no separation in the haemolysate of son K. E.

showed sickling, revealed two clearly separated components, the slower-moving one having the same mobility as a standard Hb S (fig. 2). This slower component was smaller than the component with the mobility of Hb A on agar gel electrophoresis, contrary to the finding on starch gel electrophoresis. The wife and 3 sons, including K. E., who showed a component like Hb S on starch gel electrophoresis but whose erythrocytes did not sickle, each had just one band like normal Hb A, indicating that in K. E. the slow moving Hb S like component, on starch gel electrophoresis was not Hb S. This explains the inability of his erythrocytes to sickle.

Column chromatography. Quantitative analysis of haemoglobin components of family members was made by column chromatography. These components in the propositus were: Hb A 39.5%, the component with the mobility of Hb S 43.9%, the one with the mobility of Hb A₂ 14.6% and the slowest component 2%. Percentages for the same components in the eldest daughter were 37.0, 46.8, 14.8 and 1.4% respectively. Insufficient blood was obtained from the second daughter to perform quantitative analysis on column chromatography. Data for K. E., with a component like Hb S on starch gel electrophoresis, were: Hb A 70%, the component like Hb S 26.9%, Hb A₂ 2% and the slowest component 1.1%. To further demonstrate that the component like Hb S in this son was not Hb S, we separated and purified it by column chromatography. A solubility test showed that this component, unlike solutions containing Hb S, was fully

Table 1 Hematological data in patient and family members

Sex	Age years	Hb g/100 ml	RBC 10 ⁶ / mm	Hct %	MCV μ^3	MCH pg	MCHC %	MCITC % cytes	Hb A %	Hb S or Hb O %	Hb G/S ^a and Hb A ₂ %	HbA ₁ %	HbG ₄ %	Hb alt. rele- vant %
II E., propositus	M	45	11.6	3.06	73.1	23.3	30.5	2.1	32.5	45.9	14.6		2.0	0.5
S. E., wife	F	52	13.6	4.90	69.6	28.3	31.6	1.4	67.6	0	-	2.4	0	1.0
C. E., son	M	17	12.7	4.95	82.8	25.7	31.0	0.5	97.5	0		2.5	0	1.5
Qd. E., daughter	F	15	12.2	5.25	68.6	23.2	33.9	1.6	37.0	46.8	14.6	-	1.4	0.6
Qd. E., daughter	F	14	12.6	5.70	67.5	32.1	32.7	1.0	n.c.	n.c.	n.c.	n.c.	n.c.	0.9
K. E., son	M	11	11.9	5.04	66.0	23.6	33.1	0.8	70.0	26.9	-	2.0	1.1	1.5
M. E., son	M	10	11.9	4.90	77.8	24.9	31.5	0.6	97.5	0		2.5	0	0.6

Hb A₂ cannot be estimated in the presence of Hb G/S.

Not examined.




Fig. 3. Starch gel electrophoresis in urea-veronal buffer pH 8.0 of the polypeptide chains of purified haemoglobin components.

soluble in the standard phosphate buffer solution. The haemolyzates of the mother and the 2 other sons separated only into Hb A and Hb A₂, the Hb A₂ level being normal (2.4% in the mother and 2.5% in the eldest and youngest sons).

Polypeptide chain studies The different components were separated by column chromatography, concentrated, dialyzed, and their purity was determined on starch gel electrophoresis. The study of globins from the purified haemoglobin samples on starch gel electrophoresis in a urea-veronal buffer at pH 8.0 revealed that the haemoglobin with the mobility of Hb A in the probandus and his 2 daughters indeed had normal α - and β -chains. The component with the mobility of Hb S however had 4 polypeptide chains: normal α - and β -chains and abnormal α - and β -chains (fig. 3). The abnormal β -chains resembled those of Hb S. These findings indicate that the component with the mobility of Hb S actually consisted of 2 different haemoglobins: (1) Hb S (whose presence explained the positive sickling) and (2) a haemoglobin whose mobility was similar to that of Hb S on starch gel electrophoresis at pH 8.6 but which had abnormal α -chains. The patient's haemoglobin component with the mobility of Hb A₂ showed a similar abnormal α -chain and an abnormal β -chain resembling that

Table II Amino acid composition of the 9a and 9b peptides of the second son K.F.

Amino acid	Peptide 9			Peptide 9b (= 5b)		
	Present work	Molar ratio Literature value for Hb G	Number ² of residues reported for Hb G	Present work	Molar ratio Literature value for Hb G	No. of residues reported for Hb G
Lysine	1.82	1.91	2	0.99	0.91	1
Histidine				3.04	2.28	3
Aspartic acid	1.19	1.09	1	4.39	4.01	4
Threonine	0.94	0.87	1			
Serine				1.76	1.83	2
Proline				0.90	1.04	1
Alanine	1.80	2.13	2	5.13	4.92	5
Valine	1.14	0.96	1	2.09	2.03	2
Methionine				0.16	(1)	1
Leucine	1.00	1.00	1	3.00	3.00	3

BAGLIONI and IMRANI [3].

The greatest portion of the methionine in our analysis was oxidized to methionine sulfoxide which appears on the chromatogram as peak before the aspartic acid peak [11].

DISCUSSION

From the clinical and haematological findings for the patient and his two daughters, in all of whom the abnormal genes for Hb G and Hb S were present simultaneously we concluded that interaction between the 2 abnormal genes does not lead to significant impairment of health. However mild anaemia may be present, and their peripheral blood showed slight anisocytosis and poikilocytosis and a few target cells. In the case of simultaneous occurrence of Hb G and Hb E described by PUGH *et al.* [12] the patient, a child had severe anaemia and clinical symptoms. However the condition in that case was complicated by homozygosity for the Hb S gene, itself leading to severe anaemia. The child's mother on the other hand was doubly heterozygous for Hb G and Hb S and had only mild anaemia and slight changes in the peripheral blood.

Biochemically our patient and his two daughters, all with the same abnormal haemoglobin pattern, again provide evidence that normal and abnormal α -chains and normal and abnormal β -chains are produced independently as reported by other investigators. Identical peptide chains form symmetrical dimers, which combine at random and

lead to the formation of 4 major haemoglobins. As in the case of PUGH *et al* [19] 2 haemoglobins besides Hb G and Hb S are formed, Hb A with normal α and β -chains and Hb G/S with abnormal α - and β -chains. Figure 3 shows that in our patient's component 2, which consists of Hb G and Hb S the spots indicating α^0 and β^A are more pronounced than the spots indicating α^A and β^S which means that the amount of Hb G is higher than Hb S. This is in agreement with the observations of PUGH *et al* in the only other known family with Hb G and Hb S. Using a different quantitative technique they showed in their patient's mother who carried the genes for Hb G as well as for Hb S that the amount of Hb G was higher than the amount of Hb S. They postulated that the presence of some type of non-allelic genetic regulator might have impaired the normal α -chain production. The decreased availability of α_2^A subunits would then result in lower proportion of Hb A and Hb S. Whether this is always the case in Hb G and Hb S combinations cannot be said since the family of PUGH *et al* and the one described in this paper are the only ones available for study.

Genetically the family we have described is of interest because the propositus, who had two abnormal genes, was married to a normal woman. Since 2 of his children inherited both his abnormal genes, one child inherited only one abnormal gene, and 2 inherited no abnormal haemoglobin, it can be concluded that the genes are not alleles. Hence, the 2 abnormal genes are either located in 2 different chromosomes that were inherited independently or are linked in one chromosome but one son received only one abnormal gene due to crossing over. Unfortunately descriptions of such critical matings have been too few to permit a more accurate evaluation of the chromosomal relationship of the genes. In the family reported by PUGH *et al*., in which the genes for Hb G and Hb S were segregating, the observed inheritance of Hb G and Hb S was complicated because the husband was a Hb S trait carrier and therefore not normal. One child from this mating was heterozygous for Hb G and homozygous for Hb S, another was normal, and the other children were not available for study.

As already mentioned, the segregation of the genes for Hb G and Hb C β has been described more often than the combination of Hb G α and Hb S β . Since the genes for Hb C and Hb S are alleles, the mode of inheritance for Hb C also applies for Hb S and information regarding the chromosomal relationship between the Hb S β and Hb G α genes can also be derived from families in which Hb C and Hb G are

segregating. Unfortunately again in the publications about such combinations, critical matings for genetic study were rarely reported. In the family described by RAPER *et al.* [13] a man doubly heterozygous for Hb G and Hb C was married to a normal woman and they produced one doubly heterozygous child and one Hb C trait carrier. Matings less suitable for genetic information have been reported by others. In the family described by WEAVERALL *et al.* [20] a man with the Hb C trait married a woman heterozygous for Hb G. Of the 3 offspring of this mating who were examined, one was normal, one heterozygous for Hb G and 3 were doubly heterozygous for Hb G and Hb C. In the family reported by REIDER and NAUGHTON [14] a man homozygous for Hb C married a woman heterozygous for Hb G and they produced one child who was doubly heterozygous for Hb G and Hb C. In this case the Hb G was Hb G Baltimore instead of Hb G Philadelphia. In the family with Hb G and Hb C described by ATWATER *et al.* [1] the husbands of the women reported were not examined. Another combination of an α -chain abnormality with a β -chain abnormality was reported by HALL-CRAIGS *et al.* [5] in a family in which the genes for Hb S and for Hb Sta II were segregating. On starch gel electrophoresis the Hb Sta II had the same mobility as Hb S and was shown to be an α -chain abnormality, but the fingerprints revealed that it differed from Hb G. Three matings in this family were available for study. In one the husband and wife both doubly heterozygous for Hb S and Hb Sta II produced 2 children, one heterozygous for Hb S and one for Hb Sta II. In the second mating, a Hb S trait carrier married a woman doubly heterozygous for Hb S and Hb Sta-II. Five children resulted from this marriage, two were heterozygous for Hb S, one was homozygous for Hb S and one doubly heterozygous for Hb S and Hb Sta II while the fifth was homozygous for Hb S and heterozygous for Hb Sta II. In the third mating, a man doubly heterozygous for Hb S and Hb Sta II who was twice married to normal women, fathered 4 children, two were Hb Sta II trait carriers, one was normal, and one was doubly heterozygous for Hb S and Hb Sta II.

In another family in which abnormal α -chain and abnormal β -chain haemoglobins were found together Hb S was combined with Hb Hopkins-2 [18], a fast moving haemoglobin that later was shown to be abnormal in the α -chains. In the second generation of this family a critical mating took place between a woman doubly heterozygous for Hb S and Hb Hopkins-2 and a normal man, resulting in 7 children. Of 6 of them studied, one was doubly heterozygous for Hb S and

Hb Hopkins-2, 3 were heterozygous for Hb S and 2 for the fast moving Hb Hopkins-2.

From the findings so far reported and from the additional family described in this paper a close chromosomal linkage between the genes for Hb G_A and Hb S β is indeed unlikely

Acknowledgment

We wish to thank Mr ROBERT MOONSHAW of the Hooper Foundation for technical help in this study

Summary

A second family with Hb G Philadelphia (an α -chain abnormality) and Hb S is described, in which the probandus, Negro man, was doubly heterozygous for Hb G Philadelphia and Hb S and had 4 major haemoglobins: Hb G, Hb S, Hb A, and Hb G/S. His wife was normal. Two of his five children were doubly heterozygous for Hb G and Hb S and had the same haemoglobin pattern as the father; two others were normal, and another child inherited only the gene for Hb G Philadelphia. In this family the interaction between the genes for Hb G Philadelphia and Hb S led to mild anaemia and slight changes in the peripheral blood.

References

1. ATWATER, J.; SCHWARTZ, L. R. and TOGART, L. M. A variety of human haemoglobin with 4 distinct electrophoretic components. *Blood* 15: 901-908 (1960).
2. BAGLIONI, C. An improved method for the fingerprinting of human haemoglobin. *Biochem. Biophys. Acta* 48: 392-396 (1961).
3. BAGLIONI, C. and LORAM, V. M. Four adult haemoglobin types in one person. *Nature, Lond.* 189: 465-467 (1961).
4. CHESKOFF, A. I. and PATTIT, N. M. J. The amino acid composition of haemoglobin. III. A quantitative method for identifying abnormalities of the polypeptide chains of haemoglobin. *Blood* 24: 750-756 (1964).
5. HALL-CRAIG, M.; MARSDEN, P. D.; RAPER, A. B. LEHMANN, H. and BRALL, D. Heterozygous sickle-cell anaemia arising from two different haemoglobins S. Interaction of haemoglobins S and Stanleville-II. *Brit. med. J.* 4: 87-89 (1964).
6. HILL, R. L. and SCHWARTZ, H. C. A chemical abnormality in haemoglobin G. *Nature, Lond.* 184: 641-642 (1959).
7. HURMAN, T. H. J. and DORF, A. M. Studies on the heterogeneity of haemoglobin. IX. The use of Tris (hydroxymethyl) aminomethanes-HCl buffers in the anion-exchange chromatography of haemoglobins. *J. Chromatogr.* 23: 160-169 (1963).
8. LORAM, V. M. Abnormal human haemoglobins. I. The comparison of normal human and sickle-cell haemoglobins by fingerprinting. *Biochem. Biophys. Acta* 20: 539-545 (1958).
9. ITANO, H. A. Solubilities of naturally occurring mixtures of human haemoglobin. *Arch. Biochem.* 47: 148-185 (1953).

10. McCURDY P R.; PEARSON, H. and GERALD, P S. A new haemoglobinopathy of unusual genetic significance. *J lab. clin. Med.* 58: 86-94 (1961)
11. MOORE, S. and STEIN, W H. Chromatographic determination of amino acids by the use of automatic recording equipment. In COLOWICK and KAPLAN's *Methods in enzymology* Vol. 6, pp. 819-831 (Academic Press, New York 1963).
12. POON, R. P. MONGAL, T V and MORGAN, V. Sickle cell anaemia with two adult haemoglobins - Hb S and Hb G Philadelphia/S. *Blood* 23: 206-215 (1964)
13. RAPEL, A. B. GAMMACK, D. B.; HUTTON, E. R. and SMOOTHER, E. M.; Four haemoglobins in one individual. A study of the genetic interaction of Hb-G and Hb-C. *Brit. med. J.* 2: 1257-1261 (1960)
14. REIDER, R. F. and NAUGHTON, M. A.; Haemoglobin G (Baltimore) A new abnormal haemoglobin and an additional individual with four haemoglobins. *Bull. Johns Hopk. Hosp.* 116: 17-22 (1963)
15. ROMONOW, A. R.; ROMON, M.; HARRISON, A. P. and ZIMMER, W W; A new technique for differentiation of haemoglobin. *J lab. clin. Med.* 50: 745-752 (1957).
16. SCHWARTZ, H. C. SPART T II; ZIMMER, W W; NEEL, J V; ROMONOW, A. R. and KAUFMAN, S. F. Combinations of haemoglobin H haemoglobin S and thalassemia occurring in one family. *Blood* 12: 238-250 (1957)
17. SINGER, K.; CHENKOFF, A. L. and SINGER, L. Studies on abnormal haemoglobins. I. Their demonstration in sickle cell anaemia and other haematologic disorders by means of alkali denaturation. *Blood* 6: 413-428 (1951)
18. SMITH, E. W. and TORREY, J V; Study of two abnormal haemoglobins with evidence for a new genetic locus for haemoglobin formation. *Bull. Johns Hopk. Hosp.* 102: 38-45 (1958)
19. SORRISU, O. An improved procedure for starch-gel electrophoresis. Further variations in the serum proteins of normal individuals. *Biochem. J.* 71: 585-587 (1959)
20. WEATHERALL, D J. BOLEY, A. T. and BAGLIONI, C.; Four haemoglobins in each of three brothers. Genetic and biochemical significance. *Bull. Johns Hopk. Hosp.* 111: 143-156 (1962).

Authors addresses: Dr L. E. Lee Ingo, G.W Hooper Fdn. Institute for Medical Research, Kuala Lumpur (Malaysia); Dr A.G. Wamg, Dept. of Medicine, Section of Haematology University of California Med. Center San Francisco, Cal. (USA), and Dr RICHARD G. BRUMBY Dept. of Medicine, The Permanente Medical Group, Kaiser Hospital, Oakland, Cal. (USA)

The Second Department of Internal Medicine, Gama University School of Medicine,
Machida

Effect of Androgen Antagonist on Erythropoietic Action of Testosterone

T. SHIRAKURA, M. AZUMA and T. MAEKAWA

It has already been established that the prolonged administration of androgen results in an increase in erythropoiesis either in experimental animals or in patients with various types of aplastic anemia or with breast cancer [1-4] although the exact mechanism remains unknown. Some investigators have recently suggested that androgenic steroid exerts its stimulatory effect on erythropoiesis through increased production of erythropoietin in the kidney [5,6]. One of the authors has pointed out the fact that this steroid has an ability to enhance a response of the erythroid tissue to hypoxic stimuli [7]. It is well known that androgen has both anabolic and virilizing activity.

The experiments presented in this paper were carried out in order to clarify the following questions: Which activity is responsible for an increase in erythropoiesis? What relationship exists between erythropoiesis stimulating activity and these two main activities of androgen?

Materials and Methods

Experiment 1. Female rats of Wistar strain weighing 120 g were used as experimental animals, and divided into the following 5 groups. Each rat of group 1 received an intramuscular injection of 12.5 mg of testosterone as a mixture of enanthate and propionate in 0.1 ml of sesame oil (Eonmas depot® Tefuku-shiki Co.). Each rat of group 2 was injected with 12.5 mg of methenolone acetate (Primobolan depot® Schering AG) intramuscularly. Each rat of group 3 or group 4 received an intramuscular injection of 12.5 mg of testosterone or methenolone respectively and thereafter 10.0 mg of antiandrogenic agent, cyproterone acetate (1,2a-methylene-6-chloro-4 α -pregnadiene 17 α -ol-3,20-dione 17 α -acetate) [8] in

This compound was generously supplied by Dr. F. NEUMANN, Schering AG, Berlin.

0.2 ml of a benzyl-benzoate-castor oil mixture [1:5 (v/v)] was injected intramuscularly for a week. Group 5 was served as control, which received an intramuscular injection of both 0.1 ml of sesame oil and 0.2 ml of mixture of benzyl-benzoate-castor oil for a week.

Experiment 2. Female mice of ddY-strain weighing 20 to 25 g were made plethoric by two daily intraperitoneal injection with 0.5 ml of an 80 percent suspension of washed homologous erythrocytes. The plethoric mice were divided into 9 groups. Each mouse of group A, B, C, or group III E, F was given the following experimental procedures 6 days after single intramuscular injection with 2.5 mg of testosterone or with both similar dose of testosterone and 10 mg of cyproterone acetate, respectively: intramuscular administration of p.5 Co-units of purified erythropoietin (Ep) to group A and D, exposure to hypoxia of $\frac{1}{2}$ atmosphere for 12 h to group B and E, and intramuscular injections with 0.5 ml of normal saline to group C and F. This injection with testosterone or with both testosterone and cyproterone acetate was carried out on the day of the last infusion of erythrocyte suspension. Six days after the last infusion of erythrocyte suspension, each mouse of group G, H or I was given the above described experimental procedures except the injection with testosterone or with both testosterone and cyproterone acetate.

Experiment 3. Seventeen plethoric mice similar to those used in experiment 2 were divided into 4 groups consisting of 4 to 6 mice. Each mouse of group J, K, L or M was injected with 0.5 Co-units of Ep, both 0.5 Co-units of Ep and 10 mg or 5 mg of cyproterone acetate, 0.5 ml of normal saline, respectively.

Quantitative determination of erythropoietin was done as follows: rats were injected with 0.5 μ Ci of radioiron (^{59}Fe Cl_3) intravenously 24 h after the last injection of mixture of benzyl-benzoate-castor oil or cyproterone. Mice were similarly injected with 0.5 μ Ci of radioiron intraperitoneally 36 h after the last injection of normal saline. Ep, hypoxic stimulation. The percentage of ^{59}Fe incorporation into red cell mass was determined from the radioactivity of the blood sample taken by cardiac puncture on 24th h in rats and 72nd h in mice after the injection of radioiron, assuming the total blood volume of test animal is 5.0% (in rat) or 7.0% (in plethoric mouse) of the body weight.

Bioassay for erythropoietin was carried out by Mitsuoka's method [8]. Plasma samples obtained from each animal of the same experimental group were pooled and stored at 20°C until bioassay for erythropoietin activity was done. Activity of the erythropoietin in the pooled plasma sample was expressed as percentage of ^{59}Fe utilized by red cell mass of bioassay mice in 24 h.

Results

1 Effect of androgen antagonist on ^{59}Fe incorporation into red cell in testosterone or anabolic hormone treated rats. As shown in table I significant increase in both ^{59}Fe incorporation and reticulocyte counts was noted in rats injected either with testosterone (group 1) or with methenolone (group 2). The activity of erythropoietin in pooled plasma obtained from these animals was evidently elevated as compared with control rats of group 3. There was, however, no significant difference in these values between group 1 and 2. Cyproterone administration did not suppress the enhancing effect of testosterone or methenolone both on ^{59}Fe incorporation into red cell and on erythropoietin activity in

Table I. Effect of androgen antagonist on erythropoiesis and plasma erythropoietin level of female rats treated with testosterone or anabolic hormone

Experimental group	No. of animals	% ⁵⁹ F incorp. into RBC	Reticulocyte count, %	Plasma erythropoietin level, %
Rats injected with Testosterone (group 1)	5	34.8 ± 5.9	6.26 ± 1.18	4.53 ± 1.38
Methenolone (group 2)	5	31.6 ± 4.5	5.06 ± 0.29	2.21 ± 0.81
Both Testosterone and Cyproterone (group 3)	5	29.6 ± 4.0	5.02 ± 1.44	3.18 ± 1.09
Both Methenolone and Cyproterone (group 4)	5	28.5 ± 5.4	4.30 ± 1.56	2.71 ± 1.02
Normal control (group 5)	8	23.6 ± 4.8	3.5 ± 1.30	0.62 ± 0.21
Mean ± S.D. of the mean.				

Table II. Effect of androgen antagonist on erythropoietic synergism of testosterone with erythropoietin or hypoxia

Experimental group	No. of animals	% ⁵⁹ F incorporation into RBC
Mice pretreated with testosterone		
Erythropoietin (group A)	5	16.20 ± 3.15
Hypoxia (group B)	4	12.38 ± 2.48
Saline (group C)	5	3.65 ± 1.83
Mice pretreated with both testosterone and cyproterone		
Erythropoietin (group D)	5	13.49 ± 2.18
Hypoxia (group E)	4	9.15 ± 2.33
Saline (group F)	5	2.76 ± 1.67
Normal mice		
Erythropoietin (group G)	5	9.50 ± 2.24
Hypoxia (group H)	6	3.44 ± 1.12
Saline (group I)	5	0.42 ± 0.13
Mean ± S.D. of the mean.		

Table III. Effect of androgen antagonist on an enhancing ^{59}Fe incorporation into RBC in plethoric mice induced by exogenous erythropoietin

Experimental group	No. of animals	Hematocrit %	% ^{59}Fe incorporation into RBC
0.6 Co-U of erythropoietin (group J)	4	63.7 ± 3.7	18.20 ± 2.21
Both 0.6 Co-U of erythropoietin and 10 mg of Cyproterone (group K)	4	59.3 ± 4.4	19.00 ± 2.25
Both 0.6 Co.-U of erythropoietin and 5 mg of Cyproterone (group L)	4	58.5 ± 3.5	16.72 ± 4.00
Saline (group M)	3	62.0 ± 3.0	0.88 ± 0.22

Mean \pm S.D. of the mean.

plasma. Similarly cyproterone exhibited no inhibitory effect on an erythropoietic action of methenolone, as seen in table I

2 *Effect of androgen antagonist on erythropoietic synergism of testosterone with erythropoietin or hypoxia.* The results obtained are shown in table II. The combined effect of administration of testosterone with an erythropoietin injection (group A) or exposure to hypoxia (group B) on ^{59}Fe incorporation into red cell exceeded the value calculated from the sum of each stimulus (group C, G and H). From the results obtained in mice of group A and D or group II and E, it was evident that the treatment with cyproterone did not change the synergistic effect of testosterone with erythropoietin or hypoxia on erythropoiesis.

3 *Study of the inhibitory effect of androgen antagonist on erythropoiesis.* The results obtained in experiment 3 are listed in table III. Administration of 50 or 100 mg of cyproterone did not exert influence upon the enhancing ^{59}Fe incorporation into red cell induced by an exogenous erythropoietin given simultaneously

Comment

It is noteworthy that methenolone has the same erythropoietic activity as testosterone at an equal dose level, despite the fact that the virilizing effect was one fourth of that of testosterone. This finding indicates that an erythropoietic stimulating activity of testosterone may not directly related to its virilizing effect. DUARTE *et al.* have also reported similar

results [9] Cyproterone acetate used in these experiments has no estrogenic effect but blocking activity of androgen receptor in target organ [10-11]. The results obtained hereabout reveal that cyproterone has no inhibitory effect on erythropoiesis stimulating action of either testosterone or methenolone. An increase in erythropoiesis induced by testosterone should be prevented by this androgen antagonist, if an erythropoietic action of testosterone is related directly to its androgenic effect. There are some evidences indicating that increase in erythropoiesis by testosterone results from an elevation in endogenous erythropoietin activity. Cyproterone did not affect the action of exogenous erythropoietin. Thus, it is indicated from the results presented here that the erythropoietic activity of testosterone is at least independent of its virilizing effect. Administration of androgen antagonist could not inhibit a synergistic effect of testosterone with hypoxia or erythropoietin on erythropoiesis. It is also possible to say that these synergism might not be based upon the virilizing effect of testosterone, although mechanism on these synergism remains to be clarified.

Summary

The mechanism of erythropoietic action of testosterone, especially its relation to virilizing effect was studied, and the following results were obtained. (1) At an equal dose level methenolone has the same erythropoietic activity as that of testosterone. (2) Treatment with sufficient amount of cyproterone acetate failed to suppress an erythropoietic effect of testosterone, methenolone or exogenous erythropoietin. Cyproterone acetate did not prevent significant increase in erythropoietin level in plasma by injecting testosterone or methenolone. (3) Synergistic effect of testosterone with exogenous erythropoietin or hypoxia on red blood cell formation was not affected by cyproterone acetate. From these results it is suggested that the erythropoietic action of testosterone is independent of its virilizing effect.

References

1. SEITAKEIRA, T. AIZUMI, M. and MAEKAWA, T. Studies on erythropoietic action of testosterone. *Acta haemat.*, Basel 38: 49 (1967).
2. SHALITA, N. T. and DIAMOND, L. K. Testosterone-induced remissions in aplastic anemias of both acquired and congenital types. *New Engl. J. Med.* 264: 953 (1961).
3. GARBER, F. H. and PERWILL, J. C., J. Androgens and erythropoiesis. II. Treatment of myeloid metaplasia. *New Engl. J. Med.* 264: 103 (1961).
4. KLEGGY, B. J. and GOLDSTEIN, A. S. Increased erythropoiesis induced by androgenic hormone therapy. *New Engl. J. Med.* 286: 719 (1957).
5. FRIED, W. and GERSHAY, C. W. The erythropoietic response to testosterone in male and female mice. *J. lab. clin. Med.* 67: 420 (1966).
6. ALEXANDER, R.; VAUGHN, W. K. and RICHIELMAN, M. W. Erythropoietin excretion in man following androgens. *J. lab. clin. Med.* 70: 777 (1967).

7. SEIBAKURA, T. Zur erythropoetischen Wirkung von Testosteron. *Acta haemat., Basel* 39: 366 (1968).
8. MIRALTO, E. A., GORDON, A. S. and WIDDO, J. Mechanism of testosterone action in erythropoiesis. *Nature, Lond.* 206: 270 (1965).
9. DUARTE, L., MIRAL, L. S., LARSEN, J. and ARRIAS, L.: The erythropoietic effects of anabolic steroids. *Proc. Soc. exp. Biol., N.Y.* 123: 1030 (1967).
10. RAYMUND, A.: Morphogenesis of the mammary gland, in Kow and Cowen's (eds.) *The mammary gland and its secretion*, p. 3 (Academic Press, New York/London 1961).
11. NEUMANN, P. and ELGER, W. The effect of the anti-androgen 1,2 α -methylene-6-chloro- Δ^4 -pregnadiene-17 α -ol-3,20-dione-17 α -acetate (cyproterone acetate) on the development of the mammary glands of male foetal rats. *J. Endocrin.* 36: 347 (1966).

Departments of Clinical Chemistry and Internal Medicine, University of Uppsala, University Hospital, Uppsala

Maintenance Therapy of Pernicious Anaemia

Comparison of Cyanocobalamin, Hydroxocobalamin and a Cyanocobalamin-Zinc-Tartrate Complex

A. KILLANDER and I. WERNER

The proper evaluation of different compounds for maintenance therapy in pernicious anaemia has always been difficult. It is well known that following interruption of treatment the time at which a relapse occurs may vary considerably in different patients [19, 15, 8, 4]. In a previous communication we reported the serum B_{12} levels in 45 patients after discontinuation of B_{12} therapy [12]. Twenty patients reached low levels (100 pg/ml and less) within the first year and a further 20 within the second year. One patient was still normal after 26 months whereas the remaining 4 cases did not show low values until 44 months or more after the specific treatment had been discontinued. The reasons for this large individual variation are incompletely known.

The earliest sign of B_{12} deficiency is a subnormal serum level of this vitamin [13, 10]. By taking serial blood samples different B_{12} compounds can be compared, using the patient as the control. The results of such a study are presented in this paper. The substances tested were cyanocobalamin (CN B_{12}), hydroxocobalamin (OH B_{12}) and cyanocobalamin-zinc tannate complex (Zn B_{12}). These abbreviations are used throughout the paper.

Material

The series consisted of 22 patients with untreated pernicious anaemia. In all cases positive diagnosis was indicated by the presence of the following criteria: macrocytic anaemia, megaloblastic bone marrow, histamine-fast achlorhydria, serum B_{12} concentration of 100 pg/ml and less and typical response to B_{12} therapy. In 17 cases all 3 B_{12} preparations

were studied consecutively at least once. The remaining 5 patients for different reasons were given only II of the compounds. All vitamin B₁₂ compounds used contained 1 mg/ml. The following preparations of the above mentioned substances were used Hepagon forte® (cyanocobalamin) Redhol® Hepagon novum® (hydroxycobalamin) Depimar® (cyanocobalamin-calciumtartrate)¹

Methods

Routine haematological methods were used. The assay of vitamin B₁₂ activity in serum and urine was performed microbiologically using *Escheria gracilis* strain [8]. In our laboratory values of 100 pg/ml or less are defined as being abnormally low and indicating B₁₂ deficiency. Values between 100 and 150 pg/ml are regarded as borderline and those between 150 and 900 pg/ml as normal. Urine was collected for 24 hour periods, kept in refrigerator at +4°C for not more than 48 h. Frozen aliquots were stored at -20°C until assayed. In some cases ¹⁴Co- or ⁵⁷Co-labelled vitamin were used in the excretion studies. The radioactivity was measured in 1,000 ml volumes in a scintillation counter. The rate of absorption of the different compounds from the site of injection was studied using radioactive vitamin and surface counting.

Each patient received as initial injection of 1 mg of either CN B₁₂, OH B₁₂ or Zn B₁₂. Haemoglobin concentration, red cell count, reticulocyte count and serum B₁₂ levels were estimated at frequent intervals following the initial injection until normal blood levels were seen. After this period haemoglobin or haematocrit determinations and serum B₁₂ levels were performed monthly or in some cases every second month. The interval from the injection to the first low serum B₁₂ value was taken as a measure of the duration of the therapeutic effect of the substance tested. After the second consecutive low value a second injection of another type of B₁₂ was given. The haemoglobin or haematocrit values as well as the serum B₁₂ levels were followed monthly as before. A third injection again of different substance was given following the finding of two further consecutive subnormal values. In some cases the experiment was continued for up to 3 more injection-relapse cycles.

Results

All 5 preparations were studied in 17 patients. Five of these had CN B₁₂, 5 had OH B₁₂ and 7 had Zn B₁₂ as their first injection. A full haematological remission was obtained in all patients by this initial injection of 1 mg of vitamin B₁₂. No differences were found between the groups of patients with regard to the time and height of the reticulocyte peak or the rate of increase in the number of red cells. Haematological remission was also maintained during the following experiments and no neurological symptoms or signs developed in any patient. Nor were any other symptoms encountered which could be attributed to B₁₂ deficiency.

We are greatly indebted to AB Astra, Sweden, Merck, Sharp & Dohme Inc., Rahway N.J. USA and Arpocor Pharmaceutical Company, Kankakee, Ill., USA for the gift of these preparations.




Fig. 1 Seventy-two hour urinary excretion of vitamin B₁₂ after single injection of 1 mg of CN B₁₂, OH B₁₂ and Zn B₁₂. Each block represents 72 hour period in one patient.

Urinary Excretion

The 72 hour urinary excretion of CN B₁₂, OH B₁₂ and Zn B₁₂ was studied in 9, 13 and 11 patients respectively. Nine patients were subjected to 2 or 3 excretion studies. The excretion of CN B₁₂ and OH B₁₂ is negligible after 72 h. In the case of Zn B₁₂ the situation is variable. Usually there is a protracted excretion between 72 h and 168 h, in some cases amounting to 5–10%. The results are presented in figure 1. The mean and range of excretion for the 3 substances were CN B₁₂ 746 µg (543–1 000), OH B₁₂ 284 µg (99–647) and Zn B₁₂ 112 µg (3–535). Although there was considerable variation between the different patients it was evident that much more was lost after a single injection of 1 mg of CN B₁₂ than of the other 2 compounds tested. About 75% of the CN B₁₂, 30% of the OH-compound and 10% of the Zn B₁₂ was lost in the urine during the first 3 days.

In a few cases excretion studies were performed using both an isotope technique and microbiological assay. In the case of CN B₁₂ alone or in the zinc-tannate complex there was good agreement between the results obtained from the two methods. In some cases that were given OH B₁₂ the excretion of radioactivity was considerably higher than the corresponding microbiological activity. The reason for this discrepancy was most probably that the urine had been left at room temperature. We have found that urine samples left at room temperature will at times cause a fall in B₁₂ activity when OH B₁₂ is present but not with solutions of CN B₁₂. The figures given for OH B₁₂ excretion thus




Fig. 2. Rate of absorption of 1 mg radioactive CN B₁₂ (—○—) OH B₁₂ (---○---) and Zn B₁₂ (—○—) from the site of injection.

represent minimum values as it cannot be excluded that some of the urine samples may have been subjected to mishandling as mentioned above

Rate of Absorption

This was studied in 7 patients. A possibility of a difference between subcutaneous and intramuscular administration was investigated in one patient. One mg of radioactive CN B₁₂ was injected intramuscularly in the gluteal region and subcutaneously in the thigh on 2 consecutive days. There was a slight difference in the absorption rate between the 2 routes of administration. Fifty % of the dose had disappeared 42 min after the intramuscular injection and 48 min after the subcutaneous injection. In the other 6 patients the radioactive compounds were only given intramuscularly. The absorption rate of the 3 compounds differed considerably as illustrated in figure 2. Thus, 50% of the injected dose of CN B₁₂ disappeared 26 and 42 min after the injection (2 cases). The corresponding figures for OH B₁₂ was 2.5 h (one case) and for Zn B₁₂ 1 to 2.4 days (4 cases).

The Serum B₁₂ Levels

The time from the injection to the first serum B₁₂ level found to be 100 pg/ml and below was considered as the duration of the therapeutic




Fig. 3. The serum B_{12} values of case H.F.

effect. This level was chosen since all patients, when started on therapy had serum B_{12} values below this level. In order to ascertain that a stable subnormal B_{12} level had been reached the next injection was not given until a second low value had been obtained. In this way the conditions at the time of injection were considered to be as standardized as possible without exposing the patients to the risks of a relapse. It is reasonable to believe that the B_{12} deficiency was most pronounced at the time of the first injection. For this reason the 3 compounds were injected in random order. In this way other possible systematic errors were also avoided.

The results showed a considerable individual variation, the extremes are represented by patient H. F. and K. J. Their serum B_{12} levels after the injection of the different compounds are illustrated in figure 3 and 4. In the case of H. F. the effect of the first CN B_{12} injection did not even last one month. The effect of the long-acting preparations was 1 to 3 months. In the case of K. J. the effect of CN B_{12} lasted 2.5 months. After the injection of Zn B_{12} the serum B_{12} level remained above 100 pg/ml for 18 months. After the same amount of OH B_{12} the B_{12} levels were above 100 pg/ml for more than one year when the patient died from a cerebral haemorrhage.

The data from all 22 patients are shown in figure 5. The mean values are given in table I. It is evident that the duration of the therapeutic effect of OH B_{12} and Zn B_{12} is considerably longer than



Fig 4. The serum B_{12} values of case K.J.

Fig 5. The duration of serum B_{12} levels above 100 pg per ml following injections of 1 mg of $CN\ B_{12}$, $OH\ B_{12}$ and $Zn\ B_{12}$. The preparations are pictured in the order of administration.

Table 1

Substance	No. of injection-relapse-cycles	Duration of cycle in months	
		mean	range
Cyanocobalamin	21	2.1	1- 7
Hydroxocobalamin	20	7.1	2-22
Cyanocobalamin-zinc-tannate	22	6.3	2-18

that of CN B₁₂. The results also suggest that the effect of CN B₁₂ given as the first injection was much shorter (1 to 2 months) than the effect of the same compound given as second or third injection (1 to 7 months). No significant difference related to the order of injections was found between the other two preparations. The explanation for this prolonged effect of cyanocobalamin was that there probably remained a certain depot effect of the previously given OH B₁₂ or Zn B₁₂. A depot effect of this kind might well influence the short period of normal B₁₂ level after injections of CN B₁₂ but be of no significance in the longer periods following injections of OH B₁₂ or Zn B₁₂. However the number of the observations was too small to permit any definite conclusions. No significant differences could be observed between the duration of the effects of OH B₁₂ and Zn B₁₂.

Discussion

During the last few years several reports on the therapeutic effect of so-called long acting B₁₂-preparations have been published. The preparation studied are in principle of two types. One is the OH B₁₂, the protracted effect of which is due to its affinity to both specific and un-specific binding proteins in blood and tissues [7]. The other type is represented by preparations in which either zinc-tannate [18] or tannate in a sesame oil/aluminium monostearate gel [16] have been added to CN B₁₂ in order to decrease its solubility. In this study only the zinc-tannate-cyanocobalamin complex was used. The cyanocobalamin tannate complex in aluminium monostearate/sesame oil gel (B₁₂ TAM- ϕ -Dumex) was not available when this investigation was started.

Several reports have been published comparing the effect of OH B_{12} with that of CN B_{12} . It is evident that the urinary excretion of OH B_{12} is much lower than that of CN B_{12} [5 11 6]. The large individual variation found by us has been reported by several authors and there are also considerable differences in the excretion data reported by different laboratories.

The absorption rate from the injection site was studied by GLAM *et al.* [5] and by KILLANDER and SCHILLING [11]. They found a slower rate of absorption with OH B_{12} compared to CN B_{12} . Our results agree with their findings. In our 4 cases that were given Zn B_{12} , 50% of the radioactivity had disappeared by about 2 days. No other reports on the absorption rate of Zn B_{12} seem to have been published. KARSTEN *et al.* [14] working with B_{12} TAM found an appreciable activity at the site of injection 2 months after the administration of 1 mg. The absorption rate measured as the disappearance of 50% of the radioactivity was about 20 days. The absorption rate for the TAM preparation thus seems to be extremely slow compared to that of the substances studied in the present investigation.

Serum B_{12} levels after single injections of OH B_{12} have been reported by several authors. They all found much higher levels both initially and after several weeks when compared with CN B_{12} in pernicious anaemia patients [2, 20, 3]. After a single injection of 1 mg of OH B_{12} normal values of serum B_{12} were observed in several patients for periods of 6 to 13 months. The present study clearly demonstrates these differences between the hydroxo- and cyanoforams of the vitamin, although the individual variation is considerable (fig 5). No other reports are available of the effect of Zn B_{12} on the serum B_{12} levels in pernicious anaemia patients. Our results indicate an effect quite similar to that of OH B_{12} . Studies on the B_{12} TAM have also shown a protracted effect of the same order of magnitude [1].

It is evident that the urinary excretion of vitamin B_{12} is much less after the injection of OH B_{12} and Zn B_{12} than after CN B_{12} . Both OH B_{12} and Zn B_{12} are able to maintain a normal serum B_{12} level for a much longer time than CN B_{12} . These two points indicate that better results can be obtained with these 2 preparations than with CN B_{12} .

The close similarity of the effects of OH B_{12} and Zn B_{12} is somewhat surprising. To judge from the low disappearance rate and the urinary excretion figures a much longer duration of the zinc-tannate compound would have been anticipated. A prolonged urinary excretion of Zn B_{12} observed in a few patients might be one explanation. A defect utiliza-

tion of the compound would also explain the above findings. The OH B₁₂ represents a more physiological form of the vitamin and it can be assumed that what is retained is also used and metabolized normally in the body. Zn B₁₂ is an artificial, non-physiological compound of the vitamin and zinc tannate. Without further evidence it cannot be assumed that this highly insoluble material will be completely utilized by the body.

Summary

A comparative study was performed on 3 types of vitamin B₁₂: cyanocobalamin (CN B₁₂), hydroxycobalamin (OH B₁₂) and cyanocobalamin-zinc-tannate complex (Zn B₁₂). The rate of absorption from the site of injection of CN B₁₂, OH B₁₂ and Zn B₁₂ measured as the disappearance of 50% of the radioactivity was approximately 40 min, 2.5 h and 2 days respectively. The 72-hour urinary excretion rate after injection of 1 mg of the B₁₂ preparation was on the average 75% for CN B₁₂, 30% for OH B₁₂ and 10% for Zn B₁₂. A complete haematological remission was obtained in all cases after single injection of 1 mg of all three substances. The serum B₁₂ level was maintained above 100 pg/ml for an average time of 2.1 months with CN B₁₂, 7.1 months with OH B₁₂ and 6.3 months with Zn B₁₂. It is concluded that the effect of OH B₁₂ and Zn B₁₂ is superior to that of CN B₁₂.

References

1. BASTIEN-MADSEN, P.; NØRREGAARD, S.; SCHWARTZ, M.; HANSEN, T. and MØLLER-GRASCH, E. Serum-vitamin B₁₂ during maintenance therapy in pernicious anaemia with depot preparation of vitamin B₁₂. *Lancet* ii: 739 (1966).
2. BOCHER, M. S., BOTTOMLEY, A. G. and ISRAELI, M. G. G. Hydroxycobalamin for pernicious anaemia. *Lancet* ii: 173 (1964).
3. CHALMERS, J. N. M. and SEWTON, N. K. Comparison of hydroxycobalamin and cyanocobalamin. In the treatment of pernicious anaemia. *Lancet* ii: 1305 (1965).
4. DARY, W. J.; JONES, E.; CLARK, S. L., J.; McQUAMITY, W. J.; DE OLIVEIRA, J. D.; PIERCE, C.; KRYVY, J. and LE BENOIST, J. The development of vitamin B₁₂ deficiency by untreated patients with pernicious anaemia. *Amer. J. clin. Nutr.* 6: 315 (1958).
5. CLARK, G. B. J.; SKELTON, N. R.; LEE, D. H.; JONES, E. L. and HARDY, W. W. Hydroxycobalamin. I. Blood levels and urinary excretion of vitamin B₁₂ in man after single parenteral dose of aqueous hydroxycobalamin, aqueous cyanocobalamin and cyanocobalamin-zinc-tannate complex. *Blood* 18: 511 (1961).
6. HEDERICH, H. L. und GABER, E. E. Intravitale Retention und Exkretion des Aquocobalamins, einer für die Therapie geeigneten natürlichen Vitamins B₁₂-Depotform. *Klin. Wochschr.* 39: 689 (1961).
7. HERTZ, H.; KENTHEDER, H. P. and HOFF-JENSEN, E. Studies on vitamin B₁₂ retention: comparison of retention following intramuscular injection of cyanocobalamin and hydroxycobalamin. *Scand. J. Haemat.* 1: 5 (1964).
8. HUTNER, S. H.; BACH, M. K. and ROW, G. I. M. A sugar-containing basal medium for vitamin B₁₂-sensitivity with Euglena: application to body fluids. *J. Protoc.* 3: 101 (1956).
9. JONES, E.; TELLMAN, G. C. and DARY, W. J. Observations on relapses in pernicious anaemia. *Ann. intern. Med.* 30: 374 (1949).

10. KILLANDER, A.: Oral treatment of pernicious anaemia with vitamin B₁₂ and purified intrinsic factor. *Acta med. scand.* 160: 339 (1958)
11. KILLANDER, A. and SCHILLING, R. F.: Studies on hydroxocobalamin. *J. Lab. clin. Med.* 57: 553 (1961)
12. KILLANDER, A. and WERNER, I.: Studies on maintenance treatment of pernicious anaemia; in HEDERSTRÖM Vitamin B₁₂ und Intrinsic Factor 2. europ. Symp. über Vitamin B₁₂ und Intrinsic Factor p. 663 (Einko Stuttgart 1962)
13. KRISTENSEN, H. P. ■ LUND, J.; ØSTLUND, A. S. and PEDERSEN, J.: Maintenance therapy in pernicious anaemia. *Lancet* i: 1266 (1957)
14. KRISTENSEN, K., BASTRUP-MADSEN, P.; NØRREGAARD, S. og SCHWARTZ, M.: Et injicerbart B₁₂-vitamin-præparat (Betolven) med rettet absorption. *Ugeskr. Læg.* 124: 1681 (1962)
15. SCHWARTZ, S. O. and LEONARD, H.: Relapses in pernicious anaemia. *J. amer. med. Ass.* 124: 837 (1944)
16. SCHWARTZ, M.; BASTRUP-MADSEN, P., NØRREGAARD, S. and KRISTENSEN, K.: A vitamin-B₁₂ preparation with retarded absorption. *Lancet* ii: 1181 (1962)
17. SKOUBY, A. P.: Retention, distribution og forbrug af B₁₂-aktivt efter parenteral indgift af hydroxocobalamin (Vibeden). *Ugeskr. Læg.* 126: 253 (1966)
18. THOMPSON, R. E. and HUGHES, R. A.: Studies on a long-acting vitamin B₁₂ preparation. *Amer. J. clin. Nutr.* 7: 311 (1959)
19. WALDENSTRÖM, J.: Remissioner vid leverbehandlad pernicios. *Nord. Med.* 16: 3206 (1942)
20. WHITEY, J. and KELF TRICK, G. S.: Hydroxocobalamins and cyanocobalamins in Addisonian anaemia. *Lancet* i: 16 (1964).

Laboratory of Experimental and Clinical Hematology Pavlov Institute of Physiology of the
USSR Academy of Sciences, Leningrad

DNA Synthesis by Erythroblasts in Normal Man and in Some Disorders of Erythropoiesis

A. J. JAROSHEVSKY V. J. PLOTKIN and G. J. SHEKTER

At present H-thymidine, a specific precursor of DNA, is generally used for the study of the proliferation of the bone marrow cells. Our paper presents investigations on the proliferative activity of the erythroblasts in 13 normal subjects and in 20 patients with marked disorders of erythropoiesis.

Materials and Methods

Bone marrow samples were obtained by sternum puncture and were cultivated in liquid medium containing the patient's own plasma and Haeck's isotonic solution with heparin. ³H-thymidine (specific activity 3.6 c/g) was added to the medium in the end concentration equal to 0.1 µc/ml. The bone marrow suspension in the nutrient medium was carried in 4 tubes in 1 ml and cultivated in shaking incubator at 37°C. In the first tube the incubation was stopped after 15 min, in the other tubes after 1/2, 1 and 2 h. After the incubation the tubes were centrifugated and smears were prepared from the sediment and fixed with methanol during 10 min. Autoradiography was carried out by the method of Zaslavsky [21]. A liquid nuclear emulsion of the R-type was used.

The smears were stained using Boy's technique [5]. Thirty to 40 young cells (proerythroblasts and basophilic normoblasts), 100 polychromatophilic normoblasts and 50 orthochromatic normoblasts were calculated. The percentage of labeled cells was calculated in each group of cells.

The generation time of cells was calculated using the formula of Dornow and Dornow [8] for the exponentially growing population

$$T = \frac{\ln 2}{\lambda} \quad \text{where} \quad \lambda = \frac{\Delta N}{(N + N_p) \Delta t}$$

T = generation time. $\ln = 0.693$. ΔN = accretion of the number of cells during time t. N = number of cells in period of DNA synthesis. N_p = proliferative pool, i.e. the ratio of cells capable for division and all cells of the given species.

Emulsion "R" is produced at the Research Chemo-photographic Institute, Moscow (USSR)

Table 1 Clinical and hematological data of 15 patients with hypoplastic and iron deficiency anemia

Pat. No.	Diagnosis	Age years	Sex	Length of disease, years	RBC/mm ³ × 10 ⁹	Hb, g %	Ht, %	WBC/mm ³ × 10 ⁹	Leucocytes %						Thrombocytes/mm ³ × 10 ⁹	Serum iron, mg %
									stiff cells	segmented neutrophils	lymphocytes	Sedimentation rate mm/h	Reticulocytes, %			
1	Hypoplastic anemia	48	F	0.3	3.1	11.7	1.1	3.3	2.5	38	39	11	1.8	95		
2	Hypoplastic anemia	63	M	0.3	3.0	10.6	1.0	4.6	14.5	20	37.5	10	1.2	20		
3	Hypoplastic anemia	27	F	0.5	1.4	4.35	0.92	2.0	22	17	53	8	-	10		
4	Hypoplastic anemia	19	F	1.2	2.5	6.33	1.0	2.0	10	29	49	20		10		
5	Hypoplastic anemia	14	M	0.2	3.0	11.33	1.1	3.26	1	8	82	20		37.3		
6	Chronic posthemorrhagic anemia	29	F	0.73	4.46	9.8	0.67	5.5	0.5	72.5	13	16	2.3	3.79	11	
7	Chronic posthemorrhagic anemia	31	M	5	3.9	9.5	0.73	4.7	2	63	25	-				
8	Chronic posthemorrhagic anemia	47	F	1	3.5	9.3	0.81	3.5	1.5	51	32	22		318	14	
9	Chronic posthemorrhagic anemia	49	F	1	4.8	8.2	0.5	5.5	1	74	11.3	11	0.8	328		
10	Chronic posthemorrhagic anemia	40	F	0.8	4.0	9.2	0.68	6.33	6	63.3	22.5	11	1.2		50	
11	Chronic posthemorrhagic anemia	50	F	2	4.4	9.8	0.63	4.6	0.5	68.5	21.5	17			55	
12	Chronic posthemorrhagic anemia	34	M	3	5.2	10.3	0.6	5.1	2.5	55.5	52.5	12	1	296	40	
13	Essential hypochromic anemia	57	F	3	4.7	10	0.8	5.1	1	59	18	12	0.7	220	70	
14	Essential hypochromic anemia	41	F	0.5	4.4	9.4	0.73	4.7	0.5	60.3	30.3	12		240	50	
15	Essential hypochromic anemia	46	F	16	3.6	8.5	0.7	4.7	0.5	70	21.5	12	0.2		20	

Table II. Clinical and hematological data of patients suffering from polycythemia vera

Pat. No.	Age years	Sex	Length of disease years	RBC/ $\text{mm}^3 \times 10^9$	Hb, g%	WBC/ $\text{mm}^3 \times 10^9$	Thrombo- cytes/ $\text{mm}^3 \times 10^9$	Sedim. rate mm/h	Viscosity of blood	Hematocrit %	Increase of liver spleen	
1	39	M	1	6.44	21.0	13.0	520	2	16.6	63/17	+	+
2	43	M	14	8.1	18.3	7.2	130	1.5	8.5	70/30	+	+
3	42	F	2	6.08	17.6	14.2	600	2	III	80/20	+	+
4	58	M	3	6.95	21.0	29.2	400	2	12.5	79/21	+	+
5	34	F	5	7.25	23.6	4.4	170	1	16.6	68/12	+	+

It was assumed in the calculations that there is a constant concentration of ^3H -thymidine in equal to 1 L., all cells after a period of DNA synthesis are divided and their destruction is minimal.

Control subjects were donors selected for bone marrow transplantations. Among the patients 5 had hypoplastic anemia, 5 polycythemia vera and 10 iron-deficiency anemia (7 chronic posthemorrhagic and 3 essential hypochromic anemias). The clinical and hematological data of the patients are shown in tables I and II.

Results

1 Normal subjects. After 15 min incubation of bone marrow in the presence of ^3H -thymidine the percentage of the label in pronormoblasts and basophilic normoblasts was 76.6 ± 0.73 and in polychromatophilic normoblasts 23.0 ± 0.86 . After 2 h incubation there was a significant increase of the label ($p < 0.01$) up to 88.8 ± 1.1 and 37.6 ± 2.4 correspondingly (orthochromic normoblasts did not incorporate ^3H thymidine).

The generation time of pronormoblasts and basophilic normoblasts was 17.8 ± 0.94 h, and that of polychromatophilic normoblasts 11.2 ± 1.1 h.

2. Hypoplastic anemia. After 15 min of cultivation the percentage of the label was 31.5 ± 6.06 in pronormoblasts and basophilic normoblasts and 8.2 ± 2.04 in polychromatophilic normoblasts. After 2 h the percentage increased up to 66.5 ± 5.03 and 14.6 ± 1.34 correspondingly.

The generation time of pronormoblasts and basophilic normoblasts was 4.9 ± 0.6 and that of polychromatophilic normoblasts 17.6 ± 3.72 h.

3 *Polycythaemia vera*. After 15 min cultivation the percentage of the label was 68.2 ± 1.87 in pronormoblasts and basophilic normoblasts and 19.7 ± 2.45 in polychromatophilic normoblasts. After 2 h it was 85.5 ± 2.93 and 33.3 ± 4.1 correspondingly.

The generation time of pronormoblasts and basophilic normoblasts was 11.7 ± 1.2 h, and in polychromatophilic normoblasts it was 11.6 ± 0.9 h.

4 *Chronic posthemorrhagic anemia*. After 15 min cultivation the percentage of the label was 69.8 ± 3.66 in pronormoblasts and basophilic normoblasts and 24.3 ± 3.65 in polychromatophilic normoblasts. After 2 h incubation the label was 86.9 ± 1.9 and 32.5 ± 2.6 correspondingly.

The generation time of pronormoblasts and basophilic normoblasts was 12.7 ± 1.5 h and that of polychromatophilic normoblasts 17.5 ± 3.39 .

5 *Essential hypochromic anemia*. After 15 min incubation the percentage of the label was 76.3 ± 2.0 in pronormoblasts and basophilic normoblasts and 22.0 ± 0.26 in polychromatophilic normoblasts. After 2 h it was 87.6 ± 3.9 and 31.6 ± 1.2 correspondingly.




Fig 1 Uptake of ^3H -thymidine in erythrocytic precursors of healthy subjects and patients with some disorders of erythropoiesis. ● normal subjects, ■ hypoplastic anemia, ○ polycythaemia vera, △ essential hypochromic anemia, ▲ chronic posthemorrhagic anemia. — pronormoblasts and basophilic normoblasts. --- polychromatophilic normoblasts.

The generation time of pronormoblasts and basophilic normoblasts was 22.7 ± 5.83 h and in polychromatophilic normoblasts 16.0 ± 4.16 h.

All results are demonstrated graphically in figure 1

Discussion

The results of the present study in normal subjects are in agreement with those of other authors [1-3, 7, 11, 13, 16, 19, 20].

There are only few publications on the DNA synthesis of bone marrow cells in hypoplastic anemia [1, 9, 10, 12, 14, 15, 17]. According to these results our studies indicate a decrease of the cells synthesizing DNA and of the intensity of DNA synthesis. The marked fall of labeled cells after 15 min incubation also illustrates the decrease of DNA producing cells in the bone marrow of patients with hypoplastic anemia. The observation during 2 h shows that in these patients the increase of the label of pronormoblasts and basophilic normoblasts is 3 times greater than in normal subjects. However the label does not reach the normal values by the end of incubation. The high increase of the labeled pronormoblasts and basophilic normoblasts can be explained by a shortened presynthetic period G₀ in the mitotic cycle of these cells, that is followed by an increased proliferative possibility of a small part of pronormoblasts preserving their ability for DNA synthesis. A marked shortening of the generation time confirms this assumption.

In hypoplastic anemia the slight increase of labeled polychromatophilic normoblasts and the more prolonged generation time may signify a prolongation of the presynthetic G₀ period and, possibly of DNA synthesis.

The significant decrease of the label ($p < 0.01$) after 15 and 30 min incubation of the bone marrow of patients with polycythemia vera confirms a diminution of the cells taking part in proliferation. It is evident that a considerable part of cells is in the 'rest period' (G₀-period). The appearance of substances like inhibitors [8] or chalones [4] in the bone marrow of these patients cannot be excluded. These substances are contained in mature erythrocytes and prevent an entry of young cells into the mitotic cycle. By the end of the incubation the percentage of the label is almost normalized, that indicates the accelerated passing of cells through all periods of the mitotic cycle. This is

confirmed by a shortening of the generation time of pronormoblasts and basophilic normoblasts. The shortening of the mitotic cycle of pronormoblasts and basophilic normoblasts may be one of the factors that lead to the pathological increase of erythrocytes in polycythemia vera.

There is no significant difference in the percentage of labeled cells between normal subjects and patients with iron deficiency. Thus there is no disturbance of DNA synthesis of the erythroid cells of patients with iron deficiency anemias. At the same time the generation time of polychromatophilic normoblasts is increased.

It is evident that the latter depends on the delay of polychromatophilic normoblasts in the presynthetic period (G_1) that may be stipulated by the disturbance in hemoglobinisation. It is of interest, that the generation time of pronormoblasts and basophilic normoblasts in essential hypochromic anemia was 10 h longer than in chronic posthemorrhagic anemia.

Summary

The DNA synthesis of the erythroid cells was investigated in bone marrow cultures by an autoradiographic method using ^3H -thymidine. A decrease of the label was found in hypoplastic anemia indicating a considerable diminution of the proliferative pool of erythroid cells. There was a slight decrease of labeled cells in polycythemia vera at the beginning of incubation indicating some diminution of proliferation. However by the end of incubation period the percentage of the labeled cells was normalized. In iron deficiency anemias the ^3H -thymidine incorporation did not differ from that in normal subjects.

References

1. AZARIS, G. Differentiation, proliferation and maturation of haemopoietic cells studies in tissue culture. In WOLFFENBUEHLER and O'CONNOR's *Ciba Found. Symp. on Haematopoiesis. Cell production and its regulation*, p. 99 (Churchill, London 1960).
2. BOED, V. P., FLICKNER, T. M., CHAVETZ, E. P., REASON, J. R., BIECHER, C. and SCHWARTZ, P. K. Proliferative potentials of bone marrow and blood cells studies by *in vitro* uptake of ^3H -thymidine. *Acta haemat.*, Basel 21: 1 (1959).
3. BOED, V. P., FLICKNER, T. M., CHAVETZ, E. P., REASON, J. R. and ROBERTSON, I. S. Cell turnover in blood and blood-forming tissue studied with tritiated thymidine; in STOKEMAN's *The Kinetics of Cellular Proliferation*, p. 118 (Grune & Stratton, New York 1959).
4. BOCCALON, W. S. Mitotic and functional homeostasis—speculative review. *Cancer Res.* 25: 1684 (1965).
5. BOED, J. *Autoradiography in Biology and Medicine* (Moscow 1958).
6. CHAVETZ, E. P., BOED, V. P., FLICKNER, T. M. and KILMAN, S. A. The use of tritiated thymidine in the study of haematopoietic cell proliferation. In WOLFFENBUEHLER and

- O'Connor's Ciba Found. Symp. on Haematopoiesis. Cell proliferation and its regulation, p. 70 (Churchill, London 1960).
7. CACCIOTTI, F. P.; FLISZBERG, T. M.; RICHIE, J. R.; BOND, V. P. and HOOVER, W. L.: Dynamics of proliferating system of man studied with tritiated thymidine. *J. clin. Invest.* 37: 887 (1958).
 8. DORVICA, A. K. and DORVICA, O. K.: The analysis of mitotic cycles; in *The studies in cells cycles and metabolism of nuclear acids in cells differentiation*, p. 5 (Leningrad 1964).
 9. FEINSTEIN, F. F.: *Aplastic and Hypoplastic Anemia* (Moscow 1965).
 10. FEINSTEIN, F. F.; KOZDRETZ, G. I. and KARANOVA, L. L.: Autoradiographic and cytochemical studies of blood cells in aplastic and hypoplastic anemia patients. *Probl. Hematol. peritel. Krovi* 2: 19 (1963).
 11. GROSSER, G.: Proliferative capacity of normal bone marrow (radioautographic study with tritiated thymidine). *Stachelzer Med. Intern.* 6: 165 (1963).
 12. KARPOV, A. P.: Autoradiographic studies of hematopoiesis in hypo- and aplastic anemias. 43 *Plenum Uchenogo Soveta of Central Institute of Hematology and Blood Transfusion*, vol. II, p. 329 (Moscow 1967).
 13. KENN-ELLAM, M.; HARRIS, F. B. and GYTHAHL, F.: *In situ* study of DNA-synthesis time and cell cycle time in erythrocyte precursors of normal and thalassaemia subjects using ^3H - and ^{14}C -thymidine double labeling technique. *Acta haemat., Basel* 38: 170 (1967).
 14. KILLMANN, S. A.: Effect of deoxyuridine on incorporation of tritiated thymidine. Difference between normoblasts and megaloblasts. *Acta med. scand.* 175: 483 (1964).
 15. LAJTHA, L. G.: On DNA labeling in the study of the dynamics of bone marrow cell proliferation in STOKELMAN' *The Kinetics of Cellular Proliferation*, p. 175 (New York 1959).
 16. LAJTHA, L. G. and OLIVER, R.: Studies on the kinetics of erythropoiesis—model of the erytron; in WOLSTENHOLME and O'Connor's Ciba Found. Symp. on Haematopoiesis. Cell production and its regulation, p. 289 (Churchill, London 1960).
 17. MORSCHLER, S. and SPECK, B.: Experimental studies on the mechanism of action of benzene on the bone marrow (Radioautographic studies using ^3H -thymidine). *Acta haemat., Basel* 38: 104 (1967).
 18. OSGOOD, F. F.: A unifying concept of the etiology of the leukemias, lymphomas and cancers. *J. med. Cancer Res.* 18: 135 (1957).
 19. SCHIND, J. R.; KELLY, J. M.; OWEN, C. A. and TOWSE, W. N.: DNA and RNA synthesis of marrow cells of normal subjects and patients with plasmocytic disorders. *Blood* 20: 790 (1962).
 20. SCHIND, J. R.; KELLY, J. M.; TOWSE, W. N. and OWEN, C. A.: *In situ* DNA and RNA synthesis in human bone marrow cells—study of 12 normal and 12 patients with lymphoplasmocytic disorders. *Blood* 27: 310 (1966).
 21. ZAKHAROV, L. N.: Application of radioactive isotopes in cytology. In the *Radioactive Isotopes in cytology*, p. 5 (Leningrad 1959).

Department of Biology and Genetics, Medical College of Virginia, Richmond, Va.

Change from Fetal to Adult Hemoglobin in Relation to Changes in the A Antigen of Human Erythrocytes

F J GRUNDBACHER

Fetal erythrocytes differ from those produced in adult individuals not only in size and in the type of hemoglobin but also in antigenic properties of the cell membrane. Fetal erythrocytes possess an antigen that is no longer present in red cells of adults [6] and the ABH antigens are weaker in fetal red cells than in those of adults. Strength or reactivity of the A antigen increases during fetal life and infancy until adult values are reached at 2 to 3 years of age, thereafter remaining relatively unchanged for the rest of the individual's life [2]. Change of the A antigen therefore overlaps the change from fetal to adult hemoglobin that takes place during the last trimester of gestation and early infancy. At birth both the A antigen and hemoglobin are in process of undergoing change.

The question arose as to whether change in the A antigen and change in hemoglobin are closely interrelated. This was determined by utilizing blood samples of newborn infants and multivariate analyses. Results on the interrelation between strength of the A antigen and percentage of adult hemoglobin, as well as findings on effects of the infant's sex and birth weight are presented in this report.

Materials and Methods

Freshly collected samples of blood from the umbilical cord were used. Strength of the A antigen and blood group subtypes of A were determined as previously described [3, 4].

A modification of the technique of SODERFELT *et al.* [8] was used for determining fetal hemoglobin. KOH solution was used at 1/10 M, and the 1 M solution was stored at 4°C. The $(\text{NH}_4)_2\text{SO}_4$ solution was saturated at 25°C, diluted to 73% saturation, and also stored at

4 C. Washed and packed red cells were hemolyzed with distilled water and toluene. After centrifugation, the 2 upper layers were discarded and the red solution filtered through double Whatman No. 2 paper filter. With the filtrate and distilled water hemoglobin solutions were prepared that gave reading of exactly 500 units in Klett-Summerson colorimeter with green filter (corresponding to O.D. = 1.00). Three test tubes (size 13 x 100 mm) each with 1.5 ml of the standardized hemoglobin solution, were prepared from each sample of blood. Temperature was standardized to 25°C in constant temperature water bath. To each tube 1.0 ml of 1/10 N KOH, which had been prewarmed to 25°C, was added at determined intervals. After exactly 5 min of incubation, 2.0 ml of cold $(\text{NH}_4)_2\text{SO}_4$ solution was added to each tube. The tubes were inverted twice and the content filtered through dry No. 2 Whatman paper filter. Filtration was repeated through the same filter at 15 min after the addition of $(\text{NH}_4)_2\text{SO}_4$. Optical density was determined twice: first, after the second filtration + 30 min after the addition of $(\text{NH}_4)_2\text{SO}_4$ and again, after the third filtration at 45 min after the addition of $(\text{NH}_4)_2\text{SO}_4$. Percentage of fetal hemoglobin of sample was computed from the mean of the 6 readings (3 tubes measured twice) and the values converted to adult hemoglobin (100 minus percentage of fetal hemoglobin = adult hemoglobin).

Correlation coefficients were used, as more meaningful presentation of the relative magnitude of association between variables is possible than with regression coefficients. Partial correlation coefficients, form of multivariate analysis, have been described, for example, by KENDALL and STUART [7].

Percentage of fetal hemoglobin was determined in cord blood samples of 97 infants. Only 86 infants, however, could be included in the analysis as 6 mothers were uncertain about their estimated date of conception; 5 non-Caucasians were not included because of known racial differences in birth weight and development [3]. The strength of the A antigen was determined in 54 A_1 Caucasian infants born to mothers of blood type A. Two girls, one resulting from 250 and an other from 297 day pregnancy represented the extremes in duration of pregnancy among the infants in whom strength of the A antigen had been determined. Duration of gestation ranged from 210 days (boy) to 305 (girl) among the infants in whom fetal hemoglobin had been determined.

Results

Figure 1 shows the frequency distribution for percentage of adult hemoglobin in the 86 infants and strength of the A antigen in the 54 A_1 infants. The figure reveals wide variation between infants. By coincidence the values for percentage of adult hemoglobin and strength of the A antigen are of similar magnitude.

In 24 infants, both strength of the A antigen and percentage of adult hemoglobin were determined. The results, illustrated in figure 2 reveal a positive association between the two variables. The simple correlation coefficient between strength of the A antigen and percentage of adult hemoglobin was $r = 0.52 \pm 0.12$ which, for 22 DF is highly significant ($P < 0.01$). Part of this association might result from a common effect of duration of gestation or a common effect of weight. These effects were corrected with partial correlation analysis.




Fig. 1 Frequency distribution of strength of the A antigen and percentage of adult hemoglobin in newborn infants.




Fig. 2 Association in infants in whom both strength of the A antigen and percentage of adult hemoglobin were determined. The dots represent individual values.

The partial correlation coefficient (holding both birth weight and duration of gestation constant) was $r_{AHWO} = 0.44 \pm 0.18$ for 20 DF this is significant ($P < 0.05$). Thus, there remains a significant association between strength of the A antigen and percentage of adult

Table I Mean percentage of adult hemoglobin and mean strength of the A antigen in newborn infants

Sex	Number of infants	Mean duration of gestation days	Mean birth weight kg	Mean percentage of adult hemoglobin
Boys	50	278.4 \pm 1.9	3.36 \pm 0.33	27.49 \pm 0.80
Girls	36	283.8 \pm 1.7	3.34 \pm 0.43	29.54 \pm 1.00
				Mean strength of the A antigen
Boys	31	280.9 \pm 1.3	3.40 \pm 0.48	24.78 \pm 1.11
Girls	23	278.3 \pm 2.4	3.44 \pm 0.44	28.62 \pm 1.32
Strength determined in immunohemolytic test				

hemoglobin that is independent of birth weight and of duration of gestation.

Means and standard errors for percentage of adult hemoglobin and strength of the A antigen are presented in table I for boys and girls separately. Percentage of adult hemoglobin was slightly higher in girls than in boys but the difference was not statistically significant ($P > 0.05$). Duration of gestation was significantly lower in boys than in girls and this accounts in part for the observed higher mean percentage of adult hemoglobin in girls than in boys. A slight difference, however, was still discernible among the infants resulting only from pregnancies of 270 to 290 days duration: the mean percentage of adult hemoglobin for girls was 29.7 ± 1.23 and that for boys was 28.0 ± 0.96 .

Strength of the A antigen, on the other hand, was significantly higher in girls than in boys ($P < 0.05$). As table I shows, the average duration of gestation was slightly higher for the 31 boys than for the 23 girls, i.e., an even larger difference in antigen strength may be expected for equal duration of gestation.

Simple and partial correlation coefficients are presented in table II. The table shows that the simple correlation coefficient between percentage of adult hemoglobin and duration of gestation was slightly higher than that between percentage of adult hemoglobin and birth weight. Both were highly significant ($P < 0.01$). The partial correlation coefficients, holding either duration of gestation or birth weight constant, were markedly lower than the corresponding simple correlation coefficients.

Table II. Simple and partial correlation coefficients of percentage of adult hemoglobin and strength of the A antigen with birth weight and duration of gestation

		Birth weight (W)	Duration of gestation (G)
Percentage of adult hemoglobin (H)	Simple corr. coeff.	$r = 0.34^* \pm 0.10$	$r = 0.36^* \pm 0.09$
	Partial corr. coeff.	$r_{HW,G} = 0.18 \pm 0.11$ (holding duration of gestation constant)	$r_{HG,W} = 0.24^* \pm 0.10$ (holding birth weight constant)
Strength of the A antigen (A)	Simple corr. coeff.	$r = 0.42^* \pm 0.11$	$r = 0.21 \pm 0.13$
	Partial corr. coeff.	$r_{AW,G} = 0.31 \pm 0.13$ (holding duration of gestation constant)	$r_{AG,W} = 0.03 \pm 0.14$ (holding birth weight constant)
$P < 0.05$		$P < 0.01$	

Table II further reveals that strength of the A antigen is more closely correlated with birth weight than with duration of gestation, the partial correlation coefficient between strength of the A antigen and duration of gestation being close to zero. The partial correlation coefficients thus show a trend in the opposite direction: strength of the A antigen was closer correlated with birth weight than with duration of gestation, while percentage of adult hemoglobin showed a slightly closer association with duration of gestation than with birth weight.

Discussion

Newborn infants revealed wide variation in strength of the A antigen of red cells and in percentage of adult hemoglobin. The analyses disclosed that part of this variation resulted from variation in duration of gestation and variation in birth weight. However, holding duration of gestation and birth weight constant in partial correlation analysis, still revealed a significant association between strength of the A antigen and percentage of adult hemoglobin. An association between strength

of the A antigen and percentage of adult hemoglobin was thus demonstrated that is independent of variation in duration of gestation and variation in birth weight. Despite this association, the results have also provided evidence that change in the A antigen and change in hemoglobin are not fully interdependent. This was demonstrated by the following findings (a) the correlation between strength of the A antigen and percentage of adult hemoglobin was less close than could be expected if the change were fully synchronized (fig 2) (b) strength of the A antigen was much closer correlated with birth weight than with duration of gestation, while percentage of adult hemoglobin was slightly closer correlated with duration of gestation than with birth weight (c) an apparent effect of sex was more marked for strength of the A antigen than for percentage of adult hemoglobin (d) change in hemoglobin is completed at an age before strength of the A antigen has reached adult values [2] These findings suggest that change in the A antigen and change in hemoglobin may be controlled by different factors.

The partial correlation coefficients determined in the present study may be used to provide a measure of the causes that affect the change in hemoglobin and the change in the A antigen, in particular to determine whether change is predominantly a function of chronological age or of the infant's development (expressed in birth weight). Either of the two might be feasible. Duration of gestation, however, was found to be an almost negligible determinant for the A antigen when compared with the effects associated with birth weight. The significant partial correlation coefficient between strength of the A antigen and birth weight (holding duration of gestation constant) suggests that relative development of the infant (expressed in weight) has a marked effect on the change in the A antigen. In general, rapidly developing infants (expressed in birth weight) are expected to show a relatively faster increase in strength of the A antigen than slower developing infants. This conclusion is further supported by the finding of a higher strength of the A antigen in girls than in boys. Girls are known to develop faster than boys (physiologic, skeletal) despite the fact that boys exceed girls in size and weight [1-9]. In connection with properties of the erythropoietic system, the faster skeletal development in girls than in boys, as reported by CHAMBERLAIN [1] is of particular interest.

In contrast to the A antigen, percentage of adult hemoglobin was found to occupy more an intermediate position in its association with duration of gestation and birth weight. The significant partial correlation coefficient between duration of gestation and percentage of adult

hemoglobin indicates that the change from fetal to adult hemoglobin is markedly influenced by chronological age of the infant. Thus, change in hemoglobin seems to be more dependent on time than on the infant's weight, while for the A antigen the reverse is the case.

The significant partial correlation coefficient between strength of the A antigen and birth weight indicates also that weight is not merely an expression of size, but may provide information on the relative development of the infant. This has long been known to be valid in cases of prematurity. The present results reveal, however, that this is applicable even for infants resulting from pregnancies of the same duration.

Summary

Strength of the red cell A antigen and level of adult hemoglobin were found to be significantly correlated in newborn infants, even after correction for variation in birth weight and duration of gestation. Furthermore, strength of the A antigen was significantly higher in girls than in boys and much closer associated with birth weight than with duration of gestation. On the other hand, percentage of adult hemoglobin was somewhat closer associated with duration of gestation than with birth weight. The results indicated that relative development of the infant (expressed in birth weight) has a marked effect on the change in the A antigen, while the change in hemoglobin is more dependent on chronological age of the infant.

References

1. CROFTON, A. Prevalence and distribution of ossification centers in the newborn infant. *Amer J Dis Child* 77: 333-361 (1949).
2. GRUBBACHER, F. J. Changes in the human A antigen of erythrocytes with the individual's age. *Nature, Lond.* 204: 192-194 (1964).
3. GRUBBACHER, F. J.: Immunohemolysis as a method for quantitation of the A antigen of human erythrocytes. *J. Immunol.* 93: 203-212 (1964).
4. GRUBBACHER, F. J. Quantitative variation of the A antigen at birth: its significance in ABO hemolytic disease and in the infant's development. *Acta paediat. scand.* 54: 550-556 (1965).
5. HOLMAN, G. H. Studies on physiologic hyperbilirubinemia of Negro and White premature infants. *Pediatrics* 22: 1113-1133 (1958).
6. IRBY, E. W., LEIDMAN, H. and MOURANT, A. E. A rabbit serum containing specific agglutinin for the red cells of the newborn. *Brit. med. J.* 48: 602-604 (1953).
7. KENDALL, M. G. and STURGEY, A. The advanced theory of statistics. Vol. 2. Inference and relationship (Griffin, London 1961).
8. SINGER, R., CHODKOFF, A. L. and SOWAR, L. Studies on abnormal hemoglobin. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 413-428 (1951).
9. TANNER, J. M. Growth at adolescence. 2nd ed. (Blackwell, Oxford 1962).

Department of Experimental Hematology Instituto Venezolano de Investigaciones Científicas, Hematology and Blood Bank Section and Medical Department University Hospital, Caracas

Congenital Deficiency of Fibrin Stabilizing Factor (Factor XIII)

A Report of the First Case from Latin America

T. ARENDS, J. M. GUEVARA and J. R. RANGEL

The cases of congenital deficiency of the fibrin stabilizing factor (FSF) (synonyms factor XIII Laki and Lorand factor fibrinase, Atoka diathesis) described to date have been found in Europe, Switzerland [1] Finland [2, 3] France [4, 5] Italy [6, 7] England [8] Greece [9] and Denmark [10]. It has also been reported in Israel [11] in the United States [12-13] and Canada [14]. No cases have been previously reported in Latin America.

The case reported here concerns a FSF deficiency studied in a Venezuelan native which was classified as congenital by the results obtained from clinical and laboratory tests.

Methods

The coagulation tests were performed by the standard methods [15], and the plasma clot solubility in 5% urea was done according to Losowsky *et al.* [8]. The defect of these patients being in the clot, it was thought that re-dissolving it with trypsin and studying electrophoretically difference might be observed when compared with the normal subjects. The following method was used: 1-5 ml of ovalated plasma mixed with 0.5 ml of 0.025 M of CaCl_2 , incubated 30 min at 37°C, the clot was tapped loose and washed 3 times with N. Cl 0.85 M and then trypsin digested with 1 drop of commercial trypsin (NBCo) 4 mg/ml at 37°C for 2 h, shaking gently at intervals 2 or 3 times. Trypsin digestion was stopped adjusting to pH 6.4 with 0.5 M acetic acid, and centrifuged at 2000 rpm. Acetate cellulose electrophoresis of the supernatant liquid was made applying the sample 6 times.

hemoglobin indicates that the change from fetal to adult hemoglobin is markedly influenced by chronological age of the infant. Thus, change in hemoglobin seems to be more dependent on time than on the infant's weight, while for the A antigen the reverse is the case.

The significant partial correlation coefficient between strength of the A antigen and birth weight indicates also that weight is not merely an expression of size, but may provide information on the relative development of the infant. This has long been known to be valid in cases of prematurity. The present results reveal, however, that this is applicable even for infants resulting from pregnancies of the same duration.

Summary

Strength of the red cell A antigen and level of adult hemoglobin were found to be significantly correlated in newborn infants, even after correction for variation in birth weight and duration of gestation. Furthermore, strength of the A antigen was significantly higher in girls than in boys and much closer associated with birth weight than with duration of gestation. On the other hand, percentage of adult hemoglobin was somewhat closer associated with duration of gestation than with birth weight. The results indicated that relative development of the infant (expressed in birth weight) has a marked effect on the change in the A antigen, while the change in hemoglobin is more dependent on chronological age of the infant.

References

1. CANTARIS, A. Prevalence and distribution of ossification centers in the newborn infant. *Amer J Dis Child* 7: 355-361 (1949).
2. GRUNDMACHER, F. J. Changes in the human A antigen of erythrocytes with the individual age. *Nature Lond.* 204: 192-194 (1964).
3. GRUNDMACHER, F. J. Immunoelectrophoresis as a method for quantization of the A antigen of human erythrocytes. *J Immunol.* 95: 205-212 (1964).
4. GRUNDMACHER, F. J. Quantitative variation of the A antigen at birth: its significance in ABO hemolytic disease and in the infant's development. *Acta paediat. scand.* 54: 550-556 (1965).
5. HOLMAN, G. H. Studies on physiologic hyperbilirubinemia of Negro and White premature infants. *Pediatrics* 22: 1115-1133 (1958).
6. LEE, R. W.; LEHRMAN, H. and MOUNTAIN, A. E. A rabbit serum containing specific agglutinin for the red cells of the newborn. *Brit. med. J.* 4: 602-604 (1953).
7. KIRKPALL, M. G. and STUART, A. The advanced theory of statistics; Vol. 2; Inference and relationship (Oxford, London 1961).
8. SCHICK, R.; CRICKMORE, A. L. and SAWYER, L. Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 415-428 (1951).
9. TANNER, J. M. Growth at adolescence; 2nd ed. (Blackwell, Oxford 1961).

Table 2. Effect of the mother's plasma on the patient's clots. Incubation of the clots in 5M urea, expressed after 8 h and DELAGE [14]

Subject studied	Correction power of plasma added <i>in vitro</i>							
	Pure	1:2	1:4	1:8	1:16	1:32	1:64	1:128
Control	++	++	++	+	++	+	+	0
Mother	++	++	++	+	+	0	0	0

and indirect platelet count were all normal. The solubility of the recalcified plasma clot was demonstrated in 5M urea solution. Other clinical, genetic and biochemical tests were normal, except the hemoglobin which was somewhat low (10.1 g/100 ml). Peripheral blood smear showed mild hypochromia of the red cells.

Physical therapy was instituted, consisting of moderate exercises and electrostimulation of the right anterior tibial muscles.

A year after she was discharged, the patient was hospitalized in coma in her home town and died within 24 h. Post mortem examination revealed intraparenchymatous cerebellar hemorrhage with rupture of the upper part of the right cerebellar lobe.

Electrophoresis of the recalcified plasma clot. The electrophoresis of the trypsin digested clot revealed, in addition to the albumin and fibrinogen, 2 other fractions migrating ahead of the albumin. Other minor fractions, slower than albumin, were not identified (Fig. 1). The patient's trypsin digested clot and that of her mother's, did not show difference when compared with the results obtained in normal subjects.

Family studies. The solubility of the plasma clot in 5M urea was done to the mother and maternal uncle, not finding abnormalities in either one. The capacity of correction of the mother's diluted plasma, done according to Jovan et al. [3] was slower than the normal control (table 1). This method has been used to determine heterozygous subjects.

Discussion

MacFARLANE [16] estimated the probable incidence of FSF deficiency to be 0.1×10^{-6} inhabitants, which makes it one of the coagulation inborn errors of lowest frequency. Nevertheless, the possibility of mistaking it with the hemophilias should be kept in mind when dealing with hemophiloid states. The fact that to this writing only one case has been found in Venezuela - with a population of more than 9,500,000 - apparently confirms the reported low incidence of this disorder.

The genetic mechanisms of this condition has been considered as determined by a recessive autosomic gene although abnormal results found in the plasma of parents of some patients with congenital deficiency of FSF [1, 5, 13, 14, 17] allows the postulation of a possible

Table II. Clinical characteristics of the published

Case	Sex	Age years	Country	Parents consangu. deficient	Other family members studied	non-deficient
1	M	7	Switzerland	yes	1 brother (case 2) 1 cousin	2 great-uncles 2 cousins
2	M	18m	Switzerland	yes	case 1	-
3	M		Finland	no	7	7
4	M	6	France	no	-	1 brother
5	F	2	Italy	yes	case 18	-
6	M	14m	France	no	mother ²	-
7	M	4	France	yes	parents ²	
8	F	32	Finland	yes		
9	M	26	USA	no	1 brother (case 10)	-
10	M	23	USA	no	case 9	
11	M	12	Canada	no	parents	
12	M	28	England	no	-	
13	M	4	England	no		
14	M	3	England	no	-	
15	M	24	Greece	?		
16	M	12	Denmark	no		parents
17	F	29	Israel	yes		
18	F	1	Italy	yes	1 sister (case 5)	parents
19	M	3	USA	no	2 siblings parents grand-mother	maternal grand-father ¹
20	F		USA	no	parents 2 sisters 1 brother ²	
21	F	20	Venezuela	no	mother	

Age at the time of diagnosis

Plasma clot was soluble in 5M urea

Partial deficiency of F5F demonstrated by titration

cases of congenital deficiency of FSF (Factor XIII)

embry- onal	Bleeding manifestations				Hemostat.		Authors
	ecchy- moses	hema- tomas	dental	other	Clea- rnat.	eff. of transf.	
+	+	+	—	Post wounds, subdural hematomas	slow	yes	DUCHEBT <i>et al.</i> , 1961 [1]
+	+	+	—			?	
—	—	—	—	post wounds			IKKALA and NEVANLINNA, 1964 [2]
+	+	—	—	post wounds		yes	MAHLE, 1963 [4]
—	+	+	+	post wounds		yes	DI NELLI, 1963 [6]
—	—	+	—	otorrhagia, cerebro- meningeal		yes	JONES <i>et al.</i> , 1964 [5]
—	+	+	—	post wounds		yes	
+	—	—	—	hemoperi- toneum, hemarthrosis		yes	IKKALA <i>et al.</i> , 1964 [3]
?	+	+	+	epistaxis	slow	yes	HAMPTON <i>et al.</i> , 1963 [12]
—	+	+	+	epistaxis		yes	
—	+	+	—	hemarthrosis, subdural hematoma		yes	BAIR and DELAGE, 1963 [14]
—	—	+	—	hemoperi- toneum		yes	
+	+	+	—			yes	LOEWEN <i>et al.</i> , 1963 [8]
+	+	+	—			yes	
—	—	—	—	post pen- ectomy	slow		THEVENIN <i>et al.</i> , 1963 [9]
+	+	—	—	post wounds		yes	
+	+	—	—	post wounds, hemarthrosis, subdural hematoma	slow	yes	AMER and KATZ, 1965 [10]
+	+	—	—	hemotho- soma	slow	yes	FISHER <i>et al.</i> , 1966 [11]
—	+	+	+	post wounds		yes	OTT and <i>et al.</i> , 1966 [7]
—	+	+	—	post wounds, hemarthrosis		yes	BUTTER, 1967 [13]
+	+	+	—	post wounds		yes	BOURMEX and ALTA 1968 [17]
+	+	+	—	post wounds, cerebellar hemorrhage		cs	this report

Partial deficiency of FSF demonstrated by thromboelastography

Platelets transglutaminase test

FSF levels

J. H. P. Jorrem and P. H. J. Huisman: *A Laboratory Manual on Abnormal Hemoglobins*.
2nd ed. Blackwell Oxford/Edinburgh 1968. 126 p. Price 30 s.

This manual was, as stated by the authors, 'primarily written for the medical pathologists and the laboratory workers receiving samples of blood for investigation but who have not made special study in this field'. Indeed, the book is clearly and concisely written both in its initial part on clinical data and in the subsequent chapters on biochemical evaluation of abnormal hemoglobins. Much practical information reflects the vast personal experience of the authors, and many useful details are given which cannot be easily found in the original literature. The procedures include only few and important references to original publications which facilitates reading. In the reviewer's opinion, there is too much referring from one chapter to another. On page 48 the authors state that 'the elution rates (on DEAE-Sephadex) are similar to those seen in DEAE-cellulose chromatography' but in the corresponding section the reader again is referred to CM-chromatography concerning the same question. The reader is also supposed to be familiar with migration patterns of abnormal hemoglobins on electrophoresis (e.g. plates 3 and 4). The later chapters cannot be well understood without the complete reading of the earlier parts of the book. In general, the second edition of the *Laboratory Manual on Abnormal Hemoglobins* is most welcome gift to every investigator interested in hemoglobinopathies. E. BACK, Basel

H. S. Cox: *Medical Cyto-Technology* Butterworth, London 1968. 65 p. Price 10 s.

The small monograph is concerned exclusively with exfoliative cytology and describes the current diagnostic methods including the technique for obtaining and preparing specimens of vaginal, cervical and endometrial smears, bronchial aspirates, gastric washings and sputa. The staining techniques are reported and the characteristics of normal and malignant cells as well as the problems of cyto-screening are briefly discussed. Some recommendations for laboratory training are given at the end of the booklet, which offers a concise introduction in cytology for students, general pathologists and technicians and also stimulates more detailed studies necessary for the specialized cytologist. H. R. MARTI, Aarau

L. H. B. Waller and J. B. Rowden: *Human Hemoglobin Variants and their Identification* Butterworth, London 1968. 56 p. Price 10 s.

The booklet contains in its first 15 pages a brief introduction to the field of hemoglobinopathies with summaries on the hemoglobin molecule, the genetic code, the normal hemoglobins, the thalassemias, the Hb M variants and the inheritance and geographical distribution of the most frequent abnormalities. In these short chapters many details had to be omitted, only a small selection of abnormal hemoglobins are mentioned and the heterogeneity of thalassemia is incompletely reported. In the main part of the booklet the current laboratory techniques are described with details necessary to perform the methods. Different techniques for detection of inclusion bodies, the sickle cell test, several methods of alkali denaturation, the technique of electrophoresis on cellulose acetate, starch gel and black, agar gel, polyacrylamide gel and paper, the ion exchange chromatography, the heat denaturation, Hb S solubility test and the stain for Hb F in red cells are given. The small volume is certainly a valuable help for pathologists and technicians. H. R. MARTI, Aarau

S. 362c. Die Thrombocytentransfusionen. Untersuchungen mit radioaktiv markierten Thrombocyten. Fischer Stuttgart 1968. 119 s., 32 Abb. Preis DM 29.50.

Plättchentransfusionen haben im Laufe der letzten Jahre an Bedeutung gewonnen, da von klinischer Seite her besonders im Zusammenhang mit der intensiven zytostatischen Behandlung der Neoplasien, die Nachfrage stark gestiegen ist. Das erweckte Interesse spiegelt sich auch in der rasch zunehmenden Flut der diesem Thema gewidmeten Literatur. Ein Überblick in der Art der vorliegenden Monographie kommt deshalb sicher einem allgemeinen Bedürfnis entgegen. Dabei hat der Autor sich die Sache nicht leicht gemacht: er begnügt sich nicht mit der Zusammenstellung der Literatur, sondern er hat versucht, die verschiedenen Ansichten und die noch offenen Fragen — und es sind deren viele selbst zu überprüfen und mit besonderen Versuchsanordnungen einer Lösung näher zu bringen. Mit Recht legt der Autor für die Beurteilung der Funktionstüchtigkeit der Plättchen das Hauptgewicht auf die Überlebenszeit radioaktiv markierter Thrombocyten. Ein ausführlicher erster Teil ist der Methodik der Thrombocytenmarkierung (^{51}Cr und DF^{51}P) und allen damit zusammenhängenden Problemen gewidmet. Unter dem für die Beurteilung der Thrombocytenfunktion herangezogenen *in vivo*-Methoden verdient vor allem die vom Autor erstmals auf Thrombocyten angewandte Zellsichtphorese Beachtung. Im Zusammenhang mit der Herstellung von Thrombocytenkonserven hat der Autor die wichtige Frage des geeignetsten Antikoagulans noch einmal aufgegriffen und mit Hilfe der *in vivo*-Methoden überprüft. Dabei konnte er die Überlegenheit der ACD -Lösungen mit niedrigem pH bestätigen. Zur Konservierung der Thrombocyten wird anhand eigener Versuche Stellung bezogen. Die Beschreibung der klinischen Indikationen der Plättchentransfusion wird zum Ablauf genommen, um Fragen des Thrombocytenumsatzes bei den verschiedenen Thrombopenieformen eingehend zu diskutieren. Im Abschnitt über die Thrombopenien als Folge eines vermehrten Verbrauchs finden sich interessante Beiträge zu den postoperativen Thrombopenien; die eigentlichen Verbrauchsagglutopathien, die regelmäßig mit einer Thrombopenie einhergehen, finden jedoch keine Erwähnung. Der letzte Abschnitt ist immunologischen Aspekten der Thrombocytentransfusion gewidmet, wobei der Kreis so weit gezogen ist, dass fast das ganze Gebiet der Thrombocyten-Immunologie Berücksichtigung findet. Neben der Gegenüberstellung (und Wertung) der verschiedenen Methoden zum Antikörpernachweis scheinen uns die Untersuchungen zur Frage der Spezifität der Isantikörper besonders wertvoll. Beachtung (und Nachprüfung) verdient sodann die Feststellung, dass das Serum von TTP-Patienten die elektrophoretische Beweglichkeit normaler Thrombocyten regelmäßig zu vermindern vermag. Der (hypothetische) Autoantikörper verhält sich offenbar in dieser Hinsicht anders als die Isantikörper, welche in der Regel nicht zu einer Beeinträchtigung der elektrophoretischen Beweglichkeit führen. Im übrigen hat der Autor die Erfahrung anderer bestätigt, dass die Überlebenszeit der Plättchen den nur zu seltenen Hinweis auf das Vorliegen von Antikörpern zu geben vermag. Von praktischer Bedeutung ist schließlich der Nachweis, dass Hämolyse oder Agglutinine des ABO-Systems mit erhöhtem Titer zum beschleunigten Abbau ABO-inkompatibler Plättchen führen.

Die Monographie vermittelt eine Fülle von höchst interessanten und wichtigen Daten aus dem Kapitel der Thrombocytenphysiologie und -pathologie. Bei der Vielseitigkeit des Gebotenen mag der Titel des Buches sogar etwas zu bescheiden angefallen sein. Andererseits vermisst der praktisch orientierte Leser vielleicht eine verbindliche Empfehlung, wie im Einzelfall für die Thrombocytentransfusionen vorzugehen sei, z.B. in Bezug auf Wahl des Präparates (PRP oder Konzentrat), technische Durchführung der Konzentration unter Berücksichtigung aller dokumentierten Erkenntnisse, Anzahl der benötigten Spender, Möglichkeiten der Thromboprophylaxe, usw. Das Buch wird aber von jedem, der sich mit den Thrombocyten beschäftigt und der sich über die Möglichkeiten der Plättchentransfusion orientieren möchte, mit Gewinn gelesen werden. Die klare Gliederung erleichtert die Lektüre, wobei wir die am Ende jedes Abschnittes gegebene Zusammenfassung als besonders angenehm hervorheben möchten.

U. BERNER, Basel

- Age, v Murine virus-induced leukaemia, Pathogenesis (leukaemia)
- Agglutination (haemagglutination) electron microscopic examination of haemagglutination produced by iodinated *Coombs serum*, 38, 328
- v Isohaemagglutination
- Agglutinin synthesis regulation independent of antigen, 37 62
- Agglutinins; ABO blood group agglutinins in saliva, 38, 351
- v Physhaemagglutinins, Phytohaemagglutinin
- Aggregation und Disaggregation von Erythrocyten, 36, 323
- Aggregation, erhöhte, der Thrombocyten, bei essentieller Hyperlipämie, 38, 25
- Aggregation menschlicher Thrombocyten, Untersuchungen über den Einfluss von Natrium-Oleat, 40 205
- AHF (= Antihæmophilic factor = AHG A) v Factor VIII
- AHG A (= Factor VIII = Antihämophiles Globulin A) Adrenergic blockers, Factor VIII
- AER (strain of mice) leukaemia, prevention by thymectomy : varying ages, 38, 317
- Alger (= Portuguese province) haemoglobin J Paris in the South of Portugal (Alger) 37 291
- Alkaline phosphatase activity in leucocytes of some animal species, 38, 51
- Alpha-chain synthesis haemoglobin H as an acquired defect of alpha-chain synthesis (Report of two cases), 39 91
- Alpha and beta chains (polypeptide chains of haemoglobin) Thalassemia
- Alpha-Naphthyl-1-Acetyl-Esterase, v Esterase, unspezifische Monocytes
- Alpha-Thalassemie O-5-PD-Mangel mit Hämoglobinopathie und alpha-Thalassemie, 38, 167
- Aminocaproic acid (α -aminocaproic acid) Fibrinolysis, Fibrinolysis inhibitors, Haemostatic effect
- p-Aminomethylbenzoic acid, Fibrinolysis
- Aminomethylcyclohexane-carboxylic acid, Fibrinolysis, Fibrinolysis inhibitors
- Anaemia, aplastic, and myelodysplasia, Fe⁵⁵ and Cr⁵⁴ studies, 38, 139
- Hæmochromatosis
- Anaemia, plasma idiopathic paroxysmal nocturnal hæmoglobinuria following 'aplastic anaemia' 38, 57
- ; associated with trisomy-21 and partial endoreduplication, a case, 37 137
- Anaemia, Cooley's anaemia, Thalassemia major
- Anaemia, hæmolytic, congenital non-spherocytic; characterization of glucose-6-phosphate dehydrogenase in Jordanian children with congenital non-spherocytic congenital hæmolytic anaemia, 37 198
- Anaemia, hæmolytic, v Sickle cell
- Anaemia, megaloblastic, Alpha-Thalassemia, megaloblastic, Alpha-Thalassemia, Beta-thalassemia, Haemoglobin Lepore in Cambodia, Thalassemia, Thalassemia (B) Thalassemia major Thalassemia minor Thalassemia subject, Thalassemic syndrome
- Anaemia, megaloblastic, of children, chromosomal study 38, 29
- Anaemia, pernicious maintenance therapy of pernicious anaemia (Comparison of Cyanocobalamin, Hydroxycobalamin and a Cyanocobalamin-ethyl-tannate complex) 40 305
- Anaemia, refractory; serum lactate dehydrogenase activity in refractory anaemia, 40, 187
- Anaemia, sickle cell anaemia, Sickle cell
- Anaemia, sideroblastic; reversible sideroblastic anaemia caused by chloramphenicol, 38, 1
- Anaemia, Erythroblastopenia
- Anämie, hämolytische, chronische Übergang einer arzneimittelsindlichen Erythropathie bei Glukose-6-Phosphat dehydrogenase-Mangel in eine chronische hämolytische Anämie, 37 206
- Anämie, hämolytische, bei Sarkoidose der Milz, 37 126
- Anämie, hypochrome, therapie-resistente, v Atransferrinämie
- Androgen antagonist, effect on erythropoietic action of testosterone, 40 239
- Testosterone
- Anämie, Anaemia Erythroblastopenia
- Aneuploid state, Erythropoietin
- Aneuploidy Spleen cells, Trisomy-21
- Animal species alkaline phosphatase activity in leucocytes of some animal species, 39 51
- Animals, laboratory comparative haematology (Selected aspects) 38, 13 (C)

- Antibiotikum, Chloramphenicol
- Antibodies; study of various antibodies and genetically determined serum groups among aborters producing anti-Tj^a-like haemolysis and non-aborters in *Wistar Australia*, 33, 231
- ; structure and heterogeneity 36, 198 (C)
- ; Antigen
- Antibody and DNA synthesis *in vitro*, following antigenic stimulus (Studies in rabbit peripheral lymphocytes I) 39 223
- v. 'Blast' transformation, Blastoid transformation, Lymphocytentransformation
- Anticoagulants, circulating; investigation of circulating anticoagulants against AHF (= factor VIII) in three patients with haemophilia A, 39, 214
- Anticoagulant drug therapy Erythroblastopenie
- Anticorps, Antikörper
- Antigen; agglutinin synthesis regulation independent of antigen, 37 III
- ; I antigen
- Antigenic changes, multiple, in case of acute leukaemia, 37 130
- Antigenic stimulus; DNA and antibody synthesis *in vivo* following antigenic stimulus (Studies in rabbit peripheral lymphocytes I.), 39 223
- 'Blast' transformation, Blastoid transformation, Lymphocytentransformation
- Antigens, Antibodies
- Antihemaphilic globulin A (= AHG A) Adrenergic blockers, Factor VIII
- Antihemaphilic globulin B (= Factor IX = FIC), Christmas factor
- Antileukemia activity Christmas factor
- Antikörper Antibodies
- Antistreptolysin; Untersuchungen zur Korrelation von Lymphocytentransformation durch Streptolysin O *in vitro* und Antistreptolysin 38, 276
- Antibody 'Blast' transformation, Blastoid transformation
- Anti-Tj^a-like haemolysis study of various antibodies and genetically determined serum groups among aborters producing anti-Tj^a-like haemolysis and non-aborters in *Wistar Australia*, 33, 231
- Aplastic anaemia peroxylal nocturnal haemoglobinuria following aplastic anaemia 38, 37
- ; and myelocleroids, Fe⁵⁹ and Cr⁵¹ studies, 39 139
- v Hexachlorocyclohexan
- Arzneimittelempfindliche Erythropathie bei Glukose-6-Phosphatdehydrogenase Mangel, Übergang in eine chronische hämolytische Anämie, 37 206
- Atransferrinküken (kongenitale und erworbene Formen), 35, 40 (C)
- Australia, v *Wistar Australia*
- Autohaemolysis, v Haemolytic syndrome, unusual
- Automation in haematology (Symposium at the XI Congress of the International Society of Haematology) 39 381 (B)
- Autoradiographie, Technik, 39 127 (B)
- Autoradiography Benzene: Chromatinstrukturen; Double labelling technique; Erythroblast; Leukemia, cell proliferation Leukemia, lymphatic, acute; Megakaryocytes Microradiography; Mononucleosis Plasma cells Proliferative activity
- Avitaminosis B₁₂ Baboons
- Baboons isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 38, 116
- Babouin, Baboons
- Bacterial endotoxins early appearance of blast-like cells in the thoracic duct lymph of rats given bacterial endotoxins, 37 301
- Barra-Syndrom im Kindesalter 40 111 (B)
- Basic lymphology new trends (Symposium Charleroi, 1966) 40 111 (B)
- Basophilic Zellen zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymphic, 38, 282
- Basophilic reticuloblastic origin of the blood basophil in human marrow 40, 162
- B⁺ blood group; an example of aberrant blood group (B?) 38, 332
- Bence Jones Protein, zu seiner Struktur, 38, 147
- Benzene, mechanics of action on the bone marrow experimental studies (Radioautographic studies using H³-thymidine) 38, 104
- Benzene poisoning erythrocytosis after benzene poisoning, 40, 234
- Benzidine-positive protein fraction, peculiar in the plasma of newborns and children with various haemolytic conditions, 38, 361

- Benzol, Benzene
 Bence-Jones, Sarkoidose
 Beta and alpha chains (polypeptide chains of haemoglobin) v Thalassemia
 Beta-thalassaemia, heterozygous, and hereditary spherocytosis (A family study) 39 183
 v Pyruvate-kinase deficiency
 Biological fluids, proteins, v Proteins
 Biology v Experimental biology
 Blast cells; cytoplasmic shedding as a mode of formation of lymphocyte-like blast cells by new histiocytes, 40 67
 Blast-like cells in the thoracic duct lymph of rats given bacterial endotoxins, early pyknotic, 37 301
 Blast population (leukaemia) v Proliferative activity
 Blast transformation of lymphocytes delay of human lymphocyte blast transformation by homologous RNA, 39 270
 Antibody Blastoid transformation, Lymphocytentransformation
 Elastic crisis of a granulocytic leukaemia, tw. Ph 1 chromosomes, 38, 391
 Blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 39, 573
 - Antibody Blast transformation, Lymphocytentransformation
 Bleeding, Thrombocytosis, posthaemorrhagic
 Bleeding, arresting, Haemostasis, Hemorrhagic disorders, Hämostas
 Blood basophil in human marrow reticulohistiocytic origin, 40, 162
 Blood cells cytochemical demonstration of dihydroorotic dehydrogenase in blood and bone marrow cells, 39, 203
 Blood coagulation, Adrenergic blockers, Aggregation (Thrombocytes) Blutgerinnungsfaktoren, Christmas disease, Christmas factor Coagulation, Factor V Factor VIII, Fibrinolysis, Fibrinolytic, Fibrinolytic inhibitors, Fibrinolytic system, Fibrin-stabilizing factor Haemostasis, Haemostatic effect, Hageman factor deficiency Hemorrhagic disorders, Hämostas, Phosphatasen, Retraktionsvorgang, Thromboembolic diseases (B) Uræmic thrombopathy Verbrauchungskulopathie
 Blood grouping tests, 40 338 (B)
 Blood groups; an example of aberrant blood group (B?) 38, 333
 - as introduction to blood group serology (3rd ed.) 39 127 (B)
 v A antigen, ABO blood group, ABO hemolytic disease, Antigenic changes, Anti-T_H-like haemolysis, (Haemagglutination) I antigen, Isohemagglutination, Rhoeusfaktor
 Blood transfusion in clinical medicine (4th ed.) 38, 407 (B)
 Blood transfusion; International Society of Blood Transfusion, XIIth International Congress, Moscow 1969 (travel grants) 40 240
 Blood from the umbilical cord, A antigen Blut und Knochenmark, Untersuchungen (Methoden) 40 238 (B)
 Blut Proaktivator v Proaktivatorgehalt
 Blutfremde Zellen im strömenden Blut (Leberparenchymentzellen) 39 243
 Blutgerinnungsfaktoren und essentielle Hyperlipämie, 38, 219
 Blutgruppen, v Blood grouping tests (B) Blood groups
 Blutz lymphocyten, funktionsfähig, Isolierung, 38, 300
 Blutzellen, Basophile
 Blutplättchen, Platelet transfusion, Platelets, Thrombocytes, Thrombocytentransfusion (B)
 Blutplättchenretention, Retraktionsvorgang, 38, 371
 Blutplättchen, Hemorrhagic disorders, Hämostas, Retraktionsvorgang
 Bluttransfusion, v Blood transfusion (B) Transfusion (B)
 Blutzellen; über den Nachweis der Thymidylatphosphatase (Deoxyphosphatase) in Blut und Knochenmarkszellen, 40, 177
 Borek-Berens-Schwarzmark, starbes, Sarkoidose
 Bone marrow; cellular changes in the bone marrow following chronic treatment of rats with cortisol, 38, 250
 - cytochemical demonstration of dihydroorotic dehydrogenase in blood and bone marrow cells, 39 203
 - experimental studies on the mechanism of action of benzene on the bone marrow (Radioisotopic studies using H³ thymidine), 38, 104

- failure of abiding the thymus to induce recovery of bone marrow after radiation, 37 109
 injury and repair (Irradiation and mechanical disruption) 40 35
 isotypic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39 118
 reactions, 38, 403 (B)
 reticuloblastic origin of the blood hemophil in human marrow 40 162
 in *river* cell proliferation in leukaemia during relapse and remission (I. DNA and RNA synthesis of leukaemic cells in the bone marrow *in vivo*) 35, 313
 Eosinophil granules Erythroblast ()
 Erythrocyte precursors; Erythroid hyperplasia Gamma-Hexachlorocyclohexan Gamma cells Knochenmark; Knochenmark (B); Knochenmarkzellen Leukemia, myeloid, chronic Megakaryocytes; Monocytes; Myelodysplasia; Myelofibrosis; Proliferative activity Typhus abdominalis
 Book reviews, 37 159 (B); 38, 64 (B) 403-407 (B); 39 62 (B), 127 (B) 381 (B) 40 110-112 (B), 176 (B) 258-259 (B), 336-338 (B)
 Bragg, colloquium, (XV th, may 3-7 1967)
 Protides of the biological fluids, 37 224
 — (XV th, may 1-5, 1968) Protides of the biological fluids, 37 192
 Buchbesprechungen, 37 159 (B) 38, 64 (B) 403-407 (B); 39 62 (B), 127 (B) 381 (B); 40, 110-112 (B) 176 (B) 258-259 (B) 336-338 (B)
 C¹⁴ Carbon, radioactive
 Caesium chloride density gradient centrifugation, DNA, satellite
 Camphor, Haemoglobin Lepore in Camphor
 Cancer; the inheritance of leukaemia and cancer 32, 174
 Cancer chemotherapy two week course (Houston, Texas, 13-24th May 1968), 39 63
 Cancer detection Uno Internationals contra Cancer (UICC) monograph series, vol. 4 (Prepared by the Cancer Detection Committee of the Commission on Cancer Control) 38, 406 (B)
 Cancer research, Erythropoiesis (B) Thymus (B)
Canis familiaris, Dog
 Capillaries, Haemostasis, Hemorrhagic disorders, Hemostasis
 Carbanitrophenol, v Erythroblastopenia
 Carbamyl-5H-dibenzos (b, f) azepin (= Tegrilol®) v Erythroblastopenia
 Carbon, radioactive, Erythrocyte precursors; Haemoglobin, *in vitro* synthesis Mononuclear infections; Protein synthesis
 Carcinoma, Cancer detection (B), Erythropoiesis (B) Thymus (B), v *brancha* coagulopathy
Canis familiaris, Eosinophil granules, Thymus
 C57Bl mice, Leukaemogenesis
 Cell, Electrolytic (B)
 Cell cultures, Antibody; Blast transformation; Blastoid transformation, Cell proliferation; Leukocytes, *in vitro*; Lymphocytes (derivative cells); Lymphocytes and their derivative cells Lymphocytes from patients; Lymphocyte transformation Mononuclear cells Mononuclear leukocytes Mononuclear infections; Ph 1 chromosomes Spleen cells; Tissue-21
 Cell cycle time, Erythrocyte precursors
 Cell kinetics and thymidine metabolism (Frontiers in biology vol. 6) 39 381 (B)
 Cell maturity and eosinophil granules electron microscopic observations on guinea-pig marrow 36, 350
 Cell proliferation in leukaemia during relapse and remission (I. DNA and RNA synthesis of leukaemic cells in the bone marrow *in vivo*) 35, 313
 — (II DNA synthesis of leukaemic cells in the peripheral blood *in vitro*), 37 18
 Centrifugation comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between trapped volume and electrical conductivity 38, 253
Cephus, thalassaemia in *Cephus*, 38, 209
 C¹⁴ format, Mononuclear infections
 C3H/1 mice, Mouse leukaemia
 Chains, polypeptide chains, Blood Jovan proteins, Haemoglobin H, Thalassaemia Chemistry Clinical chemistry (B)
 Chemotherapy; two week course in cancer chemotherapy (Houston, Texas 13-24th May 1968) 39 63

- Chicken, v. Myeloblastosis from
 Chden, v. Dog
 Children; chromosomal study in megaloblastic anaemia of children, 39 29
 - v. Erythrocytosis, Kindealter (B) Protein fraction
 Chindinhaliges, Kombinationspräparat (Eucard ®), v. Erythropathie
 Chloramphenicol induced haemolysis *in vitro* and survival of chloramphenicol treated cells *in vitro*, 39 11
 reversible sideroblastic anaemia caused by chloramphenicol, 38, 1
 Chloramphenicol-Präparat (Parasin ®) Erythropathie
 Christmas disease in girl with female karyotype, 37 217
 Christmas factor the clotting activity of congenital factor IX deficient (Christmas) serum, 39 13
 Chromatinstrukturen die Zeitfolge der DNS-Verdopplung der Chromatinstrukturen in Interphasekernen kultivierter Leukozyten, 38, 361
 Chromatography Besser Jones Protein
 Chromo (radiochrome) v. Erythrokinetic studies
 Chromo, radioactive, - Haemolysis *in vitro*
 Chromo, radioactive, Aplastic anaemia, Thalassemia minor
 Chromosomal abnormalities chromosomal aberrations and neoplastic potentialities of thymous cells during leukemogenesis, 40 142
 decreased formation of erythrocyte antigen A and a consistent chromosome abnormality in a patient with myelomonocyte leukaemia, 38, 309
 multiple chromosomal aberrations in case of malignant myelodysplasia, 39 299
 - two Ph 1 chromosomes in blastic crisis of granulocytic leukaemia, 38, 391
 Ph-2-omy and prognosis in chronic myelogenous leukaemia, 39 102
 - of spleen cells in osteomyelodysplasia, 38, 397
 Chromosome() G 21 transy-Leukämie, acute Leukämie, myeloc, chronic Macroglobulinaemia Trisomy-21
 Chromosomal factors, Pathogenesis (Leukemia)
 Chromosomal study in megaloblastic anaemia of children, 39, 29
 Chromosome studies, v. Haemoglobin H
 Chromosomes and leukaemia, 36, 157 (C)
 Chromosomes, Christmas disease
 Chronic lymphocytic leukaemia, Leukemia, lymphocytic
 Circulating anticoagulants investigation of circulating anticoagulants against AHP (= factor VIII) in three patients with haemophilia A, 39 214
 Cirrhosis of the liver investigation on the fibrinolytic system in liver cirrhosis, 40, 265
 C¹⁴-leucine, v. Haemoglobin, *in vitro* synthesis; Protein synthesis
 Clinical chemistry quantities and units, 40, 110 (B)
 Clinical medicine blood transfusion in clinical medicine (4th ed.), 38, 487 (B)
 Clinical method, rapid, for the estimation of activity of aconitase in blood, 40, 104
 Clinical pathology; VIIIth International Congress of Clinical Pathology (Montreal, 1968), 40 176
 Clotting activity of protein fractions of congenital factor IX deficient (Christmas) serum, 39 13
 Co⁵⁷ (Co⁵⁸) Pernicious anaemia (maintenance therapy)
 Co⁵⁸ Thymus
 Coagulation; importance of coagulation besides haemostasis, 36, 133 (C)
 Coagulation of blood, Adrenergic blockers, Aggregation (Thrombocytes), Blutgerinnungsfaktoren, Christmas disease, Christmas factor Coagulation, Factor V Factor VIII, Fibrinolytic, Fibrinolysis, Fibrinolysis inhibitors, Fibrinolytic system, Fibrin-stabilizing factor Haemostasis, Haemostatic effect, Hageman factor deficiency Hemorrhagic disorders, Hämorrhagie, Phosphatase, Retikuloerythropoiese, Thromboembolic diseases (B), Uraemic thrombopathy Verbräucherkongalopathie
 Cobalt, radioactive, Pernicious anaemia (maintenance therapy) Thymus
 Cobaye, Eosinophil granules, Thymus
 Colloid, v. Chromatinstrukturen
 Collagen, abnormal, v. Hemorrhagic disorders
 Colloquium, Bruges (Protides of the biological fluids) XVth, may 3-7 1967 37 224
 - XVth, may 1 3, 1968, 39 192

- Come for over 5 weeks, 39 320
- Committee, International, for Standardization in Haematology 3rd Transactions, Strasbourg 22/27 8. 1965 (Standardization in Haematology III) 39, 404 (B)
- Normierung
- Comparative haematology of laboratory animals (Selected aspects) 36, 13 (C)
- Comparative leukaemia research (Proceedings of an International WIGGERS-GREEN symposium, Stockholm, September 1963) 39, 403 (B)
- Complexus renalis, Comparative leukaemia (B) Congress, Standardization (B)
- Thromboembolic diseases (B)
- Conductivity electrical, Electrical conductivity
- Conference of experimental biology and medicine in Switzerland (September 1966), 37 322
- Colloquium, Symposium
- Congenital deficiency of fibrin-stabilizing factor (= factor XIII) (A report of the first case from *Latin America*), 40 329
- Congenital erythrocytosis, - Erythrocytosis
- Congenital factor IX deficient (Christmas) serum, clotting activity of protein fractions, 39 13
- Congenital methaemoglobinemia (Bibliotheca haematologica Vol. 28) 40 239 (B)
- Congenital nonphagocytic haemolytic anaemia characterization of glucose-6-phosphat dehydrogenase in *Sardinian* children with congenital nonphagocytic congenital haemolytic anaemia, 37 190
- Congress; European Society of Haematology: Proceedings of the 10th Congress (Strasbourg, 23. 26. 8. 1965) (part I main lectures) 36, 1 296 (C)
- ; Proceedings part I and II 40 111 (B)
- 11th Congress (Athens, 10. 14. 9. 1967), 36, 417
- Congress, XIIth, of the International Society of Haematology Sydney (21. 26. August, 1966) (Anticipation of the International Society the European Society and the Asian-Pacific Society of Haematology), 37 323
- Congress, XIIIth, of the International Society of Haematology (New York September 1-6, 1968) 37, 320
- Congress, International, VIIIth, of Clinical Pathology (Montreal, 1/3) 40 17
- Congress, Blood transfusion Colloquium, Microcirculation, Symposium, Therapeutic, Transplantation (B)
- Conjugated oestrogens, Haemostatic effect
- Cotter's anaemia, Alpha Thalaemia, Beta-thalassaemia, Thalaemia, Thalaemia major
- Cover slip cultures, Electron microscopic examination
- Corrigendum (ad Vol. 39 [1968] 8, 282) 40 240
- Cortisol; cellular changes in the bone marrow following chronic treatment of rats with cortisol, 36, 250
- Cover slip cultures, Mononuclear cells, Mononuclear leukocytes
- Cr⁴¹ and Fe⁵⁹ studies in aplastic anaemia and myelodysplasia, 37, 199
- Cr⁵¹ Erythrokinetic studies, Haemolysis *in vitro*, Thalaemia minor
- CaCl₂ (density gradient centrifugation) DNA, satellite
- C¹⁴-thymidine, Erythrocyte precursors, Mononucleosis
- Culture des cellules, Antibody Blast transformation Blastoid transformation Lymphocyten transformation
- Cultures de tissus, Cell proliferation
- Culture des cellules; Leukocytes, kultiviert; Lymphocytes; Lymphocytes (derivative cells) Lymphocytes and their derivative cells; Lymphocytes from patients; Mononuclear cells Mononuclear leukocytes; Mononucleosis infection Ph 1 chromosomes; Splenic cells; Tumor-21
- Cytocobalamin, Pernicious anaemia (maintenance therapy)
- Cytocobalamin-cholesterol complex, Pernicious anaemia (maintenance therapy)
- Cytosolic hereditary erythromorphological anaemia due to diaphanous deficiency in three successive generations, 37 276
- Methaemoglobinemia
- Cytidine (H³-cytidine) Blastoid transformation, Plasma cells
- Cytochemical demonstration of dehydrogenase dehydrogenase in blood and bone marrow cells, 37 203
- Cyt hemolysis; cytochemische Untersuchungen zur Entwicklung der grossen

- mononukleären Zellen des Hautfensters, 38, 781
- Diagnose monocyttärer Leukämien mit zytochemischen Methoden, 40, 121
 - v Acetylcholinesterase, Alkaline phosphatase, Cytology Drüsenleberzellen, Enzyme analysis, Erythroblast, Foetal Erythrocyten, G-6-PD -, Lymphocytes (derivative cells) Lymphocytes and their derivative cells, Monocytes, Mononucleosis infections, Myeloclerosis, Plasma cells, Reticulocytes, Sickle cell disease, Thiaminepyrophosphatase
- Cytogenetic studies in acute leukaemia, 40, 192
- Cytogenetic studies, in unusual forms of chronic myeloid leukaemia, 38, 129
- v G 21 trisomy Haemoglobin H, Leukaemogenesis, Megaloblastic anaemia, Myeloclerosis, Ph 1 chromosomes, Spleen cells, Trisomy 21
- Cytological and isotopic estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39, 118
- Cytologie- étude cytologique de la transformation aigue d'une leucémie myélocytaire chronique, 39, 249
- Cytology: contribution of cytology to the study of lymphopathoses, 36, 296 (C)
- Cytoplasmic shedding as a mode of formation of lymphocyte-like blast cells by newt histiocytes, 40, 67
- Cyto-technology technique, 40, 336 (B)
- Cyto Zyto
- D- anti-D serum, v Haemagglutination
- Deckgläschen (Leukocyten-Kulturen) v Mononuclear leukocytes
- Defect of glucose-6-phosphate dehydrogenase, v Sickle cell disease
- Defects in haemorrhagic disorders, their nature, 36, 141 (C)
- Delta thalassaemia a new thalassaemic syndrome: Homozygous haemoglobin S disease delta thalassaemia, 36, 41
- Density gradient centrifugation, analytical, DNA, satellite
- Denaturation of the erythroblast, studies on the mechanism, 39, 193
- Depression of the megakaryocyte-platelet system in rats by transfusion of platelets, 38, 34
- Desaggregation und Aggregation von Erythrocyten, 36, 323
- Deoxyribonucleic acid, satellite: presence of satellite DNA (= deoxyribonucleic acid) in normal and leukaemic human tissues, 39, 75
- Deoxyribonucleic acid (= DNA) synthesis, by erythroblasts in normal man and in some disorders of erythropoiesis, 40, 315
- DNA and antibody synthesis in *in vitro*, following antigenic stimulus (Studies on rabbit peripheral lymphocytes L), 39, 223
 - *in vivo* study of DNA-synthesis time and cell-cycle time in erythrocyte precursors of normal and thalassaemic subjects using a H^3 and C^{14} -thymidine double labelling technique, 38, 170
 - ; the infectious mononucleosis cell (L. DNA synthesis) 38, 257
 - division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 38, 163
 - the proliferation of infectious mononucleosis lymphocytes *in vitro*, 38, 19
- Deoxyribonucleic acid (= DNA) v Benzene; 'Blas' transformation Blastoid transformation Erythroblast; Leukemia, cell proliferation... Lymphocyte transformation Plasma cells Reticulocytes Thymidine metabolism (B)
- Deoxyribonukleinsäure (= DNS) v Verdopplung der Chromatinstrukturen in Interphasenkreuz kultivierter Leukozyten, 38, 361
- Deutsche Gesellschaft für Hämatologie, 14. Tagung, Kiel, September 1969, 38, 382
- Development of eosinophil leukocytes, Eosinophil granules
- Dextran, hochmolekulares, Aggregation Dr. Grouhmo's syndrome, v Haemoglobin II
- Diagnose monocyttärer Leukämien mit zytochemischen Methoden, 40, 121
- Dialysing membrane, Erythropoietin
- Disphorase deficiency; hereditary methaemoglobinemic cyanosis due to disphorase deficiency in three successive generations, 37, 276
- DPHN-
- Dietary histamine and eosinophils in the rat, 40, 59
- Diffusion de la lumière (Diffusion du champ électromagnétique) Macromolécules

- Dihydroorotic acid dehydrogenase, cytochemical demonstration in blood and bone marrow cells, 39 203
- Diphosphopyridine nucleotide, reduced, DPNH ..
- Diploid metaphases, Spleen cells
- Diseases of the lymphoid tissues, Protein synthesis
- Division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 39, 163
- DNA, Deoxyribonucleic acid Deoxyribonucleotide
- DNS, Deoxyribonucleic acid Deoxyribonucleotide
- Dog: effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog, 39 4
- Double blind evaluation of the haemostatic effect of adrenochrome monomelicarbanone, conjugated oestrogens and epalutiminocaproic acid after adenosinulicetony 39 154
- Double emulsion technique, Double labelling technique
- Double labelling technique *in vivo* study of DNA-synthesis time and cell-cycle time in erythrocyte precursors of normal and thalassaemic subjects, using H^3 and C^{14} -thymidine double labelling technique, 38, 170
- DPNH (= Diphosphopyridine nucleotide, reduced)-methaemoglobin reduction deficiency hereditary methaemoglobinemia due to DPNH-methaemoglobin reduction deficiency (Report of family) 37 234
- Diphthorae
- Drepanocytosis, Sickle cell
- Drüsenbeobachten, Zytotechnik, 39 237
- Drug-sensitive erythropathy Erythropathie
- Ductus thoracicus-Lymphae zur Natur der stark basophilen Zellen in der Ductus thoracicus-Lymphae, 39 262
- Thoracic duct lymph, Thoracic duct lymphocytes
- Eben, Acetabulae Aplastic anaemia
- Baboon Erythrokinetic studies Erythropoiesis Erythropoietin; Ferritin Ferrous sulphate; Haemoglobin H Haemoglobin, *in vitro* synthesis Haemoglobin synthesis Iron deficiency Iron poisoning Iron sorbitol; Sideroblastic anaemia; Thalassaemia minor
- Elastostoffwechsel, Atransferrinämie
- Electrical conductivity comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between the trapped volume and the electrical conductivity 33, 233
- Electrical resistance, Electrical conductivity
- Electron microscopic examination of haemagglutination produced by iodinated Coombs serum, 33, 339
- Electron microscope, Basophile Zellen, Eosinophil granules, GALTHER cells, Harz body Lymphopathies, Mouse leukaemia, Phagocytes
- Electrophoresis; simple method for the quantitation of haemoglobin fractions obtained by starch-gel electrophoresis, 33, 306
- Electrophoresis, Alpha-Thalassaemia; Antibodies Anti-T β -like haemolysis Bence Jones Protein Congenital spherocytic haemolytic anaemia; Delta thalassaemia Fibrin-stabilizing factor; Haemoglobin D Haemoglobin G (Philadelphia) Haemoglobin H; Haemoglobin J Para Haemoglobin Koefler Haemoglobin Lepore in Canine, Haemoglobine, menschliche Macrocytoblastosis Methaemoglobinemia cytochrome Macrocythemia Paraproteinämie-Protein fraction Sick cell; Spherocytes; Thalassaemia (Cyto) Thalassaemia syndromes
- Elektrolyte, intrazelluläre, Transport und Funktion (Symposium in Schürs, 1967), 39 112 (B)
- Emboly Thromboembolic diseases (B)
- Embryonales Hämoglobin in roten Blutzellen menschlicher Embryonen, intrazelluläre Verteilung (Ein Beitrag zur Ontogenese menschlicher Hämoglobine), 38, 264
- Encre de chape, Macrophages
- Endoreplication, partial, Trisomy-21
- Enfants, Erythrocytosis, Knochentumor (B), Megaloblastic anaemia, Protein fraction
- Endotoxines, bacterial, Bacterial endotoxins

- England; sickle cell haemoglobin *Punjab*
diasc 8 from Ghana and D from
England, 38, 324
- Entkernung der Erythroblasten, v Erythro-
blast
- Entwicklungsstadien eosinophiler Leuko-
cyten, v Eosinophil granules
- Entzündungs-Makrophagen, v Macro-
phages
- Eryne analysis, histochemical, of peri-
pheral blood changes in murine virus-
induced leukaemia, 38, 112
- Enzyme cytochemistry v Lymphocytes
and their derivative cells
- Erynein, v Ferments
- Eosinophil granules and cell maturity:
electron microscopic observations on
guinea-pig marrow 36, 330
- Eosinophilen-Leukämie, akute- hämatisti-
scher Beitrag zum Krankheitsbild der
akuten Eosinophilen-Leukämie, 37 143
- Eosinophils, and dietary histamine in the rat,
40, 59
- the nuclear segmentation of eosinophils
under normal and pathological condi-
tions, 37 120
- Epidemiology Human leukaemia
- Épileptique erythroblastopénie non mégalo-
cytaire et sensible à l'acide folique chez
un épileptique, 39 159
- Epitoo-aminocaproic acid, Fibrinolysis,
Fibrinolysis inhibitors, Haemostatic ef-
fect
- Ernährung, Dietary histamine
- Erratum (ad V. ol. 39 [1968] S. 282), 40, 240
- Erythraemia, v Erythromyelosis
- Erythroblasts studies on the mechanism of
denaturation of the erythroblast, 39 193
- in man DNA synthesis by erythroblasts
in normal man and in some disorders of
erythropoiesis, 40 315
- PAS-positive erythroblasts in kidney dis-
eases, 37 225
- Erythrocyte precursors
- Erythroblastopénie non mégaloeytaire et
sensible à l'acide folique chez un épilep-
tique, 39, 159
- Erythrocyte antigen A, decreased forma-
tion, and consistent chromosome ab-
normality in patient with myelomonocytic
leukaemia, 39 309
- Erythrocyte glucose-6-phosphate dehydro-
genase deficiency in Hawaii, survey 37 94
- Erythrocyte glucose-6-phosphate dehydro-
genase deficiency in Romania, a survey
40, 44
- Erythrocyte I group I antigen of red cells
in leukaemia and its interaction with
Mycoplasmas *in vivo* and *in vitro*, 40, 134
- Erythrocyte precursors *in-vivo* study of
DNA-synthesis time and cell-cycle time
in erythrocyte precursors of normal and
thalassaemic subjects, using H^3 and
 C^{14} -thymidine double labelling tech-
nique, 38, 170
- Erythrocytes; Aggregation und Desaggre-
gation, 36, 323
- foetal, und foetales Hämoglobin. Ver-
gleichende Untersuchungen über struk-
turelle und funktionelle Besonderheiten
der roten Blutzelle Neugeborener und
junger Säuglinge, 38, 64 (B)
 - die intrauterine Verteilung von em-
bryonalem Hämoglobin in roten Blau-
zellen menschlicher Embryonen (Ein
Beitrag zur Ontogenese menschlicher
Hämoglobine), 38, 264
 - die Lokalisation der unspezifischen Ester-
ase in foetalen Erythrocyten und deren
Vorläufer, 37 240
 - Resorptionfunktion (Bibliotheca Haematolo-
gica, fasc. 25) 38, 404 (B)
 - Untersuchungen über die Hämynthese
in roten Blutzellen (II.: Die Bildung von
Fe²⁺-Hämoglobin in peripheren mensch-
lichen Erythrocyten *in vitro*) 38, 85
 - v Polycythaemia vera, Renkocytosis
- Erythrocytostoffwechsel und Erythroblasto-
genese bei Thalassemia minor U. Ver-
suchungen, 39 333
- Erythrocyten (Stoffwechsel und Membran-
permeabilität), Symposium
- Erythrocytes; change from fetal to adult
haemoglobin in relation to changes in the
A antigen of human erythrocytes, 40, 322
- differences between the red cell acetyl-
cholinesterase defects of paroxysmal
nocturnal hemoglobinuria and of ABO
hemolytic disease, 38, 85
 - reticulocyte and normoblast labelling
with leucine- H^3 in thalassaemic and non
thalassaemic subjects, 40, 37
 - studies of Hantz body formation, 37 1
 - transketolase activity of red blood cells
in conditions of haematological interest,
39 321

- in vivo synthesis of haemoglobin from Fe^{55} and leucine- C^3 by normal, sickle cell and thalassaemic immature red cells, 38, 200
- Agglutinin, Chloramphenicol, Electrical conductivity Erythroblasts, Erythropoietic, Erythropoiesis, Glucose-6-phosphate dehydrogenase, Glucose-6-phosphatidehydrogenase, G-6-PD 66 , Pyruvate kinase deficiency Sickie cell-beta $_{2}$, Spherocytosis
- Erythrocytosis, familial (A report of two cases, and a review) 37 63
- Erythroid activity of bone marrow Erythropoiesis
- Erythroid hyperplasia, effect on the disappearance rate of erythropoietin in the dog, 39 42
- Erythrokinetic studies in thalassaemia with simultaneous radioactive tracers (Fe^{55} and Cr^{51}) 37 63
- Erythrokinetik und Erythrozytenstoffwechsel bei Thalassaemia minor U tersuchungen, 39 333
- Erythroleukaemia, v Erythromyelosis, Haemoglobin H
- Erythromyelosis, acute, after benzene poisoning, 40 234
- Erythropathie, aneinkleiteilempfindliche, bei Glukose-6-Phosphatidehydrogenase Mangel, Übergang in eine chronische hämolytische Anämie, 37 206
- Erythropoiesis DNA synthesis by erythroblasts in normal man and in some disorders of erythropoiesis, 40, 315
- effect of androgen antagonist on erythropoietic action of testosterone, 40, 299
- erythropoietic action of testosterone, 38, 49
- the effect of testosterone, adrenal steroids and prolactin on erythropoiesis, 36, 202
- zur erythropoietischen Wirkung von Testosteron, 39 366
- isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39, 118
- production cellulaire erythropoietique (Progrès dans les recherches sur le cancer Vol. 14), 40, 238 (B)
- Erythrocyte precursors, Erythrokinetic studies, Reticulocytes, Sideroblastic anaemia
- Erythropoiesis, disturbance Haemoglobin H
- Erythropoietin; effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog, 37 42
- extra-renal production of erythropoietin in man, 39, 359
- fractionation of erythropoietin by selective membrane permeability 39 372
- Espèces d'animaux (phosphatase des leucocytes) v Animal species
- Esterase, nonspecific (NaF sensitive) Monocytes
- Esterase unspezifische; die Lokalisation der unspezifischen Esterase in festen Erythrozyten und deren Vorstufen, 37 240
- Euscard® (= cholesterinhaltiges Kombinationspräparat) Erythropathie
- European Society of Haematology Proceedings of the 10th Congress (Strasbourg, 23-28. 8. 1965) (part I main lectures) 36, 1 296 (C)
- 11th congress (Athens, 10-14. 9. 1967), 36, 417
- Proceedings of the 10th Congress, Strasbourg, 1965 (Part I and II), 40, 111 (B)
- European Society for Microcirculation, 5th Conference (as an International Conference) Gothenburg, June 24-29 1968, 39 19^a
- Evolution des leucocytes eosinophiles, v Eosinophil granules
- Experimental biology and medicine, conference in Switzerland (September 1966) 37 322
- Extirpation du rein, Erythropoietin
- Extra-renal production of erythropoietin in man, 39 359
- Extrusion of the nuclei, Erythroblast
- Facteurs locaux du premier temps de l'hémostasie, 36, 109 (C)
- Factor V (= Proaccelerin); specific inhibitor of human clotting factor V 40 273
- Factor VIII (= AHF = Antihæmophilic globulin A = AHG A) investigation of circulating anticoagulants against AHF (= factor VIII) in three patients with hæmophilia A, 39 214
- pathways of factor VIII assay 39 383
- Adrenergic blockers
- Factor IX (= PTC factor); the clotting

- activity of protein fractions of congenital factor IX deficient (Christmas) serum, 33, 11
- v Christmas disease
- Factor XII Hageman factor deficiency (Report of case found in Japanese girl) 33, 36
- Factor XIII (= fibrin-stabilizing factor); congenital deficiency of fibrin-stabilizing factor (= factor XIII) (A report of the first case in Latin America) 40, 329
- Factors (blood coagulation) Blutgerinnungsfaktoren
- Familial erythrocytosis (A report of two cases, and review) 39 63
- Family (families) study on three families with haemoglobin Lepore in Campania (Hb Lepore trait, heterozygosity for Hb Lepore and β -thalassaemia, homozygosity for Hb Lepore) 37 266
- another showing the interaction of the genes for Hb G (Philadelphia) and Hb S, 40 286
- Family with delta thalassaemia, v Delta thalassaemia
- Family (families) v Alpha-Thalassaemia, Factor XII, Fibrin-stabilizing factor Haemoglobin J Paris, Macrolobulinaemia, Methaemoglobinemia, Methaemoglobinemic cyanosis, Microcythemia, Pyruvate kinase deficiency Spherocytosis
- Fatty acids, non esterified, v Demargination
- Ferrioxon, Alpha-Thalassaemia
- Fe⁵⁷ and Cr⁵¹ studies in aplastic anaemia and myelodysplasia, 33, 139
- Fe⁵⁷-Haemoglobin; Untersuchungen über die Hämsynthese in roten Blutzellen (II. Die Bildung von Fe⁵⁷ Hämoglobin in peripheren menschlichen Erythrocyten *in vivo*) 33, 63
- Fe⁵⁹ Baboon Erythroid hyperplasia Erythrokinetic studies; Erythropoiesis; Erythropoietin; Haemoglobin H Haemoglobin, *in vivo* synthesis; Iron sorbitol, Thalassaemia minor
- Feinstruktur Basophile Zellen, Eosinophil granules, Gerson cells, Haemagglutination, Huxley body Lymphopathia, Mucosa leukaemia, Phagocytosis
- Female karyotype Christmas disease in girl with female karyotype, 37 217
- Fenestr cutaneae, Mononukleäre Zellen
- Fer v Aconitase; Aplastic anaemia; Baboons; Erythrokinetic studies Erythropoiesis; Erythropoietin; Ferritin; Ferrous sulphate Haemoglobin H Haemoglobin, *in vivo* synthesis; Hämoglobin; Iron deficiency Iron poisoning Iron sorbitol; Sideroblastic anaemia; Thalassaemia minor
- Fer metabolisme, v Atransferridinämie
- Ferment cytochemistry, Lymphocytes and their derivative cells
- Ferments; histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 33, 112
- Ferments, v Acetylcholinesterase; Aconitase Alkaline phosphatase Diaphorase Dihydroxyacid dehydrogenase Drüsen-Schleimstoffe; Esterase, unspaltliche Glucose-6-phosphate dehydrogenase Glucose-6-Phosphatdehydrogenase G-6-PD Lacryme variations (B); Monocytes Mononukleäre Zellen Nitroate cholinesterase; Pyruvate kinase deficiency Reductase Retikulozyten; Serum lactic dehydrogenase Sick cell; Thalassaemia minor Thiamidpyrophosphatase; Transketolase
- Ferritin; identification of ferritin within Gerson cells (An electron microscopic and immunofluorescent study) 37 189
- Ferrogradumet® Ferrous sulphate
- Ferrokinetic studies, Haemoglobin H
- Ferrous sulphate, slow release ferrous sulphate tablets; trial of slow release ferrous sulphate (Ferrogradumet®) in prevention of iron deficiency in pregnancy 40 200
- Fetal haemoglobin change from fetal to adult haemoglobin in relation to changes in the A antigen of human erythrocytes, 40, 322
- Fetales Hämoglobin und fetale Erythrocyten. Vergleichende Untersuchungen über strukturelle und funktionelle Besonderheiten der roten Blutzelle Neugeborener und junger Stuglinge, 33, 64 (B)
- v Embryonales Hämoglobin
- Fibrin über den Retraktionsvorgang beim Blutplasmaerinnung, 36, 371
- Fibrinase, v Factor XIII
- Fibrinogen, Aggregation
- Fibrinolysis; comparative studies on inhibitors of fibrinolysis *in vitro* and *in vivo* 39 1

- essentielle Hyperfibrinolyse und erniedrigte Fibrinolyse-Aktivität, 38, 178
 der Proaktivatorgehalt im fibrinolytischen System von Hyperfibrinolytikern, 38, 377
 therapeutische Fibrinolyse, 36, 89 (C)
- Fibrinolyse inhibitors high obstruction of urine flow as complication of the treatment with fibrinolytic inhibitors of haematuria in haemophilias, 39, 237
- Fibrinolytic system in liver cirrhosis, investigations, 40, 263
- Fine structure Basophile Zellen, Eosinophiler granulosa, GALLON cells, Haemagglutination, Histo body Lymphoplasmas, Mouse leukaemia, Phagocytosis
- Finger prints Alpha-Thalassaemia, Haemoglobin J Para, Haemoglobin Koehler Sickle cell
- Fluorescent antibody technique, GALLON cells
- Foetale Erythrozyten die Lokalisation unspezifischer Esterasen in foetalen Erythrozyten und deren Vorstufen, 37 240
- Foetal, Foetal...
- Foeto-Maternal Incompatibility Symposium, 11th International (Brussels, 15. 16. 11. 1968) 32, 382
- Fose, Leberparenchymszellen Liver carcinoma
- Folsäure, acid - erythroblastopenia non megalocytare et sensible à l'acide folique chez un épileptique, 37 159
- Formae (CM-formae) Mononucleosis infection
- Fortachrisberichte, Thyroid (B)
- Fowl, Myeloblastosis virus
- Fractionation of erythropoiesis by selectin membrane permeability 38, 372
- FXF v. Fibrin-stabilizing factor
- Fixation and Transport intramedullärer Elektrolyte (Symposium, Schürer, 1967) 39 381 (B)
- Gafer diseases, Myeloblastosis virus
- Gammaglobulin, Antibodies
- Gammaglobulin, v. Agglutination
- Gammaglobulin (Hypergammaglobulinemia), Macroglobulinemia
- Gammaglobulin, Knochentumoren nach beruflicher Einwirkung des Ionisierenden Gammaglobulin (Lindes) 38, 337
- Ganglions lymphatiques, position, Lymphoplasmas
- GALLON cells; identification of ferritin within GALLON cells (An electron microscopic and immunofluorescent study), 37 189
- Gefäße, v. Hemorrhagic disorders, Hemostasis
- Geldrollenaggregation Aggregation
- Genetically determined serum groups, Anti-Tp-like haemolysis
- Genetics, v. Alpha-Thalassaemia Anti-Tp-like haemolysis, Delta thalassaemia, Erythrocytosis, Fibrin-stabilizing factor-Haemoglobin D Haemoglobin G (Philadelphia), Haemoglobin J Para, Hageman factor deficiency Leucocyte variations (B) Microglobulinemia, Methaemoglobinemia (B) Microcythemia, Primates in medicine (B) Pyruvate kinase deficiency Sickle cell - Spherocytosis, Thalassaemia
- Genetics, human, Isoenzyme variations (B)
- Genotype, Isohemagglutination
- Geographical haematology 40e Zealand symposium, proceedings, 37 322
- Geographie remarques sur l'hématologie géographique, 36, 1 (C)
- Germinal (Blastomeres) Reaktionsvorgang
- Gesellschaft Deutsche Gesellschaft für Hämatologie, 14 Tagung, Kiel, September 1969, 39 382
- Gesellschaften, European Society of Haematology International Society of Haematology Microcirculation
- Gewebskulturen, Cell cultures, Tissue cultures
- Gewebestest, Basophile
- γG Globulin, Antibodies
- Glanz, sickle cell haemoglobin D Pupal disease 5 from Glanz and D from England, 38, 324
- Glanz bands, Eosinophils
- Glasperien, Eosinophils
- Globulin (gamma globulin) Agglutination, Gamma G globulin, Gamma globulin
- Globulin, Antibodies
- Glucose-6-phosphate dehydrogenase (= G-6-PD) survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Hawaii, 37 94
- 1 survey for erythrocyte glucose-6-de-

- hydrogenase deficiency in *Ruminants*, #0 44
 - characterization in *Sorialis* children with congenital nonspherocytic haemolytic anaemia, 37 193
 - and sickle cell disease, 36, 399
 - v *Acetylcholinesterase*
- Glucose-6-phosphatdehydrogenase-Mangel mit Hämoglobinopathie und alpha-Thalassaemie, 39 167
- Überang einer autoimmunempfindlichen Erythropathie bei Glucose-6-Phosphatdehydrogenase Mangel in eine chronische hämolytische Anämie, 37 206
- G-6-PD (= Glucose-6-phosphat dehydrogenase) - Mangel mit Hämoglobinopathie und alpha-Thalassaemie, 39, 167
- Glycolysis des leucocytes humains, mesurée *in vitro*, effet de l'insuline et de quelques autres facteurs, 37 181
- G-6-PD v Glucose-6-phosphate dehydrogenase, Glucose-6-Phosphatdehydrogenase
- Golcophosphatase v Thiaminpyrophosphatase
- Granules, eosinophil, and cell maturity-electron microscopic observations on guinea-pig marrow 36, 350
- Granulocytic leukaemia, chronic; two Ph 1 chromosomes in blastic crisis of granulocytic leukaemia, 36, 391
- Granulinsytopose unter physiologischen und pathologischen Bedingungen (Experimentelle Medizin, Pathologie und Klinik, Bd. 17) 38 403 (B)
- Gravidity Abortion, Iron deficiency
- Grupe, v Ruten-
- Grossesse, Abortion, Iron deficiency
- Groupes sanguins, v A antigen, ABO blood group, ABO hemolytic disease, Aberrant blood group, Antigenic changes, Anti-Ty-like haemolysis, Blood grouping tests (B), Blood groups (B), (Haemagglutination) I antigen, Isohaemagglutination
- G 21 theory as case of acute myeloblastic leukaemia, 38, 142
- Guinea-pig, Eosinophil granules, Thymus
- Haemagglutination electron microscopic examination of haemagglutination produced by admixed Coombs serum, 38, 338
- Isohaemagglutination
- Haemagglutinin, Agglutinin
- Haematological disease, unusual as usual haematological syndrome with pyruvate-kinase deficiency and thalassaemia minor in the kindred, 39, 345
- Haematological diseases transketolase activity of red blood cells in conditions of haematological interest, 39, 321
- Haematological and serological behaviour of chicks inoculated with myeloblastosis virus, 37 311
- Hämatologie Strahlenschäden und Strahlenklinikologie (Schriftenreihe der Erlanger Fortbildung, Bd. 31) 39 331 (B)
- ; v Hématologie (B)
- Haematolite, v Electrical conductivity
- Haematology symposium in haematology (Symposium at the 11th Congress of the International Society of Haematology) 39, 331 (B)
- comparative, of laboratory animals (Selected aspects), 36 13 (C)
- European Society of Haematology: Proceedings of the 10th Congress (Strasbourg, 23.-28.8.1963) (part I main lectures) 36, 1 296 (C)
- Proceedings part I and II, #0, 111 (B)
- 11th Congress (Athens, 10. 14 9 1967), 36, 417
- 11th Congress of the International Society of Haematology (Sydney August 21-26, 1966) (Amalgamation of the International Society the European Society and the Asia-Pacific Society of Haematology) 37 232
- 11th Congress of the International Society of Haematology (New York, September 1-6, 1968), 39 320
- Geographical haematology Hematologia (B) Vererbung, Standardization (B)
- Haematopoiesis, Eosinophil granules
- Haematopoietic crisis, Bone marrow cells
- Haematopoietic, Erythropoiesis, Erythropoietin
- Haematuria high obstruction of urine flow as complication of the treatment with fibrinolytic inhibitors of haematuria in haemophilic, 39, 237
- Haemoglobin, Methaemoglobinemia, Methaemoglobinemic cyanosis
- Haemm, Hämone
- Haemoglobin change from fetal to adult haemoglobin as relation to changes in the

- A antigen of human erythrocytes, 40 322
 Untersuchungen über die Hämsynthese
 in roten Blutzellen (II: Die Bildung von
 Fe²⁺-Hämoglobin in peripheren mensch-
 lichen Erythrocyten *in vitro*) 38, 63
- Haemoglobin fractions; simple method for
 quantitation of haemoglobin fractions
 obtained by starch-gel electrophoresis,
 38, 306
- Haemoglobin, *in vitro* synthesis, from Fe²⁺
 and leucine -C¹⁴ by normal, sickle-cell
 and thalassaemic immature red cells, 38,
 200
- Hämoglobin-Synthese Atransferrin-
 armen, Hämsynthese, Reticulocyten
- Haemoglobin A, Adult haemoglobin,
 Haemoglobin fractions; Haemoglobin
 Koefliker-Hämoglobine, menschliche
 Thalassemie
- Haemoglobin A₂ (derivative from haemo-
 globin A) Protein fraction
- Haemoglobin D; sickle cell haemoglobin D
Payel disease: S from Ghana and D from
 England, 38, 324
- Haemoglobin D^{LA} Los Angeles (D *Payel*
 a, β , 121 Glu NH₂) in Thai family 39,
 151
- Haemoglobin E, Thalassemia (Ceylon)
- Haemoglobin F Fetal haemoglobin;
 Fetales Hämoglobin (B) Haemoglobin
 fractions; Hämoglobine, menschliche
 Microcythemia
- Haemoglobin G (Philadelphia); another
 family showing the interaction of the
 genes for Hb G (Philadelphia) and Hb S,
 40 286
- Hämoglobin Gower I und II, Häm-
 globine, menschliche
- Haemoglobin H as an acquired defect of
 alpha-chain synthesis (Report of two
 cases) 39 81
- Haemoglobin H, Alpha-Thalassemie,
 Thalassemia, Thalassemia (Ceylon)
- Haemoglobin J Para in the South of
 Portugal (Algarve), 39, 291
- Haemoglobin Koefliker new acquired
 haemoglobin appearing after severe
 haemolysis a, macro 141 Arg β , 37 17*
- remarks on the so-called 'Haemoglobin
 Koefliker' 39 60
- answer to the remarks on 'Haemoglobin
 Koefliker' of Besson, Filippi, Cozzi and
 Maggese, 39 61
- Haemoglobin Lepore in *Campania*, study on
 nine families (Hb Lepore trait, hetero-
 zygosity for Hb Lepore and β -thalas-
 semia, homozygosity for Hb Lepore) 37
 266
- Haemoglobin 'Typ Mexico Alpha
 Thalassemic
- Haemoglobin plasma modified (HbP₅₁)
 Haemoglobin Koefliker
- Haemoglobin S; sickle cell *Payel* disease:
 S from Ghana and D from England, 38, 324
 ; disease delta thalassemia, homozygous:
 new thalassaemic syndrome, 36, 412
 ; Haemoglobin O (Philadelphia)
- Haemoglobin Th, Haemoglobin frac-
 tions
- Hämoglobine, menschliche die intrasch-
 kuläre Verteilung von embryonalen
 Hämoglobinen in roten Blutzellen mensch-
 licher Embryonen (Ein Beitrag zur
 Ontogenese menschlicher Hämoglobine)
 38, 264
- Haemoglobinen
- Hämoglobinopathie; G-6-PD-Mangel mit
 Hämoglobinopathie und alpha-Thalas-
 semie, 39, 167
- Hämoglobin Koefliker Haemoglobin
 Lepore in *Campania*, Haemoglobins (B)
 Thalassemia, Thalassemia syndrome
- Haemoglobin bunnus haemoglobin va-
 rians and their identification, 40 336 (B)
 laboratory manual on abnormal haem-
 oglobins, 40 336 (B)
 man haemoglobins including the haem-
 oglobinopathies and their identifica-
 tion, 37 17 (B)
- Hämoglobinurie differences between the
 red cell acetylcholinesterase defects of
 paroxysmal nocturnal haemoglobinuria
 and ABC hemolytic disease 39 85
 paroxysmal nocturnal haemoglobinuria
 following splenic trauma 38, 57
 relationship of paroxysmal nocturnal
 haemoglobinuria to other pill-dependent
 hemolytic anemia due to acetylcholin-
 esterase 37 88
- Haemoglobin Koefliker
- Hämolyse properties of some european
 mammals, 38, 275
- Hämolyse, neonatal due to transient
 activity of inherited pyruvate kinase de-
 ficiency 40 115
- Hämolyse, severe haemoglobin Koefliker

- a new acquired haemoglobin appearing after severe haemolysis; *in vitro* 141 Arg. 37 174
- Haemolysis *in vitro*; studies on chloramphenicol induced haemolysis *in vitro* and survival of chloramphenicol treated cells *in vitro* 33, 11
- Haemolysis, v ABO hemolytic disease, Anti-TP-like haemolysis
- Haemolytic anaemia, v Sickle cell..
- Haemolytic anaemia, congenital nonspherocytic, v Anacmia, haemolytic, congenital, nonspherocytic
- Haemolytic diseases a peculiar benzidine-positive protein fraction in the plasma of newborns and children with various haemolytic conditions, 36, 361
- Haemolytic syndrome, unusual an unusual haematological syndrome with pyruvate-kinase deficiency and thalassemia minor in the kindreds, 39 345
- Haemolytic systems, pH-dependent, relationship of paroxysmal nocturnal haemoglobinuria to other pH-dependent haemolytic systems role of acetylcholinesterase, 37 68
- Hämolytische Anämie bei Sarkoidose der Milz, 126
- Hämolytische Anämie, chronische, v Anämie, hämolytische, chronische
- Hämometerprüfung; Normierung in der Hämatologie (Mitteilungen der Hämometerprüfstelle) 33, 63
- Haemophilia high obstruction of urine flow as complication of the treatment with fibrinolytic inhibitors of haematuria in haemophiliacs, 39 237
- in evaluation of circulating anticoagulants against AHF (= factor VIII) in three patients with haemophilia A, 39, 214
- World Federation of Hemophilia. International Symposium (Montreal, 26-28th August 1968), 39 63
- Christmas disease, Factor VIII
- Haemorrhagic disorders the nature of the defects in hemorrhagic disorders, 36, 141 (C)
- Haemorrhagic symptoms, v Christmas disease
- Haemorrhage v Thrombocytosis, post haemorrhagic
- Haemostasis importance of coagulation besides haemostasis, 36, 133 (C)
- ; v Hemorrhagic disorders, Hémostasie
- Haemostatic effect double blind evaluation of the haemostatic effect of adrenochrome monooxycarbazone, conjugated oestrogens and epsilon-aminocaproic acid after adrenalectomy 40 154
- Hämsynthese im roten Sturzaffen, Untersuchungen. (II. Die Bildung von Fe²⁺ Hämglobin in peripheren menschlichen Erythrocyten *in vitro*), 33, 63
- Hämsynthese, Atransferrinämie, Retikulozyten
- Häem. v. Hém. (Hém.)
- Hageman factor (= Factor XII) deficiency (Report of one found in a Japanese girl) 33, 36
- H antigen, ABO blood group
- Haufenster; cytochemische Untersuchungen zur Entwicklung der grossen mononukleären Zellen des Haufensters, 33, 281
- Haufenstermakrophagen, v Macrophages
- Hawell, survey for erythrocyte glucose-6-phosphate dehydrogenase deficiency in Hawell, 37 94
- Hb A, v Adult haemoglobin, Haemoglobin A, Thalassemia
- Hb A₂ (derivative of Hb A) v Protein fraction
- Hb D v Haemoglobin D
- Hb E, Haemoglobin E
- Hb F v Fetal haemoglobin, Haemoglobin F Microcythemia
- Hb G, v Haemoglobin G (Philadelphia)
- Hb Gower I und 2, Haemoglobin Gower I und 2
- Hb H, Haemoglobin H
- Hb J Paris, v Haemoglobin J Paris
- Hb Koefiker Haemoglobin Koefiker
- Hb Lepore, v Haemoglobin Lepore Isomorphs
- Hb Typ Mexico v Haemoglobin Typ Mexico
- HbPM, Haemoglobin Plasma Modified
- Hb S, Haemoglobin S
- Hb Th, Haemoglobin Th
- HCCN, Hexachlorocyclohexan
- H³-cytidine, v Riboid transformation, Plasma cells
- H³-deoxycytidine-3-monophosphate, Mononucleoside
- Huxley body studies of Huxley body formation, 37 1
- Hémagglutination, v Isohémagglutination

- Hématologie (Propédeutique médicale Vol. I) (portugais) 32, 403 (B)
- Hématologie géographique, remarques, 36, 1 (C)
- Hématologie; Société Européenne d'Hématologie 10^e congrès (Strasbourg 23. 28. 8. 1965) comptes rendus (1^{re} partie rapports principaux) 36, 1 296 (C)
- comptes rendus (1^{re} et 2^e partie), 40, 111 (B)
- 11 congrès (Athènes, 10. 14. 2. 1967) 36, 417
- actualités hématologiques, 32, 62 (B)
- Hæmatology
- Hémine; Index H²-dérydine des mégarocytes de la souris intacte et injectée d'hémine, 32, 43
- Hemoglobin H as an acquired defect of alpha-chain synthesis (Report of cases) 39 91
- Hemoglobin H, Hemoglobin H
- Hemophilia, Haemophilia
- Hemorrhagic disorders; the nature of the defects in hemorrhagic disorders, 36, 141 (C)
- Hémostasie; facteurs locaux du premier temps de l'hémostasie, 36, 109 (C)
- Hæmostasis, Hemorrhagic disorders
- Hem .. (Hém ..), Haem
- Hepar Leberparenchymszeller, Liver cirrhosis
- Heparin (antihæparin activity) Christmas factor
- Hereditary methaemoglobinæmia cyanosis due to diaphorase deficiency in three successive generations, 37 276
- Hereditary methaemoglobinæmia due to DPGH-methaemoglobin reductase deficiency (Report of family) 37 284
- Hereditary spherocytosis and heterozygous beta-thalassaemia (A family study) 39 183
- Heredit v Isotypic variations (B)
- Hæradopathy Alpha-Thalassaemia, Beta-thalassaemia, Christmas factor Congenital nonspherocytic hemolytic anaemia, Delta thalassaemia, Erythrocytosis, Fibrin-stabilizing factor Haemoglobin D, Haemoglobin G (Philadelphia) Haemoglobin J Paris, Haemoglobin Koefliker Haemoglobin Lepore in *Canis*, Hageman factor deficiency Hereditary Macrolobulæmæmia, Methaemoglobinæmia (B) Microcythaemia, Pyruvate kinase deficiency Sick cell Thalassemia..., Thalassemia major Thalassemia
- Hæmaphrodit, true Aberrant blood group
- Heterogeneity and structure of antibodies, 36, 198 (C)
- Heterozygosity for Hb Lepore and β -thalassaemia, homozygosity for Hb Lepore, Haemoglobin Lepore in *Canis*
- Heterozygous beta-thalassaemia, Hereditary spherocytosis
- Hexachlorcyclohexan (Gamma-Hexachlorcyclohexan) Knochenmarkschäden nach beruflicher Einwirkung des Insektizids Gamma-Hexachlorcyclohexan (Lindan), 38, 337
- Histamine, dietary and eosinophils in the rat, 40 59
- Histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 38, 112
- Histochemistry Acetylcholinesterase, Alkaline phosphatase, Cytology Dihydroorotic acid dehydrogenase, Drüsen fieberhaften, Enzyme analysis, Erythroblast, Fœtale Erythrocyten, G-6-PD Lymphocytes (derivative cells) Lymphocytes and their derivative cells, Lymphoplasmas, Monocytes, Mononuclear infection, Mononukleäre Zellen, Monosyllable Leukämien, Myeloider Leukämie, Plasma cells, Reinkleocyten, Sick cell disease, Thiaminpyrophosphatase
- H²-leucine, Plasma cells, Reticulocyte
- Hochpolymere Substanzen, Macromolecules
- Hodokus, morbus Reticulosis
- Homme, Hämoglobine, menschliche Isotypic variations (B) Human Mase ()
- Hormonas, immunologische Lymphocyten
- Homologous RNA, Ribonucleic acid, homologous
- Homotransplantation, Erythropoietin (extra-renal)
- Homotransplantation reactions, Lymphocytes
- Homotransplantation reaction, Lymphocytes
- Homozygosity for Hb Lepore, heterozygosity

- for Hb Lepore and β -thalassaemia, v Haemoglobin Lepore in *Compens*
- Homozygous haemoglobin S disease delta thalassaemia new thalassaemic syndrome, 36, 412
- Homozygous $\beta\beta$ -thalassaemia (or microcythemia) with high haemoglobin F in *Sick* family three cases, 40, 220
- Hormones, v Erythropoiesis, Erythropoietin, Testosterone
- HP-thymidine Index HP-thymidine des mégakaryocytes de la souris intacte et injectée d'hémine, 38, 43
- HP-thymidine, (HP-thidine) v Benzene, Blastoid transformation Chromatin-structuren DNA synthesis Eosinophils; Erythroblast; Erythrocyte precursors Leukemia, acute Leukemia, cell proliferation Metabolism of leukocytes Macrophages Mononucleosis Plasma cells Proliferative activity; Thoracic duct lymph. Thymidine metabolism (B)
- Hätschen, v Myeloblastosis virus
- Humans, leukocytes - v Leukocytes human
- Human blood platelets, nitroacetylcholine, 39, 129
- Human clotting factor \ a specific inhibitor 40, 273
- Human erythrocytes, v A antigen
- Human genetics, v Isosyme variations (B)
- Human haemoglobin variants and their identification, 40, 338 (B)
- Haemoglobins
- Human leukaemia, pathogenesis, 36, 183 (C)
- Human leukaemia, viral theory 36, 174 (C)
- Human lymphocyte; delay of human lymphocyte blast transformation by homologous RNA, 39, 270
- Antibody Blastoid transformation, Lymphocytransformation
- Human marrow v Basophils
- Human mononuclear leukocytes, *in vivo* transformation, (L. Comparison of cells in suspension and attached to coverslips) 36, 333
- (1) Precursors of large mononuclear cells on coverslips 37, 32
- Human tissues (normal and leukemic), v DNA, satellite
- Hund, Dog
- HP-thidine, Leukemia, cell proliferation, Plasma cells, (HP-thymidine)
- Hydroxycyclobutane, v Pernicious anaemia (maintenance therapy)
- Hypergammaglobulinemia, v Macroglobulinemia
- Hyperlipämie erhöhte Aggregation der Thrombocyten bei essentieller Hyperlipämie, 38, 93
- essentielle, und Blutgerinnungsfaktoren, 38, 219
- j essentielle, und verminderte Fibrinolyse-Aktivität, 38, 178
- der Prokaryotengehalt im Strahlentischen System von Hyperlipämien, 38, 377
- Hypophysis, v Prolactin
- Hypotransferrinämie, v Atransferrinämie
- Hypoxia, v Erythropoiesis
- I analysis of red cells in leukemia and its interaction with Mycoplasmas *in vivo* and *in vitro* 40, 134
- Idiopathic aplastic anaemia, associated with trisomy-21 and partial endoreduplication, case 37, 137
- v Aplastic anaemia
- Icterus, hämolytischer v Sarkoidose
- Immunoelektrophoresis, v Paraproteidämie
- Immunoblasts, v Lymphocytes
- Immunochimistry v Antibodies
- Immunoelectrophoresis, Antibodies, Macroglobulinemia
- Immunofluorescent technique, Cancer cells
- Immunoglobulins, v Antibodies
- Immunologische Hamodrome Lymphocytes
- Immunology v Human leukaemia, Primates in medicine (B)
- Immunoreaktionen, Thymus (B)
- Inclusion de Haves, Haves body
- Index HP-thymidine des mégakaryocytes de la souris intacte et injectée d'hémine, 38, 43
- India ink, v Macrophages
- Infectious mononucleosis division of leukocytes already in DNA synthesis from patients with acute leukemia and infectious mononucleosis, 38, 163
- j infectious mononucleosis cell (L: DNA synthesis) 38, 237
- the proliferation of infectious mononucleosis lymphocytes *in vitro*, 38, 19

- zur Zytochemie der Drüsenfieberzellen, 39 257
- Inflammation (macrophages of inflammation), Macrophages
- Inheritance of leukaemia and cancer 39, 174
- Inherited pyruvate kinase deficiency v Pyruvate kinase deficiency
- Inhibitor specific, of human clotting factor V 49 273
- Inhibitors, v Fibrinolysis inhibitors
- Injury of bone marrow and repair (irradiation and mechanical disruption) 40 55
- Isomerkörper v Hainc body
- Insektizid Knochenmarkschäden nach beruflicher Einwirkung des Insektizids Gamma-Hexachloro-cyclohexan (Lindan) 38, 337
- Insuline effet de l'insuline et de quelques autres facteurs sur la glycolyse des leucocytes humains, associée ou non, 37 161
- Inspektoratuna commune, v Hamfenster
- International Committee for Standardization in Haematology 3rd Transactions, Strasbourg, 22-27 8. 1963 (Standardization in haematology 111) 38, 404 (B)
- Normierung
- International Conference on Microcirculation (5th Conference of the European Society for Microcirculation), (Göteborg, June 24-29, 1968), 39 192
- International Congress, VIIth, of Clinical Pathology (Montreal, 1969) 40 176
- International Congress, 8th, of the Transplantation Society (Paris, June 1967) 37 322
- Proceedings (Advance in transplantation), 40 176 (B)
- International Council of Nurses, 39 382
- International Society of Blood Transfusion, XIIIth Congress, Moscow 1969 (travel grants) 40 240
- International Society of Haematology XIII Congress, Sydney 21-26 August 1966 (Amalgamation of the International Society the European Society and the Asian-Pacific Society of Haematology) 37 323
- International Society of Haematology XIII Congress, New York, 1-6. 9. 1968, 39, 320
- International Symposium, 11th, on Feto-Maternal Incompatibility (Brussels, 15. 16. 11. 1968) 39 382
- International Symposium on Hemophilia, Montreal (26-28th August 1968) (World Federation of Hemophilia), 39, 63
- International Symposium sur la recherche comparée dans les leucémies (IIIème) Paris 11-13 juillet 1967 37 323
- International Warshaw-Garc synopsism, Leukaemia research (B)
- International, (L.) Symposium über Stoffwechsel und Membranpermeabilität von Erythrozyten und Thrombozyten, Wien (17.-20. Juni 1968) 39, 63
- Interphascherne; die Zeitfolge der DNA-Verdopplung der Chromatinstrukturen in Interphascherne kultivierter Leukozyten, 38, 361
- Intoxication, Benzene, Benzene poisoning, Iron poisoning
- Intrazelluläre Elektrolyte, Transport und Funktion (Symposium in Schöden, 1967) 40, 112 (B)
- Iode, radioactive, Effortolym
- Iodized Coombs serum, Electron microscopic examination
- Iron deficiency; acronitase activity 37 33 trial of slow release ferrous sulphate (Ferrogadumet®) in prevention of iron deficiency in pregnancy 40, 200
- Iron, metabolism, Atransferrinämien
- Iron poisoning fetal peroral iron poisoning in young women, 40, 90
- Iron orbital, studies on the metabolism, 37 233
- Iron, Apathic anaemia Baboon Erythrocyte hyperplasia; Erythropoiesis Erythropoietin Ferritin; Haemoglobin H; Haemoglobin, in vivo synthesis Hirs-synthese Sideroblastic anaemia (Haemoglobin minor
- Irradiation, Bone marrow injury Leukaemogenesis, Pathogenesis (Leukemia), Strahlenhaematologie (B), Strahlen-schaden (B), Thymus
- Isosymes, Isosyme variations (B)
- Isobömmagglutination; études quantitatives de l'isobömmagglutination, 36, 239 (C)
- Isolierung funktionellfähiger Blutsynthesen, 38, 300
- Isotope, radioactive, Apathic anaemia; Autohaemolysis (B); Baboon; Benzene Blastoid transformation Chromatinstrukturen DNA synthesis; Eosinophils; Erythroblast; Erythrocyte precus

- non Erythroid hyperplasia Erythrokinetic studies; Erythropoiesis; Erythropoietin Fibrinolysis; Haemoglobin H Haemoglobin, *in vivo* synthesis Haemolysis *in vitro*; Haemorrhage H¹⁴-cytidine; Iron sorbitol; Leukaemia, acute Leukaemia, cell proliferation; Leukocytes, leukemic Macrophages Megakaryocytes Metabolism of leukocytes Mononuclear; Pernicious anaemia (routine neurope therapy) Plasma cells Platelets Proliferative activity Protein synthesis Reticulocyte Thalassemia minor Thoracic duct lymphocytes Thrombocytes-transfusion (B)
- Isotopic and cytological estimations of marrow erythroid activity in normal and riboflavin deficient baboons, 39 118
- Isotype variations in man (Monographs in human genetics, Vol. 1) 38, 404 (B)
- Italian ancestry (partial) v Pyruvate-kinase deficiency
- J¹⁰⁰ Fibrinolysis
- Japanese girl, v Hageman factor deficiency
- Jay-system, v Anti-TJ¹⁰⁰-like haemolysis
- Jones, v Bence Jones Proteins
- JULLARD JEAN JULLARD prize, 39 320
- Kaninchen, Rabbit
- Kapillaren, v Capillaries
- Karyogram, v G 21 trisomy Idiopathic Karyotype Leukemia, acute Leukemia, myeloid, chronic Leukemogenesis Macroglobulinemia; Megaloblastic anaemia Myelomonocytic leukemia Myeloid leukemia Osteomyeloid leukemia Ph 1 chromosomes Spleen cells Trisomy-21
- Karyotype, female Christmas disease in girl with female karyotype, 37 217
- Karminon, Cancer detection (B) Thyroid (B)
- Kerne (Zellkerne) Chromatinstrukturen, Chromosomen, Erythroblast (Entkernung) Karyogram
- Kernsegmentierung, Eosinophil
- Ketten (Polypeptidketten α - und β -Ketten am Haemoglobin) v Thalassemia
- Ketten (Polypeptid-Ketten) Bence Jones Proteins
- Kidney Erythropoietin (extra-renal) Uraemic thrombopathy
- Kidney blockade, Fibrinolysis inhibitors
- Kidney diseases PAS-positive erythroblasts in kidney diseases, 37 225
- Kinder v Erythrocytosis, Megaloblastic anaemia, Protein fraction, Pyruvate-kinase deficiency
- Kinderalter des Bart-Syndrom im Kinderalter 40 111 (B)
- Klinisch, Clinical (B)
- Knochenmark über den Abbau von Zellen im Knochenmark des Menschen und der Ratte, 40, 252
- Knochenmark und Blut, Untersuchungen, (Methoden) 40 258 (B)
- Knochenmark, v Bence Bone marrow Bone marrow injury; Bone marrow reactions (B); Cortisol; Eosinophil granules Erythroblast(s) Erythrocyte precursors, Erythroid hyperplasia; Glucocorticoids Knochenmarkveränderungen Leukemia, cell proliferation; Leukemia, myeloid, chronic Megakaryocytes Monocytes Myeloid leukemia Pansplenectomy Proliferative activity
- Knochenmarkschäden nach beruflicher Einwirkung des Insektizids Gamma-Hexachlorcyclobenzol (Linden), 38, 557
- Knochenmarkzellen über den Nachweis der Thiaminpyrophosphatase (Gluco-phosphatase) in Blut und Knochenmarkszellen, 40 177
- Knochenmarksveränderungen bei Typhus abdominalis, 37 11
- Kongulopathie Vererbungskongulopathie bei metastasierendem Prostatakarzinom, 40, 95
- Kobalt⁶⁰ Thyroid
- Kohlenstoff, radioaktiver Erythrocyte precursors Haemoglobin, *in vivo* synthesis Mononuclear
- Kollagen, anomalies, v Hemorrhagic disorders
- Koma, v Coma
- Kongenital v Congenital
- Kongress, Blood transfusion, Colloquium, Congress, Haematology (B), Microcirculation, Symposium, Therapy
- Krebs, Cancer detection (B) Thyroid (B)
- Krebsforschung, Fortschritte Erythropoiesis (B)
- Labelling index (leukaemia blast cells), Proliferative activity
- Laboratory animals, comparative haematology (Selected aspects) 36, 15 (C)

- Laboratory manual on abnormal haemoglobins, # 336 (B)
- Lactic dehydrogenase (= LDH); serum lactic dehydrogenase activity in refractory anaemia, # 187
- ; Virus-induced leukaemia
- Lapin, Rabbit
- Latin America, v Fibrin-stabilizing factor
- LDH, v Lactic dehydrogenase
- Lebensdauer der Erythrozyten, Erythrokinetik
- Leber Liver cirrhosis
- Leberparenchymszellen im Leukosytenkonzentrat. Blutfremde Zellen im strömenden Blut, # 243
- Leitfähigkeit, elektrische Electrical conductivity
- Letter to the editor (Haemoglobin haelliker) # 60
- Leucémie, myélocyttaire; étude cytologique de la transformation aigüe d'une leucémie myélocytaire chronique, # 49
- Leucémies IIIème Symposium International sur la recherche comparée dans les leucémies, Paris 11-13 juillet 1967 # 323
- Leucine (¹⁴C-leucine) Haemoglobin, *in situ* synthesis; Plasma cells; Protein synthesis
- Leucine-H³; reticulocyte and normoblast labelling with leucine-H³ in thalassaemic and non thalassaemic subjects, # 37
- Plasma cells
- Leukaemia, cell proliferation during relapse and remission; (I. DNA and RNA synthesis of leukaemic cells in the bone marrow *in situ*), # 5, 313
- (II. DNA synthesis of leukaemic cells in the peripheral blood *in vivo*) # 16
- Leukaemia and chromosomes, # 5, 157 (C)
- Leukaemia on the I antigen of red cells in leukaemia and its interaction with Mycoplasma *in vitro* and *in vivo*, # 134
- Leukaemia; isolation of Mycoplasma in leukaemia and other diseases, # 9
- presence of satellite DNA in normal and leukemic human tissues, # 75
- Leukaemia, acute; cytogenetic studies, # 192
- ; division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, # 103
- ; proliferative activity of the cells of acute leukaemia in relapse and in steady state, # 193
- Leukaemia, granulocytic, chronic two Ph 1 chromosomes in blastic crisis of granulocytic leukaemia, # 391
- ; (Philadelphia chromosome) : Leukemia and chromosomes
- Leukaemia, lymphocytic, acute; metabolism of leukocytes in case of acute leukaemia, # 294
- Leukaemia, lymphocytic, chronic: the potential of lymphocytes from patients with leukaemia and reticuloses to transform under influence of phytohaemagglutinin, # 100
- ; complete remission (Report of case) # 230
- the inheritance of leukaemia and cancer # 174
- Leukaemia, human, pathogenesis, # 183 (C)
- Leukaemia, human, viral theory # 174 (C)
- Leukaemia, mouse leukaemia; transmission of mouse leukaemia by oral route, # 1
- Leukaemia, myeloblastic, acute multiple antigenic changes in case of acute leukaemia, # 150
- ; O 21 transcytosis in case of acute myeloblastic leukaemia, # 142
- Leukaemia, myeloblastic, Myeloid leukaemia
- Leukaemia, myeloid, chronic cytogenetic studies in unusual forms of chronic myeloid leukaemia, # 129
- Leucémie myélocytaire
- Leukaemia, myelomonocytic, chronic Ph¹ duality and prognosis in chronic myelomonocytic leukaemia, # 102
- Leukaemia, myeloid, Myeloblastic virus
- Leukaemia, myelomonocytic; decreased formation of erythrocyte antigen A and consistent chromosome abnormality in patient with myelomonocytic leukaemia, # 309
- Leukaemia, plasma cell leukaemia, Plasma cells
- Leukaemia preleukaemia (A report of four cases) # 20
- Leukaemia, relapse, Leukaemia, cell proliferation
- Leukaemia, remission, Leukaemia, cell proliferation
- Leukaemia research, comparative (Pro-

- ceedings of an International Workshop-Gut symposium, Stockholm, September 1965), 38, 405 (B)
- IIIème Symposium International sur la recherche comparée dans les leucémies, Paris, (11-13 juillet 1967) 37 323
- Leukaemia, therapy; platelet transfusion therapy film, 37 160
- Leukemia, virus histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 38, 112
- prevention of AKR (strain of mice) leukaemia by thymectomy at varying ages, 38, 317
- Leukemia, v Leukaemogenesis
- Leukaemic cell the mononucleate and leukaemic cell (IL RNA synthesis) 40 28
- Leukemia, cell proliferation
- Leukaemic leukocytes *in vivo* uptake of ^3H -methionine by normal and leukaemic leukocytes, 40, 18
- Leukämie, eosinophile, akute — klinischer Beitrag zum Krankheitsbild der akuten Eosinophilen-Leukämie, 37 143
- Leukämien, monocytäre, Diagnose mit zytochemischen Methoden, 40, 121
- Leukaemogenesis chromosomal aberrations and neoplastic potentialities of thymus cells during leukaemogenesis, 40, 142
- Leukemia, v Leukaemia
- Leukemogenesis, Leukaemogenesis
- Leukocyte culture, v Cell cultures Leukocytes, mononuclear
- Leukocyten, kultivierte: die Zeitfolge der DNS-Verdopplung der Chromatinstrukturen in Interphasekernen kultivierter Leukocyten, 38, 361
- Leukocytes, neutrophils, v Granulocytopenia (B)
- Leukocytenkonzentrat blutbildende Zellen im serösen Blut (Leberparenchympellen) 38, 245
- Leukocytes, blood leukocytes, peripheral, Spleen cells
- Leukocytes division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 38, 163
- Leukocytes of some animal species, activity of alkaline phosphatase, 37 31
- Leukocytes, eosinophil, Eosinophil granules
- Leukocytes humana, glycolyse, mesurée *in vivo*, effet de l'insuline et de quelques autres facteurs, 37 161
- Leukocytes, leukaemic (and normal) *in vivo* uptake of ^3H -methionine by normal and leukaemic leukocytes, 40 18
- Leukocytes, metabolism in a case of acute leukaemia, 37 294
- Leukocytes, mononuclear human, transformation (I. Comparison of cells in suspension and attached to coverslips), 36, 333
- the transformation of human mononuclear leukocytes *in vivo* (II: Fixation of large mononuclear cells on coverslips), 37 32
- Leukocytes, v Lymphocytes (derivative cells)
- Leukosen, v Therapie
- Libri, 37 159 (B) 38, 64 (B) 403-407 (B) 39 62 (B) 127 (B) 381 (B) 40, 110-112 (B) 176 (B), 238-239 (B), 336-338 (B)
- Lichtstreuung, Macromolecules
- Lien, GANGLIA cells, Affix, Splenomegaly Spleen cells
- Light scattering, v Macromolecules
- Linden Knochenmarkschichten nach beruflicher Einwirkung der Insektizide Gamma-Henochlorcyclohexan (Linden) 38, 337
- Lipidämie (Hyperlipidämie); erhöhte Aggregation der Thrombocyten bei essentieller Hyperlipidämie, 38, 95
- essentielle Hyperlipidämie und Blutgerinnungsfaktoren, 38, 219
- essentielle Hyperlipidämie und ererbte Fibrinolyse-Aktivität, 38, 178
- der Prokollagengehalt im fibrinolytischen System bei Hyperlipidämie, 38, 377
- Liver cirrhosis investigations on the fibrolytic system in liver cirrhosis, 40 263
- Liver Leberparenchympellen
- Livres nouveaux, 37 159 (B); 38, 64 (B), 403-407 (B); 39, 62 (B), 127 (B), 381 (B) 40, 110-112 (B) 176 (B) 238-239 (B)
- Lösungen, v Macromolecules
- Los Angeles, v Haemoglobin D
- Lumière, diffusion, v Macromolecules
- Lymph node puncture, Lymphopathia
- Lymphatic leukaemia, v Leukemia, lymphocytic
- Lymphé des Doctus thoracicus sur Natur der stark basophilen Zellen in der Doctus thoracicus-Lymphé, 38, 282

- ; Thoracic duct lymph
 Lymphocyte culture delay of human lymphocyte "blast" transformation by homologous RNA, 39 270
 Antibody Blastoid transformation, Lymphocyten transformation
 Lymphocyte-like blast cells; cytoplasmic shedding as mode of formation of lymphocyte-like blast cells by newt histiocytes, 40 67
 Lymphocyte stimulation, 40 239 (B)
 Lymphocyten Isolierung funktionsfähiger Eukaryocyten, 38, 300
 Lymphocyten und Proteine 36, 50 (C)
 Lymphocyten transformation durch Streptomyces *in vivo* und Antistreptolysin-Untersuchungen zu deren Korrelation, 38, 276
 Lymphocyte culture, Lymphocytes
 Lymphocytes; division of leukocytes already in DNA synthesis from patients with acute leukemia and infectious mononucleosis, 38, 163
 Lymphocytes, "blast" transformation; delay of human lymphocyte "blast" transformation by homologous RNA, 39 270
 Antibody- Lymphocytes, blastoid transformation; Lymphocyten transformation
 Lymphocytes, blastoid transformation blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 39 373
 Antibody; Lymphocytes, "blast" transformation Lymphocyten transformation
 Lymphocytes; measurements of protein synthesis by lymphocytes *in vitro* in diseases of the lymphoid tissues, 40, 241
 ; the proliferation of infectious mononucleosis lymphocytes *in vitro*, 38, 111
 Lymphocytes of thoracic duct; the types of rat thoracic duct lymphocytes which respond to phytohemagglutinin *in vitro*, 38, 121
 Lymphocytes from patients with leukemia and reticuloses, potential to transform under the influence of phytohemagglutinin, 37 100
 Lymphocytes, peripheral blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 39, 373
 Antibody Lymphocytes, "blast" transformation, Lymphocyten transformation
 Lymphocytes, peripheral, of rabbit, studies (I. DNA and antibody synthesis *in vivo*, following antigenic stimulus), 39, 223
 "Blast transformation, Blastoid transformation, Lymphocyten transformation
 Lymphocytes and their derivative cells *in vivo*, studies; (I: Biochemical constituents) 36, 344
 —; (II. Enzyme cytochemistry), 37 42
 Lymphocytes, Drüsenförmigen, Macrophages, Mononuclear leukocytes
 Lymphocytic leukemia, Leukemia, lymphocytic
 Lymphogranulomatosis, Reticuloses
 Lymphoid blast cells, v Lymphocyte-like blast cells
 Lymphoid tissues, diseases, Protein synthesis
 Lymphology new basic trends (Proceedings of symposium held at Charleroi [Belgium] 1966 [Experientia Suppl. 14]), 40, 111 (B)
 Lymphomas, Leukemogenesis, Therapie
 Lymphopathies; contribution of cytology to the study of lymphopathies, 36, 296 (C)
 Lysokinas, Proaktivatorgehalt
 Macroglobulinaemia WALTERS' macroglobulinaemia (A family study) 36, 184
 Macroglobulinaemien, african, 36, 26 (C)
 Macromolecules; configurations des macromolécules en solution méthodes d'étude, 36, 63 (C)
 Macrophages on the origin of the skin window macrophages, 36, 586
 Lymphocytes (derivative cells) Mononukleäre Zellen
 Maintenance therapy of pernicious anaemia (Comparison of Cyanocobalamin, Hydroxocobalamin and Cyanocobalamin-Zinc Thionate Complex) 40 305
 Makro Macro
 Maladie de sommeil, Macroglobulinaemias
 Malignant myelodysplasia multiple chromosomal aberrations in case of malignant myelodysplasia, 39 299
 Man extra-renal erythropoietin production in man, 39, 339
 isosyme variations in man (Monographs in human genetics, Vol. 1) 36, 404 (B)
 Man, A antigen; Neophile; Erythropoietin Hämoglobine, menschliche

- Hämsynthese; Human... Leukocytes
human Platelets Thrombocytes
- Man haemoglobins including the haemoglobinopathies and their investigation, 37 159 (B)
- Haemoglobins
- MARCHIAFAVA-MICHELLE, v. Paroxysmal nocturnal hemoglobinuria
- Marrow erythroid activity in normal and riboflavin deficient baboons, isotopic and cytological estimations, 39 118
- Mastzellen (Blutmastzellen und Gewebemastzellen) Basophils
- Materials, exogenous haemolysing properties of some exogenous materials, 38 273
- Maturation of erythrocytes, v. Erythroblast, Reticulocytes
- Mice, Leukaemia virus, Leukaemogenesis, Mice, Mouse leukaemia, Souris
- Mechanical disruption, Bone marrow injury
- Mechanism of denaturation of the erythroblast, studies, 39 193
- Medical cyto-technology # 336 (B)
- Médicamentouse, érythropathie médicamenteuse, v. Erythropathie
- Medicine, experimental, v. Experimental biology
- Mediterranean anaemia, Alpha-Thalassaemia, Beta-thalassaemia, Haemoglobin Lepore in *Camponotus*, Thalassaemia, Thalassaemia (B) Thalassaemia major Thalassaemia minor Thalassaemic subjects, Thalassaemic syndrome
- Medulla osseus, Benzene Bone marrow Bone marrow injury Bone marrow reactions (B) Cortisol Eosinophil granules Erythroblast() Erythrocyte precursors Erythroid hyperplasia Gamma-Hexachlorocyclohexan GAUCHER cells Knochenmark Knochenmark (B) Knochenmarkzellen Leukaemia, cell proliferation Leukaemia, myeloid, chronic Megakaryocytes Monocytes Myeloid leukaemia Pannyleme Proliferative activity Typhus abdominalis
- Meerschweinchen, Eosinophil granules, Thymus
- Merting, Haematology
- Megakaryocyte response in posthaemorrhagic thrombocytosis of mice, 39 112
- Megakaryocytes depression of the megakaryocyte-platelet system in rats by transfusion of platelets, 38 81
- Index HP-thymidine des megakaryocytes de la souris intacte et injectée d'hémine, 38 43
- Megaloblastic anaemia of children, chromosomal study 39 29
- Megalocytes, v. Erythroblastopole
- Membranpermeabilität (Erythrocyten und Thrombocyten) v. Symposium
- Mensch, v. Isotype variations (B) Menschliche Hämoglobine, Hämoglobine, menschliche
- Menschliche Thrombocyten, Thrombocyten
- Menschliches Knochenmark; über den Abbau von Zellen im Knochenmark des Menschen und der Ratte, # 252
- Micropterothanol, effect on antibodies, Antibodies
- Metaphases, diploid, v. Spleen cells
- Metabolism of iron sorbitol, studies, 37 253
- Metabolism of leukocytes in a case of acute leukaemia, 37 294
- Metabolismus, v. Erythrocyten (Stoffwechsel) Erythrocytenstoffwechsel
- Methaemoglobinemia, congenital (Bibliotheca haematologica, v. ol. 28), # 239 (B)
- Methaemoglobinemia, hereditary due to DP/3H-methaemoglobin reductase deficiency (Report of family) 37 284
- Methaemoglobinemic cyanosis, hereditary due to diaphorase deficiency in three successive generations, 37 276
- Methionine (³⁵S L-methionine) in vivo uptake of ³⁵S L-methionine by normal and leukaemic leukocytes, # 111
- Methode, v. Acentase, Anticoagulation (B) Autoradiographie (B), Elastid transformation (microculture), Blood grouping tests (B) Erythrocyten, Cyto-technology (B) Double labelling technique, Erythropoietin, Factor VIII, Haemoglobin fractions, Haemoglobins (B), Knochenmark (B) Monocytaire Leukämie
- Mice; histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 38 112
- prevention of AKR (strain of mice) leukaemia by thymectomy at varying ages, 38 317
- ; megakaryocyte response in posthaemorrhagic thrombocytosis of mice, 39 112
- Leukaemogenesis, Mouse leukaemia Souris

- McNELL, v. MARCHIAS A.**
McNELL, v. RUTTI
Microautoradiography Autoradiography (B); Benzene Chromatinstruktur; Double labelling technique Erythroblast Leukemia, cell proliferation; Megakaryocytes Metabolism of leukocytes Mononucleosis; Plasma cells Proliferative activity
Microcirculation; European Society for Microcirculation, 5th Conference (as an International Conference) Gothenburg June 24-29 1968, 39 192
Microculture; blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture technique, 39 373
 - Antibody 'Blast' transformation, Lymphocytemetamorphosis
Microcythaemia three cases of homozygous β -thalassaemia (or microcythaemia) with high haemoglobin F in Sardinian family 40, 220
Monocytic type of sickle cell-beta thalassaemia disease, Sick cell-beta
Microscope électronique, Basophile Zellen, Eosinophil granules, GADCHER cells, Haemagglutination, Hertz body Lymphoplasma, Mouse leukaemia, Phagocytosis
Microscope en contraste de phase, Lymphocyte-like blast cells
Mix hämolytische Anämie bei Sarkoidose der Milz, 37 126
 GADCHER cells, Spleen cells, Splenomegaly
Mitochondrien, Renalmyocytes
Mitosis, Proliferative activity Trisomy-21
Mitotic activity Mononucleosis infections
Moelle osseuse, Benzene Bone marrow Bone marrow injury Bone marrow reaction (B) Cortisol Eosinophil granules Erythroblast(s) Erythrocytic precursors; Erythroid hyperplasia Garama Hepa-chlorocyclobuten GADCHER cells Knochenschmark; Knochenmark (B); Knochenmarkzellen Leukemia, cell proliferation Leukemia, myeloid, chronic; Megakaryocytes; Monocytes; Myelocytosis Panniculitis; Proliferative activity; Typhus abdominalis
Molecular genetics, Primates in medicine (B)
Molge vulgaris Lymphocyte-like blast cells Monocytes; on the origin of monocytes, 32, 177
Monocytes (transformed in macrophages) Macrophages
Monocytic leukaemia, Myelomonocytic leukaemia
Mononuclear leukocytes, human, transformation *in vitro* (I. Comparison of cells in suspension and attached to coverslips) 35, 333
 - (II. Precursors of large mononuclear cells on coverslips) 37 32
 Blast-like cells
Mononuclear infections; division of leukocytes already in DNA synthesis from patients with acute leukaemia and infectious mononucleosis, 38 163
 -; the infectious mononucleosis cell (I. DNA synthesis) 35, 257
 the mononuclear and leukaemic cell (II. RNA synthesis) 40 28
 the proliferation of infectious mononuclear lymphocytes *in vitro*, 32, 19
 zur Zytochemie der Drüsenleberzellen, 39 257
Mononukleäre Zellen, grosse, des Harnseners, zytochemische Untersuchungen zu ihrer Entwicklung, 39 281
Monosytäre Leukämien, Diagnose mit zytochemischen Methoden, 40, 121
Morbus GADCHER, GADCHER cells
Morbus HODGKIN, Reticuloses
Morbus WALDEYER, Macroglobulinaemia ()
Mouse leukaemia, transmission by oral route, 40 1
 Leukaemogenesis, Mice, Murine virus-induced leukaemia, Souris
Murine virus-induced leukaemia; histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 38, 112
 prevention of AER (strain of mice) leukaemia by thymectomy at varying ages, 38, 317
 Leukaemogenesis, Mice, Mouse leukaemia, Souris
Mus musculus, Leukaemogenesis, Mice, Mouse leukaemia, Murine virus-induced leukaemia, Souris
Mycoplasma fermentans (AJ ovale); isolation of mycoplasmas in leukaemia and other diseases, 40 9

- Hämsynthese: Human... Leukocytes
humans Platelets Thrombocytes
- Man haemoglobins including the haemoglobinopathies and their investigation, 37 159 (B)
- v Haemoglobins
- MARCHALAVA-MICHELL, v Paroxysmal nocturnal hemoglobinuria
- Marrow erythroid activity in normal and riboflavin deficient baboons, isotopic and cytological estimations, 39 118
- Mastzellen (Blutmastzellen und Gewebemastzellen) v Basophils
- Material, exogenous haemolysing properties of some exogenous materials, 38, 273
- Maturation of erythrocytes, v Erythroblast, Retikulozyten
- Mice, v Leukaemia virus, Leukaemogenesis, Mice, Mouse leukaemia, Souris
- Mechanical disruption, v Bone marrow injury
- Mechanism of demarcation of the erythroblast, studies, 39, 193
- Medical cyto-technology 40 336 (B)
- Médicamenteuse, erythropoïétique médicamenteuse, v Erythropoïétique
- Medicine, experimental, v Experimental biology
- Mediterranean anaemia, Alpha Thalaemia, Beta-thalassaemia, Haemoglobin Lepore in *Camels*, Thalaemia, Thalaemia (B) Thalaemia major Thalaemia minor Thalaemic subjects, Thalaemic syndrome
- Medulla osseum, v Benzene Bone marrow Bone marrow injury Bone marrow reactions (B) Cortisol Eosinophil granulocytes Erythroblast() Erythrocyte precursors Erythroid hyperplasia Gamma-Hexachlorocyclohexan GASTROINTESTINAL; Knochenmark Knochenmark (B) Knochenmarkzellen; Leukaemia, cell proliferation Leukaemia, myeloid, chronic Megakaryocytes; Monocytes Myeloclerosis Panmyelose Proliferative activity Typhus abdominalis
- Meerschweinchen, v Eosinophil granulocytes, Thymus
- Meeting, Haematology
- Megakaryocyte response in posthaemorrhagic thrombocytosis of mice, 39 112
- Megakaryocytes depression of the megakaryocyte-platelet system in rats by transfusion of platelets, 38, 34
- l'index H³-thymidine des mégakaryocytes de la souris intacte et injectée d'hémine, 38, 43
- Megaloblastic anaemia of children, chromosomal study 39, 29
- Mégakaryocytes, v Erythroblastopénie
- Membranpermeabilität (Erythrocytes und Thrombocytes) v Symposium
- Mensch, v Isosync variations (B), Man()
- Menschliche Hämoglobine, Hämoglobine, menschliche
- Menschliche Thrombocyten, Thrombocyten
- Menschliches Knochenmark, über den Abbau von Zellen im Knochenmark des Menschen und der Ratte, 40, 252
- Mercurioethanol, effect on antibodies, Antibodies
- Metaphases, diploid, Spleen cells
- Metabolism of iron sorbitol, studies, 37 253
- Metabolism of leukocytes in case of acute leukaemia, 37 294
- Metabolismus, v Erythrocyten (Stoffwechsel) Erythrocytenstoffwechsel
- Methaemoglobinemia, congenital (Bibliotheca haematologica, Vol. 28) 40, 239 (B)
- Methaemoglobinemia, hereditary due to DPNH-methaemoglobin reductase deficiency (Report of family) 37 284
- Methaemoglobinemic cytolysis, hereditary due to diaphorase deficiency in three successive generations, 37 276
- Methionine (5th L-methionine) in vivo uptake of 5th L-methionine by normal and leukaemic leukocytes, 40, 18
- Méthode, v Acetate, Automation (B), Autoradiographie (B), Blastoid transformation (microculture), Blood grouping tests (B), Blütlymphocyten, Cyto-technology (B) Double labelling techniques, Erythropoietin, Factor VIII, Haemoglobin fractions, Haemoglobins (B) Knochenmark (B) Monocytes Leukocytes
- Mice; histochemical enzyme analysis of peripheral blood changes in murine virus-induced leukaemia, 38, 112
- ; prevention of AKR (strains of mice) leukaemia by thymectomy at varying ages, 38, 317
- megakaryocyte response in posthaemorrhagic thrombocytosis of mice, 39, 112
- v Leukaemogenesis, Mouse leukaemia Souris

- Origin of monocytes, 32, 177
- Orotic acid, Dihydroorotic acid dehydrogenase
- Oryctolagus cuniculus, Rabbit
- Osmotic fragility Spherocytosis
- Osteomyeloclastosis; chromosomal abnormalities of spleen cells in osteomyeloclastosis, 33, 397
- Panbilmoytopenie mit Panmyelose, 40 75
- Panmyelophthie, Hexachlorcyclohexan
- Panmyelose mit Panbilmoytopenie, 40 75
- PAP-NICOLAOU technique v. Cyto-technologie (B)
- Papio cynomolgus, Baboons
- Paraproteinaemie und plasmazelluläre Zellproliferation bei Polycythaemia vera, 38, 240
- Parasin 6 (= Chloramphenicol-Präparat), Erythropoietin
- Paroxysmal nocturnal haemoglobinuria differences between the red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease, 32 83
- following 'aplastic anaemia' 38 57
- ; relationship to other pH-dependent hemolytic systems role of acetylcholinesterase, 37 88
- ; Haemoglobin Koelliker
- PAS (= periodic acid Schiff)-positive erythroblasts in kidney diseases, 37 225
- Pathogenesis of human leukaemia, 35, 163 (C)
- Pathogenesis and treatment of thromboembolic diseases (International Symposium, Basel, 29. III 9. 1965) 38, 407 (B)
- Pathology Clinical pathology Granulocytopenie (B)
- Pavian, Baboons
- Poma (fenêtre centrale), Macrophages, Mononukleäre Zellen
- Peptid chains, Bowen Jones Protein
- Periodic acid Schiff positivity PAS
- Peripheral lymphocytes, Lymphocytes, blastoid transformation
- Periphere Nist, Leberparenchymzellen
- Perle de verre, Blütllymphocyten
- Pernicious anaemia maintenance therapy of pernicious anaemia (Comparison of Cyanocobalamin, Hydrosocobalamin and Cyanocobalamin-ethyl-tannate complex), 40, 305
- Postekki, Insekthäut
- PHA, Phytohemagglutinin
- Phagocytose; über den Abbau von Zellen im Knochenmark des Menschen und der Ratte, 40 252
- Phase contrast microscope, Lymphocytenblasten
- Ph¹ chromosomes (= Philadelphia chromosomes); Ph¹-diagnosis and prognosis in chronic myelogenous leukaemia, 39 102
- two in blastic crisis of granulocyte leukaemia, 39 391
- Chromosomes, Myelocytosis
- pH-dependent haemolytic systems, Haemoglobinuria
- Philadelphia chromosomes, Ph¹ chromosomes
- Phosphatase, alkaline, activity in leukocytes of some animal species, 32, 51
- Phosphatase, acid, of platelets during coagulation and storage of blood, 40 48
- Phytohemagglutinin (= PHA); blastoid transformation of rabbit peripheral lymphocytes by phytohemagglutinin using microculture techniques, 32, 573
- ; Lymphocytes and their derivative cells *in vivo*, studies (I. Biochemical constituents), 35 344
- ; the potential of lymphocytes from patients with leukaemia and reticuloses to transform under influence to phytohemagglutinin, 37 100
- the types of rat thoracic duct lymphocytes which respond to phytohemagglutinin *in vitro* 38, 121
- Agglutinin, Antibody 'Blast' transformation, Lymphocytentransformation, Lymphocytes and their derivative cells
- Prüfverfahren of factor VIII assay 38, 385
- Pituitary Prolactin
- Placcho, Haemostatic effect
- Plaquettes sanguines, Hämorrhagie disorders, Hämostase, Platelet transfusion, Platelets, Retraktionsvorgang, Thrombocyten, Thromocytentransfusion (B)
- Plasma; peculiar benzidine-positive protein fraction in the plasma of newborns and children with various haemolytic conditions, 36 361
- Atransferrinase
- Plasma cells; cytochemical and autoradiographic investigations on normal and myelomatous plasma cells, 39 79

- Plasma**, trapped volume of plasma; comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between the trapped volume and the electrical conductivity 38 233
- Plasmaretikuläre Zellproliferation und Paraproteinkämie bei Polycythaemia vera**, 38, 240
- Plasmin (Plasminogen) v Fibrinolyse, Fibrinolyse**
- Plasminogen activation, inhibitors, v Fibrinolysis inhibitors**
- Plasmacytoma, Plasmazelluläre Zellproliferation**
- Plastic substances, new haemolyzing properties of some exogenous materials**, 38 273
- Plastic transfusion therapy (leukaemia) film**, 37 160
- Platelets and phosphates of platelets during coagulation and storage of blood**, 40 48
- **depression of the megakaryocyte-platelet system in rats by transfusion of platelets**, 38, 34
- **nitroacetylcholinesterase in human blood platelets**, 39 129
- **Hemorrhagic disorders, Hémostase, Platelet transfusion, Retraktionsvorgang, Thrombocyten, Thrombocytentransfusion (B)**
- Poisoning (benzene) erythromyelosis, acute, after benzene poisoning**, 40 234
- Poisoning (iron) fatal peroral iron poisoning in young women**, 40 90
- Polycythaemia vera Paraproteinkämie und plasmaretikuläre Zellproliferation bei Polycythaemia vera**, 38, 240
- Erythrocytosis**
- Polypeptide chains, Haemoglobin III**
- Polypeptide chains (alpha and beta chains of haemoglobin) Thalassemia**
- Polyploidy (endoreduplication) partial, v Triosity-21**
- Populations of molecules, Antibodies**
- Portugal, haemoglobin J Para in the South of Portugal (Algarve)** 39 291
- Proteins, v Myeloblastosis virus**
- Pregnancy Iron deficiency**
- Preleukemia (A report of four cases)** 39 20
- Preleukemia states, Pathogenesis (leukaemia)**
- Primary macroglobulinaemia, Macroglobulinaemia**
- Primates in medicine (Vol. 1) (First Holloman symposium on Primate Immunology and molecular genetics) # 110 (B)**
- Prize; JEAN JUILLARD prize**, 39 320
- Proaccelerin, Factor V**
- Proaktivatorgehalt im fibrinolytischen System von Hyperlipämikern**, 38, 377
- Proceedings of the 10th congress of the European Society of Haematology (Strasbourg, 23. 28.8 1965) (part I: main lectures)** 36 1 296 (C)
- Proceedings of the 10th Congress of the European Society of Haematology Strasbourg, 1965 (Part I and II) #**, 111 (B)
- Proceedings of the 1st International Congress of the Transplantation Society 1967 (Advances in transplantation) #** 176 (B)
- Proceedings, Geographical haematology Leukemia research (B) Lymphology (B) Standardization (B) Thromboembolic diseases (B) Transplantation (B)**
- Production cellulaire érythropoïétique (Progrès dans les recherches sur le cancer Vol. 14) #** 238 (B)
- Proerythrocytes, Foetale Erythrocyten Progrès, v Thymus (B)**
- Proctan, testosterone and adrenal steroids, effect on erythropoiesis**, 38, 292
- Proliferative activity of the cells of acute leukaemia in relapse and in steady state**, 38, 193
- Propedeutica medica, Vol. I Hematologia (portugiesisch)** 38 403 (B)
- Prophylaxis, Rhesus factor**
- Prostatatumour, metastaserende, v erblichshakosgalopatie**
- Protein sur Struktur des Bence Jones Proteins**, 38, 147
- Protein fraction peculiar benzidine-positive protein fraction in the plasma of newborns and children with various haemolytic conditions**, 36, 361
- Protein fractions, clotting activity of congenital factor IX deficient (Christmas) serum**, 39 13
- Protein synthesis by lymphocytes *in vivo* in diseases of the lymphoid tissues, measurements**, 40 241
- Proctan and Lymphocytes**, 35, 30 (C)

- Proteins, v. *Macromolecules*, *Paraproteins*, *Antibodies*
- Proteins, iodinated, v. *Electron microscopic examination*
- Proteins of the biological fluids XVIth colloquium, Bruges, (May 3-7 1967) 37 224
- Proteins of the biological fluids XVIIth Colloquium, Bruges, (May 1-5 1968) 39 192
- PTC factor (= Plasma thromboplastic component = Antihaemophilic globulin B = Factor IX) Christmas disease, Christmas factor
- Poikiloderm; sickle cell haemoglobin
- Poikiloderm: S from Ghana and E from England, 38, 324
- Poikiloderm Haemoglobin E
- Punktion der Lymphknoten, Lymphopathien
- Pyroninophile Zellen, v. *Basophile Zellen*
- Pyruvate kinase deficiency; neonatal haemolysis due to transient severity of inherited pyruvate kinase deficiency 40, 166
- ; an unusual haematological syndrome with pyruvate-kinase deficiency and thalassaemia minor in the kindreds, 39 343
- Quantitation of haemoglobin fractions obtained by starch-gel electrophoresis, simple method, 38, 306
- Quantitative études quantitatives de l'hémagglutination, 36, 239 (C)
- Quantitation and units in clinical chemistry 40 110 (B)
- Quantifizierung des Fibrins, Retraktionsvorgang
- Rabbit blood transformation of rabbit peripheral lymphocytes by phytohaemagglutinin using microculture technique 39 373
- Antibody 'Blas' transformation, Lymphocytentransformation
- Rabbit peripheral lymphocytes, studies (I DNA and antibody synthesis *in vitro*, following antigenic stimulus) 39, 223
- 'Blas' transformation, Blastoid transformation, Lymphocytentransformation
- Radiation; failure of sticking the thymus to induce recovery of bone marrow after radiation, 37 109
- Leukaemogenesis, Pathogenesis... (leukaemia) *Strahlentherapie* (B)
- Radioactive tracers, Isotope, radioaktive
- Radioautography Microautoradiography
- Radio-carbon, Erythrocyte precursors; Haemoglobin, *in vivo* synthesis Mono-nucleoside Protein synthesis
- Radio-chrome, v. *Aplastic anaemia*, Erythrokinetic studies, Haemolysis *in vivo*, Thalassaemia minor
- Radio-cobalt, Pernicious anaemia (maintenance therapy) Thymus
- Radio-iodine, Fibrinolysis
- Radio-iron, Aplastic anaemia; Baboon; Erythroid hyperplasia; Erythrokinetic studies; Erythropoiesis Erythropoietin
- Haemoglobin H Haemoglobin, *in vivo* synthesis Hämythothese Iron sorbitol Thalassaemia minor
- Radio-sulfur Leukocytes, leukaemic Platelets
- Rat über das Abbau von Zellen im Knochenmark des Menschen und der Ratte 40 252
- cellular changes in the bone marrow following chronic treatment of rats with cortisol, 38, 250
- depression of the megakaryocyte-platelet system in rats by constriction of platelets, 39 34
- eosinophils and dietary histamine in the rat, 40, 59
- thoracic duct lymphocytes, which respond to phytohaemagglutinin *in vivo* types, 38, 121
- Agglutinin, Thoracic duct lymph
- Rat, GALTHER cells, Milt, Spleen cells, Splenomegaly
- RACHNER murine leukaemogenic virus, Virus-induced leukaemia
- REBOCKsche Methode, Haftenasser Macrophages
- Red cells transketolase activity of red blood cells in conditions of haematological microcytosis, 39, 321
- red cell acetylcholinesterase defects of paroxysmal nocturnal hemoglobinuria and of ABO hemolytic disease, differences, 39, 85
- 1 Erythrocyt—
- Reductase; hereditary methaemoglobinemia due to DPNH-methaemoglobin reductase deficiency (Report of family) 37 284

- Reduplikation, Chromatinstrukturen
 Refractory anaemia, v Anaemia, refractory
 Reifung der Retikulozyten, 36, 273 (C)
 Relapse of leukaemia, v Leukaemia; cell proliferation Proliferative activity
 Remission, complete, in chronic lymphocytic leukaemia (Report of a case) 40 230
 Remission of leukaemia, v Leukaemia cell proliferation Proliferative activity
 Ren *extra-renal* production of erythropoietin in man, 39, 339
 Fibrinolysis inhibitors, Kidney diseases, Uraemic thrombopathy
 Renoprival state, v Ren
 Repair; bone marrow injury and repair (Irradiation and mechanical disruption) 40, 33
 Replication, v Chromatinstrukturen
 Resistance, electrical, Electrical conductivity
 Reticulocyte and Normoblast labelling with leucine- H^3 in thalassaemic and non thalassaemic subjects, 40 37
 Reticuloocytes, *Reifung*, 36, 273 (C)
 Reticulohistiocytic origin of the blood basophil in human marrow 40 162
 Reticuloses, lymphocytes the potential of lymphocytes from patients with leukaemia and reticuloses to transform under the influence of phytohemagglutinin, 37 100
 Retikulozyten, phagocytierende, im Knochenmark, v Phagokytose
 Retraktionsvorgang beim Blutplasmagerinnung, 36, 371
 Reversible sideroblastic anaemia caused by chloramphenicol, 38, 1
 Rezeptorfunktion der Erythrozyten (Bibliotheca Haematologica, fasc. 25) 38, 404 (B)
 Rhousfactor anti-Rh serum, Haemagglutination
 Rhous factor 11th International Symposium on Foeto-Maternal Incompatibility (Brusch, 15. 16. 11 1968), 39 382
 Riboflavin metabolic and cytological estimations of marrow erythrobl activity in normal and riboflavin deficient baboons, 39 118
 Ribonucleic acid (= RNA) homologous; delay of human lymphocyte blast transformation by homologous RNA, 39 270
 Ribonucleic acid (= RNA) synthesis the mononucleoside and leukaemic cell (II. RNA synthesis), 40, 28
 Ribonucleic acid (= RNA) *in vivo* synthesis, Leukemia, cell proliferation
 Ribonucleic acid (= RNA) v Antibody Blastoid transformation, Lymphocyten-transformation, Plasma cells, Retikulozyten, Thalassemia
 Ribosomen, v Retikulozyten
 Ristrit-Gaussen-Microtill, Thalassemia minor
 Ring chromosome, Leukemia, granulocytic, chronic
 RNA, Ribonucleic acid..
 Rotationdispersion, optische, Debye Jones Protein
 Ross Eritzellen, Erythrocyten, Erythrocytes
 Rouszellen-aggregates Aggregation
 Rousella, a survey for erythrocyte glucose-6-dehydrogenase deficiency in Rousella, 40, 44
3^{me} v Platelets
 Sauglinge, junge, v ABO haemolytic disease, Fetales Hämoglobin (B), Neonatal Protein fraction
 Saliva; ABO blood group agglutination in saliva, 38, 351
Salmonella enteritidis, Bacterial endotoxins
 Sardinian children; glucose-6-phosphate dehydrogenase, characterization, in Sardinian children with congenital nonspherocytic haemolytic anaemia, 37 198
 Sardinian families, G-6-PD
 Sarkoidose der Milz; hämolytische Anämie bei Sarkoidose der Milz, 37 126
 Satellite DNA; presence of a satellite DNA in normal and leukaemic human lymphocytes, 39, 73
 Scattering, Light scattering, Macromolecular
 Scharfmann, Sarkoidose
 Schlafkrankheit, v Macroparöxiomania
 Schwangerschaft, Abortus, Iron deficiency
 Schweiß, radioaktiver Platelets
 Schüttelung counting Leukemia, lymphatic, acute
 Sedimentations-Diagramme, Debye Jones Protein
 Segmentation, nuclear of eosinophils under

- normal and pathological conditions, 37
120
- Selective membrane permeability Erythropoietin
- Serological and haematological behaviour of chicks inoculated with myeloblastosis virus, 37 311
- Serology as introduction to blood group serology (3rd ed.) 37, 127 (B)
- Serum lactic dehydrogenase activity in refractory anaemia, 40, 187
- Serravallo, Atrazacrinolones
- Sex hormones, Testosterone
- Sex (true hermaphrodite) Aberrant blood group
- Sickle (mostly v. Δ microcytosis)
- Sickle-cell anaemia; as synthesis of haemoglobin from Fe²⁺ and isocyste-C²⁺ by normal, sickle-cell and thalassaemic immature red cells, 37 200
- Sickle cell-beta thalassaemia disease, two subtypes a) Normocytic type of sickle cell-beta thalassaemia disease b) Macrocytic type of sickle cell-beta thalassaemia disease (Thalassaemia syndromes VI.) 37 181
- Sickle cell disease and glucose-6-phosphate dehydrogenase, 35 390
- Sickle cell haemoglobin D Pampel disease 8 from Ghana and D from England, 35 324
- Siderochromische Störung der Erythropoese, Sideroblastic anaemia
- Sideroblastic anaemia, reversible, caused by chloramphenicol, 38 1
- Straßburgerische, Leukemia research (B) Proceedings (B) Standardisation (B) Thrombocytotic diseases (B) 1 or handling
- St. L-methionine, Methionine
- Stia window macrophages, origin, 35 386
- Mononukleäre Zellen
- Streping sickness, Macroglobulinaemia
- 'Stuffed blood' phenomenon, Aggregation
- Society Deutsche Gesellschaft für Hämatologie, 14 Tagung, Kiel, September 1969 37, 382
- European Society of Haematology Proceedings of the 10th Congress (Strasbourg, 23. 28. 8. 1965) (part I main lecture) 35, 1 296 (C)
- ; Proceedings (part I and II) 40 111 (B)
- 11th Congress (Athens, 10. 14. 9. 1967) 35, 417
- 11th Congress of the International Society of Haematology (Sydney August 21 '66, 1966) (Amalgamation of the International Society the European Society and the Asian-Pacific Society of Haematology), 37 232
- 12th Congress of the International Society of Haematology (New York, September 1-8 1968) 37, 320
- Transplantation Society 1th International Congress (Paris, June 1967), 37 322
- Transplantation Society 1st International Congress, 1967 Paris, proceedings (Advance in transplantation) 40, 176 (B) v. Blood transfusion, Δ microcirculation, Standardisation (B)
- Sodium fluoride sensitive esterase, Δ monocytes
- Solutions, Δ macromolecules
- Soufre, radioactive, Platelets
- Souris l'index H³-thymidine des méga-karyocytes de la souris intacte et infectée d'hépatite, 37 43
- Leukemia virus, Leukemogenesis
- Δ lice, Δ leucemia
- Southern Portugal Portugal
- Species, animal, Animal species
- Speichel, Saliv
- Spherocytosis, hereditary and heterozygous beta-thalassaemia (A family study), 37 183
- Congenital nonspherocytic hemolytic anaemia
- Spleen cells chromosomal abnormalities of spleen cells in osteomyelodysplasia, 38 39
- GARTNER cells, Mice
- Spinohegallies, tropical, Δ macroglobulinaemia
- Standardisation in haematology III (3rd Transactions of the International Committee for Standardisation in Haematology Strasbourg 22./27. 8. 1965) 38, 404 (B)
- Normierung
- Starch-gel electrophoresis simple method for the quantitation of haemoglobin fractions obtained by starch-gel electrophoresis, 38 308
- Statistische Auswertung, A antigen ABO hemolytic disease Aggregation (Throm-

- bocytin) Anti-T_H-like haemolysis
 Blutgerinnungsfaktoren; Cortisol Eosinophil granules Erythroid hyperplasia
 Factor VIII Fibrinolysis Glycylase
 Haemoglobin, *in vitro* synthesis Haemolytic properties ; Haemostatic effect; Haemopoiesis- Index HP-thymidine; Isohaemagglutination Lymphocyto-transformation Metabolism of leukocytes
 Proliferative activity; Protein synthesis Saliva; Transketolase
- Steady state of leukaemia, v Proliferative activity
- Steroids, Adrenal steroids, Cortisol, Testosterone
- Stimulation lymphocyte stimulation # 253 (B)
- Stoffwechsel, Erythrocytenstoffwechsel, Metabolism
- Stoffwechsel (Erythrocyten und Thrombozyten) Symposium
- Storage of blood acid phosphatases of platelets during coagulation and storage of blood, # 48
- Strahlenschäden und Strahlenhämatologie (Schriftenreihe der ärztlichen Fortbildung Bd. 31) 39 381 (B)
- Strahlenwirkung, v Leukemogenese, Pathogenesis (leukaemia) Thymos
- Streptokinase, Fibrinolysis
- Streptolysin O Untersuchungen zur korrelation von Lymphocyto-transformation durch Streptolysin O *in vitro* und Antistreptolysin # 276
- Antibody "Blau" transformation, Blastoid transformation
- Structure and heterogeneity of antibodies, 36, 198 (C)
- Submicroscopical structure, v Basophile Zellen, Eosinophil granules, GAUCHER cells, Haemagglutination, Hader body Lymphopathia, Mouse leukaemia, Phagocytosis
- Substances tensio-actives, Desaggregation
- Suckling, Fetuses Haemoglobin (B)
- Sulfatase, Nitroreductase
- Sulfur radioactive, Leukocytes, leukaemic platelets
- Surface-active substances, Desaggregation
- Survival of chloramphenicol treated cells *in vitro* and chloramphenicol induced haemolysis *in vitro*, 36, 11
- Survival time, v Erythrokinetik
- Symposium, International, on Hemophilia, Montreal, 26-28th August 1968 (World Federation of Hemophilia) 39 III
- 11th, International on Feto-Maternal Incompatibility (Brussels, 13. 16. 11 1968) 39, 382
- 111ème, International sur la recherche comparée dans les leucoses, Paris, 11-13 juillet 1967 39 323
- 1 International Symposium über Stoffwechsel und Membranpermeabilität von Erythrocyten und Thrombozyten (Wien, 17-20. Juni 1968) 39 63
- Symposium, v Automation (B), Elektrolyte (B) Experimental biology Geographical haematology Leukaemia research (Warczew-Gaw) (B), Lymphology (B), Prognosis in medicine (B), Thrombotic diseases (B)
- Tagungsberichte, v Verhandlungen
- Technik der Autoradiographie, 39 127 (B)
- Technique, v Automation (B), Cyto-technology (B)
- Tägéral® v Erythroblastopoenie
- Tensio-actives, substances tensio-actives, Desaggregation
- Testosterone, adrenal steroids and prolatin, effect on erythropoiesis, 36, 252
- effect of androgen antagonist on erythropoietic action of testosterone, # 259
- zur erythropoetischen Wirkung von Testosteron, 39 366
- studies on erythropoietic action of testosterone, 36, 49
- Thai family haemoglobin D_{II} Los Angeles (D Punjab, $\alpha_2\beta_2$ 121 Glu NH₂) in Thai family 39 151
- Thalassemia, 36, 256 (C)
- ; (β -thalassaemia) Haemoglobin Lepore in *Camponotus*
- in *Cybus*, 39 209
- ; G-6-PD-Mangel mit Hämoglobinopathie und alpha-Thalassaemie, 39, 167
- hereditary spherocytosis and hereditary beta-thalassaemia (A family study), 39 183
- ; reticulocyte and normoblast labeling with leucine-¹⁴C in thalassaemic and non thalassaemic subjects, # 37
- three cases of homozygous β -thalassaemia (or microcythaemia) with high

- haemoglobin F in *Sickle cell family* #0 220
in vitro synthesis of haemoglobin from Fe⁵⁹ and leucine-C¹⁴ by normal, sickle-cell and thalassaemic immature red cells, 37 200
- Thalassaemia major; erythrokinetic studies in thalassaemia with strontaneous radioactive tracers (Fe⁵⁹ and Co⁵⁷) 37 63
 —; *in-vivo* study of DNA-synthesis time and cell-cycle time in erythrocyte precursors of normal and thalassaemic subjects, using H³- and C¹⁴-thymidine double labelling technique 33, 170
- Thalassaemia minor: modes of presentation, #3, 34
 ; Untersuchungen über Erythrokinetik und Erythrozytenstoffwechsel bei Thalassaemia minor 37 333
 as unusual haematological syndrome with pyruvate-kinase deficiency and thalassaemia minor in the kindreds, 37 345
- Thalassaemia syndromes, 38, 405 (B)
 —; (VL Two subtypes of sickle cell beta thalassaemia disease) Normocytic type of sickle cell - beta thalassaemia disease; b) Microcytic type of sickle cell-beta thalassaemia disease) 37 181
- Thalassaemic syndrome new Homozygous haemoglobin S disease delta thalassaemia, 38 412
- Therapeutische Fibrinolyse 36 89 (C)
- Therapie der Leukosen und malignen Lymphome (Internationale Arbeitstagung Wien, 1969) #3, 240
- Therapy Erythroblastopenie, Iron deficiency Leukaemia, lymphocytic (complete remission), Pernicious anaemia (maintenance therapy), Placental transfusion therapy Transfusion (B), Thrombocytransfusion (B) Thrombotic diseases (B)
- Thermodynamic approach, Isothermization
- Thiaminpyrophosphatase ("Gonophosphatase") in Blast- und Knochenmarkszellen, der Mäuschen, #0 177
- Thoracic duct lymphocytes; the types of rat thoracic duct lymphocytes which respond to phytohemagglutinin *in vivo*, 38, 121
 —; early appearance of blast-like cells in the thoracic duct lymph of rats given bacterial endotoxins, 37 301
- Thrombocyten erhöhte Aggregation der Thrombocyten bei essentieller Hyperlipämie 38, 95
 Untersuchungen über den Einfluss von Natrium-Oleat auf die Aggregation menschlicher Thrombocyten, #3, 205
 Hemorrhagic disorders, Hemostase, Platelets, Retraktionsvorgang Transfusion; placental
- Thrombocyten (Stoffwechsel und Membranpermeabilität) Symposium
- Thrombocytransfusion (Untersuchungen mit radioaktiv markierten Thrombocyten) #0 337 (B)
 —; Transfusion placental
- Thrombocytosis, posthaemorrhagic in mice, megakaryocyte response, 39 112
- Thrombotic diseases, pathogenesis and treatment (International Symposium, Basel, 29. 8. 1965) 38, 407 (B)
- Thrombolytic, Fibrinolytic
- Thrombopathy uraemic, investigation, #0, 113
- Thrombopoietin, Thrombocytosis, posthaemorrhagic
- Thymectomy; prevention of AKR (strain of mice) leukaemia by thymectomy at varying ages, 38, 317
- Thymidine metabolism and cell kinetics (Frontiers in biology vol. 6) 39, 381 (B)
- Thymidine (C¹⁴-thymidine, H³-thymidine) Erythrocyte precursors, Mononuclear
- Thymidine (H³-thymidine) Bone marrow Blasted transformation Chromatinstruktur DNA synthese Eosinophils; Erythroblast; Erythrocyte precursors Index H³-thymidine Leukaemia, acute Leukaemia, cell proliferation; Macrophages Metabolism of leukocytes Mononuclear Plasma cells Proliferative activity Thoracic duct lymphocytes
- Thymus (Recent results in cancer research, vol. 5) 38 406 (B)
 failure of shielding the thymus to induce recovery of bone marrow after radiation, 37 109
 (thymomas) chromosomal aberrations and neoplastic potentialities of thymus cells during leukemogenesis, #0 142
- Thier, Laboratorien, Comparative haematology
- Tierarten (Phosphatase in Leukocyten) Animal species

- Tissue cultures, v Antibody Blast' transformation; Blastoid transformation Cell proliferation Leukocytes, kultivierte Lymphocyten transformation Lymphocytes; Lymphocytes (derivative cells) Lymphocytes and their derivatives; Lymphocytes from patients Lymphocytes, peripheral Mononuclear cells Mononuclear leukocytes Mononucleosis Ph 1 chromosomes Spleen cells; Tri-
scopy 1
- Tp v Anti-Tp-like haemolysis
- Tonillectomy v Haemostatic effect
- Toxines, v Bacterial endotoxines
- Transaminic acid (= active homer of amino-methylcyclohexane-carboxylic acid) Fibrinolysis, Fibrinolysis inhibitors
- Transactions, (3rd) of the International Committee for Standardization in Haematology Strasbourg, 22-27 8. 1963 (Standardisation in haematology III) 38 404 (B)
- Transactions, Leukaemia research (B) Normierung Proceedings, Proceedings (B) Thromboembolic diseases (B)
- Transferrin Atransferrinämien (kongenitale und erworbene Formen) 36 40 (C)
- Transformation of human mononuclear leukocytes (L. Comparison of cells in suspension and attached to coverslips) 36, 333
- (II Precursors of large mononuclear cells on coverslips) 37 32
- Transfusion blood transfusion in clinical medicine (4th ed.) 38, 407 (B)
- International Society of Blood Transfusion, XIIIth International Congress, Moscow 1969 (travel grants) 40 240 sanguine, actualités (2^e cours européen de transfusion sanguine organisé par le Conseil de l'Europe, Strasbourg, 1966) 40 110 (B)
- plastic transfusion therapy (leukaemia) film, 37 160
- Thrombocytentransfusion (B) Platelets
- Transferrin activity of red blood cells in conditions of haematological interest, 39 321
- Transmission of mouse leukaemia by oral route, 40 1
- Transplantation, advances (Proceedings of the 1st Congress of the Transplantation Society Paris, 1967), 40, 176 (B)
- , 37 322
- Transplantation, Erythropoietin (extra-renal)
- Transplantation reactions, Lymphocytes Transport und Funktion intrazellulärer Elektrolyte (Symposien in Schöber, 1967) 40 112 (B)
- Trapped volume of plasma; comment on the method of determining the trapped volume of plasma after centrifugation based on the correlation between the trapped volume and the electrical conductivity 38, 255
- Trasylol® Fibrinolysis
- Treatment and pathogenesis of thromboembolic diseases (International Symposium, Basel, 29 8. i 9. 1965) 38, 407 (B)
- Trisomy-21; case of idiopathic aplastic anaemia associated with trisomy-21 and partial endoreduplication, 37 157
- G 21 trisomy in a case of acute myeloblastic leukaemia, 38, 142
- Trithion, v Cytidine DNA synthesis Echinophils H³-cytidine H³-leucine H³-uridine Leucine H³ Leukaemia, cell proliferation, Macrophages Thymidine (H³-thymidine)
- Tumoren, v Cancer Cancer chemotherapy Cancer detection (B) Erythropoietin (B) Leukaemogenesis, Thymus (B), 1^{er} bruchstetagepathic
- Turbidimetry Spherocytosis
- Tusche, Macrophages
- Typhus abdominalis, Kaschmarl-Kocher Änderungen, 37 11
- UICC, v Union Internationale contre Cancer
- Ultracentrifuge, Bruce Jones probe, Microglobulinacromies
- Ultracentrifuge, analytical, DVA, anal-
lyse
- Ultrastructure, Basophile Zellen, Eosinophil granules, Glomeruli cells, Haemophagocytosis, Heter body Lymphop-
thias, Mouse leukaemia, Phagocytosis
- Umbilical cord blood from the umbilical cord, v A antigen
- Units and quantities in clinical chemistry 40 110 (B)
- Union Internationale contre Cancer. Monograph series, vol. 4 Cancer detec-

- tion (Prepared by the Cancer Detection Committee of the Commission on Cancer Control) 37 406 (B)
- Unusual haemolytic syndrome Haemolytic syndrome unusual
- Uraemic thrombocytopathy Investigation, 40 113
- Uridine (H³-uridine), Leukaemia, cell proliferation Metabolism of leukocytes; Plasma cells
- Urine flow, obstruction high obstruction of urine flow as a complication of the treatment with fibrinolytic inhibitors of haematuria in haemophilia, 39 237
- Valerian, Hemorrhagic disorders, Histamine
- Vaguer disease, Erythrocytosis
- Varia, 36, 417 37 100, 224 323 38 63 39 63, 182, 320, 322; 40 176, 340
- Vasculitis faciens vasculitis Hemostatic
- Vascular anomalies, Hemorrhagic disorders
- Verbreitungsgeographie des metastasierenden Prostatakarzinoms, 40 93
- Vergiftung, Benzene Benzene poisoning Iron poisoning
- Vergleichende Haematologie, Comparative haematology
- Verhandlungen des 10. Kongresses der Europäischen Gesellschaft für Hämatologie (Surreyburg, 23. 28. 8. 1963) (I Teil Hauptvorträge) 36 1 296 (C)
- (I and II Teil), 40 111 (B)
- Verhandlungen, Leukaemia research (B)
- Proceedings, Proceedings (B), Standardization (B) Thromboembolic diseases (B)
- Venese, Hemorrhagic disorders, Hemostatic
- Viral theory of human leukaemia, 36, 174 (C)
- Virus AER (strain of mice) leukaemia, prevention by thymectomy at varying ages, 38 317
- Virus-induced leukaemia, murine histochemical cytochrome analysis of peripheral blood changes in murine virus-induced leukaemia, 38, 112
- Virus leukaemia, Leukaemia research (B)
- Leukocytogenesis Mouse leukaemia
- Virus, myeloblastoma virus haematological and serological behaviour of chicks inoculated with myeloblastoma virus, 37 311
- Vitacide Macropolietides
- Vitamin B₁₂ Riboflavin
- Vitamin B₁₂ Pernicious anaemia (maintenance therapy)
- Waldenström's Macroglobulinaemia (A family study), 38 184
- Macroglobulinaemias
- Wenger-Green symposium, Leukaemia research (B)
- Werte Australis study of various antibodies and genetically determined serum groups among aborters producing anti-T₂-like haemolysis and non-aborters in Waver Australis, 38, 251
- Widerstand, elektrischer Electrical conductivity
- Women, aborters, Aborters
- World Federation of Hemophilia (International Symposium, Montreal, 26-28th August 1968) 39 63
- Zelle Elektrolyte (B)
- Zellkerne, Chromosomes, Karyogram, Kerne, Nuclei
- Zellkerne (der Erythroblasten) Nuclei
- Zellstrukturen, Antibody "Blast transformation Blastoid transformation; Cell culture Leukocytes, kulturelle Lymphocytenstransformation; Lymphocytes Lymphocytes (derivate cells); Lymphocytes and their derivatives; Lymphocytes from patients Lymphocytes, peripheral Mononuclear cells; Mononuclear leukocytes; Mononuclear Ph 1 chromosomes Spleen cells, Trisomy-21
- Zellproliferation, plasmazelluläre; Para-proliferation und plasmazelluläre Zellproliferation bei Polycythemia vera, 38, 240
- Zell Cell
- Zytochemie der Drüsenfibrosen, 39 257
- Zytochemische Methoden Diagnosis mononuclear Leukämien mit zytochemischen Methoden, 40 121
- Zytochemische Untersuchungen zur Entwicklung der grossen mononukleären Zellen des Haufens, 38, 231
- Zyto Cyto

Index autorum ad Vol. 36-40

(B) = Book reviews - Buchbesprechungen - Livres nouveaux
(C) = Communications - Vorträge - Communications

- Abbott, C. R., Roberts, B. E.
Adams, D. 37 109
Agarwal, A. V., Khanna, P. C.
Aksoy M., and Erdem, B., 37 181 39 183
Aksoy M., Erdogan, G.
Alemio, L., v. Salas, E.
Alexiou-Terzaki, V. Kesse Elias, M.
Alford, Dorothy A., Lewis, J. P.
Allen, F. H. Jr. 40 338 (B)
Almici, P. Buonomano, G., Coiro, F. de
Vargas, F. and Varone, G. L., 40 134
Almici, P. Coraggio, F., Coiro, V. de Var
gas, F. and Varone, G. L., 40 9
Angelopoulos, B., Karafis, D. Tsoukantas,
A., and Eleftheriadou, A., 37 234
Antonaki, J. A., Felber J. P. et Vannotti,
A., 37 161
Antonini, J. L., Ragen, P. A.
Ard, E., Thompson, R. B.
Arendt, T. Goetz, J. M., and Rangel,
J. R., 40 329
Arai, I. Mura, S.
Arai, M., Okada, S., Takabayashi, J. Ku
bo, T. Inoue, M., and Sano, S., 39 193
Ayres, M., Saitano, F. M., and Ludwig, O.
K., 37 150
Asuma, M., Shirakura, T.
Bach, C., Buser, A. M., Sartoris, S., Ver
gato F. and Fazio, M., 39 270
Baib, A. G. 36 157 (C)
Bai-Macari, B., Macarionis, N.
Bando, F. De Cataldo, F.
Barrigan, Marjorie A., Paglia, D. E.,
Schneider A. S., and Valentine, W. N.,
39 345
Beale, D. Marti, H. R.
Beale, D. v. Ward, P.
Beck, E., 39 381 (B); 40 111 (B), 336 (B)
Beck, E. A., Ziegler G., Schmid, R., and
Ludin, H., 39 1
Beckman, L., 39 404 (B)
Begenmann, H., Trepel, F.
Bell, W. N. v. Thompson, R. B.
Benkó, S., Csikó, B., Jód, F. Kaiser G.,
and Bód, A., 39 333
Bernard, J. 39 62 (B)
Bernard, J. et Raffé, J. 36 1 (C)
Berke, A., v. Klehauer E. F.
Bianchi, L., v. Hinzewaldt, Ch.
Bianchi, P. v. Quattrin, N.
Bianco, L., Salvatoni, E.
Bód, A., Benkó, S.
Blenkinsopp, Evelyn C., and Blenkinsopp,
W. K., 40 59
Blenkinsopp, W. K., Blenkinsopp, Eve
lyn C.
Böhle, E., v. Ehrly A. M.
Boettcher, B., 39 351
Boic, Karin, Borch, D.
Boll, L., 39 403 (B)
Boorman, Kathleen E., and Dodd, Barbara
E., 39 127 (B)
Borges, A., and Desforger, J. F. (and Pot
vin, Beatrice), 37 1
Borovickzy Ch. G. de, 39 404 (B)
Borovickzy K. G. v. 39 63
Boser, M., Ducha, M., and Fornari, G., 40
166
Bottel, E., Hippel, G., Coiro, F. and Mar
gioni, G., 36 361; 39 60
Braun, W. v. Welter O.
Braunwieser H., Holschnecht, F.

- Braunsteiner H., Rensenbrink, J.
 Braunsteiner H., v. Schmalz, F.
 Braunsteiner H., v. Spötl, F.
 Bridges, J. M., Sloane, Katharine M.
 Brown, A. K., Elves, M. W., Gimson, H. H.,
 and Pell-Holerton, R., 33, 184
 Bucher U. 37 62 (B), 40, 337 (B)
 Büchner T. und Pfeiffer R. A., 33, 361
 Böder R., 40, 110 (B)
 Bötter R., Lopez, V.
 Boormano, G., Altucci, P.
 Burnett, R. C., Lie-Injo, L. E.
 Borslem, R. W., Poller L., and Wachs, H.,
 40 200
 Busch, D. (und Boie, Karin) 37 206
 Busel, M., Bachi, C.
 Curoi, G., Rondeneff, E. G.
 Castello, R., Roemen, C.
 Castello, R., San Miguel, J. G.
 Castoldi, G. L., Yam, L. T. and Mitus,
 W. J. 39, 203
 Cataldo, F. De, De Cataldo, F.
 Cernick M., Koler V. and Jeretin, S.,
 40 90
 Chatterjee, J. B., Ghosh, S. K.
 Chatterjee, J. B., Swarup, Soehila
 Christakopoulos, P., Malamos, B.
 Clemen, R., Quattrio, N.
 Cress, M., and Huber H., 39 300
 Cress, M., Schmalz, F.
 Clever J. E., 39 361 (B)
 Clotten, R., Heimpel, H.
 Cocco, F., Altucci, P.
 Collen, B., Tytgat, G.
 Collette, J. M., Jantet, G., and Schoffelech,
 E., 40 111 (B)
 Collinge, Margaret, Elves, M. W.
 Constantin, R., Spötl, F.
 Cooper E. H., Hale, A. J. and Milton, J.
 D. 38, 19
 Coraggio, F., Altucci, P.
 Cordeiro Ferreira, N., Trincão, C.
 Coroco, G., Omedli, E., and Polli, E., 39
 73
 Costa, S., Scherrini, F.
 Coto, V., Altucci, P.
 Cox, H. S. 40, 336 (B)
 Cozi, F., Bottini, E.
 Creveld, S. van, van Creveld, S.
 Crosby W. H., Weissman, M. B.
 Csallik, R., Benkő, S.
 Czernik, F., Lachowicz, W.
 Dabak, M., Boser, M.
 Daumet, J., Hamburger J. and Mathe, G.
 (Editores) 40 176 (B)
 Davey M. G., Lawrance, J. R., Lander
 H., and Robson, H. N., 37, 65
 de Borovickszay Ch. G., Borovickszay Ch.
 G. de
 De Cataldo, F. and Bardo, F. 38, 383
 de Melo, J. Martins, v. Martins de Melo, J.
 De Rosa, L., Quattrio, N.
 Desforges, J. F., Borges, A.
 Deutsch, E., 36, 89 (C)
 Deutsch, E., and Fischer M., 37 1
 de Vargas, F. v. Altucci, P.
 De Vreckler R., Tytgat, G.
 Dewhurst, F. and Poller L., 37 13
 Doçol, K., Erdogan, G.
 Dini, E., Quattrio, N.
 Dionisi, D., Rondeneff, E. G.
 Dodd, Barbara E., Boorman, Kathleen E.
 Doppenschmidt, H., v. Ehrly A. M.
 Dos Santos Nascimento, J., Trincão, C.
 Dabach, U. C., 38, 404 (B)
 Dybbæk R., and Jørgensen, K., 40, 110 (B)
 Dabole-Ferrère, H., 39, 249
 Duckert, F., Koller F.
 Duda Soares, A., Parreira, F. 38, 403 (B)
 Ebara, H., Nakao, K.
 Ehrly A. M., und Müller H. E., 36, 323
 Ehrly A. M., Doppenschmidt, H., und
 Böhle, E., 40 205
 Eleftheriades, A., v. Angelopoulos, B.
 Elen, Kome-Efina, M., Malamos, B.
 Elves, M. W., Collinge, Margaret, and Is-
 raeli, M. C. G., 37 100
 Elves, M. W. and Israeli, M. C. G. 38, 129
 Elves, M. W., Brown, A. K.
 Elves, M. W., Gough, J.
 Erdem, S., Aksoy M.
 Erdogan, G., Aksoy M., and Doçol, K.,
 37 137
 Ferreras, P., Pardo, B.
 Fazio, M., Bachl, G.
 Felber J. P., Antonelli, J. A.
 Ferreira, N., Cordeiro, v. Cordeiro Ferreira, N.
 Filippi, G., Bottini, E.
 Fiffel-Warmer Sabine, et Wurmer R.,
 36 239 (C)
 Finch, C. A., Rosenzweig, A. I.
 Florell, G., Balle, E.
 Florani, L., Ricco, G.
 Flecher M., Deutsch, E.
 Flecher R., und Hennekauer H. H., 40
 177

- Florey M. J. v Mathias, F. A.
 Focio, A., 36 371
 Forbes, J. J. v Lawton, J. W. M.
 Fornaini, G., v Bosu, M.
 Fort, R. W. v Roberts, R. E.
 Foy H., Koodi, Athena, Harris, Eileen B.,
 and Preston, J. K., 39 118
 Frick, P. 38 403 (B) 39 301 (B) 40 111 (B)
 Frick, P. G., v Schmidt, J. R.
 Fudenberg, H. H., v Vos, G. H.
 Gabutti, V. v Pileri, A.
 Gallo, E., v Ricco, G.
 Gardikas, C., 40 34
 Gardikas, C., Lyberatos, C., Pyrovolakis, J.
 and Pappayannis, A., 40 16
 Gardner E. Jr v Lewis, J. P.
 Gardner F. H., Lafort, M. T.
 Garoto, F. v Pileri, A.
 Gergely G. Kriza, F.
 Germano, G., et Scholer 1. 39 159
 Gibich, S. K., Swarup, Sushila
 Gibernan, E., 39 255
 Ginelli, E., Corneo, G.
 Girard, J.-P. 39 223 40 239 (B)
 Gloor F. 38, 406 (B)
 Göt, E., und Vitz, L., 39 243
 Gosh, S. K., Swarup-Mitra, Sushila, Char-
 trajes, J. B. 40 104
 Gough, J. and Elvea, M. W. 36, 344 37 4
 Graf Keyserlingk, D. 40 252
 Grumbich, F. 38, 404 (B)
 Grumm, J. 40 111 (B)
 Gross, L., 40 1
 Grundbacher F. J. 40 322
 Grumock, D. Klemm, D.
 Guera, J. M., Arends, T.
 Gullbring, B., and Lagerlöf, B., 37 311
 Gunson, H. H., v Brown, A. K.
 Gvfiaki, E., Kosc-Elias, M.
 Gvfiaki, E., Malamos, B.
 Hammrich, Gaele, and Landy M., 37 301
 Haug, A., 38, 407 (B) 40 110 (B)
 Hale, A. J. Cooper E. H.
 Hamburger J. Damsert, J.
 Harris, E. B., Kosc-Elias, M.
 Harris, Eileen B., Foy H.
 Hathorn, M., Lewis, R. A.
 Hauswaldt, Ch., Raju, S., Bianchi, L. und
 Humstein, W. 37 143
 Hauswaldt, Ch., v Klemm, D.
 Heckner H., 40 238 (B)
 Heilmeyer L., 36 40 (C)
 Heilmeyer L., Heimpel, H.
 Heimpel, H., Schmidt, W. Clotten, R.,
 und Heilmeyer L., 38, 63
 Heine, K. M., Stobbe, H., Herrmann, H.,
 und Hofer E., 39 276
 Heller A., v Klein, H. O.
 Hennekeuser H. H., v Fischer R.
 Herrmann, H., Heine, K. M.
 Hertenslein, Ch., v Wetter O.
 Herz, F. Kaplan, Eugene, and Scherz,
 Elsie S., 39 83
 Hewett, B. Jr Thompson, R. B.
 Heywood, J. D. v Rosenzweig, A. I.
 Hixig, W. H., 36 30 (C)
 Hofer E., v Heine, K. M.
 Holzknecht, F. und Braunsteiner H., 38,
 219
 Holzknecht, F. v Rensenbrink, J.
 Holzknecht, F. Spöhl, F.
 Honetz, N., Moser K., Neumann, E., und
 Seipel, H., 39 333
 Horiochi, H., v Nakao, K.
 Haber H., v Gress, M.
 Hudson, G., 36, 330
 Hughes, J. 36 109 (C)
 Humman, P. H. J. Jones, J. H. P.
 Hunslein, W. Hunsfeldt, Ch.
 Humstein, W. v Klemm, D.
 Hunt, D. M., Mathias, F. A.
 Hunter J. and Nelson, M. G., 38 57
 Humman, R. G., Lehmann, H.
 Inoue, M., Arai, M.
 Isterbeck, H. van, van Isterbeck, H.
 Iaralla, M. C. G., Ehas, M. W.
 Jackson, C. W. Odeh, T. T. Jr
 Jain, N. C., 39 51
 Jantet, G., Collette, J. M.
 Jantet, G., Collette, M.
 Jurechewsky A. J. Plotkin, V. J. and Sock-
 ser C. J. 40 315
 Jepsen, Joanne H., and Lowenstein, L.,
 38 292
 Jereth, S., v Oerold, M.
 Jin, R. T. S., 37 94
 Jørgensen, K., Dybbæk R.
 Jones, J. H. P. and Humman, P. H. J. 40
 336 (B)
 Jos, F. v Baskö, E.
 Kahai, E. A., 36, 196 (C)
 Kaiser G., Brinkö, S.
 Kaplan, Eugene Herz, F.
 Karalis, D. Angelopoulos, R.
 Karobath, H., Lechner K.
 Kay R. W. Lewis, R. A.

- Koser O. 32, 127 (B)
 Kerkmeester L., van Creveld, S.
 Kose-Elias, M., Harris, E. B., and Gyftaki, E., 37 170
 Kose-Elias, M., Gyftaki, E., Alexiou-Terzaki, V. and Koukouloumatou, A., 40 37
 Kose-Elias, M., Gyftaki, E., Alexiou-Terzaki, V. and Malamou, B., 39 133
 Keyserlingh, D. Graf, Graf Keyserlingh Khan, M. H., and Martin, H., 33, 142, 391 39 299
 Khanchaja, P. C., and Agarwal, K. N. 38, 11
 Khouri, F. F. Shakkil, M. J. and Venkatesh, S., 40, 192
 Kieley J. M., v. Schmidt, J. R.
 Kiliander A., and Werner L., 40 303
 Kionoglou, K. A., Matsaniotis, N.
 Klehner E. F., Tang, T. E., and Reiche, K., 32, 264
 Klein, H. O., and Heller A., 37 223
 Kleinbauer E., 30 64 (B)
 Klemm, D., Grunick, D. Wicherich, J. Hanevaldt, Ch., and Hanevaldt, W. 30, 240
 Koller F. 36, 133 (C)
 Koller F. Dockert, F. and Strein, F. 38 407 (B)
 Koller Th. jr. 38 273
 Kondi, Athena, Foy H.
 Koukouloumatou, A., Kose-Elias, M.
 Kratochvil, C. H. (Editor) 40 110 (B)
 Krums, F. Gergely O., and Rák, K., 39, 112
 Krück, F. (Editor) 40, 112 (B)
 Kubitz, P. Poláček, J.
 Kubo, T. Arai, M.
 Kuter W. Černý, M.
 Kynoch, P. A. M., Ringelmann, B.
 Lafort, M. T. and Gardner F. H., 37 88
 Lagerhof, B., 40, 142
 Lagerhof, B., Gullbring, B.
 Lammik, J. O., 36 333 37 32
 Lander H., Davey M. G.
 Landy M., Haasmarck, Gleda
 Lawkowitz, W. and Casrski, B. 36 13 (C)
 Lawrence, J. R., Davey M. G.
 Lawton, J. W. M., and Forbes, I. J., 40 241
 Lechner K., Regels, H., Waldhölzl, W. und Karobath, H., 40 93
 Leder L. D. Löffler H.
 Lehmann, H., 37 256 (C)
 Lehmann, H., and Huntman, R. G., 37 159 (B)
 Lehmann, H., Marti, H. R.
 Lehmann, H., v. Ringelmann, B.
 Lehmann, H., v. Trincas, C.
 Lehmann, H., Waid, P.
 Lewis, J. P. Alford, Dorothy A., Wright, C.-S., Gardner E. jr. Rathjen, J. H. jr. and Moore, R. R., 39 372
 Lewis, R. A., Kay R. W., and Hathorn, M., 36 299
 Lewis, R. A., Ringelmann, B.
 Lewis, S. M. (Editor), 37 331 (B)
 Lie-Injo, L. E., Wang, A. C., and Bennett, R. C., 40 286
 Lie-Injo, L. E., von, G. H.
 Ling, N. R., 40 239 (B)
 Löffler H., and Leder L. D. 40, 73
 Lohr O. W. 36, 273 (C)
 Lopez, V. Pflughaupt, R., and Böcker R., 40, 273
 Lorber M., and Nemes, J. L., 37 189
 Lorlin, P. A., Ringelmann, B.
 Lorlin, P. A., v. Trincas, C.
 Lowenstein, L., Jepsen, Joanne H.
 Ludwig, O. J., Ayres, M.
 Lüdin, H., Beck, E. A.
 Lyberatos, C., Garthias, C.
 MacKinnon, J. A. A., 38 163
 Mackawa, T., Nakao, J.
 Mackawa, T. Shirakura, T.
 Maggioni, G., Bordini, E.
 Maghail, E., Rondanelli, E. G.
 Maler C., Wynn, S.
 Maj Sz., Pawchid, S.
 Malamou, B., Gyftaki, E., Kose-Elias, M., and Christakopoulos, P. 32, 200
 Malamou, B., Kose-Elias, M.
 Masonis, F. Matsaniotis, N.
 Markham, T. 37 321
 Marti, H. R., 40 239 (B)
 Marti, H. R., 37 159 (B); 38, 64 (B) 403, 404 405 (B) 40, 336 (B)
 Marti, H. R., Beale, D., and Lehmann, H., 37 174
 Marti, H. R., Lehmann, H., and Beale, D. 37 61
 Martin, H., Khan, M. H.
 Martins de Melo, J. Trincas, C.
 Martz, G., 38 405 (B)
 Masera, P. Filieri, A.
 Mathe, G., Damsel, J.
 Mathias, P. A., Hunt, D. M., Florry M. J. and Segel, B. V. 38 112

- Matsumoto, N., Kikunagon, K. A., Macone, F., and East-Macdon, B., 37 29
 Mangel, T. K., v. Schumacher H. R.
 Mauri, C., v. Quaglini, D.
 McFeely A. E., v. Schumacher H. R.
 McGuire, Patricia, v. Ragen, P. A.
 Melo, J. Martins de, v. Martins de Melo, J.
 Meloni, T., v. Schettini, F.
 Mercall, D., 37 406 (B)
 Meulen, van der, v. Moll van Charante van der Meulen, C. C.
 Milton, J. D., v. Cooper E. H.
 Mirand, E. A., Murphy G. P., Steerer, R. A., Weber H. W., and Reising, P. P., 37 359
 Miron, W. J., v. Casoldi, G. L.
 Miwa, S., Arai, J. Tachada, T., Shimbura, M., Teramura, K., and Sumaga, Y., 37 37
 Mochtar I. A., v. van Greveld, S.
 Moeschlin, S., 37 405 (B)
 Moeschlin, S., v. Schmid, J. R.
 Moeschlin, S., and Speck, B., 37 104
 Moll van Charante-van der Meulen, C. C., van Greveld, S.
 Molison, P. L., 37 407 (B)
 Moloney W. C., v. Rosenhal, D. S.
 Moore, R. R., Lewis, J. P.
 Moquin, R. B., v. Schumacher H. R.
 Moracek, A. (Editor) 37 407 (B)
 Morrison, J. H., and Toepfer J. R., 37 250
 Moser K., Hoeser, N.
 Motulsky A. G. Rosenzweig, A. I.
 Müller H. E., Ehrly A. M.
 Mukherjee, C. L., v. Raha, P. K.
 Murphy G. P., Mirand, E. A.
 Nacta, J. P. and Wreck, M., 37 42
 Nagaraman, N., and Schumacher, P. K., 37 209
 Na-Nakorn, S., v. Wasi, P.
 Najjar, Y., 37 238 (B)
 Nakakaki, K., Shiba, H., and Nishimura, Y., 37 317
 Nakao A., Mackawa, T., Horinaka, H., Shirakura, T. and Ebura, H., 37 233
 Nascimento, J. Dos Santos, v. Dos Santos Nascimento, J.
 Nelson, M. G., v. Hunter J.
 Neron, J. L., Lorber M.
 Neumann, E., v. Hoeser, N.
 Nishimura, Y. v. Nakakaki, K.
 Odarichenko, N., 37 238 (B)
 Odell, T. T. Jr. Jackson, C. W. and Reiter R. S., 37 34
 Odom, J., v. Thompson, R. B.
 Oechalin, R. J., 37 11
 Oechalin, R. J., v. Schmid, J. R.
 Ohsayhi, S., 37 276
 Okada, S., v. Awal, M.
 Owen, C. A. Jr., v. Schmid, J. R.
 Owen, P. A., 36 141 (C)
 Pabie, A., v. Seitz, Z.
 Paglia, D. L., v. Baughman, Marjorie A.
 Papayannis, A., v. Gardikas, C.
 Pardo, P., Simó, E., Ribas-Mendó, M., and Ferreras, F., 37 230
 Parralra, F., v. Dacia Soares A.
 Paschia, C. N., v. van Greveld, S.
 Pavlovsky A., 37 296 (C)
 Pawchki, S., Maj, S., and Topolka, Paula, 37 397
 Pedersen, B., 37 102
 Pell-Ilderton, R., v. Brown, A. K.
 Pellitiero, C., v. Kewald, E.
 Peters, H., 37 240
 Pfeiffer R. A., v. Böchner T.
 Pfingshaup, R., v. Lopez, V.
 Pileri, A., Gabardi, N., Masera, P. and Gervasio, F., 37 193
 Plotkin, V. J., v. Jaroshevsky A. J.
 Pollock, J. and Kubicek, P., 37 49
 Pollock, J. v. Rorell, B.
 Poiler L., v. Burdett, R. W.
 Poiler L., v. Dewhurst, F.
 Polli, E., v. Corneo, G.
 Pontarol, S., Wasi, P.
 Potvin, Beatrice, v. Borges, A.
 Prato, N., v. Riccio, G.
 Preston, J. K., Foy H.
 Pyrah, R. D., v. Roberts, B. E.
 Pyrovolakis, J. v. Gardikas, C.
 Quaglini, D., Torelli, U., Sauti, S., and Masari, C., 37 79
 Quattrini, N., Burchi, P. Cimini, R., De Rosa, L., Dani, Z., and Venturo, V., 37 266
 Ragen, P. A., McGuire, Patricia, and Antonina, J. I., 37 309
 Raha, P. K., Sarkar H. K., and Mukherjee, C. L., 37 332
 Raya, S., v. Haerwaldt, Ch.
 Rák, K., v. Kétes, F.
 Rangeli, J. R., Arrada, T.
 Rathjous, J. H. Jr. Lewis, J. P.
 Redetzky H., and Thiele, H. (Editors), 37 381 (B)
 Regele, H., v. Lechner K.

- Reitano, G., Silvestroni, E.
 Rieker, R. S., Odell, T. T. Jr.
 Renrenbrink, J., Holzknecht, F. and
 Braunsteiner, H., 38, 93
 Reteg, F. P., Mirand, E. A.
 Rewald, E., and Pellitero, C., 37 62
 Ribes-Mundó, M., Pardo, P.
 Ribes-Mundó, M., Roeman, C.
 Ricco, G., Gallo, E., Fiorina, L., and Praso,
 V. 38, 306
 Richaerich, R., 40 110 (B)
 Riecke, W. O., and Schwarz, M. R., 38, 121
 Ringelblum, B., Lewis, R. A., Lorkin, P. A.,
 Kynoch, P. A. M., and Lehmann, H.,
 38, 324
 Roberts, B. E., Abbott, C. R., Forti, R. W.
 and Pyrak, R. D., 39 20
 Robinson, J. B., Waller, L. H. B.
 Rotson, H. V., Davey M. G.
 Rogers, A. W. 39 127 (B)
 Rondocelli, E. G., Magliolo, E., Caroli, G.,
 and Dionisi, D., 40 67
 Ross, L. de, De Ross L.
 Rosenthal, D. S., Skarin, A. T. and Molo-
 ncy W. C., 40 187
 Rosencraig, A. I., Heywood, J. D. Mon-
 sky A. G., and Finch, C. A., 39 91
 Rotzki, B., and Földiek, J. 39 129
 Rozman, C., Castillo, R., Ribes-Mundó,
 M., and Sarda, J. 37 217
 Rozman, C., Wocznar, S., and Saca-Ser-
 ranis, J. 40 234
 Ruffin, J., Bernard, J.
 Sabonis, E. M., 39, 373
 Sadron, Ch., 36, 63 (C)
 Sacz-Serranis, J., Rozman, C.
 Salen, G., and Schumacher H. R., 37 294
 Salmo, F. M., Ayres, M.
 San Miguel, J. O., and Castillo, R., 40, 113
 Santos Nascimento, J. Dos, Dos Santos
 Nascimento, J.
 Sarkar H. K., Raha, P. K.
 Sartoris, S., Becki, C.
 Sassi, S., Quangkoo, D.
 Schettini, F. and Meloni, T. 37 198
 Schettini, F. Meloni, T. and Costa, S., 37 63
 Scheye, Elise S., Herz, F.
 Schleicher, E. M., 40 162
 Schmidt, F. and Braunsteiner, H., 38, 281;
 39 177 and 121
 Schmidt, F. Cirone, M., and Braunsteiner
 H., 39 257
 Schmid, J. R., Kieley J. M., Tanze W. V.,
 and Owen, C. A. Jr. 36, 313
 Schmidt, J. R., Oechalia, R. J. Frick, P. G.,
 and Moeschlin, S., 37 16
 Schmid, R., v. Beck, L. A.
 Schmidt, W., Heimpel, H.
 Schnappan, H., and Schnorr, B., 39 282
 (Corrig. 40, 240)
 Schnerer J. H., 40 44
 Schneider, A. S., Baughman, Marjorie A.
 Schnorr, B., Schnappan, H.
 Schockenich, E., Colletta, J. M.
 Scholer, Y., Germano, G.
 Schüttmann, W., Stiefitz, R.
 Schumacher H. R., McFeely A. E., and
 Mangel, T. K., 40, 28
 Schumacher H. R., Moqum, R. B.,
 McFeely A. E., and Mangel, T. K., 39
 237
 Schumacher H. R., Sales, G.
 Schwarz, M. R., Riecke, W. O.
 Seidl, S., 40 337 (B)
 Seipel, H., Honetz, Y.
 Seno, S., Arai, M.
 Shahid, M. J., Khouri, F. P.
 Shekter, C. J., Jaroshevsky A. J.
 Shimizu, M., Igawa, S.
 Shirakura, T. 39 366
 Shirakura, T., Nakao, K.
 Shurakura, T., Aruma, M., and Mackawa,
 T. 38, 49; 40 299
 Shiba, H., v. Nakakuki, K.
 Siegel, B. V., Mathias, P. A.
 Silvestroni, E., Bianco, L., and Reitano, G.,
 40 220
 Simó, E., Pardo, P.
 Skarin, A. T., Rosenthal, D. S.
 Sloane, Kathrine M., and Bridges, J. M.,
 40 18
 Soares, A. Dacia, v. Dacia Soares A.
 Sparrevohn, S., and Walff, H. R., 37 120
 Speck, B., v. Moeschlin, S.
 Spötl, F., Comestantini, R., and Holzknecht,
 F. 38, 377
 Spötl, F., Holzknecht, F. and Braunstei-
 ner H., 38, 178
 Strews, R. A., Mirand, E. A.
 Steinhouse, N. S., v. Vos, G. H.
 Sibbe, J., van Greveld, S.
 Stiefitz, R., Seebbe, H., and Schüttmann,
 W. 38, 337
 Seebbe, H., 40, 238 (B)
 Seebbe, H., Helms, K. M.

